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Summary
One treatment modality for atrial fibrillation, the most common cardiac arrhythmia, is radiofre-
quency catheter ablation in which fibrotic tissue is created around the pulmonary veins. The
procedure has major drawbacks, hence a new treatment modality would be beneficial. This is
the first in silico study for the feasibility of a non-invasive treatment of atrial fibrillation with
scanned ion beams, which are successfully used in cancer radiotherapy. In collaboration with
the Mayo Clinic (Rochester, Minnesota, USA) the first comparison between different irradiation
techniques to cardiac target volumes was carried out in this work. In the presented results it
was shown that the dose deposition to organs at risk could be drastically reduced compared to
a potential non-invasive treatment of atrial fibrillation with photons. As a result of the actively
applied ion beam, interference effects were observed when irradiating the moving cardiac vol-
umes. The motion influences of respiration and heartbeat were studied individually and the
resulting displacement was examined. To achieve a homogenous dose deposition in the mov-
ing target volumes, motion mitigation techniques (gating and rescanning) were successfully
applied. The results will be validated in animal experiments at GSI in 2014.
Zusammenfassung
Eine Behandlungsmöglichkeit für Vorhofflimmern, der verbreitetsten Art von Herzrhyth-
musstörungen, ist Radiofrequenzablation mit Hilfe von Kathetern, bei der Narbengewebe um
die Pulmonarvenen erzeugt wird. Dieser Eingriff hat schwerwiegenden Nachteile, so dass
eine neue Behandlungsmöglichkeit wünschenswert wäre. Dies ist die erste in silico Studie,
die die Durchführbarkeit einer nicht-invasive Behandlungsmöglichkeit für Vorhofflimmern mit
gescannten Ionenstrahlen untersucht. Diese werden erfolgreich in der Strahlentherapie von Tu-
moren eingesetzt. In dieser Arbeit wurde in Kollaboration mit der Mayo Clinic (Rochester, Min-
nesota, USA) der erste Vergleich zwischen verschiedenen Bestrahlungsarten von Zielvolumina
im Herzen durchgeführt. In den Ergebnissen konnte gezeigt werden, dass die Dosisbelastung
der umliegenden Risikoorgane im Vergleich zu einer potentiellen nicht-invasiven Behandlung
von Vorhofflimmern mit Photonen drastisch reduziert werden konnte. Aufgrund des aktiv ap-
plizierten Ionenstrahls wurden Interferenzeffekte bei der Bestrahlung bewegter Herzvolumina
beobachtet. Der Bewegungseinfluss von Atmung und Herzschlag wurden unabhängig voneinan-
der untersucht und die resultierende Auslenkung erforscht. Um eine homogene Dosis in den
bewegten Zielvolumen zu erreichen wurden bewegungskompensierende Methoden (gating und
rescanning) erfolgreich angewandt. Die Ergebnisse sollen in Tierstudien, die 2014 an der GSI
durchgeführt werden, validiert werden.
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Motivation
Atrial fibrillation is the most common cardiac arrhythmia [ESC10, CE09]. One out of four peo-
ple over forty are estimated to suffer from this condition in the course of their lifetime. While
genetics play a role in the development of atrial fibrillation in younger patients, age is an impor-
tant risk factor for this cardiac arrhythmia and the prevalence is estimated to double in the next
fifty years due to aging of society. In atrial fibrillation, an unorganized atrial activity leads to a
quivering motion and hence the heart is not able to sustain a healthy pumping rhythm. This is
not in itself life threatening, but it alters the quality of life of the patients and increases the risk
of the patients to suffer a stroke [Ben98, Wol91].
A typical treatment modality for atrial fibrillation is catheter ablation. Based on the land-
mark paper by Haissaguerre et al. [Hai98], where electrical signals causing atrial fibrillation
where found to originate from the pulmonary veins in 97 % of the studied cases, it is assumed
that atrial fibrillation is triggered and sustained by the same anatomical site in the majority of
patients. With catheter ablation flexible catheters are inserted into the patient to deposit ra-
diofrequency energy around the junction between pulmonary veins and atria. This creates a
scar which inhibits the signal propagation from the pulmonary veins into the heart’s conduction
system. Catheter ablation requires the anesthetization of the patient for multiple hours while
it offers only a limited treatment success rate. Major complications and even death may occur
due to this procedure [Cap05, Cap10]. Alternative treatment modalities are thus warranted.
Radiosurgery has the potential to become a new technique for these patients [Ber12]. In a
study by Sharma et al. [Sha10], it was demonstrated that the irradiation of various cardiac tar-
get sites with a focused photon beam changed the electrical pathway of the heart’s conduction
system. Based on the experience gained in cancer radiotherapy, an improved treatment outcome
for such a deep seated target is expected for carbon ions. Compared to photons, particles like
carbon ions deposit their energy in a defined area at the end of their particle track, the so called
Bragg peak [Wil46]. This enables particles to deposit a high dose to the target while sparing the
surrounding tissue [Kra00]. The physical and biological properties of carbon ions, combined
with active beam delivery and beam shaping [Hab93], led to successful clinical results in treat-
ment of deep seated, static tumors in the GSI pilot project from 1997 to 2009 [Schu07]. Based
on the convincing treatment outcome, other centers like the Heidelberg Ion-Beam Therapy Cen-
ter (HIT) and CNAO (Centro Nazionale di Adroterapia Oncologica) were build, where patients
are now treated with scanned carbon ion beams on a regular basis [PTCOG13, Loe13].
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Scope of this work
This is the first in silico survey to study the feasibility of a non-invasive treatment modality for
atrial fibrillation with carbon ion radiosurgery [Ber12]. Thereby the irradiation of ablation sites
in the junction between pulmonary veins and atria will be studied in human data. Another
potential ablation site for atrial fibrillation, the AV node, will be studied in porcine data sets. A
single fraction dose of 25 Gy will be applied to the cardiac target volumes.
When intending to irradiate non-static targets, interference effects between target motion and
the actively applied ion beam can cause local under and over dosages [Phi92, Ber08]. In or-
der to ensure a homogenous dose in the target area, motion mitigation techniques are needed.
Different motion mitigation techniques will be studied in this dissertation. The application of
irradiation during only a selected part of the motion cycle (gating) [Kub96] as well as the
repeated scanning of the same slice with a reduced dose so that averaging effects cause a ho-
mogenous dose deposition in the target volume (rescanning) [Phi92] will be analyzed. For
the feasibility of a non-invasive treatment modality for atrial fibrillation with carbon ions, two
independent motion influences have to be considered. On the one hand the heartbeat, a fast
but small amplitude motion, and on the other hand the respiration of the patient, a typically
slow motion with big amplitude. Respiration and heartbeat gated CTs of human patients will
be studied and the resulting treatment planning studies will be presented. In preparation for
animal studies planned at GSI in the summer of 2014 treatment plan results for porcine data
will also be investigated.
The structure of this dissertation is as follows. Chapter 1 will give an overview over the phys-
ical and biological fundamentals of radiotherapy. Different radiotherapy applications will be
presented and a special emphasis will be given on the treatment of moving targets. Further-
more, the cause of atrial fibrillation and its resulting risk factors will be presented. Currently
existing therapies and the potential benefit of a non-invasive treatment modality will be dis-
cussed. In chapter 2, the influence of respiratory motion on pulmonary veins ablation sites in
humans will be discussed. The feasibility to use gating as motion mitigation technique for this
case will be investigated. In chapter 3, the displacement of the pulmonary veins ablation site
due to heartbeat will be examined in human data. Rescanning will be studied as motion mitiga-
tion technique for this motion component. In preparation for the planned animal experiments,
which will be carried out as a first experimental feasibility study in the summer of 2014 at GSI,
chapter 4 will discuss an AV node ablation with carbon ions in porcine data. The underlying
heartbeat motion will be studied and rescanning as motion mitigation technique will be utilized.
Discussion of the overall results will be given in chapter 5, while chapter 6 will conclude the
findings and give a short outlook on future directions.
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1 Introduction - research background and
fundamentals
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Radiosurgery has the potential to become a new and non-invasive treatment modality for
atrial fibrillation (AF), the most common cardiac arrhythmia. Irradiation with photons is known
to alter the electrical pathway of the heart’s conduction system [Sha10]. Based on the expe-
rience gained in cancer radiotherapy promising results are expected by the usage of scanned
carbon ion beams. In order to explain the underlying physical and biological differences be-
tween carbon ions and photons as well as other ions (e.g. protons), and also the resultant
benefits of carbon ions when irradiating a deep seated target, the physical and radiobiological
fundamentals will be explained in the first section of this chapter. In the second section the dif-
ference in radiotherapy application will be outlined, with special emphasis on the irradiation of
moving targets. In the last section the basics of the heart’s conduction system will be presented.
Abnormalities, risk factors and underlying mechanisms causing cardiac arrhythmia in general
and atrial fibrillation in particular will be explained. The currently existing treatment modalities
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for atrial fibrillation, as well as their limitations and risk factors will be presented in order to
motivate the benefits of a non-invasive treatment modality.
1.1 Physical and biological basics of radiotherapy
The usage of radiation for medical purposes is almost as old as its detection. Shortly after
W.C. Roentgen discovered X-rays in 1895 it was first used for the treatment of a cancer patient
[Hal06]. With the development of accelerators and the resulting study of ion energy deposition
profiles particles were connected to their therapeutic implications and benefits [Wil46]. In the
following the physical and biological fundamentals of radiotherapy will be presented.
1.1.1 Dose
The dose D is defined as the deposited energy per unit mass [ICRU93]:
D =
dE
dm
; [D] = 1G y = 1
J
kg
(1.1)
The magnitude of the deposited dose in a material depends, among other factors, on the
used particle type, as they underlie different physical interaction mechanisms, which will be
explained in the following.
1.1.2 Interaction of radiation with matter
Photons and ions interact differently with matter, resulting in different depth-dose-profiles (see
figure 1.1). In the energy range used for radiotherapy, photons deposit their highest local dose
shortly after entering the material while ions display an inverse depth-dose-profile. Thereby
most of their energy is deposited in a defined area at the end of the particle track, the so-called
Bragg Peak region, which is beneficial when irradiating a deep seated target as the dose to
the surrounding normal tissue can be drastically reduced. Even though the interaction mecha-
nisms for the energy deposition of both, photons and ions, occurs primarily through secondary
electrons, the underlying processes differ.
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Figure 1.1.: Depth dose distributions of photons and carbon ions at different energies. Photons
display an exponential decrease after a certain build up. Ions on the other hand
interact differently with matter, resulting in an increased dose deposition at the end
of the particle track, the Bragg peak. Figure taken from [Sch10].
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Interaction of photons with matter
Photons undergo different processes when passing matter, like coherent scattering or Rayleigh
scattering, photoelectric effect, Compton scattering and pair production. The probability for
each process depends on one hand on the energy of the primary photons as well as on the
atomic number of the absorbing material, while the strength of these dependencies varies in
turn for the different processes [Lil06]. The overall decrease of the photon beam intensity when
passing a material can be described by the following formula:
I = I0 · e−Nσx = I0 · e−µx (1.2)
where I0 represents the intensity of the incident photon, x the depth of the material in units
of length, N the atomic density of the material and µ is the attenuation coefficient. The lat-
ter is directly related to the overall cross section σ, which is a measure of the probability of
the occurrence of an interaction mechanism. It has contributions from all single interaction
processes.
σ = σrayleigh+σphotoelectric+ Zσcompton+σpairproduction (1.3)
In the energy range of radiotherapy (between 100 keV and 25 MeV) the dominating process is
Compton scattering [Alp98]. The attenuation of the photon beam results thus in the following
way: The Compton electrons are scattered in a strongly forward direction, leading to a build
up effect in deeper layers of the material. The maximum of the depth-dose profile is reached
when the electrons are completely stopped at a certain depth, which is called the mean electron
range (and is dependent on the initial photon energy). Afterwards the dose deposition decreases
exponentially (see eq. 1.2).
Interaction of ions with matter
Interaction of ions with matter occurs via one of the following processes: elastic coloumb scat-
tering from target nuclei (nuclear stopping) and inelastic collision with target electrons (elec-
tronic stopping). In the mildly relativistic region used in radiotherapy (energies of less than
500 MeV/u) the total stopping power of ions is dominated by electronic stopping, resulting
in ionization and excitation of the target atoms. The Bethe-Bloch formula [Bet30, Blo33], de-
scribing the mean rate of energy loss of relativistic ions, can thus be corrected for low particle
energies [Nak10], resulting in the following approximation:
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where Ne is the materials electron density, e and me are the charge and mass of an electron,
ε0 the electrical field constant and I the mean excitation energy of the absorber material. The
effective projectile charge ze f f can be approximated by the Barkas formula [Bar63], where β is
the projectile speed in units of c:
ze f f = z

1− e−125βz 23

(1.5)
The main dependencies of the mean rate of energy loss can be seen in equation 1.4. It is
proportional to ze f f and inversely proportional to v
2. The overall depth dose distribution can
thus be understood in the following way: in the beginning the particles have a high energy and
thus high velocity, causing a small dose deposition. While passing the material, the velocity of
the projectile decreases, causing the energy deposition to increase. At low particle energies,
close to the particle range, target electrons are collected, causing ze f f to decrease and leading
to a decrease in dose deposition. The position of the maximum specific energy loss around the
particle range is known as Bragg peak.
Range straggling and lateral scattering
Even though electronic stopping via inelastic collisions with target electrons is the main inter-
action process in the therapeutic energy range, elastic Coulomb scattering from target nuclei is
still occurring and represents the main reason for lateral scattering. In an analytical approxi-
mation by Molière [Mol48], the angular spread of the overall deflection in a material has been
described. It is on one hand dependent on the mass of the target nuclei, where a higher mass
causes a larger angular spread for the same material thickness. And on the other hand it is in-
versely proportional on the momentum of the projectile, causing carbon ions to have a smaller
lateral deflection than e.g. protons. Experimental validation comparing carbon ions to protons
having the same range in water (15.6 cm, 150 MeV protons and 285 MeV/u 12C ions) resulted
in an approximately three times smaller angular spread [Sch10].
Range straggling is caused by the statistical fluctuations of single electronic stopping events.
In case of large number of collisions or thick layers of material these fluctuations can be approx-
imated by a Gaussian probability distribution [Bor40, Ahl80, Ric12]. This leads to an inverse
proportional dependence between the ratio of the straggling width σR with the mean range R
and the square root of the ion mass M ( σR/R ∝ 1/pM ). This results in a smaller range scat-
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tering for heavier ions. Experimentally, the ratio between the straggling width and the mean
range was found to be 3.5 smaller for carbon ions compared to protons [Sch10].
Nuclear fragmentation
At large penetration depths, when the projectile ions have lost most of their energy, projectile
fragmentation processes start to be relevant for ions heavier than protons. Mostly lower Z
fragments are produced, which move with approximately the same velocity and in the same
direction as the primary ions. This causes dose tails behind the Bragg peak position (see figure
1.2). Thus the resulting depth-dose distribution is actually the sum of the energy deposition of
the projectiles and the resulting fragments.
Figure 1.2.: Depth dose distribution of carbon ions. Besides the energy deposition of the pri-
mary ions (red), the produced fragments (blue curve) contribute to the overall dose
deposition (black) and are especially visible in the dose tail behind the Bragg peak.
Figure taken from [Gro04].
Nevertheless, the produced fragments also offer the chance for PET (Positron Emission To-
mography) monitoring, without additional radiation exposure for the patient. As peripheral
collisions are more frequent then central ones [Kra00] isotopes like 11C and 10C are often pro-
duced when 12C ions penetrate through tissue. Both isotopes are β+ emitters. They annihilate
with electrons in the human body, producing two γ-rays which travel in opposite directions.
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Track structure
For inelastic collisions with atomic target electrons, only about 20 % of the initial projectile
energy is used to overcome the electron binding energy [Kra92]. A high amount of energy is
transformed into the kinetic energy of the secondary electrons, so-called δ-electrons. These δ-
electrons can in turn emerge from the primary particle trajectory and undergo frequent elastic
and inelastic scattering. If their energy is sufficiently high they can induce further ionization in
more distant locations, leading to a high number of additional electrons. The radial dose fall
off is approximated by a 1/r2 law, illustrating that the radial dose quickly falls off with larger
radial distance r [Cha76, Kat99]. The range of the δ-electrons is restricted to a maximum value
according to the kinematics of the collision between projectile and target electron. Empirically
this can be described by a power law [Kie86], where E is energy of the primary ion:
rmax ∝ E1.7 (1.6)
As stated by the Bethe equation (1.4), the energy deposition of the primary ions is dependent
on the used ion species and their energy. This results in a higher stopping power for higher
Z primary ions as well as an increased stopping power for smaller energies. Hence carbon
ions have a much higher δ-electron output than e.g. protons. Furthermore with decreasing
energy of carbon ions, the δ-electron output increases. This can be seen in figure 1.3. The
higher ionization density produced by δ-electrons is also the reason for the difference in induced
biological damage.
Linear Energy Transfer LET
The critical measure for the energy deposition of the δ-electrons is the linear energy transfer
(LET). It is defined as the locally deposited energy to the medium (average energy deposited per
unit length of track [Hal06]) and in radiobiology is given in keV/µm. Sparsely ionizing radition
(such as photons, protons and fast ions) have a low LET, while slow ions are densely ionizing
and hence have a high LET.
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Figure 1.3.: Microscopic track structure of protons (left side) and carbon ions (right side) at dif-
ferent energies. Protons and high energy carbon ions are low LET radiation and
hence sparsely ionizing. Low energy carbon ions on the other hand are high LET ra-
diation and hence densely ionizing. For comparison the size of the DNA is displayed.
Figure courtesy of Michael Krämer.
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1.1.3 Radiobiology
It was described in the previous section that both, photons and ions, are ionizing radiation
producing δ-electrons which in turn can cause subsequent ionizations. These ionizations attack
the carrier of the genetic information of the irradiated cells and hence causes them to stop
to proliferate. The biological background of these processes will be described in this section.
Furthermore the enhanced biological effect of ions compared to photons will be explained. This
is one of the potential benefits expected from a non-invasive irradiation of atrial fibrillation with
carbon ions compared to photons.
Impact of radiation on cells
In eukaryotic cells, meaning cells that contain a cell nucleus, the genetic information is stored in
the DNA (desoxyribonucleic acid), making it therefore the critical target in radiotherapy. DNA is
made of two sugar and phosphate backbones and four different base pairs (adenine A, cytosine
C, guanine G and thymine T), which bind in a defined way (A with T and C with G) and thus
form the double helix structure with a distance between the two strands of about 2 nm. The
genetic information is encoded in the sequence of the base pairs. Ionizing radiation can destroy
the described structure of the DNA, either by direct or indirect action [Hal06].
As can be seen in figure 1.4 direct effects are caused by the destruction of molecular bonds
of the DNA itself through any form of radiation. This process is considered the dominant effect
if radiation with a high LET is used. Indirect action means that free radicals are produced by the
ionizing radiation, which can then in turn damage the DNA. This phenomenon is predominant
when sparsely ionizing radiation (low LET, like photons) are used and interact with molecules
in the cell, particularly water.
Both mechanisms can cause either single strand breaks (SBS) or double strand breaks (DSB)
(see figure 1.4). SSB mean that only one of the strands is destroyed, leaving the complementary
base on the other strand intact and thus enabling a fast repair if the SSBs occur at a certain
distance from each other. DSB or clustered SSB are more complex and can cause the breakage
of the chromatin. But even these damages are usually steadily repaired. The repair mecha-
nisms only start to fail when the DSBs accumulate to local lesions. Changes in the original DNA
material is the result. Depending on the produced damage mutations, carcinogenesis or cell
death can be the result. Cell death can occur in different pathways. Apoptosis is the controlled
self-inactivation of the cell due to DNA damage and the preferred pathway in radiotherapy. Un-
controlled cell death, necrosis, typically causes severe reactions of the immune system, leading
to e.g. inflammation.
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Figure 1.4.: On the left side (a) direct and indirect radiation damages are illustrated. On the
right side (b) single strand breaks and double strand breaks are visualized. Figure
taken from [Ric12].
Relative Biological Effectiveness RBE
As outlined, at the same dose level, radiation damage depends on the LET. This means that the
induced biological effect is, amongst others, dependent on the energy and type of radiation.
This is described in the relative biological effectiveness (RBE), which is defined as follows:
RBE =
Dre fphoton
Dion

isoeffect
(1.7)
Dre fphoton is the absorbed photon dose necessary to induce a certain isoeffect and Dion is the
absorbed dose of ions at a defined energy which leads to the same effect. Comparison of RBE
values are valid only for the same effect and biological endpoint and by using the same ref-
erence radiation. This idea is used in the local effect model (LEM) at GSI for the prediction
of the RBE. By assuming that the biological effect is independent of the specific radiation type
but rather dependent on the energy deposition distribution in small sub volumes of the cell
nucleus, RBE predictions are computed in relation to the known biological response of photons
[Krae03, Fried13]. Weighting the physically absorbed dose with the RBE results in the biological
dose in units of Gray equivalent (GyE).
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The RBE depends on multiple parameters, like the endpoint, the irradiated tissue and its re-
pair mechanism, the particle type, the used dose level and the LET. The dependence between
RBE and LET is illustrated in figure 1.5. In case of X-rays (sparsely ionizing) the probability of
an induced DSB is low and in general more than one track would be required to induce DSB,
resulting in a small RBE. Irradiation with a LET around 100 keV/µm on the other hand is opti-
mal in producing a biological effect, as the density of ionization coincides with the diameter of
the DNA double helix of about 2 nm. Thus radiation with this LET has the highest probability
to induce a biological damage with DSB. More densely ionizing radiation (LET > 200 keV/µm)
produces many DSBs, leading to ionization events which are closer together than needed. The
RBE consequently decreases again, an effect known as overkill effect.
Figure 1.5.: Photon radiation with a LET of 100 keV/µm has the biggest RBE for cell killing due
to the fact that average separation between ionizing events coincides with the di-
ameter of the DNA double helix (2 nm). Figure taken from [Hal06].
Concerning the increased biological effectiveness of ions it can be stated that it is only of
advantage if the RBE is more pronounced in the target tissue compared to the normal tissue
in the entrance channel. While protons exhibit an almost constant RBE throughout the energy
deposition (a constant value of RBE = 1.1 is used), for ions heavier than oxygen the location
for the highest RBE moves towards the proximal region of the depth-dose profile, starting to
coincide with the plateau region [Kra00]. For carbon ions on the other hand the position of the
highest RBE value coincides with the Bragg peak region, enhancing the possibility of a beneficial
treatment outcome.
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1.2 Radiotherapy
The conventional method for radiotherapy remains the irradiation with photons. Nevertheless,
the biological and physical properties of ions (which were described in the previous section)
result in advantages for radiotherapy, especially when treating deep seated targets. As a result,
more and more ion facilities are opened worldwide, treating an increasing number of patients
with protons and carbon ions [Loe13]. In this section the state of the art in treating static
tumors with photon and carbon ion therapy will be summarized. Afterwards organ motion and
the resultant difficulties, as well as approaches for motion mitigation will be presented.
1.2.1 Photon therapy
As can be seen in figure 1.1, a treatment of deep seated targets with photons can be carried
out more effectively the higher the photon energy. Over the decades, different photon emission
techniques were developed which allowed for higher photon energies. Currently, photons in
the energy range of (6-25) MeV [Ber06] are used. The photons are produced with the help of
linear accelerators, which are used to shoot accelerated electrons on a target, thereby emitting
bremsstrahlung which is then used for radiotherapy.
Not only the used photon energy spectrum but also the application techniques developed over
the last decades [Buc05]. Two dimensional (2D) radiotherapy was based on radiographies and
was carried out with a single beam, which was applied from one to four different directions, usu-
ally as opposing lateral fields. As the imaging techniques advanced the treatment became also
more conformal. CT scans enabled axial anatomy and tumor visualization in three dimensions.
Hence in three dimensional conformal radiotherapy (3DCRT) more accurate dose calculations
with homogeneous fields are possible, leading to an increased normal tissue sparing. With the
development of IMRT (intensity modulated radiotherapy) the normal tissue sparing could be
further improved. In IMRT a varying number of beams from different beam directions are over-
laid while modulating the intensity of radiation within each field. This intensity modulation is
achieved by using multileaf collimators (MLC) (see figure 1.6). An exemplary IMRT treatment
plan in comparison to carbon ion irradiation can be seen in figure 1.10.
Figure 1.6.: Technical realization of IMRT by using multileaf collimators (MLC), enabling a pho-
ton dose deposition conformal to the target volume. Each lamellae can be moved
individually, enabling an intensity modulation. Figure taken from [Schl01].
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1.2.2 Carbon therapy
As already explained in section 1.1 ions display an inverse depth-dose profile and a higher bi-
ological effect compared to photons. This enables a high target conformity and a sparing of
normal tissue, both of which are beneficial for radiotherapy. Since 1954, when the first ion
beam therapy was carried out with protons at Berkeley Lab [Tob58] different projectile ions
were used and their effect on target tissue studied.
Due to the their higher momentum and thus smaller lateral scattering (see section 1.1.2) the
usage of heavy ions (heavier than protons) enables a better sparing of normal tissue and organs
at risk (OAR), even if they are close to the target volume. In contrast to other ion types, the in-
creased biological effectiveness of carbon ions coincides with the Bragg peak region (see section
1.1.3). Thus both the physical and biological properties of carbon ions offer the possibility of a
beneficial treatment outcome.
Application technique
As in photon therapy, ion therapy application and thus target conformity improved over the
decades after first treatments at Berkeley were performed by shooting the proton beam through
the complete patient head [Tob58]. Depending on the provided accelerator as well as on the
beam line properties passive and active techniques are distinguished both in beam delivery as
well as beam shaping.
Concerning beam delivery particle acceleration to the therapeutic energies of several hundred
MeV/u is carried out in cyclotrons and synchrotrons. Cyclotrons, which are used mainly in
proton centers, offer the advantage of a more compact design compared to synchrotrons and
allow a continuous beam extraction with stable intensities. On the other hand no active energy
variation is possible, requiring the need for passive energy degraders. Synchrotrons, which are
used in heavy ion centers, allow active energy variation.
Concerning beam shaping methods, which are used in order to deposit a homogeneous dose in
the target volume, passive methods are used in some carbon ion centers as well as in the ma-
jority of proton centers. The devices rely on three different beam shaping steps [Chu93]. Firstly
the beam is broadened by scattering and then further widened by using range modulators like
e.g. a ridge filter. Thereby an extended and flat, but still homogeneous, field is formed which
covers the tumor extent in longitudinal direction (Spread Out Bragg Peak: SOBP). Secondly, the
range adjustment of the SOBP is achieved via flat degraders of variable thickness. Final con-
formity to the distal target border is achieved by patient individual compensators. Collimators
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are used for a lateral conformity. A scheme of a passive beam shaping system can be seen in
figure 1.7. Passive beam shaping devices offer the benefit that the historically unstable beam
quality of research facilities - in which the first treatments were carried out - did not influence
the homogeneity of the applied dose. Moreover, beam energy changes during treatment can be
avoided, thus enabling a fast irradiation time. Nevertheless, passive beam application always
requires the manufacture of patient individual compensators and an unavoidable limitation in
volume conformity in the proximal tumor region as the SOBP width is fixed by the range modu-
lator to the largest needed depth (see figure 1.7). Material in the beam path means furthermore
intensity loss due to lateral scattering and an extra dose exposure due to fragmentation.
Figure 1.7.: Scheme of a passive beam shaping system. The beam is broadened by a scattering
system and the width of the SOBP is determined by a range modulator. Via a range
shifter the SOBP energy can be adjusted to a fixed range and thus depth. For lateral
conformity collimators are used. The longitudinal conformity to the distal border
of the target is achieved with a patient specific compensator. The proximal volume
border can not be shaped, as is indicated in the hatched areas. Figure taken from
[Sch10].
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Active beam shaping is achieved with beam scanning, which offers a very good lateral target
coverage as well as volume conformity also in the proximal field region. The target volume is
thereby subdivided into slices of the same beam energy, so called iso-energy slices (IES). Each
IES is again subdivided into a grid of target points which are irradiated sequentially. Hence
many small pencil beams are used to generate a conformal dose deposition to any arbitrary
target volume shape without the need of patient specific hardware. This drastically decreases
the amount of material the beam has to traverse and hence reduces the unwanted neutron dose
to the patient [Kad12]. Examples of beam scanning are spot scanning, which was developed
for protons at the Paul Scherrer Institute (PSI, Swiss) [Ped95] or raster scanning, which was
developed in parallel at GSI [Hab93].
At PSI a cyclotron is used and the energy variation is carried out with a degrader. The lateral
deflection of the beam position is either achieved with magnets (Gantry 2 at PSI [Ped04]) or a
combination of magnets and patient couch motion (Gantry 1). The beam is thereby switched
off between different beam positions in the order of milli seconds.
Raster scanning on the other hand works in a continuous irradiation mode for one IES. A pencil
beam is extracted from the synchrotron with a fixed energy and thus range, corresponding to a
IES of the volume. By overlaying many different energies a SOBP is created to cover the longitu-
dinal extension of the tumor (see figure 1.9b). The raster points within each IES are irradiated
by deflecting the pencil beam via two orthogonal dipol magnets on an optimized path (see figure
1.8). When the pre-defined intensity of the raster point has been reached, the beam is moved
to the next position. In order to establish a homogeneous dose coverage in the target volume
the spacing, both in raster point position as well as IES distance, can be utilized. Robustness
in longitudinal direction can be achieved with overlap of the individual IES slices. Nevertheless
the number of IES slices should be kept small in order to guarantee a short treatment time.
Hence a broadening of the Bragg Peak position is carried out with a so-called ripple filter (see
figure 1.9b). It was found that a spacing of 3 mm between IESs yields a robust result [Web99].
Furthermore the lateral overlap of the pencil beams needs to be chosen in such a way that the
possibility of minor fluctuation in beam quality and position is compensated for. As the lateral
beam profile is assumed to be Gaussian shaped and symmetric it was found that the full width
half maximum (FWHM) of the beam is optimally chosen to be three times the raster spacing
(see figure 1.9a) [Hab93].
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Figure 1.8.: Principle of the raster scanning technique at GSI. The target volume is divided into
IES, which is again subdivided into a regular grid. By varying the particle energy from
the accelerator and by deflecting the pencil beam via a magnetic scanning system
the raster points are scanned. Figure taken from [Inf05].
Figure 1.9.: Target dose homogeneity is achieved by sufficient overlap in lateral and longitudinal
directio. a) In lateral direction the FWHM of the pencil beam is adjusted to three
times the raster spacing ∆s. b) In longitudinal direction the Bragg peaks are broad-
end in depth by using a ripple filter and then stacked in depth to a SOBP. An IES
spacing∆z of typically 3 mm is chosen. Figure taken from [Ric12].
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GSI pilot project
Between 1997 and 2008 440 patients were treated with scanned carbon ions at GSI. Mostly
head and neck tumors were irradiated. The typical fractionation scheme was 20 fractions within
three weeks [Schu07]. An example of a resulting dose distribution with scanned carbon ions
in comparison to IMRT can be seen in figure 1.10. The treatment outcome for skull-based
chordomas can be seen in figure 1.11. In a later stage, also prostate and spinal cord tumors
were treated.
Figure 1.10.: Comparison of dose distributions results with IMRT (left side) and scanned carbon
ions (right side). The dose to the normal tissue and especially organs at risk like
the brainstem are drastically reduced for scanned carbon ions. Figure taken from
[Gro04]
Figure 1.11.: Treatment outcome for the irradiation of skull-based chordomas for photons
(green area), protons (blue area) and carbon ions (pink area). An improved effect
after the irradiation of chordomas can be seen when doses exceeding 70 Cobalt
Gray Equivalent (CGE) can be applied. For carbon ions a higher dose can be de-
posited in the target since the dose in the nearby OARs can be reduced. Figure
taken from [Schu07].
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The pilot project at GSI was carried out in a collaboration between GSI, the Heidelberg Uni-
versity hospital, the German cancer research center (DKFZ) and the research center Dresden-
Rossendorf. Following the success in treatment outcome [Loe13] the Heidelberg Ion-Beam
Therapy Center (HIT) was build, where patients are treated with scanned carbon ion beams
and protons on a regular basis since 2009 [Com10]. Furthermore CNAO (centro nazionale di
adroterapia oncologica, Pavia, Italy) [Ama04] started treating patients with scanned carbon ions
beams in 2012 [PTCOG13]. In total roughly 10,000 patients have been treated with carbon ions
up to the beginning of 2013 [Loe13], whereof about 2,000 patients were treated with scanned
carbon ions [PTCOG13].
1.2.3 Treatment planning
Treatment planning is the optimization process in which the needed machine delivery parame-
ters are determined for a chosen beam configuration in order to yield the prescribed dose to the
target volume, while minimising the dose to the normal tissue, ecspecially to the OARs [Ric12].
In modern radiotherapy treatment planning is based on CT scans, which represent photon at-
tenuation through different tissue types (Hounsfield units - HU) and can hence be converted to
water-equivalent depths. On the patient image data the target and OARs are contured and the
needed dose and dose constraints, respectively, are determined. For cancer radiotherapy the de-
lineation of the tumor includes certain safety margins, defined by the International Commission
on Radiation units and Measurements (ICRU). As some of these margins will be also used in the
context of cardiac targets, they will be shortly introduced here.
GTV (Gross Tumor Volume): "The GTV is the gross palpable or visible/demonstrable
extent and location of the malignant growth." [ICRU93a]
CTV (Clinical Target Volume): "The CTV is a tissue volume that contains a GTV and/or
subclinical microscopic malignant disease, which has to be eliminated. This volume thus
has to be treated adequately in order to achieve the aim of therapy: cure or palliation."
[ICRU93a]
PTV (Planning Target Volume): "The PTV is a geometrical concept, and it is defined to
select and appropiate beam size and beam arrangements, taking into consideration the net
effect of all the possible geometrical variations, in order to ensure that the prescribed dose
is actually absorbed in the CTV." [ICRU93a]
IM (Internal Margin): "The IM, commonly asymmetric around the CTV, is intended to
compensate for all movements and all variations in site, size and shape of the organs and
tissues contained or adjacent to the CTV. They may result e.g. from respiration, different
fillings of the bladder, different fillings of the rectum, swallowing, heart beat, movements
of the bowel" [ICRU99]
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Based on this definition, the ITV (Internal Target Volume) is commonly used for the volume
in which the IM encompasses the CTV (see figure 1.12).
Figure 1.12.: Treatment planning volumes as defined by the ICRU. Figure taken from [Ric12]
As a result of treatment planning the ICRU recommends that 100 % of the PTV should re-
ceive at least 95 % and not more than 107 % of the prescribed dose [ICRU93a]. In order to
study if this recommendations are met, dose-volume-histograms (DVH) are computed in the
treatment planning study process and the values V95 and V107 (the volume which receives
95 % and 107 % of the dose, respectively) determined. Furthermore D5 and D95, which
denotes the dose covering 5 % and 95 % of the volume, are extracted. The difference be-
tween these two values (D5-D95) is a measure for the dose fall off and should be, ideally,
close to zero. In general, the dose constraints of the OAR depends on the organ as well as frac-
tionation scheme and radiation type and needs to be carefully examined in each individual case.
The treatment planning system and its result, the dose optimization, depends on the radiation
type and on the used beam delivery technique. For scanned carbon ion beams the optimization
task with the in-house treatment planning software TRiP98 [Krae00] [Krae00b] needs to deter-
mine the required energies of the IESs and the pencil beam positions as well as corresponding
particle numbers for each raster point. This leads to an ’inverse’ optimization process, in which
the particle fluence to the target volume, which is given in the form of planar polygon originat-
ing from manual delineation on the axial CT slices [Ric13], is determined from the prescribed
dose distribution [Kra00]. Furthermore, as the irradiation of the most distal IES deposits a
certain dose in the more proximal slices only the distal slice receives a homogeneous fluence
distribution while all other slices require irregular dose patterns (see figure 1.13). Using the
physical and biological beam models (LEM, see RBE in section 1.1.3) the dose contributions
from all raster points to each individual target voxel are calculated [Krae10].
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Figure 1.13.: Particle fluence distribution depending on the IES, starting with the most distal one
(left) and moving to more proximal regions. Figure taken from [Krae00].
1.2.4 Organ motion in radiotherapy
Many target sites are influenced by temporal changes. Depending on the underlying mecha-
nism, one distinguishes patient positioning related organ motion and organ motion in-between
treatment fractions (interfractional motion) or during a treatment application (intrafractional
motion). The different organ motion types will be specified in this section. Furthermore motion
acquisition strategies as well as techniques to overcome the motion influence, so called mo-
tion mitigation techniques, will be presented. Finally an overview over the treatment planning
workflow including motion (four dimensional - 4D) will be given.
Motion types
An overview of the different organ motion types is given by Langen and Jones [Lan01]. Three
main categories can be determined: patient positioning related motion, interfractional motion
and intrafractional motion. Examples of these different motion types can be seen in figure 1.14.
It should be noted that all motion types can occur in a patient. Thus when dealing with in-
trafractional motion, interfractional motion as well as patient positioning needs to be accounted
for.
Patient positioning can cause changes in tumor shape as well as uncertainties in the tumor
position. A difference in positioning between image acquisition (e.g. CT) and treatment deliv-
ery may introduce systematic displacements and hence threaten the outcome of the treatment.
Patient fixation systems and dedicated protocols are applied to overcome this motion influence.
Stereotactic fixation with e.g. masks are used on a daily basis. The other two motion types
however are purely internal and are distinguished according to the time scale they occur on.
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Interfractional motion occurs within hours and days, hence between two treatment sessions
(if multiple fractions are applied). Anatomical changes caused by interfractional motion are
manifold. Prostate cancer patients are often subject to position changes due to varying gut and
bladder fillings [Fok04]. For lung cancer patients, changes in the breathing pattern are trouble-
some. Sonke et al. [Son08] reported that even though the respiratory motion trajectory is often
reproducible, the baseline of the tumor motion can vary significantly. Cancer patients in general
are also subject to tumor shrinkage [Mor09] in the course of the treatment. In order to mitigate
interfractional motion, repeated imaging needs to be carried out.
Intrafractional motion occurs on a time scale of seconds to minutes. The main reason for
intrafractional motion are respiration and heartbeat. Even though the exact motion patterns
vary from patient to patient, it can be stated that breathing is a quite regular and slow process,
with a rather big amplitude. Heartbeat on the other hand has a smaller amplitude compared to
respiration, but is a high frequency motion with 60 to 80 heartbeats per minute compared to
10 to 20 respiration cycles in the same time. These two motions superimpose and the influence
of both will be studied in the framework of this work when targeting sites in the heart. Dif-
ferent motion mitigation techniques for intrafractional motion will be presented in a seperate
subsection.
Figure 1.14.: Examples of the three major motion categories. On the left side (a) a lung tu-
mor is displayed, which moves due to the respiration of the patient (intrafractional
motion). Interfractional position changes are examplary shown in the middle (b),
where two CT scans of a prostate patient are compared. Density variations be-
tween two CT scans are shown in (c). Figure taken from [Eng11].
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Motion acquisition
For a successful irradiation of the moving target, the intrafractional motion of the target site
must be known during the treatment process. This is for example achieved by time resolved
computed tomography scans (4DCTs) and the potential usage of online motion measurement.
For the acquisition of 4DCT scans the motion signal is recorded during the imaging. The motion
cycle is then divided into N quasi-stationary sections (so-called motion phases (MP)). In every
MP a full regular CT scan is reconstructed. In order to achieve this, data is recorded in every
slice for a whole motion cycle. By correlating the data gained from the motion signal with the
recorded CT information, the scans are afterwards rearranged according to their affiliation to a
certain MP. For more information on 4DCTs the reader is refered to e.g. [Rie05].
A review of the different motion detection techniques can be found at [Eva08]. One distin-
guishes between direct measurement techniques and surrogate signals. Examples for direct
measurements are ultrasound and fluoroscopy. In fluoroscopy, the patient is irradiated with
X-rays and the absorption pattern is displayed on a fluorescent screen, hence limiting the ac-
quisition time of this method by the deposited dose. The monitoring time in ultrasound is
not limited since no ionizing radiation is needed and hence a real time imaging is feasible
[Pra12]. Nevertheless influence of air limits the resolution and thus raises difficulties when
being applied in the thorax region of the patient. Surrogate signals detect variables which are
directly related to the source of organ motion. Examples of these kind of techniques for respi-
ration are methods which correlate the movement of the torso to the phase in the respiration
cycle. One possibility is to monitor the height of the patient surface with camera systems or
laser displacement sensors or additionally using infrared markers attached to the patient’s body
[Tad98, Ber05, Schw04, Ser13]. Alternatively the volume of the torso can be measured by us-
ing a belt-like strain gauge [Li06]. Other approaches measure e.g. the airflow of the patient
[Kub96, Hanl99].
Combinations between direct measurement techniques and surrogate signal acquisition exist
and are e.g. used in the Cyberknife system. Their Synchrony system (see also 1.3.4) combines
fluoroscopy (direct) with an infrared camera system (surrogate). This offers the advantage of
a drastically reduced fluoroscopy acquisition time as it is only used to check and update the
surrogate system [Sha10].
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Motion mitigation techniques for intrafractional motion
In particle beam scanning the beam delivery interferes with the intrafractional target motion,
causing local over and under dosages in the target volume, an effect known as interplay
[Phi92, Ber08, Ber12, Loe13]. The resulting interplay pattern is dependent on many differ-
ent factors, like the beam direction, the scanning speed, the motion amplitude and starting
phase etc. Thus techniques which mitigate the influence of the underlying target motion have
to be applied. The three main techniques (rescanning, gating and tracking) will be explained in
more detail.
Rescanning, also known as repainting, is a specific approach for beam scanning and based
on statistical averaging of different interplay patterns [Phi92, Rie10]. Scanning the target N
times with a reduced dose of 1/N results in a Gaussian distributed dose around the theoretically
intended one (see figure 1.15). As the variance of the distribution is proportional to 1/
p
N the
result will be better the more rescans are used. The technical realisation of rescanning is easier
than for e.g. gating and beam tracking, especially as it does not require real-time motion moni-
toring, and results in a homogeneous dose to the inner region of the target when using enough
rescans N . Anyhow it can lead to an increased dose deposition to the surrounding, normal tis-
sue and to under dosages in the outer part of the target volume. So far rescanning has not been
used in patient treatments, but certain centers (e.g. NIRS [Fur07]) and PSI [Zen10]) plan to in
the near future.
Figure 1.15.: Principle of rescanning in film irradiations. Averaging multiple interplay patterns
leads to a homogeneous dose in the target area (solid red square). Figure taken
from [Ber09b].
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Gating is the interrupted irradiation of the target during a selected part of the motion cycle,
the gating window [Kub96, Min00, Li06] (see figure 1.16). Typically a gating window around
the most reproducible motion states are chosen, which show a comparably small motion (e.g.
end exhale in case of respiration). This technique is also used for passive beam delivery, as
it reduces the size of ITV margins. Inside the gating window a small motion, the so-called
residual motion, remains. In case of beam scanning this can result in small interplay effects.
Different approaches are studied to overcome this drawback [Fur07, Zen10, Ber09]. Gating
requires online motion monitoring and prolongs the treatment time. For centers with passive
beam delivery gating has already been successfully used [Min00, Iwa10, Has06].
Figure 1.16.: Principle of gating. Line (a) is the respiratory signal. At end exhale the gradient
of the respiration is flat, enabling an irradiation without large effects of the target
motion. The beam (c) is thus only applied during this time. The gating window
is activated as soon as the respiratory motion crosses line (b). Figure taken from
[Min00].
Beam tracking of organ motion requires the adaptation of the beam position to the target
motion in real time. It was originally proposed for IMPT [Kea01] and ideally requires no ad-
ditional margins, nor prolongs the treatment time. Prerequisite of this method is a fast beam
delivery system. Tracking is clinically used in the Cyberknife Synchrony system (see section
1.3.4). In comparison to photon irradiation, tracking with particles needs a careful considera-
tion and adaptation of longitudinal changes due to the Bragg Peak characteristic of ions. The
implemented tracking system at GSI [Gro04] uses fast deflecting dipole magnets, which are
also used in beam scanning for the lateral adaptation of the beam. The longitudinal changes
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are accounted for by two polymethyl methacrylate (PMMA) wedges, which are mounted on a
fast, linear stepmotor close to the target (see figure 1.17) [Sai09]. By changing the relative
distance between the wedges, the beam penetrates PMMA with different thicknesses, thereby
changing its energy and hence range. Even though the high precision of the system has been
proven [Ber07, Ber10, Sai09] a clinical use is not feasible yet due to the lack of fast and precise
real-time internal motion monitoring that includes partical range information.
Figure 1.17.: Principle of tracking at GSI. The lateral deflection is achieved via dipole scanner
magnets. For the longitudinal adaptation two PMMA wedges are mounted on
step motors, enabling to change the depth the particle beam has to traverse. Figure
taken from [Gro04].
Besides these major motion mitigation techniques, different combinations are currently stud-
ied. A combination between rescanning and gating is e.g. studied by Furukawa et al. [Fur07]
and Seco et al. [Sec09] and a combination of rescanning at tracking by van de Water et al.
[Wat09].
As breathing is the main reason for intrafractional motion in most radiotherapy applications,
many different other techniques have been investigated to directly mitigate the influence of
respiration. An example is abdominal pressure, which has been used in lung and liver can-
cer patients in treatments with photons [Neg01, Hof03] and recently also for scanned carbon
ions at HIT (treatment of hepatocellular cancer [Com11]). Jet ventilation [Hof03] and ap-
neic oxygenation [RPTC12] are also used to partially or completely suppress respiration of the
patient.
4D Treatment planning at GSI
In order to account for intrafractional organ motion, time-resolved (4D) treatment planning is
needed. The underlying data as well as the techniques for 4D treatment planning will be pre-
sented for the special case of scanned carbon ion beams at GSI.
As in the static case, treatment planning for ions is based on CT scans. In the special case
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of 4D treatment planning, these CT scans are time resolved (4DCTs, see section 1.2.4, Motion
acquisition). In order to use the information stored in the 4DCT, an image registration needs to
be performed. With this a voxel-to-voxel mapping between the reference phase of the 4DCT and
all other motion phases is gained, hence yielding a spatial correlation between the individual
CT phases. Usually, rigid and deformable registration methods are distinguished. While rigid
registration only contains linear transformation of the original object in all three room dimen-
sions, deformable registration also accounts for compression. Brock et al. [Bro10] published a
multi-institutional study where the accuracy of some of the available registration algorithms is
presented. It can be stated that registration accuracy of most algorithms is in the order of mil-
limeters, hence in the order of a CT voxel size, but is dependent on the image contrast (resulting
in less accurate results when the contrast is diminished).
Figure 1.18.: End-exhale, 4D reference phase of a lung cancer patient with overlying deforma-
tion field to end-inhale in a) axial, b) coronal and c) sagittal view. Figure taken from
[Ric12].
4D treatment planning at GSI is carried out with the in-house software TRiP4D. It was
mainly developed by Daniel Richter [Ric13] and is based on TRiP98 as well as a predecessor
program developed by Bert and Rietzel [Ber07b] together with the biological implementation
under influence of target motion by Gemmel et al. [Gem11]. TRiP98 was developed for static
target regions and was successfully applied in the GSI pilot project [Krae10, Krae00, Krae00b].
It is a command-line-based software without graphical interface which runs on an IBM AIX op-
erating system and is written in C programming, using a pseudo object-oriented structure. For a
detailed description of TRiP4D functionalities as well as of the software design and experimen-
tal verification the reader shall be referred to [Ric13]. However, a short overview of some of the
most important functionalities will be given here.
The 4DCT structure was implemented as a sequence of 3DCTs with a distinguished reference
CT on which the dose optimization process is carried out. Thus the existing 3D functionalities,
like the computation of water-equivalent path lengths, could be reused. Individual phases of
the 4DCT are indexed by their position in the motion cycle. TRiP4D does not include native im-
age registration functionalities but rather integrates and processes image registration output,
obtained e.g. with the open source software package Plastimatch [Sharp07]. The resulting de-
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formation maps need to be obtained in two directions (reference-moving and moving-reference)
as certain steps of the treatment planning like contour propagation require the inverse deforma-
tion maps. Contours segmentation, of target volumes as well as organs at risk, is stored as a
volume dataset model, based on the 3D segmentation module of TRiP98 with planar polygons
on axial CT slices. Based on this 4D segmentation functionality ITVs (see section 1.2.3) can
be created, which are needed for certain motion mitigation techniques like e.g. rescanning. In
general, the 4D treatment plan generation and dose optimization is very dependent on the
employed motion mitigation technique. For the ITV concept [Gra12], and hence in motion miti-
gation techniques where the dosimetric effects caused by interplay are compensated but not the
target motion itself, dose optimization is carried out on the 4DCT reference phase [Ric13]. For
beam tracking on the other hand additional optimization is carried out, as motion compensation
vectors have to be computed. Furthermore 4D optimization techniques (which include the tar-
get motion for optimization by using the full 4DCT dataset, the vectors from image registration
as well as 4DVOIs for dose optimization [Gra13, Ele12]) can be developed and applied with
TRiP4D. Based on the predecessor program of Bert and Rietzel the treatment plan is then split
into quasi-static sub-plans where the raster points and the corresponding intensities are divided
according to the motion phase they shall be irradiated in. For the overall 4D dose calculation
in TRiP4D, the sub-plans are then collected over all motion states for each dose voxel. Thereby
the voxel position is transformed according to the deformation maps and by accounting for the
radiological density distribution of the respective phase of the 4DCT. The total physical dose
results as a summation of the dose distribution from all motion states in the reference state (see
figure 1.19). For the biological dose calculation the particle and energy spectra are also accu-
mulated over all motion states and used as input for the local effect model (LEM) to calculate
the RBE [Scho94, Scho96, Gru12]. TRiP4D was extensively tested and verified in numerous
experiments [Ric12, Ric13].
Figure 1.19.: Resulting film response in experimental validation of 4D dose calculation with
TRiP4D. Images a)-e) show the individual dose deposition in each of the five motion
states. In f) the total dose deposition in 4D is displayed. On the stationary film in
g) a homogeneous dose is deposited in 3D. Figure taken from [Ric12]
39
1.3 Atrial fibrillation
Atrial fibrillation (AF) is the most common cardiac arrhythmia. It occurs in ∼ 2 % of the popu-
lation in Europe and the US [ESC10]. The lifetime risk of developing AF is ∼ 25 % for people
over forty. Since age is an important risk factor for this cardiac arrhythmia the prevalence is
estimated to double in the next fifty years due to ageing of society (see figure 1.20).
Figure 1.20.: Trend of AF incidences. The black curve indicates the projected number of patients
assuming no further increase in age-adjusted AF incidences. The green curve repre-
sents the trend assuming a continuous increase in incident rates as evident in 1980
to 2000. Figure taken from [Miy06].
Even though in itself not life threatening, AF alters the quality of life and increases the risk of
the patients to suffer a stroke. It is estimated that the stroke risk in AF patients is 5-fold higher
[Ben98, Wol91]. AF often remains undiagnosed (silent AF). It is stated that one out of five acute
strokes is attributed to AF [ESC10]. Other late effects and related events include cognitive dys-
functions like vascular dementia and impairment of left ventricular function. In general death
rates are stated to approximately double by AF [ESC10], leading to a ten year survival rate of
25 % compared to 46 % in patients with a normal sinus rhythm (age ranged from 14 to 73 years
with a median of 42 years) [Oles62, ACC06].
In the following the normal signal propagation through the heart’s conduction system will
be explained in order to contrast the occurring differences in AF. Possible causes for AF and
underlying risk factors as well as current treatment modalities will be presented.
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1.3.1 Heart’s conduction system
The conduction system of the heart controls the generation and propagation of electrical sig-
nals, so called action potentials, that cause the heart muscle to contract and hence to pump
blood [Med]. The small electrical activity of the action potentials is measurable at the surface
of the body, enabling a graphical record with an electronic recording instrument, the Electrocar-
diograph (ECG). In the following the events during a single heart beat and the corresponding
detection in an ECG (see fig. 1.22) will be explained. The action potentials can originate spon-
taneously in any of the specialized cardiac muscle cells which form the conduction system. In
a healthy heart each beat begins in the right atrium with an action potential from the sinoatrial
(SA) node (see fig. 1.21), making it the natural pacemaker of the heart. The signal then spreads
across both atrial chambers causing the muscle cells to contract (atrial systole) which is repre-
sented as the P-wave in an ECG. It is followed by a period of conduction (PR-segment in ECG) in
which the signal enters the ventricles via the atrioventricular (AV) node. As the signal spreads
the ventricles contract very rapidly (ventricular systole), which is displayed in the QRS-complex
in an ECG. Atrial activity is hidden in the ECG by the QRS complex. As the signal passes out
of the ventricles, the ventricular walls start to relax (ventricular diastole). The T-wave marks
this ventricular repolarization. The sequence of these events and the corresponding ECG traces
repeat with every single heartbeat.
Figure 1.21.: Scheme of the conduction system of the heart. Figure taken from [amc].
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Figure 1.22.: ECG trace of a normal heartbeat. Figure taken from [afib].
In AF there is unorganized atrial activity, leading to quivering motion and hence the atria are
not able to sustain a healthy pumping rhythm. An exemplary ECG trace for AF can be seen in
figure 1.23. Possible reasons and triggers for this abnormal action potential propagation are
stated in the section 1.3.3.
(a) normal sinus rhythm
(b) AF patient
Figure 1.23.: ECG traces for a normal sinus rhythm (a) and for an AF patient (b). In AF, the
tracing shows small, irregular fibrillation waved between heartbeats. The rhythm
is irregular and erractic. Figure taken from [afib].
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1.3.2 Types of atrial fibrillation
Based on the duration and presentation of the condition different types of AF are clinically dis-
tinguished [ESC10, CE09] (paroxysmal, persistent, long-standing and permanent) (see figure
1.24). Furthermore silent AF may present itself as any form of the stated AF types. As the name
indicates, the condition is asymptomatic and hence undiagnosed. It usually manifests as an AF
related complication like an ischemic stroke. About one third of people with AF are estimated
to be unaware of their condition [ESC10].
Usually AF progresses over time. Starting as short and rare episodes the condition develops
into longer and more frequent attacks [ESC10]. In figure 1.25 the typical time course of AF
is indicated. In the lower part of the diagram different periods of AF are shown (dark blue
boxes). Possible treatment possibilities at the different stages of AF are shown in the upper bars.
Medication uptake which should prevent the formation of blood clots are represented by light
blue boxes. These medications are recommended in the majority of AF patients. The red boxes
indicate system relief therapies while the grey boxes represent rate control measures.
Figure 1.24.: Different types of AF. Figure taken
from [ESC10].
Figure 1.25.: Typical time course of AF and po-
tential treatment possibilities. Figure
taken from [ESC10].
43
1.3.3 Possible causes for atrial fibrillation and risk factors
The mechanisms of AF are not yet fully understood. The multifactorial mechanisms may influ-
ence and sustain each other. Current research indicates that one can distinguish between focal
mechanisms and multiple wavelets [CE09]. For most patients with paroxysmal AF a localized,
focal trigger can be identified. This is not the case in patients with persistent or permanent AF,
where the multiple wavelet hypothesis is believed to be more accurate.
An identified focal trigger site are the pulmonary veins (PVs). In their benchmark paper Haïs-
sagurre et al. [Hai98] studied 45 patients with frequent episodes of AF ( (344 ± 326) minutes
episodes per 24 hours) finding ectopic beats1 originating from the pulmonary veins in 94 % of
the cases. The underlying mechanism why PVs become arrhythmogenic in some patients while
it remains dormant in others is still not clear [CE09]. The reason why PVs can become arrhyth-
mogenic at all is based on stages during the embryonic development, in which the common PV
is incorporated into the left atrium. Immunohistochemical studies have shown that the compo-
sition of the PV and the smooth-walled portion of the left atrium are identical (see figure 1.26)
[CE09, Doug06].
Figure 1.26.: Schematic depiction of outer side of atrial chambers with pulmonary veins (PV),
left atrial appendage (LAA), left atrial body (LAB), right atrial body (RAB), supe-
rior vena cava (SCV) and inferior vena cava (IVC). LAB and RAB are covered by
myocardium (heart muscle tissue) with smooth-walled inner aspect (blue), which
stretches out over extra cardiac segments of PV (blue area above and below dot-
ted line). In A the structures are illustrated from the outside, while B shows the
tissue types from the inside of the atria. Figure taken from [Doug06].
Furthermore, according to the multiple wavelet hypothesis AF is sustained by the continuous
propagation of several independent wavelets [CE09]. These wavelets are propagating through
the muscles of the atria in a chaotic manner. Interference effects between various wavelets lead
to amplification or cancellation. As long as the number of wave fronts does not decline a certain
threshold level AF is sustained.
1 beats which arise from cells outside the region in the heart muscle ordinarily responsible for impulse formation
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Certain risk factors and indicators for AF can be found in the AF patient group [CE09]. Ageing
generally increases the risk of developing AF. The reason might be due to age dependent loss of
atrial myocardium and the associated conduction disturbances. Hypertension is also an age de-
pendent factor which is a risk factor for the incidence of AF as well as AF-related complications
such as stroke and systematic thromboembolism. Thyroid dysfunction can be the sole cause
of AF and may induce AF related complications. 25 % of AF patients are obese [Nab09] and
20 % suffer of diabetes mellitus requiring medication. Chronic obstructive pulmonary disease
(COPD) is found in (10 - 15) % of AF patients. Nevertheless it is possibly more a marker of
general cardiovascular risk then an indicator for AF. Chronic renal disease is present in (10 -
15) % of AF patients and it is suggested that renal failure may increase the risk of AF related
complications [CE09]. Independent of the stated risk factors AF has also a genetic component,
especially considering an early onset of AF. In a study carried out by Fox et al. [Fox09] with
2243 offspring participants it was stated that the risk of developing AF compared to no parental
AF was significantly increased (multivariable-adjusted odds ratio of 1.85, 95 % confidence in-
terval). The results were even stronger when age was limited to an age younger than 75 in
parents as well as their offspring (multivariable-adjusted odds ratio of 3.23, 95 % confidence
interval).
1.3.4 Treatment modalities
The treatment modalities for AF have two main goals: to reset the rhythm or to control the ven-
tricular rate and to prevent the formation of blood clots [Mayo, CE09]. The treatment strategy
chosen for each individual patient depends on the type of AF and on careful consideration of pa-
tient individual factors, including the severity of symptoms and potential further heart problems.
Resetting the heart rhythm is the ideal treatment outcome and is carried out by cardioversion,
either based on medication (anti-arrhythmic drugs) or electrically. In an electrical cardioversion
an electrical shock is delivered to the heart, giving the conduction system of the heart the possi-
bility to restore its normal activity. Commonly used anti-arrhythmic drugs are e.g. Amiodarone.
These drugs have severe side effects and can act proarrhythmic, causing also life-threatening
ventricular arrhythmias [Mayo].
If AF can not be converted to a normal heart rhythm through the above stated methods, the
ventricular rate needs to be reduced instead. Heart rate control can be achieved either by the
usage of different medication (e.g. Lanoxib) or by AV node ablation. This procedure requires
simultaneously the implementation of a pacemaker to establish a heartbeat. As the atria are
still fibrillating, further medication with anti-arrhythmic medication as well as anticoagulants is
required.
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For paroxysmal or persistent AF further treatment modalities are needed. They include the
Maze procedure or radiofrequency catheter ablation.
In the Maze procedure scar tissue in the atria is created, inhibiting the propagation of ab-
normal action potentials. Similar to a maze, only a single pathway from the the SA node to the
AV node remains accessible for electrical impulses [CTS13]. Besides an open chest surgery, the
Maze procedure can also be carried out as minimal-invasive procedure or as cryotherapy. The
success rates as well as complications of Maze versus catheter ablation will be described in the
next section.
In catheter ablation the main strategy is anatomic based, which means that it is assumed that
AF is triggered and sustained by the same anatomical sites (the PVs [Hai98]) in the majority of
AF patients [CE09]. In radiofrequency ablation a flexible catheter is inserted into the patient
through a vein close to the groin of the patient and threaded into the heart. An electrode on the
tip of the catheter sends out radiofrequency waves, creating energy and thus heat. This is used
to create a scar close to the junction between the pulmonary veins and the atria (see figure 1.27).
Figure 1.27.: Example of circumferential PV ablation. The ablation sites are indicated by the red
dots. LI PV: Left inferior pulmonary veins, LS PV: left superior pulmonary veins, RI
PV: right inferior pulmonary veins, RS PV: right superior pulmonary veins. Figure
adapted from [Ora06].
Various ablation techniques exist, including the PV isolation by segmental ostial ablation,
circumferential PV ablation (see fig. 1.27), wide-area circumferential ablation and antral PV
isolation [Ora06, Ora03, Ouy04]. Antral PV isolation and wide-area circumferential ablation
was shown to be effective for both patients with paroxysmal and persistent AF [CE09, Ora03].
In a randomized study circumferential PV ablation was found to result in a sinus rhythm in 74 %
of patients with chronic AF [Ora06].
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The goal of PV ablation is to induce a complete electrical isolation of the PVs. This is verified
by entrance and exit block during pacing at multiple sites within the PVs [CE09]. Freedom from
recurrent AF can be predicted by termination and noninducibility of AF during catheter ablation
[Ora02, Ora06, Hai05, Hai04, Ora04]. Termination of AF indicates elimination of all triggers
and drivers of AF while noninducibility indicates the absence of residual trggers and drivers that
may initiate and perpetuate AF [CE09]. Termination is hence not a reliable predictor in patients
with paroxysmal AF while noninducibility is likely to predict that the patients are going to stay
in sinus rhythm (see figure 1.28).
Figure 1.28.: Graph showing freedom from AF reocurrence when patients had or had not in-
ducible AF after circumferential PV isolation. Figure adapted from [Ora04].
Independent of the used procedure, anticoagulants like Warfarin are used in a diversity of
patients. In order to establish international criteria for risk patients who should uptake anti-
coagulants, the CHADS2-VASc score was defined [ESC12] (Congestive heart failure: 1 point,
Hypertension: 1 point, Age (≥ 75): 2 points, Diabetes mellitus: 1 point, Stroke: 2 points,
Vascular disease: 1 point, Age (65-74): 1 point, Sex (female): 1 point). Patients who obtain
at least 2 point in the CHADS2-VASc score are prescribed anticoagulants. Patients with 1 point
might be prescribed anticoagulants, alternatively aspirin can be used. Patients with a score of 0
are supposed to only take aspirin [Fle]. The CHADS2-VASc score has been validated in multiple
studies [Lip11, Pot12, Ole12, Van11, Fri12, Ole11, Bor11].
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Catheter ablation for the treatment of AF: success rate and complications
The FAST trial compared the outcome of catheter ablation and surgical ablation in a randomized
study with a small patient population of 127 patients. 63 patients were treated with catheter
ablation, 64 with the invasive surgical ablation. The complication rate in catheter ablation was
significantly lower (15.9 % complication rate in catheter ablation versus 34.4 % in surgical ab-
lation) but at the same time the success rate in treatment outcome was reduced (36.5 % for
catheter ablation versus 65.6 % for surgical ablation after 12 months) [Boe12].
In two nationwide surveys the success rates of catheter ablation as a treatment for AF and
the resulting complications were studied [Cap05, Cap10]. The first worldwide multicenter sur-
vey was published in 2005 using data obtained from 181 centers in-between 1995 and 2002.
From these centers 90 stated to have performed 12,830 catheter ablation procedures on 8,745
AF patients. It was stated that 52 % of AF patients undergoing ablation were symptom free
without the need of further antiarrhythmic medication and 23.9 % of patients with the need of
antiarrhythmic drugs. These success rates were achieved with the requirement of a a second (in
24.3 % of patients) or even third (in 3.1 % of patients) procedure [Cap05]. Major complication
rates were reported in 6 % of patients. These complications included 4 early deaths (due to
massive cerebral thromboembolism in two patients, extrapericardial PV perforation in one pa-
tient and unknown reasons in one patient), strokes (in 20 patients), transient ischemic attacks2
(in 47 patients) and episodes of tamponade3 (in 107 patients). In a second survey which was
performed in-between 2003 and 2006 [Cap10] and included 85 catheter ablation performing
centers (16,309 patients), an improvement in treatment outcome was shown. The rate for a
successful treatment outcome without the need of further antiarrhythmic medication increased
to 70 % while the rate with the need of further antiarrhythmic medication decreased to 10 %,
resulting in an overall success rate of 80 % compared to 75.5 % in the first survey. Concerning
the number of needed procedures it was stated that 37.1 % single treatments were performed,
59.8 % dual treatments and 4.1 % triple treatments.
Recent studies furthermore show that catheter ablation procedures in AF patients are asso-
ciated with a substantial risk of developing silent cerebral embolism [Her13, Gai10, Marti13,
Med13, Schr10, Lic06]. Silent cerebral embolism can cause cognitive impairment [Kne08]. A
study by Medi et al. [Med13], which investigated the post-operative neurocognitive dysfunc-
tion in 150 patients undergoing ablation before and after the treatment, stated a 13 % - 20 %
incidence increase at long-term follow up of 3 months compared to a control group.
2 "mini-stroke"; stroke-like symptoms due to loss of blood flow, no permanent damage
3 fluid collects between the heart muscle and the pericardium, which is the sac containing the heart
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Besides these major complications general disadvantages in the treatment modality of catheter
ablation can be concluded. Procedures are tedious and can take up to five hours [Jong05]. As
fluoroscopy is still the mainstay of catheter imaging in most laboratories the patients are further-
more exposed to relatively high X-ray dose [Ber10]. From an socio-economical point of view,
catheter ablation causes high costs. A total of 13.5 billion Euro are spent on AF patients each
year in the EU [Fus06].
It can be concluded that catheter ablation offers only a limited treatment success rate while
major complications and even death due to the procedure may occur. Alternative treatment
modalities are warranted. Catheter-free ablation using carbon ions could have the potential
to accurately eliminate arrythmogenic sources at any given cardiac location. So far conducted
studies on the irradiation of cardiac target sites will be presented in the next section.
Heart irradiation and cardiac radiosurgery
Target sites in the heart have been irradiated in different procedures. Re-stenosis4 after angio-
plasty5 for example has been treated with vascular brachytherapy [Nat99, Cot05]. Thereby a
minimum dose of (8-16) Gy to a depth of 0.5 mm into the vessel wall was required, while a
maximum vessel dose did not exceed 32 Gy. Cardiac angiosarcoma, a very rare tumor type in
the heart with rare long-term survival of the patients, has been treated with carbon ions at the
Japanese facility NIRS [Aok04]. A total dose of 64 Gy was given in 16 fractions in a timeframe
of 4 weeks. Follow-up of one and a half year did not show severe side effects.
Similar to the techniques used in vascular brachytherapy, Pérez-Castellano et al. [Per06] studied
the possibility to use β-radiation as treatment modality for AF. They thereby used a phosphorus-
32 source wire centered within a balloon catheter in a study with ten mini swine. The delivered
dose was calculated to 60 Gy at a depth of 1 mm from the contacting PV wall, resulting in
observed PV fibrosis without PV stenosis or other side-effects.
In 2010 a study by Sharma et al. [Sha10] showed that they were able to successfully alter
the electrical pathway of the heart noninvasively by using stereotactic robotic radiosurgery. In
the CyberHeart system cardiac target sites in sixteen mini swine were irradiated under general
anesthesia. The procedure was as follows. Cardiac CT scans of the anesthetized and intu-
bated mini swine were acquired and an electroanatomic mapping6 was carried out before the
irradiation. The voltage was mapped to enable a comparison with the later, to be induced, elec-
4 reoccurrence of blood vessel narrowing
5 mechanical widening of narrowed blood vessel e.g. with a balloon catheter
6 CARTO system; Biosense-Webster. Three known magnetic sources are used to calculate the orientation and
position of the catheter tip in 3D, while at the same time the voltage values are determined [bw]
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trophysiological effect. Different target sites in the heart were chosen. The respiratory motion
was compensated by tracking with the CyberKnife Synchrony software, which correlates the
outside motion of radiopaque markers on the chest wall with the internal motion [Ozh08]. For
the cardiac motion an ITV approach was chosen. Target volumes were the cavotricuspid isthmus
(CTI) (nine mini swine), the AV node (two mini swine), the pulmonary vein - left atrial junction
(three mini swine) and the left atrial appendage (two mini swine). Dose ranges from 25 Gy to
80 Gy were applied (cavotricuspid isthmus: (25-80) Gy, AV node: (40-70) days, PV: (38-40) Gy
and left atrial appendage: (32-80) Gy). Post irradiation the mini swine were stored at a farm.
The follow-up time was dependent on the irradiated target in the mini swine (cavotricuspid isth-
mus: 25 to 89 days, AV node: 15 to 49 days, PV: 35 to 196 days and left atrial appendage: 16 to
33 days). In order to assess the irradiation outcome, the animals were again anesthetized and
electroanatomically mapped. Afterwards the mini swine were euthanized and targets (heart) as
well as organs at risk (lung, esophagus) were excised and fixed in formaldehyde. The results
of the irradiation can be summarized as follows: The irradiation of the cavotricuspid isthmus
evolved during the study, leading to changes in the method of targeting. While initially the
respiratory and cardiac motion were not compensated for, synchrony and cardiac ITV concepts
were later used. While all mini swine displayed a reduced conduction across the isthmus, only
two animals showed bidirectional block and hence feasibility at 30 days and 40 Gy. Targeting
the AV node, one animal had to be sacrificed due to pacemaker pocket infection. The other one
showed a complete AV block at 49 days, after being irradiated with 70 Gy. For the left atrial
appendage a decreased voltage was observed at 38 Gy after 33 days. For the left pulmonary vein
the feasibility was shown as the left atrium showed no local activation in all animals (present
from day 35 for all doses) (see figure 1.29).
Figure 1.29.: Electroanatomic voltage map of left atrium before (left side) and after (right side)
CyberHeart irradation of PVs. Prior treatment no decreased voltage can be ob-
served. Post treatment an area of low-amplitude action potential signals can be
seen. Figure from [Sha10].
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Sharma et al. stated that a dose of 25 Gy or larger was needed to see a change in the elec-
trophysiological properties in the animal model after 30 or more days. The dose needed for
myocardial fibrosis is also known from other former studies. Fajardo et al. [Faj70, Faj73] for
example studied radiation induced fibrosis in rabbit hearts. They observed myocardial fibro-
sis most often after 2 to 70 days when irradiating the rabbits with 20 Gy. Overall Sharma et
al. proved that stereotactic radiosurgery has the potential to become a noninvasive treatment
modality for e.g. atrial fibrillation.
A subsequent study carried out with the CyberHeart system [Mag11] only targeted the pul-
monary veins atrial junction. Two mini swine were irradiated with a single fraction treatment
of 25 Gy and 35 Gy and followed for 6 months. It was stated that both animals showed cir-
cumferential fibrosis, leading to an electrical isolation of the PVs, which was detected with
electroanatomic mapping. The mini swine irradiated with 35 Gy showed more extensive necro-
sis and vasculitis in intramyocardial vessels. It was stated that 25 Gy are sufficient to induce a
PV isolation with no major complications in the studied timespan.
In an animal study carried out by Blanck et al. [Bla13] 8 mini swine were irradiated with a
single fraction of seven fields with doses between 17.5 Gy and 35 Gy. A 5D ITV concept was
applied, hence applying internal margins to the upper right PV accounting for the respiratory
and heartbeat. Prior treatment electroanatomic mapping was carried out. The animals were
followed for 6 months. In this study it was stated that a reduction of the electrical signal proces-
sion with correlating local transmural fibrosis in the target region was observed at doses above
30 Gy. Nevertheless a complete block of the PVs could not be achieved. Stenosis in one branch
of the PV was observed for the highest applied dose.
All these studies were carried out with photon irradiation. Due to the physical and biological
properties of carbon ions (see section 1.1) an improved outcome is expected when treating these
deep seated target volumes as the critical organs can be better spared and a smaller volume of
the myocardium would be exposed to a lower radiation dose [Ber12]. The feasibility of this
treatment modalities with scanned carbon ions is the aim of the present work.
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influence of respiration in human data
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PVs move due to the heartbeat and respiration of the patient. Both motion types are indepen-
dent from each other and can hence be studied individually. While the influence of heartbeat is
analyzed in chapter 3, the effect of respiratory motion will be discussed in this chapter. 4DCTs
of nine lung cancer patients were recorded for cancer radiotherapy at MD Anderson Cancer
Center in Houston (MDACC, Texas, USA) where patients were treated with proton therapy and
IMRT. The same data has been used in previous studies on motion mitigation techniques using
carbon ion beams (e.g. [Lue12, Woe11]). The PV were contoured and the resulting motion pat-
tern, direction as well as motion amplitude of LPV and RPV due to respiration were studied for
all cases. Respiration is also a problematic factor for catheter ablation as it can cause changes
in catheter contact force and hence alter the result [Kum12]. For the proposed non-invasive
treatment modality with a scanned carbon ion beam the respiratory motion will endanger the
treatment outcome as it often leads to inhomogeneous dose coverage. Hence motion mitigation
techniques are needed. The resulting interplay pattern for all patients as well as gating as a
possible motion mitigation technique have been studied and the results will be presented in this
chapter. Exemplary for two patient cases rescanning inside the gating window was analyzed.
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2.1 Material and methods
Details on the input data as well as the used treatment planning parameters will be given.
Afterwards an overview on all studies will be presented and the analysis procedure will be
described.
2.1.1 Treatment planning input data
For treatment planning studies with the in-house treatment planning software TRiP4D [Ric13],
4DCT data sets, target and OAR contours as well as a deformable image registration for motion
assessment in-between the different motion phases are needed. Details on the used input data
as well as the used treatment planning parameters will be given.
In order to assess the motion of the PV due to respiration, lung cancer patient data was used.
The 4DCTs of nine patients were recorded and anonymized at MDACC. Each of the 4DCT data
consisted of ten motion phases, the reference phase was motion phase five at end exhale. The
amplitude of the respiratory motion was assessed by measuring the difference between the
(right) diaphragmatic dome in-between end exhale and end inhale on a frontal view of the
4DCT data. The amplitudes in the superior-inferior (SI) motion direction, the largest motion
component in case of respiration, ranged from 2.5 mm to 25 mm (CT slice distance and hence
resolution of 2.5 mm). The varying motion amplitudes are displayed for all patients in table 2.1.
Two of the nine patients (patient 6 and 7) displayed a very shallow breathing with an amplitude
of less than 5 mm. Five patients (patient 1 to 5) had a breathing amplitude between 10 mm and
20 mm in SI direction. Two patients (patient 8 and 9) were breathing deeply with an amplitude
bigger than 20 mm. This indicates different breathing patterns as well as varying lung volume
expansion and hence heart displacement amongst the studied patients.
Table 2.1.: Respiratory motion in the direction of the largest motion component (SI) for all in-
vestigated patients. Furthermore the lung tumor location (left lung (L) or right lung
(R)) is stated next to the tumor volume.
patient no motion [mm] tumor volume [cm3] tumor location (L/R)
1 17.5 236.5 L
2 20.0 572.2 R
3 10.0 160.2 R
4 17.5 676.1 L
5 15.0 372.1 R
6 2.5 706.1 R
7 5.0 123.8 L
8 25.0 44.7 L
9 22.5 125.3 L
54
Segmentation of the LPV and RPV was performed with an in-house display functionality for
TRiP [Hil09]. Its graphical interface allows contouring on the axial slices of the reference phase
of the 4DCT. The contours were checked and validated by a medical physicist who was involved
in the animal studies of Sharma et al. [Sha10] as well as a cardiologist from Mayo Clinic.
Only the motion influence and the motion mitigation possibilities will be studied here, hence
contouring of other volumes or organs at risk was omitted. A detailed analysis of the dose to
the organs at risk in human data is performed in chapter 3. The volumes of the contours for the
ablation sites for LPV and RPV are presented for each patient in table 2.2.
Table 2.2.: Target volume for LPV and RPV for all investigated patients.
patient no LPV [cm3] RPV [cm3]
1 1.88 5.26
2 3.57 4.79
3 6.49 11.52
4 3.66 3.87
5 2.07 4.37
6 3.40 6.34
7 4.29 6.23
8 6.89 4.84
9 2.92 2.56
Non-rigid image registration of the nine motion phases on the reference phase have been
performed with Plastimatch [Sharp07, Shack10]. A B-spline registration with the following pa-
rameters was chosen: The first step was carried out with 50 maximal iterations and an isotropic
spacing of 35 mm between the control points of the B-spline grid. In the second step, with
100 maximal iterations, the grid spacing was set to 11 mm and the regularization to λ=0.005.
The quality of registration was validated with visualization techniques: false color images and
checker board images [Bro07] as well as a qualitative check of the vector field regularization.
These tests were carried out between the two most extreme motion phases: the reference phase
at end exhale (motion phase five) and the phase at end inhale (motion phase zero).
2.1.2 Treatment planning parameters
Treatment plans without motion (3D, static) as well as with motion (4D) were generated. For
the dose optimization process, 3D treatment plans were generated to homogeneously cover the
CTVs in the reference phase while 4D treatment plans covered the ITV [Gra12], which was gen-
erated from all twenty motion phases. Besides the original volume of the CTV safety margins
have been added to the volumes of the treatment planning study. These margins were applied
in order to account for possible deviations in between treatment planning and delivery, like
positioning errors, changes between CT acquisition and treatment delivery etc. Isotropic safety
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margins of 3 mm, 5 mm and 7 mm have been chosen. The ITV volumes used as the final PTV
target were generated from the original CTV contour as well as the CTVs with margin, so that
potential range variations were considered in the margins.
The grid spacing was chosen to be 1 mm, both in x and y direction. The spacing between
the IESs were chosen to be 3 mmH2O. A maximal contour extension
1 of 1.1 times the focal
spot size of 4 mm was chosen as well as a distal contour fall off of 4 mmH2O. TRiP’s ’all points
divergent beam’ algorithm was used to calculate the absorbed dose. All treatment plans were
calculated as intensity modulated particle therapy (IMPT). Following Sharma et al. [Sha10] a
physical dose of 25 Gy was applied in one fraction in all simulations.
Three different beam entrance directions were used. For all beam directions the couch was
rotated by 90◦ while the gantry angles were set to -45◦, 135◦ and 0◦, respectively. With these
field number and directions a good sparing of normal tissue, especially of the coronary arteries
as well as of the aorta and of the trachea could be obtained (see chapter 3). The final field
directions were validated by a cardiologist from Mayo Clinic.
The generation of treatment plans is furthermore dependent on the theoretically possible beam
application. Spill length, shape and particle intensity are thus important factors. For the here
presented simulations HIT accelerator parameters have been used. Thereby a spill length of up
to 5 s is assumed. The pause in between spills has a mean value of 4.5 s. The spill shape is
rectangular. The particle intensities at HIT used for treatment planning vary between 5x106 and
8x107 particles per spill. Inbetween these two extreme intensity levels, eight different intensity
levels can be used. In the resulting treatment plan, the intensity steps are automatically chosen
[Krae00, Ric13]. The minimum particle number per beam spot was set to 11,000.
As the reconstruction of the 4DCTs was based on the time scale a phase-based motion state
detection was employed. A Lujan motion type was chosen for the motion trajectories [Luj99].
In order to consider possible divergence in the respiratory motion pattern of patients, different
periods (6 s and 8 s) as well as different starting phases (0◦ and 90◦) were used. The motion
periods were chosen according to the respiratory rate of 8 to 10 cycles per minute.
1 determines the extent of rasterpoint positions outside the target contour
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2.1.3 Treatment planning studies
3D treatment plans on the CTV volume were produced as reference values to the 4D cases, as
it represents the ideal but not deliverable dose distribution. Different ITV margins (original
and increased with 3 mm, 5 mm and 7 mm margin) were studied for all patients in the 4D
treatment plans. In order to prepare for these 4D simulations, the motion of the PVs due to
respiration was assessed. 4D plans were distinguished between an underlying motion without
any compensation, resulting in interplay patterns [Phi92, Ber08], and with the application of
gating [Kub96] as motion mitigation technique. The gating window was set to 30 % around
end exhale (reference phase five), so that motion phases four, five and six were used. For two
patient cases (patient 2 and 9) rescanning inside the gating window was furthermore studied.
Thereby four different rescan numbers (five, ten, fifteen and twenty rescans) have been studied.
Treatment plans for all patients where carried out with one beam channel combination (couch
angle of 90◦ and gantry angles of -45◦, 135◦ and 0◦), all four safety margins, the stated treatment
planning parameters and the four stated motion trajectories.
2.1.4 Analysis
For comparison of the resulting dose coverage dose-volume-histograms (DVHs) were studied.
The V95 (measure of dose coverage) and V107 (measure of over dosage) of the CTVs were an-
alyzed. As an indicator for the dose homogeneity, the width of the dose fall off was determined
by analyzing the difference D5-D95. The stated values have been evaluated for all beam ap-
plication techniques (static, interplay, gating, rescanning within gating window). Furthermore
motion-volume-histograms (MVHs) were generated in order to assess the resulting motion of
the PV due to respiration.
In order to study correlations between the diaphragm motion and the motion of the PVs the
Pearson coefficient r was determined and is reported for limits of p<0.05. Furthermore the
relation of dose analysis parameters to different margin sizes and the studied irradiation tech-
nique was analyzed by a one-way analysis of variance (one-way ANOVA) and the proportion
of variance explained (r2 - which ranges from zero (fit has no predictive value) to one) and is
reported with the corresponding p-value (p<0.0001).
Boxplots of dose analysis parameters D5-D95 and V95 over all patient data sets, motion pat-
terns and target volumes were moreover generated in order to study the influence of margin
size and irradiation mode (static, interplay and gating). Thereby the median (50th percentile)
as well as the 25th and 75th percentile are displayed next to the minimum and maximum.
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2.2 Results
In the following the results of the motion assessment as well as of the treatment planning studies
for all studied cases (static, interplay and gating as well as rescanning within the gating window)
will be presented. The expected treatment time will be discussed.
2.2.1 Motion assessment of respiration
Using the resulting deformation maps from deformable image registration the motion of the
ablation sites of LPV and RPV was assessed. Motion volume histograms (MVHs) [Ric13] dis-
playing the relative displacement of every voxel of the investigated volume to the reference
phase in all three motion directions (SI: superior-inferior, AP: anterior-posterior, LR: left-right)
as well as the absolute displacement were generated. The mean and standard deviation of these
displacement values in each motion phase of LPV and RPV are plotted for all patients and motion
directions in figure 2.1 and 2.2, respectively. The numerical values can be found in appendix A.1.
The mean and standard deviation of the displacement between the two extreme motion phases
(end exhale and end inhale) are shown for all patients in tables 2.3 and 2.4 for the differ-
ent motion directions and for the two target volumes, LPV and RPV, respectively. Depending
on the patient the absolute displacement of the pulmonary veins were found to vary between
three millimeters and more than one centimeter. From the nine studied patients patient 9 is
displaying the highest absolute displacement, both in LPV and RPV. For all patients, the largest
motion direction is SI, resulting in the largest contribution to the absolute displacement. The
largest average motion in SI direction over the entire volume reaches up to 15.5 mm for LPV and
10.9 mm for RPV. The other two motion directions show a much smaller displacement. In AP
direction the maximal motion is less than 2.5 mm (standard deviation of less than 1 mm) and
in LR the PVs move less than 2.7 mm (standard deviation of 1 mm). Over all patients, the mean
absolute displacement in-between end exhale and end inhale of the LPV is (6.8 ± 3.6) mm and
(6.8 ± 2.5) mm for RPV. For the SI direction, the mean displacement over all patients is (-6.4 ±
3.8) mm for LPV and (-6.6 ± 2.4) mm for RPV.
It can furthermore be seen that the relative displacement of the target volumes around end
exhale (motion phase five, reference phase) is small for all motion directions and patients. The
difference between motion phase four and six was only 3 mm in the absolute displacement of pa-
tient 9, which is the patient with the largest motion in the patient cohort. Hence gating around
end exhale was expected to be an adequate motion mitigation technique for the irradiation of
the PVs under influence of respiration.
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Figure 2.1.: LPV: Mean motion amplitude and standard deviation in each motion phase (MP)
relative to the reference phase under influence of respiration for all patients (patient
1: black, patient 2: red, patient 3: green, patient 4: blue, patient 5: yellow, patient
6: pink, patient 7: turquois, patient 8: brown, patient 9: olive).
Figure 2.2.: RPV: Mean motion amplitude and standard deviation in each motion phase (MP)
relative to the reference phase under influence of respiration for all patients (patient
1: black, patient 2: red, patient 3: green, patient 4: blue, patient 5: yellow, patient
6: pink, patient 7: turquois, patient 8: brown, patient 9: olive).
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Table 2.3.: LPV: Mean and standard deviation of target motion in-between end exhale (motion
phase five) and inhale (motion phase zero) for all investigated patients.
patient no ABS [mm] SI [mm] AP [mm] LR [mm]
1 5.2 ± 0.5 -5.2 ± 0.5 -0.1 ± 0.2 -0.1 ± 0.2
2 5.3 ± 0.6 -5.3 ± 0.6 -0.4 ± 0.2 -0.5 ± 0.2
3 7.1 ± 0.9 -7.1 ± 0.9 -0.4 ± 0.4 -0.5 ± 0.4
4 3.0 ± 0.4 -1.5 ± 0.3 -1.9 ± 0.3 -1.8 ± 0.5
5 5.1 ± 0.6 -4.6 ± 0.5 -0.8 ± 0.2 -2.1 ± 0.3
6 6.1 ± 0.6 -5.4 ± 0.7 -1.4 ± 0.2 -2.3 ± 0.2
7 3.9 ± 0.8 -3.6 ± 0.6 -1.0 ± 0.4 -1.1 ± 0.2
8 9.6 ± 0.9 -9.5 ± 0.9 -1.0 ± 0.5 0.5 ± 0.4
9 15.5 ± 3.0 -15.4 ± 3.0 -0.4 ± 0.5 -0.4 ± 1.0
Table 2.4.: RPV: Mean and standard deviation of target motion in-between end exhale (motion
phase five) and inhale (motion phase zero) for all investigated patients.
patient no ABS [mm] SI [mm] AP [mm] LR [mm]
1 6.1 ± 1.4 -6.0 ± 1.4 -1.00 ± 0.4 -0.1 ± 0.2
2 7.5 ± 1.4 -7.5 ± 1.4 0.1 ± 0.3 0.5 ± 0.4
3 8.1 ± 1.0 -7.9 ± 1.0 -1.5 ± 0.4 0.9 ± 0.3
4 5.5 ± 0.6 -5.3 ± 0.6 -1.1 ± 0.2 0.4 ± 0.2
5 5.4 ± 1.5 -5.0 ± 1.4 -1.9 ± 0.6 -0.8 ± 0.1
6 3.9 ± 0.5 -3.8 ± 0.5 -0.1 ± 0.2 -0.6 ± 0.5
7 3.3 ± 1.1 -3.2 ± 1.1 -0.4 ± 0.3 -0.1 ± 0.1
8 10.3 ± 1.9 -9.9 ± 1.7 -2.5 ± 0.6 1.6 ± 0.9
9 10.9 ± 1.1 -10.5 ± 1.1 -0.2 ± 0.2 2.6 ± 0.5
Possible correlations between the underlying respiration amplitude (see table 2.1) and the
displacement of the ablation sites for the PVs have been studied. It can be stated that in AP
and LR direction, no correlation was observed. In case of SI displacement the results varied
depending on the target volume. While no correlation was observed between the diaphragma
motion and the SI displacement of the LPV ablation, the site for RPV showed a strong linear re-
lationship (r=0.73, p<0.05). This resulted in a strong correlation between diaphragm motion
and the absolute displacement of the RPV ablation site (r=0.79, p<0.05). For the LPV again no
correlation was observed in the absolute displacement.
It should be noted that these findings are based on a small number of lung cancer patients
(see table 2.1), which can alter the breathing pattern and heart motion and hence the result.
It is unclear whether AF patients would display the same motion dependence and correlation
results, though the result was independent of the tumor position in the left or right lung.
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The overall displacement field between the two extreme states, end exhale and end inhale,
for two exemplary patients with a small motion amplitude (patient 7) and a large motion am-
plitude (patient 9) are shown in figure 2.3 and 2.4. In order to visualize the location of the
displacement, an axial cut of the reference state CT is underlayed. The absolute values of the
displacement vectors are shown as contour plots.
Figure 2.3.: Contour plot of Patient 7.
Figure 2.4.: Contour plot of Patient 9.
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2.2.2 Motion mitigation techniques for respiration
The absolute motion amplitudes of up to 1 cm due to respiration are expected to yield dose
inhomogeneity when not compensated for. The resulting interplay effect and dose deposition
were studied for every patient for different motion patterns and different margins to the target
volumes. The dose analysis values V95, V107 and D5-D95 were assessed and plotted. For
comparison also the corresponding values for the 3D case (static) are shown. As shown in
section 2.2.1 the motion displacement in the motion phases around end exhale (motion phase
four to motion phase six) are rather small in all patient cases. Hence gating has the potential to
be a well-suited motion mitigation technique to overcome the influence of target volume motion
due to respiration. The results of the stated dose values in case of gating on the stated phases
will be presented.
Dose deposition
A representative dose deposition for all studied techniques (static, interplay and gating) is
shown exemplary for patient 9 (as this is the patient with the largest PV motion amplitude)
in figure 2.5. Gating and interplay are shown for a motion period of 6 s and a starting phase of
0◦. The target volumes LPV and RPV were irradiated simultaneously and a margin of 3 mm was
added. It can already been seen from these dose cut figures that gating around end expiration
drastically improves the outcome compared to interplay and yields a result which is comparable
to the static case.
In order to assess the dose information for the whole volume the DVHs (see figure 2.6) of
all patients were analyzed and compared for dose homogeneity, dose coverage as well as over
dosage. The average results over all patients with the resulting standard deviation can be seen
in figure 2.7. A more detailed analysis can be found in appendix A.2, where the corresponding
numerical values are shown (tables A.19 - A.36) .
For interplay it can be seen that the results are dependent on the used motion period and
starting phase. This can be seen in the mean values of the resulting dose parameter values for
different underlying motion patterns. E.g. for LPV, the mean value of the dose coverage param-
eter over all patients is V95=(90.3 ± 4.3) % for a motion with 6 s period and a starting phase of
90◦ and (89.3 ± 5.5) % for a motion period of 8 s and starting phase of 90◦, while for a motion
period of 8 s and a starting phase of 0◦ the dose coverage is (87.1 ± 7.8) %. The safety margin
influences the treatment outcome, as e.g. the dose coverage for a motion with 6 s period and a
starting phase of 90◦ has a mean value of (94.2 ± 4.8) % with 3 mm safety margin. All these
dependencies are also valid for the other studied dose analysis parameters, dose homogeneity
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and over dosage. The improvement of the dose coverage and dose homogeneity in relation to
the size of the safety margin are also presented in figure 2.8. The explained variance of the dose
homogeneity versus the studied safety margins resulted in r2=0.30 (p<0.0001).
The underlying deformation map with its motion amplitude enables a prediction of the magni-
tude of the interplay effect. This was studied in more detail for the dose homogeneity, as these
values were normally distributed. The explained variance of the maximal motion amplitude of
the left and right PV (see table 2.3 and 2.4) and the resulting D5-D95 values for all studied
margins was r2=0.25 (p<0.0001).
Gating yielded improved results compared to interplay in all studied cases (see also figure
2.8). This is valid for dose homogeneity, dose coverage as well as over dosage. Especially
dose coverage and over dosage are comparable to the static results for all patient and motion
patterns (e.g. patient 1, V95 of 100 % for all studied motion patterns and safety margins in RPV,
see table A.20). In some patients the dose coverage is better with added safety margins (e.g.
patient 9, V95 with no margin for motion period of 6 s and starting phase of 0◦ is 94.1 % for LPV,
a V95 of 99.9 % can be achieved for the same motion pattern with a margin of 3 mm). Also in
dose homogeneity a bigger safety margin tends to improve results (e.g. in LPV of patient 1 with
motion period of 8 s with starting phase of 0◦: D5-D95 = 4.4 % with margin of 3 mm versus D5-
D95 = 3.8 % with margin of 5 mm). These findings are also shown in figure 2.8. Here the dose
coverage and dose homogeneity are shown for all patients, motion patterns and the two target
sites (LPV and RPV) depending on the used safety margin. It can be seen that the dose coverage
is already drastically improved with 3 mm margin. Also the dose homogeneity is improved with
increasing safety margin. The explained variance of D5-D95 versus all studied margins resulted
in r2=0.40 (p<0.0001). Keeping the safety margin constant, it was nevertheless found that in
some cases the dose homogeneity is not drastically improved by gating compared to interplay.
The LPV of patient 2 for example has a D5-D95 value of 6.8 % for gating with a safety margin of
3 mm (motion period of 6s and starting phase of 90◦), which is only slightly under the interplay
result of D5-D95=8.4 % for the same safety margin and motion. However, the dose homogene-
ity value of interplay in this particular patient case is already lower than in other cases (e.g.
D5-D95=10.6 % in patient 1 or 20.93 % in patient 9 for 3 mm margin and a motion period of
6 s, starting phase of 90◦).
As a method to further improve the dose homogeneity rescanning inside the gating window
was studied for two patient cases. The results are presented in the next section. It can neverthe-
less be concluded that gating of target volumes with safety margin yields results comparable to
the static irradiation in case of dose coverage and over dosage and hence is an adequate motion
mitigation technique for the irradition of the PVs under influence of respiration.
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(a) static
(b) interplay
(c) gating
Figure 2.5.: Dose distribution of patient 9 for static (a) as well as interplay (b) and gating (c) at
motion period of 6 s and a motion starting phase of 0◦. The target volume has an
added margin of 3 mm. The improved outcome of gating compared to interplay can
already be seen in these dose cuts.
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(a) LPV
(b) RPV
Figure 2.6.: Dose volume histograms for CTV of patient 9 for 3 mm safety margin irradiation
(LPV (a) as well as RPV (b)) in case of static irradiation (black), interplay (dashed)
and gating (solid). The motion patterns are shown in colors (6s 0: lujan motion with
period of 6 s and starting phase 0◦, 6s 90: lujan motion period of 6 s and starting
phase 90◦, 8s 0: lujan motion period of 8 s and starting phase 0◦, 8s 90: lujan motion
period of 8 s and starting phase 90◦).
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(a) D5-D95: LPV (b) D5-D95: RPV
(c) V95: LPV (d) V95: RPV
(e) V107: LPV (f) V107: RPV
Figure 2.7.: Mean value and standard deviation of dose analysis parameters D5-D95 (first row),
V95 (middle row) and V107 (last row) over all patients. The LPV (left column)
and RPV (right column) were studied seperately. Static (black) as well as interplay
(red) and gating (blue) are compared for four different motions and different safety
margins.
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(a) D5-D95 versus margin size
(b) V95 versus margin size
Figure 2.8.: (a) and (b): Boxplot of dose analysis parameters D5-D95 and V95 over all patient
data sets, motion patterns and target volumes (LPV: circle and RPV: cross) depending
on the used margins size (0 mm, 3 mm, 5 mm and 7 mm) and irradiation mode
(static, interplay and gating). Here, minimum and maximum of the data is plotted
within 1.5 times the interquartile range, the other data points are stated as outliers.
Figures are courtesy of Dr. Christian Graeff.
67
Rescanning of gated volume
The combination of two motion mitigation techniques, gating and rescanning, would directly
apply when not only the respiratory motion but also the heartbeat would be compensated for
(see chapter 3). In order to study the outcome of such a delivery, several number of rescans (5,
10, 15 and 20) were applied on the gated irradiation for patient 2 (as an example of a patient
with a medium absolute displacement of the target volumes) and patient 9 (with the highest
studied absolute displacement). The results can be seen in figures 2.9 and 2.11. For patient 9
the DVHs for static as well as the gating results for all motion patterns and the corresponding
results for ten rescans within the gating window are shown in figure 2.10. All numerical results
are shown in appendix A.2 (tables A.37 to A.40).
For patient 2 the dose homogeneity value of 6.8 % of the prescribed physical dose of 25 Gy
achieved with gating in the LPV (3 mm margin, motion period of 6 s and starting phase of 90◦)
can be slightly improved to 4.7 % with five rescans or 3.8 % with ten rescans. In RPV the dose
homogeneity value of patient 2 of 5.0 % for the same margin and motion can be improved to
4.8 % with five rescans and 4.1 % with ten rescans. For patient 9 the dose homogeneity value
of 5.0 % for LPV with 3 mm margin and motion period of 6 s, starting phase of 90◦ can be
improved to 3.8 % with five rescans. For the RPV dose homogeneity of 4.4 % with the same
margin and motion can be reduced to 3.9 % with five rescans. Rescan numbers higher than
ten only lead to a minor improvement. For example in Patient 9 the LPV irradiation with 3 mm
margin and the stated motion of 6 s period and 90◦ starting phase results in 3.7 %, both for
fifteen and twenty rescans, respectively.
It can be concluded that the dose homogeneity can be slightly improved with rescanning within
the gating window. A small number of rescans, e.g. five or ten, are already sufficient to yield
acceptable results and the outcome can not be improved by using higher rescan numbers. As
rescanning will be studied as motion mitigation technique for the heartbeat motion influence,
the overlay of rescanning and gating will be carried out automatically in case of an application
of the here studied non-invasive treatment modality for AF, as both, respiration and heartbeat,
need to be accounted for.
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(a) D5-D95: LPV (b) D5-D95: RPV
(c) V95: LPV (d) V95: RPV
(e) V107: LPV (f) V107: RPV
Figure 2.9.: Patient 9: Dose analysis parameters for LPV (left column) and RPV (right column).
Besides static (black), interplay (red) and gating (blue) also different rescan numbers
on the gated irradiation were applied (five (green) and ten rescans (orange)). The
results are compared for four different motions and different safety margins. For a
better visualization the rescanning data points for each motion pattern are shifted
and the result for fifteen and twenty rescans are not displayed.
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(a) LPV
(b) RPV
Figure 2.10.: Dose volume histograms for CTV of patient 9 for 3 mm safety margin irradiation
(LPV (a) as well as RPV (b)) in case of static irradiation (black), gating (solid) and
five rescans inside the gating window (dashed). The motion patterns are shown
in colors (6s 0: lujan motion with period of 6 s and starting phase 0◦, 6s 90: lujan
motion period of 6 s and starting phase 90◦, 8s 0: lujan motion period of 8 s and
starting phase 0◦, 8s 90: lujan motion period of 8 s and starting phase 90◦).
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(a) D5-D95: LPV (b) D5-D95: RPV
(c) V95: LPV (d) V95: RPV
(e) V107: LPV (f) V107: RPV
Figure 2.11.: Patient 2: Dose analysis parameters for LPV (left column) and RPV (right column).
Besides static (black), interplay (red) and gating (blue) also different rescan num-
bers on the gated irradiation were applied (five (green) and ten rescans (orange)).
The results are compared for four different motions and different safety margins.
For a better visualization the rescanning data points for each motion pattern are
shifted and the result for fifteen and twenty rescans are not displayed.
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Irradiation time
One of the disadvantages of gating as motion mitigation technique is that the irradiation time is
increased depending on the used gating window size. When a gating window of roughly 30 %
is used, like in this study, the irradiation is prolonged by a factor of three compared to the static
irradiation. In figure 2.12 the needed irradiation time for the gated irradiation of LPV and RPV
in patient 2 is shown for different safety margins and motion patterns. The duration for each
beam entry channel (gantry angle of -45◦, 135◦ and 0◦) is plotted individually. On the left side
the duration of an irradiation with a small minimal particle number (11,000 particles per beam
spot) is shown, while on the right side an irradiation with a higher minimal particle number
(55,000 particles per beam spot) is displayed. Even though a higher intensity is expected to
result in a shorter treatment time and would hence be favorable for the efficiency of the treat-
ment, it was shown that very high intensities endanger a homogenous dose coverage [Mue14].
The usage of lower intensities is hence motivated and needs to be studied in the individual cases.
As expected, the needed irradiation time increases with the used safety margin as the irradi-
ated volume increases. Furthermore the irradiation time is independent of the motion pattern
but varies depending on the used beam entry channel. While the low intensity irradiation can
take up to 120 minutes (for a safety margin of 3 mm), the overall duration can be reduced to
only 30 minutes (for a safety margin of 3 mm) for the irradiation with a higher intensity. It
should be noted that this is the gating time for the respiratory motion alone and the overall
treatment time will thus be prolonged, as cardiac motion is not yet compensated for.
(a) Patient 2: Nmin = 11,000 (b) Patient 2: Nmin = 55,000
Figure 2.12.: Irradiation time for gating for patient 2 for different intensities, different safety
margins, underlying motion patterns and beam entry channels.
72
2.3 Discussion
In this chapter the influence of respiratory motion on the PVs was studied and treatment plan-
ning studies with gating as motion mitigation technique were carried out. Respiration was found
to be an important motion component for the treatment of cardiac volumes. Recent studies in
the cardiology community also indicate that real time compensation of breathing displacement
would even be beneficial for catheter ablation [Kum12, Frie12].
Different studies on the influence of respiration on the PV motion exist as they are of inter-
est for image guided ablation procedures. Thereby relative displacements (like deformation or
splaying of the PVs) and absolute motion (translational and rotation) are distinguished. Nose-
worthy et al. [Nos05] studied the relative changes in the PV anatomy during the breathing cycle.
They thereby investigated the changing branching angle between the inferior and superior LPV
(LIPV, LSPV) and RPV (RIPV, RSPV), respectively. They stated that the PV splay increased during
inspiration (branching angle of RPVs increased from (40 ± 10)◦ to (60 ± 15)◦ and for LPVs
from (50 ± 11)◦ to (62 ± 13)◦). Furthermore they found a significant reduction in the diameter
of the RIPV and RSPV during inspiration. Ector et al. [Ect08] on the other hand stated that they
only found a slight, but significant diameter reduction in the RIPV. In their paper they further-
more studied the absolute translational motion. Their patient cohort had a mean diaphragmatic
movement of (35 ± 16) mm for the right diaphragm, resulting in an absolute mean displace-
ment for both LPV and RPV of (19.1 ± 8.6) mm. The mean inferior motion was stated to (14.6
± 7.7) mm, in anterior direction to (9.7 ± 7.6) mm and the smallest motion direction was the
leftward direction with (0.4 ± 3.8) mm. Comparing motion patterns between veins the LPVs
were found to move less in anterior direction then the RPVs, but did not differ significantly in
other directions. They found a strong association between diaphragmatic motion and inferior
PV motion.
In the here studied patient cohort of lung cancer patients a much smaller mean absolute dis-
placement of the pulmonary veins was found over all patients with (6.8 ± 3.6) mm for LPV
and (6.8 ± 2.5) mm for RPV. The SI motion had a mean value of (-6.4 ± 3.8) mm for LPV
and (-6.6 ± 2.4) mm for RPV. In AP direction the mean amplitude for all patients was (-0.8
± 0.5) mm for LPV and (-0.9 ± 0.8) mm for RPV, which corresponds to the finding by Ec-
tor et al. that the LPV move less in anterior direction than the RPV. For LR direction a mean
displacement of (-0.9 ± 0.9) mm of LPV and (0.5 ± 1.0) mm of RPV was found over all pa-
tients. Contrary to Ector et al. a significant difference in the motion of the LPV compared
to RPV was hence found in LR. A correlation between diaphragm motion and PV displace-
ment was only found in the RPV (r=0.79, p<0.05). Even though a similar result was expected
for the LPV, no correlation was observed here. It is unclear if this is due to location of the abla-
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tion site or due to the underlying lung cancer patient data in comparison to AF patient data sets.
Recent studies in the cardiology community [Kum12] concluded that also for catheter ablation
respiration plays an important role as it may reduce the catheter tip contact force. Consideration
of respiratory motion is thus recommended. Besides ventilation and apnea, Friedmann [Frie12]
also states that jet ventilation or breath-hold might be adequate strategies for catheter ablation.
Even though these techniques may also be options for a non-invasive treatment of atrial fibril-
lation with a scanned carbon ion beam, gating was studied as a motion mitigation technique in
the present work. In irradiation of cardiac volumes in the animal studies carried out at Cyber-
Heart and at the Universitätsklinikum Schleswig-Holstein in Lübeck different approaches were
used. While Blanck et al. [Bla13] used an ITV approach for the respiratory motion, Sharma
et al. [Sha10] tracked the respiration with the underlying CyberKnife Synchrony software (see
chapter 1, section 1.3.4). For particle therapy tracking is not feasible yet as no fast and precise
real-time internal motion monitoring including particle range information exists. A simple en-
largement of internal margins to produce an ITV for respiration was withdrawn due to expected
high dose deposition in critical OAR close to the target sites (see chapter 3). Gating offers the
advantage of a currently technical feasibility while keeping the dose to the normal tissue rela-
tively small. Nevertheless it leads to a prolongation of the treatment time. However, with a high
intensity of 55,000 minimum particles per spill a duration of only 30 minutes could be achieved
(patient 2, safety margin of 3 mm). This already offers a reduced treatment time compared to
the results by Sharma et al. where a treatment time of one to two hours was estimated. While
lower intensities lead to a longer treatment time, it is nevertheless known from previous studies
[Mue14] that high intensities can result in inhomogeneous dose depositions. Other methods
to reduce the treatment time might hence be needed in order to still guarantee a time efficient
delivery. Tsunashima et al. [Tsu08] studied cyclotron settings that could lead to a reduced treat-
ment time in particle gating. They thereby found that variable excitation cycles, in synchrony
with the respiratory pattern of the patient, could reduce the treatment time prolongation to a
factor two, instead of the usual factor three, for a 30 % gating window. Iwata et al. [Iwa10b]
furthermore proposed a method to reduce the needed time for energy changes inbetween IESs
in synchrotrons. By using radiofrequency knockout exciters and multiple energy operation pat-
terns, the beam would be accelerated to the maximum energy and than stepwise decelerated to
lower energies, using an extension of the respective flattops to extract the particles with varying
energies during a single operation cycle of the synchrotron.
Concerning the dose deposition with gating compared to interplay it can be concluded that
gating yields good dose coverage. The V95 values were higher than 99 % for all target sites
with safety margin of 3 mm or more and higher than 95 % in all cases without safety margin
(minimum of 95.2 % in patient 9 for LPV, no safety margin and motion period of 8 s, starting
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phase of 0◦).The V107 values were all smaller than 0.1 % (maximum of 0.1 % for patient 2,
RPV, in case of 5 mm margin and motion with period of 8 s and starting phase of 90◦). Hence
an acceptable dose coverage could be achieved. The dose homogeneity did not exceed 9.2 %
without safety margin (patient 5, LPV, no safety margin and motion period of 8 s, starting phase
of 90◦). With safety margin, the D5-D95 value did not exceed 8 %. An additional safety margin
is thus beneficial to guarantee a robust and successful treatment delivery. However, an exten-
sion of the target volume due to safety margins always results in more dose to the normal tissue
and to potential critical OARs. A limited safety margin of 3 mm or 5 mm would offer the bene-
fit of improved treatment outcome while keeping the irradiated volume low (see also chapter 3).
Rescanning within the gating window could slightly improve the results for dose homogeneity
as it reduces the influence of residual motion inside the gating window. The dose homogeneity
in the LPV of patient 9 for example (large motion amplitude) could be reduced from 5.0 %
(safety margin of 3 mm, motion period 6 s and 90◦ starting phase) to 3.8 % with five rescans.
2.4 Conclusion
The PVs were found to move due to respiration with an amplitude of up to 2cm. This dis-
placement creates interplay effects when irradiated with scanned carbon ions. Gating as motion
mitigation technique was studied. It can be concluded that this method yields improved dose
coverage (under and over dosage) and better dose homogeneity compared to interplay in all
studied patient cases, for all motion patterns and safety margins and achieves results compa-
rable to the static irradiations. It can thus be an adequate motion mitigation technique for the
irradiation of PVs under influence of respiratory motion. As rescanning is a potential technique
when compensating for displacements due to heartbeat (see chapter 3), the combination of
these two motion mitigation technique could be feasible in a potential application. Hence res-
canning inside the gating window was studied and it was shown that a small number of rescans
(e.g. five or ten) are sufficient to improve the results of dose homogeneity.
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The PVs move on one hand due to the heartbeat and on the other hand due to respiration
of the patient. Both motion types are independent from each other and can hence be studied
individually. While the influence of respiration is analyzed in chapter 2, the effect of heartbeat
motion will be discussed in this chapter. CTs of five AF patients, gated to the complete cardiac
cycle in end-expiration, were acquired at Mayo Clinic (Rochester, Minnesota, USA). The motion
direction as well as motion amplitude of LPV and RPV were studied for all cases. Motion influ-
ences on accuracy and homogeneity of the dose delivery in the PVs were studied using these
data. The resulting interplay pattern for all patients as well as rescanning as possible motion
mitigation technique have been analyzed and the results will be presented in this chapter.
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3.1 Material and methods
The input data as well as the treatment planning parameters will be stated before all conducted
studies will be specified. The analysis procedure will be explained.
3.1.1 Treatment planning input data
As was already stated in chapter 2, 4DCT data sets, segmentation of the target volumes and
OARs and deformable image registrations in-between the different motion phases are needed
for the here presented treatment planning studies using the in-house software TRiP4D [Ric13].
In order to study the displacement of the PV due to heartbeat ECG gated 4DCTs in end ex-
hale (breath hold) were studied. Five AF patient data sets (four male patients and one female)
were recorded and anonymized at Mayo Clinic (Rochester, Minnesota, USA). The CT scans were
acquired on a Sensation 64 CT scanner (Siemens). Each of the 4DCT data set consisted of
twenty temporal equally distributed cardiac motion phases, the reference phase zero started at
the R-peak of the QRS-complex (see chapter 1, section 1.3.1). In order to distinguish structures
within the heart the CT scans were contrast enhanced. The radiopaque material was adminis-
tered intravenously (150 cc Omnipaque 350 at 4 cc/sec). Segmentation of the target volumes
(LPVs and RPVs) as well as the OAR (esophagus, trachea, aorta and cardiac structures) were
carried out by a collaborating cardiologist at Mayo Clinic on the reference 4DCT phase with
Eclipse™(Varian Medical Systems). The volumes of the contours for the ablation sites for LPV
and RPV are presented for each patient in table 3.1.
Table 3.1.: Target volume for LPVs and RPVs for all investigated patients.
patient no LPV [cm3] RPV [cm3]
1 2.03 2.39
2 2.62 5.16
3 1.45 4.16
4 1.66 2.07
5 2.06 1.90
Non-rigid image registration of the nineteen motion phase on the reference phase have been
performed with Plastimatch [Sharp07, Shack10]. Here the first step of the B-spline registration
was carried out with 50 maximal iterations and an isotropic spacing of 20 mm was chosen. The
second step was carried out with 100 maximal iterations and the grid spacing was set to 3 mm.
The regularization was chosen to be λ=0.0001. The same visualization techniques as stated in
chapter 2 were used for a quality assurance of the registration (false color images and checker
board images [Bro07], a qualitative check of the vector field regularization). The stated tests
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were carried out on the one hand between motion phase 3 (the motion phase of the maximal
ventricular displacement) and the reference phase (motion phase zero) and on the other hand
between motion phase 18 (maximal displacement of the atria) and the reference phase.
3.1.2 Treatment planning parameters
Also here 3D (static) and 4D treatment plans were generated. For informations on the dose
optimization process, the ITV generation with the implementation of the studied safety margins
(0 mm, 3 mm, 5 mm and 7 mm), the used raster spacing and the dose algorithm the reader
should be referred to 2.1.2.
All treatment plans were calculated as intensity modulated particle therapy (IMPT). Part of
the study included the esophagus as critical structure in the optimization process (IMPT(OAR)).
Thereby two different dose restrictions to this OAR were used. In one part of the calculations
it was stated that the esophagus should not receive more than 70 % of the physical dose. The
strength of this restriction was determined by a weightfactor, which was set to 75 %. In a second
iteration the restrictions were stronger and the maximal physical dose to this structure was set
to 30 % with a weighting factor of 200 %. Also here a physical dose of 25 Gy was applied in one
fraction in all simulations. Since potential biological effects were not included in the studies the
applied dose is linear and the results, e.g. dose depositions to critical structures, can be scaled
to other dose values 1.
The generation of treatment plans is furthermore also dependent on the theoretically possi-
ble beam application. Spill length, shape and particle intensity are thus important factors. For
the here presented simulations GSI accelerator parameters have been used. Thereby a spill
length of 2.2 s is assumed. The pause in between spills is either 2.2 s, when no energy change is
required afterwards, or 3.2 s when an energy change is needed. The spill shape is approximated
by a Gaussian function. The particle intensities feasible at GSI vary between 2x106 and 2x108
particles per spill. Inbetween these two extreme intensity levels, fifteen different intensity lev-
els can be used. In the resulting treatment plan, the intensity steps are automatically chosen
[Krae00, Ric13]. The minimum particle number per beam spot was set to 5,000.
As the reconstruction of the 4DCTs was based on the time scale a phase-based motion state
detection was employed. In order to consider possible divergence in the heartbeat motion pat-
tern of patients, different periods (1 s and 0.7 s) as well as different starting phases (0◦ and 90◦)
were used. The motion periods were chosen according to the heartbeat rate of 60 to 80 beats
per minute.
1 only limited by the minimal particle fluence per beam spot
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Field number and beam directions
The field number and directions were systematically investigated and are listed in table 3.2. Four
different field numbers (one to four) were studied. While for one field the gantry angle was kept
constant to 0◦ and only the couch angle was changed, for higher field numbers different gantry
angles were used. These angles are illustrated in figure 3.1.
Table 3.2.: Studied field number and beam channel directions
field number couch angle [◦] gantry angle [◦]
1 field -90 0
-45 0
-135 0
2 fields 90 -60/120
90 -60/135
90 -60/0
90 -45/135
90 -45/150
90 -45/0
3 fields 90 -60/120/150
90 -60/120/0
90 -45/135/150
90 -45/135/0
4 fields 90 -60/120/-45/135
90 -60/120/0/180
90 -45/135/0/180
90 -160/90/-60/145
Figure 3.1.: Entry channels for different gantry directions for a couch angle of 90◦. The beam’s
eye view (BEV) is marked.
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3.1.3 Treatment planning studies
Besides representing a reference value for the 4D cases, 3D treatment plans were also generated
here in order to find the best suited combinations of beam entry channels as well as to study
possible safety margin limitations. In order to find a suitable field number and beam direction
for the 4D treatment planning studies, static simulations on the original CTV volume (LPV to-
gether with RPV) with the above mentioned treatment planning parameters were carried out
for all five patients. 17 different beam channel combinations were studied (see table 3.2). As a
criteria for the best possible solution the dose to OAR was assessed. Furthermore, different ITV
margins (original and increased with 3 mm, 5 mm and 7 mm margin) were studied in 3D treat-
ment plans for all patients. The resulting dose depositions were compared to dose deliveries
with the same margins where the esophagus was included in the optimization process. Possible
limitations were again analyzed according to the dose deposition in the OARs.
In order to prepare for the 4D simulations, the motion of the PVs due to heartbeat was as-
sessed. 4D plans were distinguished between an underlying motion without any compensation,
resulting in interplay patterns [Phi92, Ber08], and with the application of rescanning [Phi92] as
motion mitigation technique. For rescanning different rescan numbers (5, 10, 15 and 20) were
compared. Static, interplay as well as rescanning treatment plans for all patients were carried
out with one beam channel combination (couch angle of 90◦ and gantry angles of -45◦, 135◦
and 0◦), all four safety margins, the stated treatment planning parameters and the four stated
motion trajectories.
3.1.4 Analysis
Both the dose deposition in OAR as well as dose homogeneity in the target volume were stud-
ied. For the OAR dose-volume restrictions in esophagus, trachea, aorta and the whole heart
were compared to values from RTOG study protocols (see next paragraph). As further OARs
cardiac substructures (ventricles and coronary arteries) were studied. For comparison of the
resulting dose coverage in the target region DVHs were studied. Furthermore MVHs [Ric13]
were generated displaying the relative displacement of every voxel of the investigated volume
to the reference phase in all three motion directions. With these values the resulting motion of
the PVs due to heartbeat could be assessed.
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Dose-volume constraints for organs at risk
The dose deposition in the OAR is an important limitation and selection criteria when studying
the field number and beam channel direction as well as the possible safety margin limitations.
Since a single fraction of 25 Gy or higher is assumed to be used in this non-invasive treatment
modality, dose tolerance limits used in stereotactic body radiotherapy (SBRT) are highly related
[Ber12]. An extensive collection of dose-volume-limits for SBRT are presented in Grimm et
al. [Gri11] and the AAPM Task Group Report [AAPM10]. Both are literature reviews of limits
utilized and reported in existing publications. For the OAR in the here presented treatment
planning study (esophagus, trachea, heart and aorta) the dose-volume-limits in both literature
reviews were taken from the Radiation Therapy Oncology Group (RTOG). The RTOG is a na-
tional clinical cooperative group of over 360 institutions across the United States and Canada,
which was funded by the National Cancer Institute (NCI) [RTOG]. In their study protocols
RTOG 0631 (a phase II/III trial of SBRT for localized spine metastasis) [RTOG0631] and RTOG
0915 (a randomized phase II trial of SBRT for medically inoperable patients with stage I periph-
eral non-small cell lunger cancer) [RTOG0915] the following dose-volume-limits were stated
(see table 3.3).
Table 3.3.: Dose-volume limits for OAR.
OAR volume [cc] dose [Gy] endpoint
aorta / great vessels 10 31 aneurysm
esophagus 5 11.9 stenosis / fistula
heart 15 16 pericarditis
trachea 4 10.5 stenosis / fistula
Since the heart is not only a critical organ but also the target site in this treatment modality,
further differentiation of limits depending on the substructures of the heart are needed. Un-
fortunately, data on this topic is scarce. Literature on cardiac disease resulting from radiation
exposure mostly relies on cancer patient data treated with radiotherapy (in particular breast
cancer and Hodgkin’s lymphoma) or atomic bomb survivors. Besides the stated dose-volume
limitation, the mean dose and maximum point dose to the whole heart was studied. Further-
more the maximal irradiated heart volume (V>0) was examined. Concerning substructures the
left and right ventricle as well as the coronary arteries were analyzed for mean and maximum
dose deposition and maximal irradiated volume contribution. Since the values were not nor-
mally distributed, boxplots were generated, where the median (50th percentile), the 25th and
75th percentile and the minimum and maximum values over all patient cases are displayed.
Dose deposition in target volume and motion of PVs
The V95, V107 as well as D5-D95 of the CTVs were analyzed. The stated values have been
evaluated for all beam applications (static, interplay, rescanning). Futhermore the median and
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percentile values of these parameters over all studied motion patterns and patient cases were
generated. The relation of dose analysis parameters to different margin sizes and rescanning
number was analyzed by a one-way ANOVA and the proportion of variance explained r2 is
reported with the corresponding p-value (p<0.0001).
3.2 Results
In the following the results of the beam direction and safety margin study, of PV motion assess-
ment as well as of the treatment planning studies will be discussed. As a criteria for an adequate
field number and beam channel direction as well as safety margin limitation the dose to OAR
will be presented. The motion due to heartbeat is shown. For the treatment planning study
different dose analysis parameters will be presented and compared for different cases (static,
interplay and rescanning).
3.2.1 Beam direction
In figures 3.2 and 3.3 the resulting dose to the pertinent OARs is shown for all studied beam
directions and patients. Figure 3.2 displays the results as a boxplot over all patient cases for a
respective field number (and hence different beam directions) while figure 3.3 shows the indi-
vidual results for each patient and beam direction. The corresponding volumes result from the
dose volume limits (see table 3.3, represented by a dashed line in the plots). In all studied cases,
the difference between different beam directions for a certain patient is rather small, resulting
in no obvious preferable beam direction for the five studied patients. For the four studied OAR it
becomes furthermore obvious that while trachea and aorta are well spared for almost all beam
directions in all patients, esophagus and in particular the heart are much more critical.
In the esophagus the median dose over all patients is 7.8 Gy (75th percentile: 9.0 Gy) for
one field, 11.0 Gy (14.1 Gy) for two fields, 11.0 Gy (13.9 Gy) for three and 8.0 Gy (11.9 Gy) for
four fields. The result is dependent on the underlying patient anatomy. While the majority of
the beam directions for patient 1, 4 and 5 remain under the respective dose-volume limit, many
plans for patient 2 and 3 exceed the dose-volume constraints. For these patients dose deposi-
tions of 11.9 Gy or less are achieved in only about 98 % and 65 % of studied cases (patient 2
and 3, respectively). While a single field yields acceptable dose deposition in the esophagus, the
beam channel results in higher dose depositions in the heart and cardiac substructures like the
coronary arteries (see figure 3.4 and 3.5) and are thus inapplicable. For patient 2 higher field
numbers and thus more beam directions result in dose limit exceeding depositions. Due to this
result the esophagus was included in the optimization of the treatment delivery (IMPT(OAR)).
This was studied in comparison to a simple IMPT irradiation (see section 3.2.2).
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(a) esophagus (b) trachea
(c) heart (d) aorta
Figure 3.2.: Boxplots of dose-volume data for different field numbers (one to four fields) over all
patients and over the respective beam directions. The data is plotted for different
OARs when irradiating the LPV and RPV as IMPT in the five patient data sets. The
dose-volume-limit for each critical organ is indicated with a dashed line in each plot,
respectively.
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(a) esophagus (b) trachea
(c) heart (d) aorta
Figure 3.3.: Dose-volume data of different OAR when irradiating the LPV and RPV as IMPT in
the five patient data sets (patient 1: black, 2: red, 3: blue, 4: green, 5: orange)
with different field numbers (1 field, 2 fields, 3 fields, 4 fields) and different beam
directions. The dose-volume-limit for each critical organ is indicated with a dashed
line in each plot.
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The dose volume limit for the heart is exceeded in all patients for all beam directions (see
figure 3.2 and 3.3). As the heart is not only an OAR in this treatment modality, but some of its
substructures are also the target itself, a closer analysis of the dose deposition in the heart is
required. In the first row of figure 3.4 and figure 3.5 the mean and maximal dose deposition in
the whole heart as well as the maximal irradiated volume are shown. The mean dose over all
patients and beam directions is found to have a median of 1.3 Gy (75th percentile: 1.5 Gy). The
median over the maximum point dose is 26.6 Gy (27.1 Gy). Concerning the maximal irradiated
volume it can be seen that except for one result less than 30 % of the heart is irradiated in all
other cases. The exeption is patient 2, where this maximal volume is drastically increased with
a couch position 90◦ and gantry angles of -160◦, -90◦, -60◦ and 145◦ and reaches up to 49.9 %.
Hence this beam channel case (beam channel case 17) will be stated separately in the following
analysis. The median of the maximal irradiated volume over all patients is 16.8 % (20.5 %),
excluding beam channel case 17, and 17.4 % (20.8 %) including this case.
The results for the dose deposition in the cardiac substructures are presented in row two to
five of figure 3.4 and figure 3.5. For the ventricles (LV: second row, RV: third row), the mean
dose to both LV and RV is negligible. The maximal point dose on the other hand varies depend-
ing on beam direction and patient. Single beam directions yield a high maximal dose deposition
in the LV as in the case of a couch angle of -90◦ or -135◦ the beam traverses the LV. Consequently
for these beam directions the maximal dose to the RV is smaller. The overall maximal dose
deposition has a median of 1.4 Gy (75th percentile: 7.4 Gy) for LV and 1.3 Gy (5.0 Gy) for RV.
Besides some single beam directions no maximal point dose exceeds 11.2 Gy and 10.1 Gy for
LV and RV, respectively. Concerning the maximal irradiated volume of the ventricles, it can be
stated that the results differ depending on the studied patient. In case of the LV patient 2 has a
higher irradiated volume compared to the other patients, while for this patient on the contrary
the RV is better spared than in other patients. Over all patients the LV is irradiated to a higher
extend than the RV. For LV the maximal irradiated volume over all beam directions and patients
has a median of 1.2 % (6.0 %), when excluding the case of beam channel 17 and to 1.9 %
(6.4 %) when including this case. For RV it is 0.2 % (7.6 %) excluding the beam channel case
17 and to 0.2 % (8.3 %) including it. For the coronary arteries the beam channel 17 also results
in the highest irradiated volume. Even though the coronary arteries are found on the surface
of the whole heart and hence also on the ventricles, the irradiated volume of these structures
differ from the result of the ventricles. Here the RCA are irradiated to a higher extent than
the LCA. The median maximal value for the LCA is 15.7 % (28.0 %) including the stated beam
channel case 17 and 15.2 % (27.4 %) excluding it. For the RCA the median over the maximal
value is much higher and found to be 27.9 % (42.4 %) including the beam channel case 17 and
to 24.8 % (42.1 %) excluding it. For the mean dose deposited in the LCA one and four beam
directions result in an increased dose deposition, while three fields yield in general a low mean
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dose for all studied beam directions and patients. The same is true for the maximum point dose
in the LCA. In the case of RCA, the results seem to be independent of field number and beam
direction. Overall the median over the mean dose is 0.4 Gy (1.0 Gy) for LCA and 0.6 Gy (1.6 Gy)
for RCA. For the maximal point dose the median dose deposition over all beam directions and
patients is 6.8 Gy (10.9 Gy) for LCA. For the RCA it was found to be 5.4 Gy (7.9 Gy).
While it was not expected to find one beam direction feasible for all five patients, it is strik-
ing that no beam position results in a clear benefit for the OAR of the individual patients. This
is due to the challenging position of the PV target site, which is in direct proximity to the esoph-
agus and due to the fact that the heart is not only an OAR in this treatment modality, but also
the target site itself. Nevertheless for the analyzed cardiac substructure, especially the radiosen-
sitive LCA, it can be concluded that three beam channels seem to be beneficial for all patients.
Regarding the mean dose deposition in the LCA as well as the maximal irradiated heart volume,
combined with the requirement of a robust treatment and hence the benefit of large gantry an-
gles in between different beam channels, a couch angle of 90◦ was chosen together with gantry
angles of -45◦, 135◦ and 0◦. These beam channel directions were used for a closer analysis of
safety margin limitation as well as for the treatment planning studies for all patients.
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heart
LV
RV
LCA
RCA
Figure 3.4.: Boxplots of mean and maximum dose as well as maximal irradiated volume for dif-
ferent field numbers (one to four fields) over all patients and over the respective
beam directions. The data is plotted for different OARs (heart: first row, and car-
diac substructures (LV: second row, RV: third row, LCA: fourth row, RCA: last row)
when irradiating the LPVs and RPVs as IMPT treatment in the five patient data sets
with different field numbers and thus beam directions.
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Figure 3.5.: Mean and maximum dose as well as maximal irradiated volume of the heart (first
row) as well as cardiac substructures (second row: LV, third row: RV, fourth row:
LCA, last row: RCA) when irradiating the LPV and RPV in the five patient data sets
with different field numbers and beam directions. The different patients are dis-
played in different colors (patient 1: black, 2: red, 3: blue, 4: green, 5: orange). The
different beam channel directions are stated in the the figures of the last row.
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3.2.2 Safety margin limitations
Figure 3.6 shows the dose results for the main OARs when irradiating the PVs with no safety
margin (0 mm) and different additional, isotropic safety margins (3 mm, 5 mm or 7 mm).
The dose-volume-limits were studied according to the recommendation of RTOG (see table 3.3)
and the limit for each organ is indicated by a dashed line in the boxplots. Besides an IMPT
treatment IMPT(OAR) deliveries were also studied. Thereby the esophagus was implemented
as a critical structure in the optimization process with two different restrictions (IMPT(OAR)R1
and (IMPT(OAR)R2). In IMPT(OAR)R1 it was stated that this structure should not receive more
than 70 % of the physical dose of 25 Gy, while IMPT(OAR)R2 had stronger restrictions with the
maximal dose deposition set to 30 % of the physical dose. The results of these three treatment
deliveries are shown in each column of the plot.
As expected, the dose to the enclosed OAR increases with increasing safety margin for all pa-
tients. This is the case for both IMPT and IMPT(OAR) deliveries. Nevertheless the IMPT(OAR)
deliveries lead to a reduced dose deposition, especially in the esophagus. For no safety mar-
gin, the median dose to the esophagus over all patients was found to be 8.5 Gy (75th percentile:
12.4 Gy), which decreases to 7.0 Gy (9.0 Gy) with IMPT(OAR)R1 delivery and to 2.8 Gy (4.4 Gy)
with IMPT(OAR)R2. For 3 mm safety margin and an IMPT irradiation the median dose resulted
in 13.0 Gy (18.6 Gy) and reduces to 9.3 Gy (12.1 Gy) for IMPT(OAR)R1 and 3.5 Gy (6.0 Gy) for
IMPT(OAR)R2. With 5 mm safety margin the RTOG limit of 11.9 Gy starts to be exceeded for
IMPT(OAR)R1 deliveries as it was found to be 11.8 Gy (15.1 Gy) (compared to 19.0 Gy (22.8 Gy)
with IMPT). With the stronger restrictions on the other hand the dose to the esophagus remains
under the stated limit with 4.3 Gy (6.6 Gy). Even for a margin of 7 mm the stronger restrictions
result in an appropiate dose deposition with a median of 6.0 Gy (7.9 Gy). For IMPT(OAR)R1
the 7 mm margin result increased further to 14.3 Gy (17.1 Gy) (IMPT irradiation: 23.3 Gy
(24.6 Gy)).
Even though only the esophagus is included in the IMPT optimization process, also other OAR
profit from this irradiation mode. This can be understood as the beam stopping in front of the
esophagus (gantry angle of -45◦) is optimized into having less raster points in the IMPT(OAR)
delivery compared to an IMPT irradiation and hence a reduced dose contribution to the total
dose delivery. The other beam channels (gantry angles of 135◦ and 0◦) are hence optimized into
having more raster points compared to the IMPT delivery, contributing more to the dose depo-
sition. Adjacent OAR to the esophagus, like trachea and aorta, are thus also receiving a smaller
dose deposition from the beam channel stopping in proximity to them. As only an IMPT(OAR)
treatment leads to acceptable dose depositions in the esophagus, the median dose to the other
organs will only be stated for this delivery type.
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Over all patients the trachea is receiving a median dose of 0 Gy in all cases, since only pa-
tient 2 and 3 yield a dose in this critical structure. The 75th percentile is found to be 0.1 Gy
with no safety margin and 1.1 Gy, 3.0 Gy, 6.6 Gy for 3 mm, 5 mm and 7 mm, respectively for
IMPT(OAR)R1. For IMPT(OAR)R2 the 75th percentile results also to 0.1 Gy for no safety margin
and 0.5 Gy, 3.0 Gy, 7.4 Gy for 3 mm, 5 mm and 7 mm, respectively. All of these dose deposition
are far below the recommended dose-volume-limit for the trachea (10.5 Gy for 4 cm3).
For the aorta an IMPT(OAR)R1 irradiation with no safety margin leads to a median dose de-
position of 6.5 Gy (8.5 Gy), while 8.3 Gy (10.6 Gy), 9.8 Gy (12.3 Gy) and 11.3 Gy (14.0 Gy) are
deposited with 3 mm, 5 mm and 7 mm margin. In case of IMPT(OAR)R2 these results are further
reduced to 3.5 Gy (5.3 Gy) with no safety margin and 5.0 Gy (7.9 Gy), 6.3 Gy (12.0 Gy) and
7.8 Gy (13.6 Gy) with 3 mm, 5 mm and 7 mm margin, respectively. Also these results are far
below the critical dose-volume limit of 31 Gy for 10 cm3. It can thus be concluded that trachea
and aorta do not receive a critical dose deposition while treating the PVs with a dose of 25 Gy.
For the heart the dose-volume limits are much more critical. A median of 18.3 Gy (22.8 Gy) was
obtained for IMPT(OAR)R1 irradiations with no safety margin and 23.0 Gy (24.9 Gy), 24.3 Gy
(25.0 Gy) and 24.8 Gy (25.0 Gy) for 3 mm, 5 mm and 7 mm margin, respectively. These results
are slightly decreased with IMPT(OAR)R2 where the median is found to be 16.5 Gy (21.0 Gy) for
no margin and 20.0 Gy (24.0 Gy), 22.0 Gy (25.3 Gy) and 22.8 Gy (17.8 Gy) for 3 mm, 5 mm and
7‘mm margin, respectively. Hence all studied irradiations exceed by far the dose-volume limit
of 16 Gy for 15 cm3. A close analysis of the radiosensitive cardiac substructures is presented on
the next pages (in table 3.4 to table 3.11).
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IMPT IMPT(OAR)R1 IMPT(OAR)R2
(a) esophagus
(b) trachea
(c) heart
(d) aorta
Figure 3.6.: Boxplots of dose-volume data for different safety margins (0 mm, 3 mm, 5 mm and
7 mm) over all patients. The data is plotted for different OARs when irradiating
the LPV and RPV as IMPT (first column) or IMPT(OAR) in the five patient data sets.
The results for the different IMPT(OAR) restrictions are plotted individually, so that
IMPT(OAR)R1 (second column) are the treatment plans with a maximal dose of 70 %
of the physical dose and a weightfactor of 75 % and IMPT(OAR)R2 (third column) are
the results for the treatment plans with a maximal dose of 30 % physical dose and
a weightfactor of 200 %. The dose-volume-limit for each critical organ is indicated
with a dashed line in each plot, respectively.
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Closer analysis of the dose deposition in the heart was carried out. The result of the median
and 75th percentile over all patients is shown in table 3.4 for the mean dose and in table 3.5
for the maximal point dose. The mean deposited dose in the heart is negligible and does not
increase with the size of the safety margins. Furthermore no difference in between IMPT and
IMPT(OAR)R1 or IMPT(OAR)R2 irradiation can be observed. While also the maximum point dose
does not increase with added safety margin, it can be seen that IMPT(OAR) treatment does lead
to a higher point dose compared to an IMPT irradiation. This is higher for the irradiation with
stronger restrictions on the maximal dose to the esophagus.
Table 3.4.: Mean dose to heart: median and 75th percentile.
Margin IMPT [Gy] IMPT(OAR)R1 [Gy] IMPT(OAR)R2 [Gy]
0 mm 1.0 (1.3) 1.0 (1.1) 0.9 (0.9)
3 mm 1.3 (1.7) 1.3 (1.5) 1.1 (1.4)
5 mm 1.5 (1.9) 1.4 (1.7) 1.1 (1.4)
7 mm 1.6 (2.0) 1.5 (1.8) 1.1 (1.5)
Table 3.5.: Maximum point dose to heart: median and 75th percentile.
Margin IMPT [Gy] IMPT(OAR)R1 [Gy] IMPT(OAR)R2 [Gy]
0 mm 26.9 (27.1) 27.6 (29.6) 34.1 (36.9)
3 mm 26.2 (27.3) 28.4 (29.7) 31.6 (36.4)
5 mm 26.5 (27.1) 28.0 (29.1) 30.7 (31.6)
7 mm 26.2 (28.0) 26.8 (27.9) 30.1 (31.0)
This can be understood as the esophagus and the other adjacent OAR (trachea, aorta) receive
in general less dose with IMPT(OAR) due to the intensity reduction in one beam channel direc-
tion. Hence, the other beam channels have to deposit more particles. Especially gantry angle
0◦, which traverses the heart, is leading to an increased dose deposition in the heart. Since
this beam channel direction has to penetrate only a small volume of the heart, the maximal
irradiated volume shows a slight improvement in IMPT(OAR) deliveries compared to an IMPT
irradiation. The results are presented in table 3.6. Comparing the two IMPT(OAR) deliveries
it can be seen that the results do not change, since the number of beam channels and hence
penetrated volume does not change.
Table 3.6.: Maximal irradiated volume of heart: median and 75th percentile.
Margin IMPT [Gy] IMPT(OAR)R1 [%] IMPT(OAR)R2 [%]
0 mm 17.2 (20.0) 15.7 (18.9) 15.7 (19.3)
3 mm 19.4 (22.6) 17.4 (21.2) 17.4 (21.8)
5 mm 20.7 (24.9) 18.5 (23.2) 18.5 (23.7)
7 mm 21.8 (26.4) 19.9 (24.4) 19.9 (25.2)
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Concerning the ventricles the mean dose is negligible, with a median of less than 0.1 Gy
(75th percentile of less than 0.2 Gy) for the LV and no dose exposure to the RV (median of
0.0 Gy (75th percentile of 0.0 Gy)). For the IMPT irradiations the median and 75th percentile
of the maximal dose to the LV and RV over all patients and for all safety margin cases is shown
in table 3.7. For both ventricles the dose is slightly increasing with the size of the safety margin.
The left ventricle is receiving a higher maximum point dose than the right ventricle in case of an
irradiation with the stronger dose restrictions. Concerning the maximal irradiated volume it can
be stated that the LV is irradiated to a higher extend than the RV in all studied cases, and that
also here the affected volume is increasing with the underlying safety margin size. Nevertheless
it can be stated that the irradiated volume of both ventricles is negligible and that the maximum
point dose is small.
Table 3.7.: Maximum point dose to ventricles: median and 75th percentile.
OAR Margin IMPT(OAR)R1 [Gy] IMPT(OAR)R2 [Gy]
LV 0 mm 0.9 (2.8) 0.8 (3.3)
3 mm 1.5 (3.9) 1.7 (7.9)
5 mm 1.8 (5.0) 4.6 (6.5)
7 mm 3.2 (6.1) 6.1 (9.0)
RV 0 mm 0.0 (0.5) 0.0 (0.0)
3 mm 0.9 (2.1) 0.3 (0.9)
5 mm 2.5 (3.7) 0.0 (1.5)
7 mm 4.1 (5.0) 0.0 (3.7)
Table 3.8.: Maximal irradiated volume of ventricles: median and 75th percentile.
OAR Margin IMPT(OAR)R1 [%] IMPT(OAR)R2 [%]
LV 0 mm 4.7 (12.0) 3.9 (11.2)
3 mm 6.1 (14.7) 5.6 (14.5)
5 mm 7.3 (16.7) 7.7 (15.8)
7 mm 8.9 (18.7) 9.2 (17.9)
RV 0 mm 0.0 (0.1) 0.0 (0.0)
3 mm 0.5 (0.6) 0.2 (0.2)
5 mm 1.1 (1.7) 0.0 (1.1)
7 mm 1.8 (3.0) 0.0 (2.3)
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Concerning the coronary arteries, it can be seen that the LCA and RCA are receiving a compa-
rable, small mean dose, which has a median of less than 1 Gy in most studied cases. For both
structures the maximum point dose increases with safety margin. The maximal deposited dose
is higher in the LCA than in the RCA. In both cases the dose can be reduced with the stronger
IMPT(OAR) restriction parameters, so that it can be concluded that also these structures benefit
from the IMPT(OAR)R2 settings. Due to the small vessel size of the coronary arteries the dose
deposition results in a relatively high maximal irradiated volume. In general, the maximum ir-
radiated volume also increases with safety margin. While the maximal irradiated volume of the
RCA can be drastically reduced with stronger IMPT(OAR) settings, especially for large margins,
the volume of the LPV does not change significantly. This is due to the proximity of the upper
LCA branches to the LPV target site.
Table 3.9.: Mean dose to coronary arteries: median and 75th percentile.
OAR Margin IMPT(OAR)R1 [Gy] IMPT(OAR)R2 [Gy]
LCA 0 mm 0.2 (0.7) 0.2 (0.7)
3 mm 0.5 (0.9) 0.4 (1.7)
5 mm 0.7 (1.2) 1.0 (2.0)
7 mm 1.5 (2.0) 1.3 (2.8)
RCA 0 mm 0.3 (1.1) 0.1 (0.4)
3 mm 0.5 (0.8) 0.3 (1.0)
5 mm 0.7 (1.5) 0.1 (0.7)
7 mm 1.0 (2.0) 0.2 (1.1)
Table 3.10.: Maximum point dose to coronary arteries: median and 75th percentile.
OAR Margin IMPT(OAR)R1 [Gy] IMPT(OAR)R2 [Gy]
LCA 0 mm 6.0 (7.0) 5.2 (8.3)
3 mm 7.4 (9.4) 8.0 (15.6)
5 mm 8.7 (15.9) 12.3 (17.6)
7 mm 20.1 (23.0) 16.2 (22.0)
RCA 0 mm 3.1 (5.2) 2.8 (5.7)
3 mm 3.8 (6.5) 3.1 (7.8)
5 mm 4.3 (8.8) 3.4 (9.8)
7 mm 5.9 (15.3) 4.2 (11.9)
Table 3.11.: Maximal irradiated volume of coronary arteries: median and 75th percentile.
OAR Margin IMPT(OAR)R1 [%] IMPT(OAR)R2 [%]
LCA 0 mm 26.7 (41.0) 25.3 (38.3)
3 mm 28.5 (45.7) 28.0 (44.2)
5 mm 29.6 (49.1) 30.3 (46.5)
7 mm 31.4 (53.4) 31.2 (50.3)
RCA 0 mm 19.2 (28.6) 15.6 (23.6)
3 mm 25.1 (32.2) 21.8 (30.2)
5 mm 33.2 (37.6) 2.1 (29.6)
7 mm 39.6 (43.4) 2.1 (36.1)
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3.2.3 Motion assessment of heartbeat
Using the resulting deformation maps from deformable image registration the motion of the
ablation sites of LPV and RPV was assessed. MVHs displaying the relative displacement of every
voxel of the investigated volume to the reference phase in all three motion directions were gen-
erated. The mean and standard deviation of these displacement values in each motion phase
of LPV and RPV are plotted for all patients and motion directions in figure 3.7 and 3.8. The
numerical values can be found in appendix B.1.
The mean and standard deviation of each patient over all motion phases are stated in table
3.12. From the five studied patients patient 4 is displaying the highest absolute displacement,
both in LPV and RPV. Furthermore it can be seen that none of the motion directions can be deter-
mined as the largest contribution to the absolute displacement, neither in LPV or RPV motion.
In table 3.13 the maximal absolute displacement for each patient is presented together with the
corresponding motion phase. While motion phase six is the motion phase with the biggest dis-
placement in 30 % of all cases, no evident maximal motion phase can be assessed. On average,
the absolute amplitude over all motion phases and patients is found to be (2.7 ± 1.6) mm for
LPV and (2.6 ± 1.4) mm for RPV. In SI direction, the mean amplitude is (-0.6 ± 1.4) mm for LPV
and (-0.2 ± 1.6) mm for RPV. In AP direction it is (0.8 ± 1.0) mm for LPV and (1.0 ± 1.6) mm
for RPV, while in LR direction it is found to be (0.4 ± 0.9) mm for LPV and (-1.0 ± 1.5) mm for
RPV. Hence, averaged over all patients it can be stated that while the PVs are moving mostly in
AP direction, the contribution of the other motion directions are in the same order of magnitude.
The motion phases of the heartbeat gated CT scan are based on the ECG trace and result in
a division of a single heartbeat. The motion phases can hence be directly assigned to the con-
traction (systole) and dilatation (diastole) of both atria and ventricles. Contraction of the atria
(atrial systole) is occurring in between motion phase four and nineteen, in the same time as the
ventricular relaxation (ventricular diastole). The ventricular systole and at the same time atria
diastole are hence much shorter, occurring in the remaining motion phases twenty to three. The
maximal displacement of the atria should thus be observed in motion phase eightteen, while
the maximal amplitude of the ventricle should be observed in motion phase three. The motion
of the PVs on the other hand result in a chaotic displacement. No motion phase can be assessed
to a maximal displacement in all patient cases and no dominant motion direction is observed.
The underlying heartbeat motion which causes the PVs to move should hence be much more
complex.
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Figure 3.7.: Mean motion amplitude and standard deviation of LPV in each MP relative to the ref-
erence phase under influence of heartbeat for all patients (Patient 1: black, Patient
2: red, Patient 3: green, Patient 4: blue, Patient 5: turquois). The motion is shown in
the three studied motion directions (SI, AP, LR) and the absolute displacment.
Figure 3.8.: Mean motion amplitude and standard deviation of RPV in each MP relative to the
reference phase under influence of heartbeat for all patients (Patient 1: black, Pa-
tient 2: red, Patient 3: green, Patient 4: blue, Patient 5: turquois).
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Table 3.12.: Mean displacement of PVs over all motion phases in all patients and motion
directions.
Patient LPV: ABS [mm] LPV: SI [mm] LPV: AP [mm] LPV: LR [mm]
1 2.7 ± 1.2 -1.2 ± 0.9 1.4 ± 1.1 -0.9 ± 0.8
2 2.3 ± 1.1 1.2 ± 1.1 0.6 ± 0.5 -1.4 ± 0.9
3 2.5 ± 1.8 -0.4 ± 1.1 0.5 ± 0.8 -1.2 ± 2.0
4 4.3 ± 2.5 -3.1 ± 2.5 0.3 ± 1.4 -0.8 ± 2.5
5 2.2 ± 1.2 -0.8 ± 1.4 0.7 ± 1.1 -0.2 ± 1.0
Patient RPV: ABS [mm] RPV: SI [mm] RPV: AP [mm] RPV: LR [mm]
1 2.1 ± 0.7 -0.9 ± 0.7 1.1 ± 0.9 0.6 ± 0.6
2 2.3 ± 1.3 0.7 ± 1.1 1.0 ± 1.1 -1.2 ± 1.0
3 2.2 ± 1.2 0.2 ± 1.3 0.5 ± 1.8 0.4 ± 0.7
4 4.6 ± 2.3 -1.7 ± 3.1 1.7 ± 2.8 1.8 ± 1.0
5 2.8 ± 1.7 0.2 ± 1.8 1.0 ± 1.3 1.4 ± 1.4
Table 3.13.: Biggest absolute displacement of PVs with corresponding motion phase (MP) in all
patients.
Patient LPV: max. ABS [mm] MP
1 4.5 ± 1.7 06
2 5.3 ± 1.9 06
3 3.4 ± 2.2 08
4 5.5 ± 3.1 11
5 2.9 ± 1.5 16
Patient RPV: max. ABS [mm] MP
1 4.0 ± 1.4 06
2 5.2 ± 1.8 04
3 2.9 ± 1.4 11
4 6.5 ± 3.0 10
5 4.0 ± 4.0 15
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The overall displacement field between the extreme states of the ventricular displacement
(motion phase three) and atrial displacement (motion phase eightteen) for two exemplary pa-
tients with a small motion amplitude (patient 5) and a large motion amplitude (patient 4) are
shown in figure 3.9. In order to visualize the location of the displacement, an axial cut of the
reference state CT is underlayed. The absolute values of the displacement vectors are shown as
contour plots.
(a) Patient 4: max. motion ventricle (b) Patient 5: max. motion ventricle
(c) Patient 4: max. motion atria (d) Patient 5: max. motion atria
Figure 3.9.: Axial slices of the reference state of the CT overlayed with the absolute values of
the displacement field (obtained from deformable image registration) in the cor-
responding slice for heartbeat motion. In the top row the displacement from the
motion phase with the maximal ventricle motion to the reference phase is shown,
in the lower row the displacement from the motion phase with the maximal atrial
motion, for Patient 4 and Patient 5, respectively.
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3.2.4 Motion mitigation techniques for heartbeat
The absolute motion amplitudes of up to 6 mm due to heartbeat are expected to yield dose
inhomogeneities when not compensated for. The resulting interplay effect and dose deposition
were studied for every patient for different motion patterns and different margins to the target
volumes. The dose analysis values V95, V107 and D5-D95 were assessed and plotted. For
comparison also the corresponding values for the 3D case (static) are shown. Due to the small
motion amplitude, rescanning was studied as motion mitigation technique. The results of the
stated dose values in case of rescanning with different rescan numbers will also be presented.
Dose deposition
The dependencies of dose coverage and dose homogeneity on safety margin and rescan num-
bers are shown over all patients and motion patterns for the two target volumes, LPV and RPV,
in figure 3.10. It can be seen that ten rescans yield a robust motion mitigation technique for
the displacement of the PVs due to heartbeat motion. This will be studied in more detail in the
following.
A representative dose deposition for all studied techniques (static, interplay and rescanning
with ten rescans) is shown exemplary for patient 4 (as this is the patient with the largest PV
motion amplitude both in LPV and RPV) in figure 3.11. Rescanning and interplay are shown
for a motion period of 0.7 s and a starting phase of 0◦. The target volumes LPV and RPV were
irradiated simultaneously and a margin of 3 mm was added.
Exemplary for patient 4, DVHs of the CTV for a static irradiation as well as interplay and
ten rescans for different motion patterns and a target volume with 3 mm safety margin are
displayed in figure 3.12. In order to assess the dose information of all patients the DVHs were
analyzed and compared for dose steepness, dose coverage as well as over dosage. The average
results over all patients with the resulting standard deviation can be seen in figure 3.13. A more
detailed analysis can be found in appendix B, where the corresponding numerical values are
shown (tables B.11 - B.20).
For interplay it can be seen that the results are slightly dependent on the used motion pe-
riod and starting phase. This can be seen in the mean values of the resulting dose parameter
values for different, underlying motion patterns. E.g. for LPV, the mean value of the dose cov-
erage parameter over all patients is V95=(87.7 ± 7.4) % for a motion with 1s period and a
starting phase of 90◦ and (92.1 ± 4.3) % for a motion with 0.7 s period and a starting phase of
90◦, while for a motion with 0.7 s period and a starting phase of 0◦ the dose coverage is found
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to be (90.4 ± 3.3) %. Furthermore the result is also dependent on the studied safety margin,
so that e.g. the dose coverage for a motion with 1s period and a starting phase of 90◦ is (94.6
± 4.4) % with 3 mm safety margin. All these dependencies are also valid for the other studied
dose analysis parameters, dose homogeneity and over dosage. The improvement of the dose
coverage and dose homogeneity in relation to the size of the safety margin are also presented in
figure 3.10 (a and b). The dose homogeneity resulting from interplay as well as all rescanning
irradiations was studied in relation to the used margin size and the proportion of variance ex-
plained resulted in r2=0.35 (p<0.0001), hence favoring the application of the necessary safety
margins. It becomes obvious that a safety margin of 3 mm is already sufficient to drastically
improve the outcome.
The underlying deformation map with its motion amplitude does not enable a prediction of
the magnitude of the interplay effect. This was studied in more detail for the dose homogeneity,
as these values were normally distributed. The proportion of variance explained between the
maximal motion amplitude of the left and right PV (see table 3.13) and the resulting D5-D95
values for all studied margins resulted in r2=0.02 (p<0.0001).
As can be seen in figure 3.13 (as well as in more detail for all patients in appendix B.2) res-
canning yields improved results compared to interplay in all studied cases. This is valid for dose
steepness, dose coverage as well as over dosage. Especially dose coverage and over dosage are
comparable to the static results for all patient and motion patterns. Exemplary, the dose cov-
erage of patient 4 (with the largest absolute displacement) will be discussed. V95 for a static
irradiation of the LPV of patient 4 with 3 mm safety margin is found to be 99.8 %. With a motion
of 0.7s period length and a starting phase of 0◦ the value decreases to 90.0 %. With rescanning,
V95 can be improved to 99.8 % with only five rescans. For RPV the static dose coverage with
3 mm margin is found to be 100.0 % for this patient. With the stated motion and safety margin
the dose coverage decreases to 97.0 % in case of interplay. Even though this is an acceptable
value, the treatment gets more robust with rescanning and only five rescans are sufficient to
increase the value to 100.0 %. The improvement of dose coverage and over dosage compared
to interplay is valid for all studied rescan numbers, starting from the smallest studied rescan
number of five, as shown here. Nevertheless, in some studied cases five rescans is not enough
to yield results comparable to the static irradiation. This was studied in more detail for the dose
coverage parameter V95. For example for the LPV irradiation in patient 1 with five rescans and
a motion period of 1 s 90◦ starting phase (3 mm safety margin) V95 results in a smaller dose
coverage (93.2 %) than the static case (100 %). Even though this result is improved compared
to interplay (86.9 %), a much better result can be gained with higher rescan numbers, starting
with ten rescans (99.2 %). Also the results for dose homogeneity improves with higher rescan
numbers. For a motion pattern of 0.7 s period and 0◦ starting phase (3 mm safety margin) in
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patient 4, the dose homogeneity in case of interplay is found to be 9.9 %. With five rescans a
dose homogeneity of 5.5 % is yielded, which further decreases to 4.6 % with ten rescans, 4.4 %
with fifteen rescans and 3.9 % with twenty rescans (compared to 3.9 % in the static irradiation).
As the dose homogeneity was normally distributed, the relation between dose homogeneity and
rescan number was analyzed. Thereby interplay was included as a rescan number of one. The
explained variance was found to be r2=0.37 (p<0.0001). It can thus be concluded that rescan
numbers higher than five yield slightly better results, while ten rescans show results comparable
to the static irradiation in all studied patient cases, for all studied safety margins and for all
underlying motion patterns. This can also be seen in figure 3.10 (c) where the dose coverage
over all patients and margins is studied in relation to the used rescan number. It can be seen
that while interplay (one rescan) results into a median of 8.9 % (75th percentile of 10.0 %),
five rescans can reduce it to 6.1 % (8.1 %). With ten rescans this can be further improved to
4.1 % (5.9 %). Fifteen and twenty rescans on the other hand do not lead to an improved result
compared to ten rescans (fifteen: 4.1 % (5.9 %), twenty: 4.0 % (5.7 %)).
(a) D5-D95 versus margin size (b) V95 versus margin size
(c) D5-D95 versus rescan numbers (d) V95 versus rescan numbers
Figure 3.10.: Boxplots of dose analysis parameters D5-D95 and V95 over all patient data sets
and target volumes (LPV: circle and RPV: cross) depending on the used margins
size (0 mm: black, 3 mm:red, 5 mm: green, 7 mm: blue) or the used rescan number
(one rescan equals interplay, rescanning with five, ten, fifteen and twenty rescans).
Minimum and maximum of the data is plotted within 1.5 times the interquartile
range, the other data points are stated as outliers. Figures are courtesy of Dr.
Christian Graeff.
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(a) static
(b) interplay
(c) rescanning (10x)
Figure 3.11.: Dose distribution of patient 4 for static (a) as well as interplay (b) and ten rescans
(c) for a motion period of 0.7 s and a motion starting phase of 0◦. The target
volume has an added margin of 3 mm.
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(a) LPV
(b) RPV
Figure 3.12.: Dose volume histograms for CTV of patient 4 for 3 mm safety margin irradiation
(LPV (a) as well as RPV (b)) in case of static irradiation (black), interplay (dashed)
and rescanning with ten rescans (solid). The motion patterns are shown in colors
(1s 0: motion period of 1 s and starting phase 0◦, 1s 90: motion period of 1 s and
starting phase 90◦, 07s 0: motion period of 0.7 s and starting phase 0◦, 07s 90:
motion period of 0.7 s and starting phase 90◦).
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(a) D5-D95: LPV (b) D5-D95: RPV
(c) V95: LPV (d) V95: RPV
(e) V107: LPV (f) V107: RPV
Figure 3.13.: Mean and standard deviation of dose analysis parameters D5-D95 (first row), V95
(middle row) and V107 (last row) over all patients. The LPV (left column) and
RPV (right column) were studied seperately. Static (black) as well as interplay (red)
and different rescanning numbers (5 times: blue, 10 times: green) were compared
for different motion patterns and safety margins. For a better visualization the
rescanning data points for each motion pattern are shifted and the result for fifteen
and twenty rescans are not displayed.
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Irradiation time
In figure 3.14 the mean irradiation time over all patients for different rescanning irradiations of
LPV and RPV are shown for different safety margins and motion patterns. The duration for each
beam entry channel (gantry angle of -45◦, 135◦ and 0◦) is plotted individually. It can be seen
that the needed irradiation time increases with the used safety margin as the irradiated volume
increases. The irradiation time is independent of the motion pattern but varies depending on
the used beam entry channel. The stated results were achieved with a low intensity irradiation
(minimal particle number of 5,000). For an irradiation with 3 mm margin around LPV and RPV
the overall treatment time is calculated to (13.7 ± 0.9) min (see table 3.14) with rescanning
as motion mitigation technique for heartbeat motion. This time could be shortened if a higher
minimum particle number per beam spot (e.g. 75,000) was used, which needs to be studied.
Figure 3.14.: Mean and standard deviation of the irradiation time over all patients for different
underlying motion patterns and beam entry channels.
Table 3.14.: Mean irradiation time for LPV and RPV with a safety margin of 3 mm over all
patients.
Gantry angle [◦] time [min] total [min]
-45 4.7 ± 0.9
135 4.4 ± 0.9 13.7 ± 0.9
0 4.6 ± 1.0
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3.3 Discussion
In this chapter the influence of heartbeat motion on the PVs was studied and treatment planning
studies with rescanning as motion mitigation technique were carried out. A detailed analysis
of the dose depositions to the OAR was performed, with special emphasis on the irradiation of
cardiac substructures. Beforehand, a study of the best suited field number and beam directions
was conducted as well as an analysis of possible safety margin limitations.
3.3.1 Dose to critical structures
Concerning the dose deposition in OAR (esophagus, trachea, aorta and heart) dose-volume lim-
its from SBRT were used. In SBRT treatment a high dose is applied in a single fraction and hence
comparable to the here stated dose delivery of 25 Gy physical dose in one treatment session.
An extensive collection of dose-volume-limits for SBRT are presented in the study protocols
of the Radiation Therapy Oncology Group (RTOG). The stated dose-volume limits for trachea
(10.5G y in 4 cm3) and aorta (31 Gy in 10 cm3) were not exceeded for any of the studied field
numbers and beam channel combinations. The same is valid while keeping the chosen three
fields (couch angle of 90◦ and gantry angles of -45◦, 135◦ and 0◦) constant and changing the
studied safety margins (0 mm, 3 mm, 5 mm and 7 mm). For the esophagus on the other hand,
the dose-volume limits were much more critical. Most of the studied beam directions yielded a
dose which exceeded the stated dose-volume limit (11.9 Gy for 5 cm3). Hence IMPT(OAR) de-
liveries, including the esophagus in the optimization process, were necessary. With this delivery
technique and the above stated beam direction, the dose to the esophagus could be drastically
reduced. With restrictions to a maximum point dose of 70 % to the esophagus (IMPT(OAR)R1,
weightfactor of 75 %) only an irradiation of the PVs with 3 mm safety margin resulted in a
dose deposition into the esophagus which met the dose volume limit (median of 9.3 Gy, 75th
percentile: 12.1 Gy). This result could be further improved with different IMPT parameters
(IMPT(OAR)R2, maximum dose of 30 % and weightfactor of 200 %), enabling a safe irradiation.
Thus also safety margins higher then 3 mm should result in an uncritical dose deposition to
the esophagus. For the heart all beam channels, safety margins and delivery types (IMPT or
IMPT(OAR)) exceeded the stated dose-volume limit (16 Gy for 15 cm3). This is due to the fact
that the heart is not only an OAR but part of the target itself. Hence a closer look on the affected
cardiac substructures and the relevance of these dose depositions on cardiac toxicity and late
effects were given.
QUANTEC (quantitative analysis of normal tissue effects in the clinic) [QUANTEC10] offers
an comprehensive literature review on the available data of the last 20 years and is meant as an
update of the extensively used dose-limits proposed by Emami et al. [Ema91]. In the QUANTEC
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publication by Gagliardi et al. [Gag10] radiation dose-volume effects in the heart are presented.
It is stated that radiation-induced cardiac diseases are distinguished between acute injuries like
pericarditis2, which can turn into a chronic disease, and late injuries which manifest months
or even years after radiation exposure. Typical late injuries are congestive heart failure3, is-
chemia, coronary artery disease and myocardial infarction. It was summarized that it remains
uncertain which region of the heart is most important for radiation induced tissue toxicities.
But it is stated that the risk of cardiac events is probably related to both dose and irradiated
volume. Pericarditis seems to be related to left ventricle (LV) irradiation, and it was found that
LV shielding was able to drastically reduce the incidence rate [Car76]. It was stated that a mean
cardiac dose of 27.1 Gy and maximum dose of 47 Gy seem to act as predictors for pericarditis
[Mar98]. Wei et al. [Wei08] stated another discriminator for pericarditis which was found to be
V30 < 46 %, which translates in a mean pericardial dose of less than 26 Gy. For coronary and
ischemic events relevant substructures are assumed to be coronary arteries on the left ventricle
(LCA) [Nie07, Tay07, Tay08]. Furthermore it is stated that excess deaths from heart disease
are observed in patients receiving more than 42 Gy [Han93] and that aortic and mitral stenosis
incidences increased above a threshold dose of 30 Gy [Tay07]. For long term cardiac mortality
an increased rate was only observed at whole heart doses above 30 Gy [Han93].
Hooning et al. [Hoo07] studied the cardiovascular disease incidence in more than 4000 breast
cancer survivors after a follow-up period of more than 10 years as patients were treated from
1970 through 1986. It was the first study to examine the effects of cardiovascular risk factors
in combination to radiotherapy. They found that the risk of congestive heart failure was sig-
nificantly increased when the patients had received chemotherapy (95 % confidence interval of
1.25 to 2.73) and that smoking drastically increased the risk of the patients to suffer a myocar-
dial infarction (95 % confidence interval of 2.03 to 4.55). Concerning radiotherapy they stated
that a higher mean dose to the whole heart resulted in an increased risk of congestive heart
failure and that an irradiation of the left vs right chest wall (thus more heart volume and in
particular including the LV and apex) led to an increased risk of myocardial infarction.
A recent study by Darby et al. [Dar13] investigated more than 2000 breast cancer patients
treated in between 1958 and 2001 for coronary events like myocardial infarction, coronary
revascularization or death from ischemic heart disease. They found a mean heart dose of 4.9 Gy
(0.0 Gy to 27.7 Gy) and that the rates of major coronary events increased linearly with the mean
heart dose. They stated an increase of incidences by 7.4 % per Gy (95 % confidence interval of
2.9 to 14.5) after five years post radiotherapy.
2 inflammation of the sac containing the heart
3 heart is unable to maintain sufficient blood flow
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For the here studied seventeen beam channel combinations, applying a physical dose of 25 Gy,
the mean dose to the heart of all five studied patients was found to have a median of 1.3 Gy
(75th percentile of 1.5 Gy). The median over the maximal point dose was found to be up to
26.6 Gy (75th percentile: 27.1 Gy), while in general less than 30 % of the heart was irradiated.
With the chosen field number of three beam channels with a couch angle of 90◦ and gantry
angles of -45◦, 135◦ and 0◦, the mean dose was found to be negligible (median of 1 Gy, 75th
percentile of up to 1.5 Gy) in all studied patient cases. The median mean dose over all patients
did not increase with increasing safety margin for both IMPT(OAR) deliveries. As the LV, and
with it especially the LCA, are assumed to be radiosensitive structures within the heart the dose
depositions to these structures were analyzed in more detail. It was found that three beam
channel directions were best suited to yield a lower mean dose deposition in the LCA. Due to
robustness criteria of the treatment delivery the above stated beam channel combination was
chosen. With this delivery direction and an IMPT(OAR)R2 treatment it was found that the mean
dose to the LCA was, dependent on the used safety margin, 0.2 Gy(75th percentile: 0.7 Gy) with
no margin, 0.4 Gy (75th percentile: 1.7 Gy) for 3 mm margin, 1.0 Gy (75th percentile: 2.0 Gy)
for 5 mm and 1.3 Gy (75th percentile: 2.8 Gy) for 7 mm. The maximum point dose to the LCA
with these beam channels nevertheless led to an increased dose in the left chamber compared
to the right site. This is due to the proximity of the upper LCA branches to the LPV target site.
3.3.2 Beam channel directions and safety margins
In general, it can be stated that field number and beam direction always result in a trade-off
between dose to the OAR, irradiation time and robustness. While less fields and hence beam
directions shorten the treatment time, it does lead to a less robust treatment. In case OAR are
displaced during the treatment (intrafractional motion, see chapter 1) or move in between CT
image acquisition and irradiation (interfractional motion) beam channels with a large angle
in between them are more robust, as not all fields are affected by this displacement and hence
only a small dose would be shifted. Furthermore, opposite fields (like -45◦ and 135◦) (see figure
3.1) are more robust against potential range uncertainties and should hence be favored. Due
to this reason, combined with the smaller LCA dose deposition in case of three field numbers, a
couch angle of 90◦ and gantry angles of -45◦, 135◦ and 0◦ were selected for the safety margin
limitation studies as well as the motion mitigation treatment plans. Concerning safety margins,
which need to be applied in order to account for possible deviations in between treatment
planning and dose delivery, it can be stated that only a small margin tolerance was observed.
This is due to the difficult position of the PVs close to radiosensitive structures like the esophagus
and especially the heart. With IMPT treatment a delivery with 3 mm safety margin was found
to fulfill all the needed requirements. A more realistic safety margin of 5 mm could be achieved
with more restricted parameters in the IMPT optimization.
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3.3.3 Movement of PVs in cardiac cycle
Lickfett et al. [Lic05] analyzed the volume changes and displacement of the PVs in 25 healthy
volunteers with MRI images. They studied the posterior edge of the PV orifice and observed
that the size and location changed considerably during the cardiac cycle. Displacements of up
to 7.2 mm were found and it could be concluded that the motion amplitudes were bigger in
the coronal (left-right) than in the sagittal (anterior-posterior) direction. In more detail the
largest coronal movement was found in the left superior PV, while the largest sagittal motion
was observed in the right superior PV with 3.9 mm. The smallest saggital displacement was
2.5 mm in the left anterior PV. They suspected that the reason for movement is not resulting
from a single influence, but is rather a mix of PV contraction, atrial contraction and ventricular
force. The movement of PV due to heartbeat is also relevant for catheter ablation. Based on the
stated finding Lickfett et al. recommended to keep a 5 mm distance from the PV orifice during
PV encircling ablation in order to reduce the risk for PV stenosis. Patel et al. [Pat08] studied the
MRI images of 30 patients in sinus rhythm with paroxysmal atrial fibrillation. They stated that
the mean displacement of the pulmonary veins was small. The left lower PV was found to move
(2.7 ± 1.2) mm, the left upper PV (2.1 ± 1.1) mm, the right lower PV (1.9 ± 1.1) mm and the
right upper PV (2.3 ± 1.0) mm.
In the here studied patient cohort of five AF patients no differentiation between the upper
and lower PVs was carried out. The motion was assessed for the whole potential ablation site
of LPV and RPV, respectively. Similar to the study by Patel et al. only a small mean displace-
ment was found, resulting in an average absolute displacement of less than 3 mm (LPV: (2.71
± 1.57) mm, RPV: (2.62 ± 1.41) mm). Even though a tendency to a higher motion in AP di-
rection could be observed, the contributions of the other motion directions were in the same
order of magnitude (up to 1 mm). Hence no dominant motion direction could be determined.
The motion phases of the heartbeat gated CT scan were based on the ECG trace and resulted in
a division of a single heartbeat. Thus the motion phases could be directly assigned to the con-
traction (systole) and dilatation (diastole) of both atria and ventricles. Nevertheless no motion
phase could be assessed to yield the maximum displacement. This reinforces the hypothesis by
Lickfett et al. that the underlying heartbeat motion, which causes the PVs to move, is much
more complex.
110
3.3.4 Rescanning as motion mitigation technique
The small target volume displacement due to heartbeat led to small interplay effects, where the
dose coverage was found to have V95 values smaller than 95 % in only 31 % of the studied
cases. This result could be already improved by using safety margins, as 71 % of these cases
were irradiations with no safety margin and only 3 % of the stated cases were irradiations with
safety margins of 5 mm or more. Nevertheless also irradiations with a safety margin of 7 mm
were found to have a V95 of 89 % in some cases (e.g. in the irradiation of the LPV in patient
4 with a motion period of 1 s and a starting phase of 90◦). In order to guarantee a robust and
conformal irradiation a motion mitigation technique was hence needed. Rescanning was stud-
ied and it can be concluded that this technique yields good results.
Regarding dose coverage V95 values were higher than 99 % in 96.3 % of all studied cases
with a safety margin of 3 mm or higher. The minimum dose coverage over all studied cases with
safety margin was found in patient 1, in the irradiation of the LPV with a margin of 3 mm and an
underlying motion of 1s period and 90◦ starting phase (V95=93.2 %). This result was obtained
with five rescans. With higher rescans the dose coverage could be improved, so that only 1.5 %
of the studied cases with ten or more rescans had a dose coverage smaller than 99 % (minimum:
97.1 %; 10 rescans in patient 1, 7 mm safety margin and motion of 1 s period and 90◦ starting
phase). The dose coverage for rescans without safety margin was worse, resulting in 93.1 %
cases under 99 %. In comparison, the static irradiations without safety margin resulted in a
V95<99 % in only 17 % of the cases. V107 values higher than 0 % were obtained in 7.3 %
of all cases with safety margin (maximum of V107=3.7 % in the LPV of patient 3 with safety
margin of 5 mm, 5 rescans and motion of 1 s period and 0◦ starting phase) compared to 28.8 %
of cases without safety margin (maximum: V107=8.0 % for the LPV of patient 2 with 5 rescans
and motion of 1 s period and 0◦ starting phase. This could be reduced to V107=2.9 % with
10 rescans). With safety margin, the dose homogeneity D5-D95 did not exceed 8.9 %. Without
safety margin D5-D95 did not exceed 10.2 %. Both of these values were achieved with 5 rescans
and could be improved with 10 rescans (with safety margin to less than 7 % and without to less
than 9 %). It can hence be concluded that additional safety margins enable a more robust and
successful treatment delivery. However, if possible, these margins should be kept as small as
technical feasible, as it increases the dose deposition in OARs. Regarding rescan numbers ten
rescans yield improved results compared to five rescans. These results are not significantly im-
proved with rescan numbers higher than ten.
All these results were found for slice-by-slice rescanning, which means that each IES is irra-
diated independently with the predefined number of rescans and the adapted particle numbers.
In this case the treatment time is not prolonged. It needs to be studied if other rescanning tech-
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niques like breath-sampled rescanning [Sec09] or phase-controlled rescanning [Fur07], where
the rescanning of the individual IES are sampled according to the motion phase of the breathing
period, are applicable to cardiac motion (ECG-sampled rescanning) and if this method would
result in the need of fewer rescan numbers.
3.4 Conclusion
The PVs were found to move due to heartbeat with an amplitude of up to 6 mm. This dis-
placement creates interplay effects when irradiated with scanned carbon ions. Rescanning as
motion mitigation technique was studied. It yields improved dose coverage and dose homo-
geneity compared to interplay in all studied patient cases, motion patterns and for all safety
margins. It is thus an adequate motion mitigation technique for the irradiation of PVs under
influence of heartbeat motion. A rescan number of ten is sufficient to obtain results comparable
to the static irradiation. For the treatment delivery, IMPT(OAR) dose optimization together with
a rather small safety margin (of e.g. 3 mm or 5 mm) results in dose depositions in the OARs
(like esophagus as well as in the cardiac substructures) which are considered tolerable. In order
to achieve this an ion gantry, such as the one at HIT, is needed, as it allows for ion beam entry
channels which better spare the critical structures.
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4 Irradiation of cardiac target volumes in
porcine data
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The presented results of planning studies for a non-invasive ablation of cardiac target sites in
human data need to be experimentally validated. This will be carried out at GSI in 2014, in
collaboration with HIT and University Hospital Heidelberg as well as Mayo Clinic (Rochester,
Minnesota, USA). Porcine models will be used and the results will be compared to findings with
photon irradiation, both from literature [Sha10, Bla13], as well as from studies currently per-
formed at Mayo Clinic. For the feasibility study different cardiac target sites are conceivable:
PV isolation, ablation of the CTI as well as the AV node. In a first iteration of the experiments,
only the AV node of the pigs will be irradiated, both at Mayo Clinic with photons and at GSI
with carbon ions. The experiments are planned to enable a direct comparison between parti-
cle therapy and photon irradiation, so that many of the treatment settings are kept constant
inbetween the two centers. Also in pigs, cardiac target sites move due to respiration as well as
heartbeat, causing potential interplay effects which threaten the treatment oucome. While the
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breathing motion of the pigs is planned to be compensated with breath hold, controlled by a
respirator, the influence of heartbeat motion needs to be studied in more detail. The resulting
motion amplitude and direction will be studied and rescanning as motion mitigation technique
will be presented.
4.1 Material and methods
As in the previous chapter, the input data and treatment planning parameters will be given
before stating all performed studies. Finally, the analysis procedure will be described.
4.1.1 Treatment planning input data
In order to assess the motion of the potential cardiac target sites (PV, CTI and AV node) in pigs
under influence of heartbeat motion, ECG gated 4DCTs were studied. Four porcine data sets
were recorded at Mayo Clinic (Rochester, Minnesota, USA) under anesthesia and respiration.
The CT scans were acquired on a Definition Dual Source CT scanner (Siemens). The 4DCT data
set consisted of twenty temporal equally distributed cardiac motion phases, the reference phase
zero started at the R-peak of the QRS-complex (see chapter 1, section 1.3.1). Native CT scans
were recorded. In order to distinguish structures within the heart, contrast enhanced CT scans
were also aquired directly after the native scans. The radiopaque material was administered
intravenously (100 ml contrast media at a rate of 4 ml/sec) and the CT scans were acquired 30 s
after injection. Segmentation of the target volumes as well as the OARs (esophagus, trachea,
aorta and cardiac structures) were carried out by a collaborating cardiologist at Mayo Clinic
with Eclipse™(Varian Medical Systems) on the reference phase. The volumes of the contours
for the different ablation sites are presented for each pig in table 4.1. The location of these sites
are visualized in figure 4.1 exemplarily for pig 1. Contrary to humans pigs have only one PV
pair, distinguished inbetween inferior PV (IPV) and superior PV (SPV). The contour for the PV
encircles both of these structures.
Table 4.1.: Target volume for the different cardiac target sites for all investigated pigs.
pig no PVs [cm3] CTI [cm3] AV [cm3]
1 0.72 0.20 0.08
2 1.01 0.13 0.05
3 1.09 0.24 0.06
4 1.03 0.31 0.02
114
(a) PVs and AV node (b) PVs and CTI
Figure 4.1.: Cardiac target volumes (PV, CTI and AV node) in pig 1.
Also for these data sets, non-rigid image registration of the nineteen motion phase on the
reference phase has been performed with Plastimatch [Sharp07, Shack10]. The first step of
the B-Spline registration was carried out with 50 maximal iterations and an isotropic spacing
of 4mm, while the second step had maximal 100 iterations with a grid spacing of 1 mm. For
the contrast enhanced CT scans the regularization was chosen to be λ=0.005, while for the
native CT scans λ=0.0001 was chosen. The quality of registration was also here validated with
visualization techniques (false color images and checker board images [Bro07], aqualitative
check of the vector field regularization) between motion phase 3 and the reference phase 0 and
motion phase 18 and the reference phase.
4.1.2 Treatment planning parameters
All treatment plans were generated on contrast-enhanced CT scans (see section 4.2.1) without
motion (3D, static) as well as with motion (4D). For informations on the dose optimization pro-
cess, the used raster spacing, dose algorithm and GSI beam applications the reader should be
referred to 3.1.2.
Besides the original volume of the CTV, a safety margin has been added to the volumes of
the treatment planning study. In agreement with the Mayo Clinic radiooncology an isotropic
safety margins of 5 mm has been chosen, which will also be applied in the irradiation with pho-
tons. The ITV volumes[Gra12], which were obtained from all twenty motion phases and were
used as the final target, were generated from the original CTV contour as well as from the CTV
with margin, so that potential range variations were considered in the margins.
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All treatment plans were calculated as single field uniform dose (SFUD) deliveries, applying a
physical dose of 25 Gy in one fraction. The minimum particle number per beam spot was set to
75,000. The dose was applied from two different beam channel directions. With the fixed hori-
zontal beam line available at GSI the beam positions were chosen as two lateral fields with couch
angles of -90◦ and 90◦. With these opposing fields the treatment should be more robust against
potential uncertainties like range differences. Due to the GSI specific beam output, the particles
are applied at an angle of -2.203◦, which was integrated in the treatment plans as a gantry angle.
As the reconstruction of the 4DCTs was based on the time scale a phase-based motion state
detection was employed. In order to consider possible divergence in the heartbeat motion pat-
tern of the pigs, different motion periods (0.7 s and 0.5 s) as well as different starting phases
(0◦ and 90◦) were used. The fast motion periods were chosen according to the heartbeat rate of
the pigs, between 110 and 120 beats per minute.
4.1.3 Treatment planning studies
On the basis of 3D treatment plans on the AV node the dose to nearby OARs were studied
(see table 4.2). These were carried out on the CTV of all four pig data sets. Furthermore 3D
(static) treatment plans were produced as reference values to the 4D cases. 4D plans were
distinguished between an underlying motion without any compensation, resulting in interplay
patterns [Phi92, Ber08], and with the application of rescanning [Phi92] as motion mitigation
technique. For rescanning three different rescan numbers (5, 10 and 15) were compared. Static,
interplay as well as rescanning treatment plans for all pigs where carried out with the two stated
beam entry channels, a safety margin of 5 mm, the stated treatment planning parameters and
the four stated motion trajectories. All treatment planning studies were carried out on contrast
enhanced CT scans due to the lack of contrast on native CT scans (see section 4.2.1).
4.1.4 Analysis
The dose deposition in the OAR as well as dose homogeneity in the target volume were
studied. The dose deposition in the OARs (esophagus, trachea, aorta and the whole heart)
were compared to dose-volume restriction stated in RTOG study protocols (see table 4.2)
[RTOG0631, RTOG0915] (see chapter 3, section 3.1.4). As further OAR cardiac substructures
(ventricles and coronary arteries) were studied. Here the mean dose into the structures as well
as the maximum point dose and the maximal irradiated volume (V>0) were analyzed. Since the
values were not normally distributed, the median (50th percentile) as well as the 75th percentile
were calculated over all pigs. MVHs [Ric13] were generated to display the relative displacement
of every voxel of the investigated volume to the reference phase in all three motion directions.
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With these values the resulting motion of the cardiac target sites due to heartbeat could be as-
sessed. In particular, the motion assessable from the native CT scans were compared with the
contrast enhanced motion information. For comparison the resulting DVHs from the different
techniques were studied. The V95 (measure of dose coverage), V107 (over dosage) and D5-
D95 (dose homogeneity) to the CTVs were assessed. Futhermore the median and percentile
values (25th and 75th) of these parameters over all studied motion patterns and patient cases
were generated. In one case a one-way ANOVA was carried out and the proportion of variance
explained r2 is reported with the corresponding p-value (p<0.0001).
Table 4.2.: Dose-volume limits for OAR.
OAR volume [cc] dose [Gy] endpoint
aorta / great vessels 10 31 aneurysm
esophagus 5 11.9 stenosis / fistula
heart 15 16 pericarditis
trachea 4 10.5 stenosis / fistula
4.2 Results
In the following the results of the motion assessment due to heartbeat will be shown. Afterwards
the dose to OAR when irradiating the AV node will be presented in detail. For the treatment
planning study different dose analysis parameters will be presented and compared for different
cases (static, interplay and rescanning).
4.2.1 Motion directions and magnitude
Treatment planning for particle therapy is carried out on native CT scans, as the Hounsfield units
(HU) give information on the electron density of the structures and hence enable a calculation
of the needed particle range. In native CTs, however, the contrast between the cardiac muscle
and blood is low. A comparison between motion assessments of the cardiac target volumes in
native and contrast-enhanced CT scans will be presented for one porcine data set. Afterwards
the motion of all target volumes (PVs, CTI and AV node) will be shown for all pigs.
Motion of cardiac target volumes in contrast enhanced versus native CT scans
Only one of the four porcine data sets (pig 3) offered identical depicted anatomy between native
and contrast enhanced data sets. For all other data sets the pig was moved inbetween the CT
acquisitions. For a fair comparison this data set was hence analyzed. Using the resulting defor-
mation maps from deformable image registration the motion of the ablation sites of PVs, CTI
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and AV node were assessed in both scans of pig 3. MVHs displaying the relative displacement
of every voxel of the investigated volume to the reference phase in all three motion directions
were generated. The mean and standard deviation of these displacement values in each motion
phase are plotted for all motion directions in figures 4.2 - 4.4. It can be seen that the motion
from the contrast enhanced CT is much larger than from the native CTs. While the mean ab-
solute displacement in the native CT is smaller than 1 mm in case of PVs and AV node and
smaller than 1.5 mm in case of CTI, the contrast CT enables a motion assessment which yields
a mean absolute displacement of larger than 2 mm in all studied target volumes (see table 4.3).
The difference is especially large in the AV node. The maximal observable displacement for
this structure in case of the native CT scan is (0.2 ± 0.1) mm (MP 12), while with the contrast
enhanced CT an absolute displacement of (2.5 ± 0.4) mm is assessable in this motion phase
and the maximal absolute displacement is found to be (4.4 ± 0.1) mm (MP 5) (see Appendix
C.2). It can thus be concluded that contrast enhanced CTs are needed in order to fully assess
the motion of cardiac target volumes in pigs. Since range deviations of contrast enhanced CT
are in the order of 2.5 % compared to native CTs [Wer04] and none of the treatment plans
were applied in experiments, we decided to perform all subsequently presented calculations on
contrast enhanced CTs. This allows to incorporate the larger motion amplitudes into the studies
on influence of intrafractional motion.
Table 4.3.: Mean displacement of cardiac taget volumes in pig 3 over all motion phases.
Target ABS [mm] SI [mm] AP [mm] LR [mm]
PVs 1.7 ± 0.8 -0.2 ± 0.6 0.7 ± 0.9 0.1 ± 0.8
contrast CT CTI 1.6 ± 0.6 0.4 ± 0.5 0.7 ± 0.7 0.2 ± 0.6
AV 2.8 ± 0.4 0.0 ± 0.3 2.0 ± 0.3 -1.4 ± 0.6
PVs 0.9 ± 0.4 0.0 ± 0.4 0.1 ± 0.5 -0.1 ± 0.5
native CT CTI 1.1 ± 0.5 -0.1 ± 0.6 0.6 ± 0.5 -0.1 ± 0.5
AV 0.1 ± 0.1 0.1 ± 0.1 0.0 ± 0.1 0.0 ± 0.1
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Figure 4.2.: PV: mean motion amplitude and standard deviation in each MP of the heartbeat
relative to the reference phase. The displacement is shown for the three studied
motion directions (SI, AP, LR) and the absolute displacment. Comparison between
native CT data (black) and contrast CT (red) for pig 3.
Figure 4.3.: CTI: mean motion amplitude and standard deviation in each MP of the heartbeat
relative to the reference phase. Comparison between native CT data (black) and
contrast CT (red) for pig 3.
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Figure 4.4.: AV node: mean motion amplitude and standard deviation in each motion phase
(MP) of the heartbeat relative to the reference phase. Comparison between native
CT data (black) and contrast CT (red) for pig 3.
Motion of cardiac target volumes due to heartbeat
The mean and standard deviation over all target volume voxels of the contrast enhanced CTs
are plotted for each motion phase and for all pigs and motion directions in figure 4.5 to 4.7.
The numerical values can be found in appendix C.2. It can be seen that the displacement within
the cardiac target volume varies dependent on the studied pig and are hence dependent on the
underlying anatomy. Furthermore the highest absolute displacement can be observed in differ-
ent pigs, depending on the studied target volume. While the PVs move the most in pig 1 with a
displacement of up to 5 mm, pig 2 has the largest motion both in CTI and AV node (more than
6 mm in both structures, respectively) (see also table 4.4). In this table it can be seen that the
maximal absolute displacement varies depending on the studied volume. The CTI moves with a
bigger amplitude than the other two target volumes in three of the four studied pigs (difference
found in pig 3). The smallest displacement is found in the PVs, again in three of the four studied
data sets (again the difference is found in pig 3). This can be interpreted in connection to the
placement of the target volumes within the heart. While the PVs are found in the upper part of
the atria, the CTI is located in the lower part of the atria and hence the influence of the ventric-
ular motion should be bigger. The AV node is in between the atria and ventricles and was found
to have an intermediate absolute displacement in most cases (exception in pig 3). Independent
of the studied target volume the largest contribution to the absolute displacement is found in
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AP direction for all pigs (see table 4.5). This can also be seen in the mean displacements over
all pigs. For the PVs the mean amplitude in SI direction is (0.3 ± 0.8) mm, (1.5 ± 1.1) mm
in AP direction and (-0.5 ± 1.0) mm in LR direction. In case of the CTI the mean amplitude
in SI is (0.8 ± 0.7) mm, (1.8 ± 0.7) mm in AP and (0.5 ± 0.9) mm in LR. For the AV node it
is (0.7 ± 0.3) mm in SI, (2.4 ± 0.4) mm in AP and (-0.7 ± 0.5) mm in LR. On average, the
absolute amplitude over all motion phases and pigs is found to (2.3 ± 0.8) mm for the PVs, (2.8
± 0.7) mm for CTI and (3.0 ± 0.4) mm for the AV node.
It can be seen in table 4.4 that no motion phase can be directly connected to the maximal
absolute displacement of the target volumes. As stated in 3.2.3 the maximal displacement of
the atria should be observed in motion phase eighteen, while the maximal amplitude of the
ventricle should be observed in motion phase three. While this pattern is not directly connected
to the motion of the cardiac volumes it can nevertheless be seen that for all pigs the displace-
ment in the biggest motion direction (AP) results in a shallower motion in between MP 6 and 13
compared to the other MPs. For the PVs the motion in pig 1 (pig with the largest motion in this
target volume) has a range of less than 0.5 mm in the interval between MP 6 and 13, while the
motion ranges more than 3 mm in the other MPs (see appendix C.1). The same can be observed
in case of the CTI, where pig 2 has a less shallow motion range of about 2 mm within MP 6 and
13, but nevertheless a larger motion range of up to 4 mm in the other MPs. Also for the AV node
the motion within the MP interval (6-13) is lower (up to 2 mm) compared to the the other MPs
(range of about 4.5 mm) in pig 2.
Table 4.4.: Biggest absolute displacement of target volumes for all pigs with corresponding MP.
Target pig 1 [mm] (MP) pig 2 [mm] (MP) pig 3 [mm] (MP) pig 4 [mm] (MP)
PVs 4.2 ± 1.1 (13) 3.7 ± 1.6 (12) 2.4 ± 0.9 (06) 3.1 ± 1.0 (11)
CTI 5.8 ± 1.0 (07) 6.3 ± 0.5 (08) 2.2 ± 0.6 (11) 4.0 ± 0.8 (13)
AV 4.9 ± 0.3 (13) 6.0 ± 0.2 (11) 4.4 ± 0.1 (05) 3.6 ± 0.7 (10)
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Table 4.5.: Mean displacement of target volumes over all MPs for all pigs and motion directions.
Target Pig ABS [mm] SI [mm] AP [mm] LR [mm]
PVs 1 2.9 ± 0.7 0.2 ± 1.0 2.0 ± 1.3 -1.1 ± 1.1
2 2.3 ± 0.9 0.9 ± 0.9 1.4 ± 1.7 -0.6 ± 1.0
3 1.7 ± 0.8 -0.2 ± 0.6 0.7 ± 0.9 0.1 ± 0.8
4 2.1 ± 0.6 0.3 ± 0.4 1.8 ± 0.7 -0.2 ± 0.7
Pig ABS [mm] SI [mm] AP [mm] LR [mm]
CTI 1 3.5 ± 0.8 0.7 ± 0.8 2.3 ± 0.8 1.5 ± 0.9
2 3.5 ± 0.8 1.0 ± 1.0 2.4 ± 0.5 0.3 ± 1.2
3 1.6 ± 0.6 0.4 ± 0.5 0.7 ± 0.7 0.2 ± 0.6
4 2.1 ± 0.5 0.8 ± 0.4 1.7 ± 0.5 0.0 ± 0.5
Pig ABS [mm] SI [mm] AP [mm] LR [mm]
AV 1 3.0 ± 0.4 0.4 ± 0.4 2.5 ± 0.5 -0.7 ± 0.4
2 3.7 ± 0.4 1.9 ± 0.3 3.0 ± 0.3 0.1 ± 0.4
3 2.8 ± 0.4 0.0 ± 0.3 2.0 ± 0.3 -1.4 ± 0.6
4 2.1 ± 0.4 0.5 ± 0.2 1.7 ± 0.3 -0.7 ± 0.4
Figure 4.5.: PV: Mean motion amplitude and standard deviation in each MP under influence of
heartbeat for all pigs, obtained from contrast enhanced CT scans (pig 1: black, pig
2: red, pig 3: blue, pig 4: green).
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Figure 4.6.: CTI: Mean motion amplitude and standard deviation in each MP under influence of
heartbeat for all pigs, obtained from contrast enhanced CT scans (pig 1: black, pig
2: red, pig 3: blue, pig 4: green).
Figure 4.7.: AV node: Mean motion amplitude and standard deviation in each MP under influ-
ence of heartbeat for all pigs, obtained from contrast enhanced CT scans (pig 1:
black, pig 2: red, pig 3: blue, pig 4: green).
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The overall displacement field for two exemplary pigs with a small motion amplitude (pig
4) and a large motion amplitude (pig 2) of the AV node are shown in figure 4.8. The field is
shown for the maximal displacement motion phase of the respective pigs (motion phase 11 for
pig 2 and motion phase 10 for pig 4, see table 4.4). In order to visualize the location of the
displacement, an axial cut of the reference state CT is underlayed. The absolute values of the
displacement vectors are shown as contour plots.
(a) Pig 2: max. abs. motion (MP 11)
(b) Pig 4: max. abs. motion (MP 10)
Figure 4.8.: Axial slices of the reference state of the CT overlayed with the absolute values of
the displacement field (obtained from deformable image registration) in the corre-
sponding slice for heartbeat motion. Above: the resulting displacement of pig 2 is
shown in MP 11. Below: the results for pig 4 in MP 10.
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4.2.2 Dose to organs at risk when irradiating the AV node
Due to the fact that the AV node is located in a large distance to the OARs (see figure 4.1),
the dose deposition in the studied structures is not critical. Esophagus, trachea as well as the
aorta are receiving no dose in all studied cases. Only the heart is receiving up to 7 Gy for
the studied volume of 15 cm3. The respective dose-volume limit of 16 Gy to 15 cm3 is hence
not exceeded. The dose deposited in the stated heart volume ranges from 4.8 Gy (pig 3) to
7.3 Gy (pig 4), which corresponds to 19 % and 29 % of the physical dose. Hence even higher
doses of up to 40 Gy would not exceed the dose volume limit. The results of a more detailed
analysis of the affected cardiac substructures can be seen in table 4.6. Here the mean dose to
the whole structure is stated next to the maximal point dose for all pigs and studied structures.
Furthermore the maximal irradiated volume is shown.
Table 4.6.: Mean as well as maximum point dose to the whole heart and different cardiac sub-
structures as well as maximal irradiated volume of the structures for all pigs.
OAR Pig mean dose [Gy] max. dose [Gy] max. volume [%]
Heart 1 0.6 25.8 14.0
2 0.5 25.4 12.7
3 0.8 25.3 17.4
4 0.8 25.7 16.6
LV 1 0.5 26.3 6.7
2 0.5 26.3 6.1
3 0.3 26.1 5.1
4 0.4 26.0 4.5
RV 1 0.3 25.2 9.1
2 0.2 25.2 8.0
3 0.4 25.3 9.6
4 0.5 25.8 14.3
LCA 1 0.8 7.4 19.9
2 0.6 7.2 13.5
3 0.2 6.4 8.9
4 0.7 7.4 14.6
RCA 1 1.5 9.2 37.6
2 1.1 8.4 24.0
3 1.4 9.8 37.3
4 1.4 9.6 34.1
Due to the physical dose deposition of 25 Gy in the AV node the heart is receiving a relatively
high maximum point dose with a median of 25.6 Gy (75th percentile: 25.8 Gy) over all pigs.
The mean heart dose is found to have a median of 0.7 Gy (0.8 Gy) and the median of the
maximal irradiated volume over all porcine data sets is 15.3 % (17.7 %). Comparing the dose
deposition in the left and right ventricles it can be seen that the maximum point dose is higher
in the LV than in the RV, with a median of 26.2 Gy (26.3 Gy) compared to 25.2 Gy (25.5 Gy).
Nevertheless the mean dose is comparable with a median of 0.5 Gy (0.5 Gy) for the LV and
0.4 Gy (0.5 Gy) for the RV and the maximal irradiated volume is smaller for the LV compared
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to the RV with a median of 5.6 % (6.4 %) compared to 9.3 % (11.9 %). It should be noted
that the total volume of the LV is much larger than the RV (e.g. about three times larger in
pig 1), so that the absolute maximal irradiated volume results to be larger in case of the LV.
Concerning the coronary arteries, it can be seen that the mean and maximal point dose to the
LCA is smaller than to the RCA, resulting in a median mean dose of 0.6 Gy (0.7 Gy) in LCA
compared to 1.4 Gy (1.4 Gy) in RCA and a median maximum point dose of 7.3 Gy (7.4 Gy) in
LCA compared to 9.4 Gy (9.7 Gy) in LCA. Also the maximal irradiated volume is much smaller
in the LCA compared to the RCA, resulting in a median maximum volume of 14.1 % (17.2 %)
versus 35.7 % (37.5 %).
4.2.3 Motion mitigation techniques for AV node irradition
The resulting interplay effect, caused by the displacement of the AV node of up to 6 mm, and
dose deposition were studied for every porcine data set for different motion patterns and 5 mm
margin to the target volume. The dose analysis values V95, V107 and D5-D95 were assessed
and plotted. For comparison, also the corresponding values for the 3D case (static) are shown.
Rescanning was studied as motion mitigation technique. The results of the stated dose values
in case of rescanning with rescan numbers of five, ten and fifteen will be presented.
Dose deposition
Different motion pattern DVHs of fifteen rescans compared to the interplay results as well as a
static irradiation are displayed for pig 2 (as this is the pig with the largest motion amplitude
in the AV node) in figure 4.9 for 5 mm safety margin. A representative dose deposition for all
studied techniques (static, interplay and rescanning with fifteen rescans) is shown exemplary
in figure 4.10. Rescanning and interplay are shown for a motion with a period of 0.5 s and
a starting phase of 90◦. The target volume was irradiated with an added margin of 5 mm. It
can already be seen from this dose cut figures that rescanning with fifteen rescans improves
the outcome compared to interplay and yields a result which is comparable to the static case.
Due to the mechanism of rescanning, the field size is slightly increased compared to the static
irradiation.
In order to assess the dose information of all pigs, the DVHs were analyzed and compared
for dose steepness, dose coverage as well as over dosage. The results for all porcine data sets
are shown in figure 4.11. The corresponding numerical values can be found in appendix C (ta-
bles C.14 - C.17).
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The resulting interplay pattern is dependent on the underlying motion period and starting
phase. This can also be seen in the mean values and standard deviations of the dose analysis
parameters over all pigs for different motion patterns. The dose coverage for example is found
to have a mean value of V95=(84.3 ± 17.5) % for a motion with 0.7 s period and a starting
phase of 0◦, while it is found to be (91.0 ± 10.3) % for the same period and a starting phase of
90◦. For a period of 0.5 s the mean dose coverage over all pigs is found to be (84.5 ± 8.0) %
with a phase of 0◦ and to (86.0 ± 24.0) % for a phase of 90◦. The resulting high standard de-
viation shows that the result is also dependent on the studied porcine case.These dependencies
are also valid for the other studied dose analysis parameters, dose homogeneity and over dosage.
It can furthermore be seen in figure 4.11 (as well as numerical values for all pigs in appendix
C.1) that rescanning can improve the results for dose steepness, dose coverage as well as over
dosage compared to the interplay case in all studied motion cases for three out of four pigs.
Only pig 2, which was found to have the largest absolute displacement of the AV node out
of the four studied porcine data sets, results in some rescanning cases where slightly inferior
results compared to interplay are achieved. This is the case in dose steepness, where a mo-
tion with 0.7 s and 90◦ starting phase is D5-D95=8.2 % with five rescans and D5-D95=7.9 %
with ten rescans compared to D5-D95=6.2 % without any compensation (interplay). For the
same motion the dose coverage is found to be V95=43.6 % with five rescans compared to
V95=99.0 % with interplay. This result can already be improved with ten rescans, where V95
is found to be 98.5 %. In over dosage a motion pattern (period of 0.5 s and starting phase
of 0◦) is found to have inferior results with ten rescans compared to interplay (9.3 % versus
0 %). The results for ten rescans could be slightly improved with fifteen rescans, so that, e.g.,
the dose coverage is found to be V95=100 % for the stated motion pattern (0.7 s period and
90◦ starting phase) (static: 100 %). For pig 4, which has the smallest absolute displacement of
the AV node in the studied porcine cohort, all rescanning results yield improved results com-
pared to interplay. Moreover it can also be observed here that ten and fifteen rescans result in
better dose analysis parameters and even tops the static outcome in some cases. E.g. the dose
steepness is found to be D5-D95=3.0 % with a motion period of 0.5 s and starting phase of
0◦ for fifteen rescans and to be 5.1 % with ten rescans, while in the static case it is found to
be 5.5 %. In this case also five rescans result in an improved dose steepness (D5-D95=4.9 %).
Regarding the dose coverage, fifteen rescans yield results comparable to the static case (100 %)
for all motion patterns, while ten rescans yield comparable results (e.g. 97.8 % for motion pe-
riod of 0.7s and starting phase of 90◦, interplay: 74.3 %). Five rescans on the other hand show
inferior results with, e.g., D5-D95=86.3 % for a motion period of 0.5s and a starting phase of 0◦.
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(a) pig 2
(b) pig 4
Figure 4.9.: Dose volume histograms for CTV of pig 2 (largest absolute displacement of AV node)
and pig 4 (smallest absolute displacement of AV node) for 5 mm safety margin irra-
diation of AV node in case of static irradiation (black), interplay (dashed) and res-
canning with fifteen rescans (solid). The motion patterns are shown in colors (0.7s
0: motion period of 0.7 s and starting phase 0◦, 0.7s 90: motion period of 0.7 s and
starting phase 90◦, 0.5s 0: motion period of 0.5 s and starting phase 0◦, 0.5s 90:
motion period of 0.5 s and starting phase 90◦).
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(a) static (b) interplay
(c) rescanning (15x)
Figure 4.10.: Dose distribution of pig 2 for static (a) as well as interplay (b) and fifteen rescans
(c) at motion period of 0.5 s and a motion starting phase of 90◦. The target volume
has an added margin of 5 mm. The improved outcome of rescanning compared to
interplay can already be seen in these dose cuts. For interplay and rescanning the
dose was calculated in a reduced volume as indicated by the white dashed line.
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(a) D5-D95
(b) V95
(c) V107
Figure 4.11.: Dose analysis parameters D5-D95 (first row), V95 (middle row) and V107 (last row)
for all porcine data sets when irradiating the AV node with 5 mm safety margin.
Static (black) as well as interplay (red) and different rescanning numbers (5 times:
blue, 10 times: green) were compared for different motion patterns and safety
margins. For a better visualization the rescanning data points for each motion
pattern are shifted and the results for fifteen rescans are not displayed.
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(a) D5-D95 (b) V95 (c) V107
Figure 4.12.: Boxplot of dose analysis parameters D5-D95, V95 and V107 over all porcine data
sets (pig 1: black, pig 2: blue, pig 3: red, pig 4: green) and motion patterns de-
pending on the used technique (I: interplay, R5: five rescans, R10: ten rescans, R15:
fifteen rescans, S: static). Figures are courtesy of Dr. Christian Graeff.
Figure 4.12 shows the results of the dose analysis parameters over all pigs and motion pat-
terns depending on the studied technique. It can be seen that for all studied cases, rescanning
yields improved dose depositions compared to the interplay case. For D5-D95 the median of
the ideal, static case is 5.0 % (75th percentile: 5.6 %), which increases to 10.1 % (13.9 %) for
the interplay distribution. With five rescans this can be already improved to 7.1 % (8.4 %). A
slightly better improvement is observed from ten rescans on, whereas no further benefit result
from more than ten rescans (5.2 % (6.1 %) for ten rescans versus 5.2 % (5.7 %) for fifteen
rescans). As this dose analysis parameter was normally distributed, the correlation between
the dose homogeneity and rescan number was analyzed. Thereby interplay was included as a
rescan number of one. The proportion of variance explained resulted in r2=0.46 (p<0.0001).
For V95 interplay resulted to have a median of 92.1 % (25th percentile: 75.9 %) versus 100 %
(100 %) for the static case. The dose coverage could be improved to 99.8 % (25th percentile:
94.5 %) with five rescans and even to 100 % (100 %) for ten and fifteen rescans. For the
over dosage the static case was found to have a median of 0 % (75th percentile: 0 %) which in-
creased to 0 % (6.3 %) for interplay and could be reduced to 0 % (0 %) already with five rescans.
It can be concluded that five rescans are already sufficient to improve the interplay results,
but ten or more rescans are needed in order to have treatment planning results comparable to
the static irradiation. In order to enable a correct dose-escalation study ten or fifteen rescans
are hence favorable. For the here studied motion pattern and porcine data set cases this rescan
number would lead to a dose deposition corresponding to the planned dose deposition.
131
Irradiation time
In figure 4.13 the irradiation time for rescanning of AV node are shown for all pigs and the two
studied beam channel directions (couch angle 90◦ and -90◦). The stated results were achieved
with a low intensity irradiation (minimal particle number of 75,000 per beam spot1). For an
irradiation with 5 mm margin the treatment time over all pig data sets results to a mean value
of about one minute per field (see table 4.7). Thus the overall treatment time would result to
(1.9 ± 0.1) min with rescanning as motion mitigation technique for heartbeat motion in porcine
data. Theoretically, this result could be further reduced with a higher minimum particle number
and hence a higher irradiation intensity. Nevertheless these irradiation times are already very
short due to the small target volume. It needs to be observed in the upcoming experiments if
these short treatment times can be verified.
Figure 4.13.: Irradiation time of fifteen rescans for all pigs and beam entry channels.
Table 4.7.: Mean irradiation time for AV node with a safety margin of 5 mm over all pigs.
Couch angle [◦] time [min]
-90 0.9 ± 0.1
90 1.0 ± 0.1
total 1.9 ± 0.1
1 As this resulted in the maximal particle number still yielding a homogenous dose deposition in case of static
irradiation. Further analysis is needed.
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4.3 Discussion
In this chapter the influence of heartbeat motion on different cardiac target volumes (PVs, CTI,
AV node) in porcine data sets was studied and treatment planning studies with rescanning as
motion mitigation technique were carried out. The dose deposition to OAR, including cardiac
substructures, was analyzed. This analysis is motivated by the planned experiments on the
feasibility of the non-invasive ablation of cardiac target sites with carbon ions in pigs. In exper-
imental cardiology, dogs as well as pigs are most frequently used. As dogs are known to display
certain differences in anatomy and physiology compared to man [Hug86, Cri98] it is planned
to use pigs in the upcoming GSI experiments.
Even though it seems to be accepted in literature that the anatomy of pig hearts are very
similar to that of humans [Lum66, Dou72, Hug86, Coo91, Whi93] Crick et al. [Cri98] car-
ried out a detailed comparison between the anatomy of porcine and human hearts. They found
several significant differences which they suspected to arise mainly from the different orien-
tation of the bodys (unguligrade versus orthograde) and hence location of the heart in the
thorax and from the differing form of the thorax itself. While the upper and lower borders of
the hearts were found to have similar size and features, the general shape differs as the pig
hearts are more ’Valentine’ shaped and the human hearts more trapezoidal. This also leads
to important differences in the internal anatomy. While in human hearts the right atrium is
typically larger than the left, the atria of pigs have a similar size. Concerning the left atrium,
only two orifices for the pulmonary veins exist, while humans have four pulmonary vein open-
ings. The right atrium was furthermore stated to differ significantly from the human heart,
especially in the atrial appendage. Regarding the ventricles Crick et al. stated that the right
ventricle was observed to have a similar structure like human hearts, such as the tricuspid and
pulmonary valvar arrangements. But also here differences were found (e.g. the orientation of
the pulmonary valve). The left ventricles seem to have similar features to the human struc-
ture, but the ventricular wall was found to be much thicker in porcine. Furthermore it was
stated that the left chambers of the pig hearts were significantly bigger compared to the right
chambers, so that the apex was found to be composed entirely of left ventricular musculature.
Also in human hearts the left ventricle is bigger than the right one. Concerning coronary cir-
culation it was noted that most pigs displayed a blood supply to the sinus and atrioventricular
node by branches of the right coronary artery, while in humans this is observed to a lesser extent.
Due to the different anatomy of pigs compared to humans it was expected to find different
results in the motion of the cardiac target volumes as well as in the dose deposition to the OAR.
The findings will be discussed in the next subsections.
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4.3.1 Movement of cardiac target volumes in cardiac cycle
Due to the dense muscular structure of the heart contrast enhanced CT scans were acquired in
comparison to native scans. Deformable image registrations were carried out on both data sets
and the resulting motion displacement of the cardiac target volumes were assessed. It could
be concluded that native CT scans do not enable an estimation of either the motion amplitude
or direction. While e.g. the mean absolute displacement of the AV node was found to (0.1 ±
0.1) mm in the native scans of pig 3, the mean absolute displacement on contrast CT scans
was found to be (2.0 ± 0.4) mm. This difference is sufficient to completely alter the results of
the treatment planning study as an interplay pattern would be expected with the motion field
from the contrast enhanced CT scans, while the motion of the native scans would be too small
to yield an interplay effect. It is thus obvious that contrast enhanced CT scans are needed in
order to correctly assess the motion of the cardiac target volumes. As contrast enhanced CT
scans change the Hounsfield unit information, which are needed for range informations in par-
ticle therapy, it is not intented to deliver treatment plans created on these data sets. In the
case of treatment planning studies for pure feasibility it can nevertheless be accepted as the
range information does not need to be applied. In the planned experiments at GSI a strategy
to use the motion displacement field of the contrast enhanced CT, while carrying out the treat-
ment planning on native CT scans, is nevertheless needed. A first concept could be to enable
a robust stabilization of the pigs during CT acquisition so that no position difference between
the native CT scan and the injection of the contrast agent is induced. This would hence enable
a direct application of the deformation field of the contrast enhanced CTs on the native CT scans.
Based on the contrast enhanced CT scans the motion of the cardiac target volumes - PV, CTI
and AV node - in all four porcine data sets was assessed. It could be observed that the CTI
moved the most in all four pigs, followed by the AV node. The PV moved to a lesser extend in
all four pigs. It was assumed that these findings were connected to the location of the target
volumes within the heart, where the PVs are found in the upper atria and the CTI in the lower
atria, hence increasing the influence of the stronger ventricular motion. As the AV node is found
in between ventricles and atria it can be hypothesized that the position is more stable and hence
the influence of the ventricular motion on the displacement of the structure is slightly reduced.
Furthermore it was found that in all four porcine data sets as well as for all three studied car-
diac target volumes the displacement in AP direction was larger than in the other two motion
directions (SI and LR). For the porcine data sets a shallower motion range of the target volumes
was furthermore observed in-between MP 6 and 13, enabling a potential application of gating
as another motion mitigation technique for the compensation of heartbeat motion in swines.
Nevertheless a close analysis of the individual motion pattern of the respective pig is needed as
the motion differed among the animals.
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4.3.2 Dose to organs at risk for the irradiation of AV node
Due to a lack of corresponding data dose-volume limits for the studied OAR (esophagus, tra-
chea, aorta and heart) were taken from the RTOG protocols for SBRT treatments of humans.
These limits were not exceeded in the irradiation of AV node with 5 mm safety margin. It can
be argued that this is due to the large distance of the target volume from the analyzed criti-
cal structures. Nevertheless the resulting dose deposition with carbon ions is also smaller than
the results for photon irradiation. A study by radiologists from the collaborating Mayo Clinic
[Song14] stated that an IMRT irradiation of the AV node with 5-6 mm margin and (32± 0.6) Gy
in the same porcine data sets resulted in a mean dose to the esophagus of 1.6 Gy. In case of
carbon ions no dose deposition was found in this structure (mean: (0 ± 0) Gy). The mean dose
to the trachea was found to be 2.2 Gy with IMRT delivery, while also here no dose was deposited
with carbon ions (mean: (0 ± 0) Gy). Concerning the mean overall cardiac dose it was stated
that an IMRT delivery would result in (4.7 ± 1.3) Gy. For carbon ions a mean cardiac dose of
(0.03 ± 0.00) % of the physical dose was found, resulting in (0.7 ± 0.1) Gy for 25 Gy or (1.0
± 0.1) Gy for 32 Gy, respectively. The better sparing of the critical structures with carbon ions
compared to IMRT is on one hand due to the reduced beam channel number. On the other hand
the physical advantages of carbon ions compared to photon delivery (e.g. Bragg peak) become
obvious in these results. For a more detailed comparison of OAR dose depositions with photons
compared to carbon ions, the reader shall be referred to chapter 5, section 5.1.3. The study by
Song et al. also included an analysis of the dose deposition when irradiating the AV node with
proton beams [Song14]. Here a single AP field was applied, resulting in (30.7 ± 0.2) Gy to the
AV node. The mean overall cardiac dose was stated to result to (3.6 ± 1.5) Gy. The dose depo-
sition to the surrounding heart is hence higher in case of proton irradiation compared to carbon
ions. This is especially striking since only one field was used in proton treatment compared to
the here presented two carbon ion beam channels, hence resulting in a bigger irradiated cardiac
volume. Nevertheless it should be kept in mind that the beam channels can not be directly
compared, since two lateral fields were used in carbon ion treatment planning, while a single
AP field was applied in proton therapy.
The dose deposition in the cardiac substructures was also studied in the AV node irradiations
with carbon ions. The LV resulted to receive a slighthy higher maximum point dose compared to
the RV, while the mean dose in the two structures were comparable and the maximal irradiated
volume was smaller for the LV compared to the RV. In the study by Crick et. al it is stated that
the LV is significantly bigger compared to the RV in swines and that sensitive structures like
the apex are composed entirely of LV musculature [Cri98]. It can thus be understood why the
maximal irradiated volume of the LV is significantly smaller than the RV even though the beam
channels are symmetrical in lateral position. Concerning the coronary arteries it was found that
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the mean and maximal point dose to the LCA is smaller than the RCA and also the maximal irra-
diated volume of the LCA is smaller compared to the RCA. Since no dose limit information exist
it is unclear whether the larger exposure of the RCA compared to LCA is problematic, especially
since pigs were stated to supply the SA and AV node via branches of the RCA.
4.3.3 Rescanning as motion mitigation technique for AV node irradiation
In the irradiation of cardiac volumes in the animal study carried out at CyberHeart and at Uni-
versitätsklinikum Schleswig-Holstein in Lübeck, both with photons, only an ITV approach was
used in order to compensate for heartbeat motion [Sha10, Bla13]. Due to the interference ef-
fects between the active carbon ion beam application and the assessed motion of up to 6 mm of
the AV node due to heartbeat, a different approach was needed for carbon ions. Rescanning was
studied as potential motion mitigation technique for the non-invasive ablation of the AV node
with an underlying heartbeat motion in swines.
By analyzing the dose coverage, dose homogeneity and over dosage for different underlying
motion patterns it was found that rescanning results in an appliable dose deposition. The dose
coverage was higher than 99 % in 85 % of all studied cases and even increased to 91 % of the
studied cases when more than ten rescans were analyzed (100 % for only fifteen rescans). V107
values higher than 0 % were obtained in 15 % of all cases, which further reduced to 6 % of
the studied cases when only the DVHs for ten and fifteen rescans were evaluated. V107=0 %
was found in all studied cases for fifteen rescans. The dose homogeneity D5-D95 did not exceed
8 % for ten rescans. This value could be slightly improved to 7 % with fifteen rescans. For five
rescans, the dose homogeneity reached up to 11 %. It could be concluded that rescanning with
ten rescans yields better results compared to only five rescans, while additional rescans do lead
to a further improvement of the outcome.
All these results were found for slice-by-slice rescanning, which means that each IES is irra-
diated independently with the predefined number of rescans and the adapted particle numbers.
In this case the treatment time is not prolonged. As stated in 3.3.4 ECG-sampled rescanning,
analog to breath-sampled rescanning [Sec09] or phase-controlled rescanning [Fur07], could be
studied as a potential application. Due to the shallower displacement of the porcine cardiac
target volumes between motion phase six and thirteen, gating [Kub96] on the cardiac cycle
might be another feasible motion mitigation technique. In order to keep the treatment time as
short as possible a fast beam extraction modality for synchrotrons with radiofrequency knock-
out exciters is needed. This exist, e.g., at the National Institute of Radiological Science (NIRS)
in Japan [Nod96, Fur05] and at the Heidelberg Ion Therapy Center (HIT) [Schoe11].
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4.4 Conclusion
Contrast enhanced CT scans are needed in order to assess the motion of cardiac target volumes
due to heartbeat motion. Potential cardiac target volumes in swine move due to heartbeat with
an amplitude of up to a couple of millimeters and the dominant motion direction was found to
be in AP direction. The displacement of the AV node creates interplay effects when irradiated
with carbon ions. Rescanning as motion mitigation technique was studied. Rescanning with
fifteen rescans yields improved dose analysis parameters compared to interplay in all studied
pig cases and for all underlying motion patterns and achieved results comparable to the static
irradiations. It is thus an adequate motion mitigation technique for the planned experimental
validation in animal models where the AV node will be irradiated. Dose-volume limits to the
surrounding OAR were not exceeded.
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The treatment planning results presented in the previous chapters are the first feasibility study
to investigate the use of carbon ions for a non-invasive treatment of AF. Currently existing treat-
ment procedures for this cardiac arrhythmia have major drawbacks and due to the prevalence
of this condition a new treatment modality would be beneficial [Cap05, Cap10]. It could be
shown that scanned ion beams have the potential to become an accurate, fast and non-invasive
treatment approach for AF.
Cardiac target volumes like the PVs or the AV node move due to respiration of the patient
as well as due to heartbeat. When treating moving targets with a scanned carbon ion beam
interference effects between the particle delivery and the interfractional target motion are ob-
served, leading to over and under dosages in the target volume and hence endangering the
treatment outcome. Motion mitigation techniques are thus needed, which were studied in-
dependently for the respiratory and heartbeat motion influence. Cardiac target volumes are
surrounded by critical structures and organs at risk (OAR) like esophagus, trachea and aorta. A
detailed analysis of the OAR dose depostion was carried out, which will be discussed in section
5.1.2. In section 5.1.3 special emphasis will be given to the reduced OAR dose deposition with
scanned carbon ions compared to a non-invasive treatment with photons. The target volume
displacement will be discussed in section 5.2.1. Afterwards the findings of treatment planning
studies with motion mitigation techniques will be discussed in section 5.2.3.
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5.1 Dose deposition
In the here presented feasibility study of a non-invasive treatment of AF with carbon ions, a
physical dose of 25 Gy was applied in all treatment plans. This dose was chosen according
to the publication by Sharma et al. [Sha10], in which it was stated as the minimal needed
dose in order to see an electrophysiological effect induced by photon irradiation. Older studies
with photon irradiations in animal models support the finding by Sharma et al. in which doses
higher than 20 Gy seem to be sufficient in order to induce fibrotic tissue [Faj70, Faj73]. A short
overview will be given in section 5.1.1.
A close analysis of the dose deposition to the OARs was carried out in the here presented
work. Human data was studied for PV isolation (chapters 2 and 3). In preparation for ani-
mal studies, which will be carried out at GSI in 2014, the irradiation of the AV node in pigs was
analyzed (chapter 4). The findings will be discussed in section 5.1.2 and a comparison with
photon irradiation will be given in 5.1.3. For critical structures like the aorta, esophagus, tra-
chea and the heart itself dose-volume limits from SBRT were used [RTOG0631, RTOG0915]. As
the heart is not only an OAR in this studied treatment, but the target site itself, the dose-volume
limits for this organ were often exceeded. Closer analysis of the irradiated cardiac substructures
was hence performed.
5.1.1 Dose to target area
Sharma et al. stated that a dose of at least 25 Gy is needed in order to induce a change in the
conduction system of the heart with photon beams [Sha10]. Nevertheless also higher doses have
been applied in the animal model study, reaching up to 80 Gy. Part of the planned animal experi-
ments at GSI will be a dose escalation study, in which the needed carbon ion dose, for the gener-
ation of the desired fibrosis in the target area, will be examined more closely. It is already known
from former studies on the effect of radiation on the heart which single fraction dose depositions
are sufficient in order to induce fibrotic tissue [Faj70, Faj73, Phil64, Bis65, Ste68, Efs56].
Fajardo et al. [Faj70, Faj73] investigated the evolution of radiation induced myocardial dam-
age after a single dose of 20 Gy in rabbits as well as a fractionated treatment, both with 6 MV
photons. They stated that their findings were independent of the time course of the irradia-
tion, hence if the dose was applied as a single fraction or in different fractions. They found
that there are three distinct stages in the evolution of radiation induced cardiac damage and
divided it into an acute phase (an inflammtion within the first 48 hours), a latent stage (which
can last up to seventy days) and the late stage where fibrotic lesions occur. Their explanation
for the formation of fibrotic tissue is a failure of microcirculation, resulting from a failure of the
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complete reconstruction of capillaries in the endothelial cells after irradiation. They state that
the occuring ischemia leads to myocardial fibrosis, which becomes maximal beyond 120 days.
Other studies by Phillips et al. [Phil64] and Bishop et al. [Bis65] irradiated hearts of dogs and
rodents with single photon doses of 60 Gy to 96 Gy. Both authors stated that they found se-
vere functional abnormalities as well as myocardial fibrosis or even necrosis [Ste68]. Efskind et
al. [Efs56] found fatal myocardial damage after 80 Gy photon irradiation to the heart of rabbits.
It can thus be assumed that the required dose for the desired generation of fibrotic tissue in
the cardiac target volumes will require at least 20 Gy, while high single fraction doses of up to
60 Gy might induce necrosis, which needs to be avoided. Preliminary studies using the LEM for
the calculation of biological doses in single fraction deliveries with the stated 25 Gy resulted to
have a RBE of 1.1. This needs to be verified. Nevertheless studies exist, where the RBE was
found to become smaller with high single fraction doses and reaching a plateau [Cara07]. In
this case the physical dose could be considered proportional to the biological dose. Hence the
dose to the target volume, as well as the dose to the critical structures, could be directly scaled
to the desired value.
5.1.2 Dose to OAR
In the studied human data it was found that the dose deposition in the aorta and trachea were
uncritical and did not exceed the stated dose-volume limits. This was valid for all the studied
safety margins (3 mm, 5 mm and 7 mm) of the target volume, independent of the fact that
the OAR dose deposition correlates with margin size. The esophagus on the other hand is an
endangered organ due to its proximity to the studied irradiation site of the PVs. Different beam
directions and field channel numbers were studied in IMRT setting, none of which resulted in a
satisfactory sparing of this structure. Dose-volume exceeding results were already obtained for
a small safety margin of 3 mm in some patient cases, or even without the usage of any margin
in other cases. An IMPT(OAR) treatment was hence necessary, where the maximal dose to the
esophagus was implemented in the dose optimization process. Two different IMPT(OAR) set-
tings were used. One which was planned to deposit no more than a maximal dose of 17.5 Gy
(70 % of 25 Gy) in this organ and another with a maximal dose of 7.5 Gy (30 % of 25 Gy)
to the structure. While the weaker restriction already led to an improved result, the dose de-
positions were still too high, for one patient case even with only 3 mm margin. The stronger
restriction on the other hand resulted in dose depositions that did not exceed the dose-volume
limit in any studied patient case and for any studied safety margin. The dose restrictions for the
esophagus even led to a further reduced dose deposition in the trachea of the studied patients
due to the direct proximity of these two organs with respect to the used beam channel directions.
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In order to guarantee a safe delivery in a potential patient application a dedicated protocol
to ensure adequate esophagus sparing is nevertheless needed. Possible solutions to detect range
uncertainties before the delivery of the high single fraction dose are pre-irradiations with small
doses in the order of mGy [Bent12] and the usage of in-beam PET monitoring with a probing
beam [Fie10, Lin12], which are presented in more detail in section 5.2.2. Analog to studies by
Rucinski et al. [Ruc13], Christodouleas et al. [Chr13] and van Gysen et al. [Gys14] for prostate
cancer or studies by Viswanathan et al. [Vis13] for gynecologic cancers it was furthermore con-
sidered if the injection of a spacer like hydrogel would be beneficial in order to increase the
distance between the esophagus and the ablation sites. Due to an increased risk for infections
in the cervical region this approach is considered unfeasible in this case (Prof. Christoph Bert,
personal communication, April 10, 2014).
Even though the dose-volume limits for the heart were exceeded, it should be noted that the
heart is also the target volume in this feasibility studied. Further analysis of the maximal point
dose, the maximal irradiated volume as well as the median dose were in good agreement to lim-
itations stated in literature [Gag10, Mar98, Wei08, Han93] and hence no pericarditis should be
expected. Concerning the irradiated cardiac substructures it was found that three beam direc-
tions yielded a lower mean dose to the LCA. A mean dose over all patient cases of up to 1.5 Gy
for 7 mm safety margin was found. According to a study by Darby et al. [Dar13] major coronary
events increase by 7.4 % per Gy photon irradiation after five years post radiotherapy. Due to
the advanced age of the atrial fibrillation patient cohort the irradiation of the coronary arteries
might hence play a less significant role. Moreover, recent studies indicate that an irradiation of
the heart with carbon ions might even lead to beneficial effects in the intercellular communcia-
tion. Studies by Amino et al. indicate that single fraction carbon ion irradiations of more than
10 Gy lead to an increased expression of Connexin 43 (Cx43) [Ami06, Ami10]. This protein
is involved in the construction of gap junctions in mammalian hearts, which are intercellular
channels enabling current flow and hence the propagation of action potentials (see chapter 1,
section 1.3.1). It has been shown that remodelling of connexin expression and gap junction
organization are featured in pathological conditions of the heart, including ischemia and heart
failure [Sev04, Sev08]. Recent studies indicate that connexin expression is also implied in the
induction and sustaining of AF [Kan04, Pol01, Yeh01, Bik11]. Amino et al. could show in animal
models that a cardiac irradiation with carbon ions led to a dose-dependent upregulation of Cx43
expression [Ami06], lasting for at least one year [Ami10]. It was found that this result improved
the conductivity and repolarization of the animal hearts, hence having the potential for an ad-
diational antiarrhythmic effect. The clinical relevance of these findings needs to be investigated.
Due to the anatomical differences of pigs compared to humans and due to the larger dis-
tance of the AV node to critical structures (esophagus, trachea and aorta) dose depositions
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to OAR for the irradiation of the AV node in the planned animal model were found to be negli-
gible. Dose-volume limits were not exceeded and the stated OARs as well as the radiosensitive
cardiac substructures were well spared. The dose-volume limits for the heart were also not ex-
ceeded. Maximal point dose to the heart as well as maximal irradiated volume and mean dose
were also in very good agreement to the literature findings for human data. Late effects due
to e.g. coronary events would also not be expected from the obtained dose deposition in these
structures. It should be noted that a potential detection of these events would not be feasible
due to the short lifespan of the animals in the planned animal model feasibility study at GSI.
5.1.3 Dose to OAR: Comparison to photons
A non-invasive treatment with carbon ions is expected to result in a better sparing of the sur-
rounding tissue and OARs compared to an irradiation with photons. In order to study this
assumption results of treatment planning studies based on the same patient data sets and the
resultant dose deposition to the OAR were studied. This was carried out both for human data
sets as well as porcine data sets. The photon treatment plans are courtesy of Dr. Limin Song
and Dr. Amanda Deisher (Mayo Clinic, Rochester, Minnesota, USA).
Human data
Photon treatment plans were carried out on the reference CT phase of patient 2 and patient 4
(see chapter 3) with a 6 MV photon beam. These two data sets were chosen as the carbon ion
treatment plans resulted in the highest studied dose deposition to the esophagus in patient 2,
while patient 4 resulted in the lowest dose deposition to this structure in the studied patient
cohort. The photon plans were carried out as a seven field IMRT(OAR) treatment (see figure
5.1). The delivery was also planned as a single fraction irradiation of 25 Gy. For the ITV
generation the PVs target volumes were isotropically expended by 3 mm. The final PTV was
generated by applying an additional isotropic expension of 5 mm margin to the ITV. For the
carbon ion treatment, which were carried out as IMPT plans, an isoptropic safety margin of
5 mm was added to the CTV. Afterwards additional ITV margins were generated from the 4DCTs,
accounting also for range variations [Gra12]. The IMPT plans were computed with three beam
channel directions (see chapter 3, section 3.2.1). The CTV target volume as well as the contours
of the OAR were kept identical in both photon and carbon study, enabling a direct comparison
of the treatment planning outcome.
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(a) Patient 2 : photons (IMRT) (b) Patient 2 : carbon ions (IMPT)
(c) Patient 4 : photons (IMRT) (d) Patient 4 : carbon ions (IMPT)
Figure 5.1.: Comparison of dose cuts with photons (IMRT) and carbon ions (IMPT) treatment
are shown for Patient 2 and Patient 4, respectively. As target volumes for the LPV
and RPV the CTV is displayed. Photon treatment plans are courtesy of Dr. Amanda
Deisher, Mayo Clinic, USA. The results of both treatment plans are displayed in the
software Slicer.
Table 5.1.: Dose-volume limits for OARs. The volumes are stated in cc, dose values in Gy. The
photon irradiation (IMRT) is compared with two different IMPT setting for carbon
ions (weak: maximal 70 % of the physical dose to the esophagus, strong: maximal
30%). The maximal applicable phyical dose to the target region for the dose-volume
limits of the critical structures is stated in the last column for the strong IMPT setting.
Patient OAR Volume Dose endpoint IMRT IMPT (weak) IMPT (strong) max.D (strong IMPT)
2 aorta / great vessels 10 31 aneurysm 22.0 14.3 15.3 50.6
esophagus 5 11.9 stenosis / fistula 24.6 22.5 7 42.5
heart 15 16 pericarditis 27.1 25.3 30.0 (13.3)
trachea 4 10.5 stenosis / fistula 7.6 4.3 3 87.5
4 aorta / great vessels 10 31 aneurysm 21.3 8.5 6.3 123.0
esophagus 5 11.9 stenosis / fistula 20.2 18.5 3.5 85.0
heart 15 16 pericarditis 26.1 24.5 22.3 (18.0)
trachea 4 10.5 stenosis / fistula 0 0 0 ∞
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(a) Patient 2 : photons (IMRT) (b) Patient 2 : carbon ions (IMPT)
(c) Patient 4 : photons (IMRT) (d) Patient 4 : carbon ions (IMPT)
Figure 5.2.: Comparison of DVHs are displayed for a treatment with photons (IMRT) versus car-
bon ions (IMPT). Target dose deposition are shown in black for the LPVs and brown
for the RPVs, the dose to the esophagus is displayed in red, the trachea dose in
green, the aorta dose in blue, the heart dose in orange, the lung dose in purple
and the spinal cord dose in light blue. Photon treatment plans are courtesy of Dr.
Amanda Deisher, Mayo Clinic, USA. For the carbon ion treatment plans different
IMPT parameters are shown, where a better sparing of the esophagus is achieved
with stronger limitation parameters, shown in dashed lines (Eso_sIMRT).
Table 5.2.: Integral dose in [Gy×cm3] for photon treatment (IMRT) and the two studied
IMPT(OAR) deliveries for carbon ion irradiation (weak: maximal 70 % of the physi-
cal dose to the esophagus, strong: maximal 30 %).
Patient OAR IMRT IMPT(OAR) (weak) IMPT(OAR) (strong)
2 esophagus 359 184 80
trachea 81 57 48
aorta 983 388 356
heart 13,863 2,762 2,544
lung 10,932 4,761 4,326
5 esophagus 166 81 32
trachea 20 0 0
aorta 912 264 180
heart 6,992 1,250 1091
lung 11,274 3,126 2,730
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Due to the different interaction mechanism of photons and ions with matter (see chapter
1, section 1.1.2), and the resulting inverse depth dose profile of ions the surrounding tissue
- including the OARs - can be better spared with carbon ions. Hence smaller field channel
numbers can be chosen (see figure 5.1). The sparing of the OAR are shown both in the result-
ing dose-volume deposition to OARs in table 5.1 as well as in the comparison of the resulting
DVHs for photons and carbon ions (see figure 5.2). For the carbon ion study two different
IMPT(OAR) parameter settings were used and both results are shown: An IMPT(OAR) delivery
with a weak dose restriction to the esophagus of maximal 70 % of the physical dose of 25 Gy
and an IMPT(OAR) setting with a stronger restriction of maximal 30 % physical dose to the
esophagus. As can be seen in table 5.1 the IMPT(OAR) delivery with the weaker restriction to
the esophagus results in dose-volume depositions comparable to the studied photon treatment,
while the irradiation with the stronger dose restrictions results in a much better sparing of the
studied OARs. An exception is the heart, as it is also the target volume itself. This structure
requires a closer analysis on the irradiated substructures. Nevertheless it can already be seen
from the DVH information of both patients, that the irradiated heart volume is drastically re-
duced with carbon ions compared to photons, due to the reduced number of beam channels
feasible with carbon ions. The dose cut images (figure 5.1) also display that the left ventricles
are better spared with a non-invasive irradiation of the PVs with carbon ions due to the chosen
beam channel directions. It can thus be expected that this leads to a better sparing of the ra-
diosensitive left coronary arteries.
Another method to compare the dose distribution for two different delivery techniques and
quality beams is to calculate the integral dose, a measure of the total energy absorbed in the
treated volume [Kha10]. It is calculated as the product of the mass of the irradiated tissue and
the absorbed dose. Here, no organ specific density was assumed, but the integral dose was
calculated as the dose volume product. The results for different critical structures (esophagus,
trachea, heart, aorta and lung) are shown in table 5.2 and it can be seen that the absorbed
energy of these organs can be drastically reduced with carbon ions compared to photons.
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Porcine data
Photon treatment plans for the irradiation of the AV node were carried out on different CT
phases for all four porcine data sets (see chapter 4) as a five field IMRT treatment (see figure
5.3) with 6 MV photons. In order to keep the ITV margin small the center phase of the motion
was chosen as planning phase. This resulted in a treatment planning on 70 % of the cardiac
phase for pig 1, on 20 % for pig 2, 0 % (reference phase) for pig 3 and 70 % for pig 4. The
delivery was also planned as a single fraction irradiation of 25 Gy. For the ITV additional 3 mm
isotropic expansions were used, resulting in the final PTV. For a fair comparison the shown car-
bon ion results were calculated on the same CT scan phases. The plans are SFUD irradiations
with an isoptropic safety margin of 5 mm to the CTV. The SFUD carbon ion plans were generated
with two opposing beam channel directions (see chapter 4). The target volume as well as the
contours of the OAR were kept identical in both deliveries, enabling a direct comparison of the
treatment planning outcome.
The sparing of the OARs are shown both in the resulting dose-volume deposition in table
5.3 as well as in the comparison of the resulting DVHs for photons and carbon ions (see fig-
ure 5.4). Due to the inverse depth-dose profile of carbon ions a reduced number of beam
channel entry directions is feasible, resulting in a better sparing of the OARs compared to an
irradiation of the AV node with photons. Due to the used beam channel directions it can be
seen that the esophagus as well as the trachea do not receive any dose deposition. The dose
deposition in the aorta is negligible, resulting in an irradiated volume of less than 10 cc. Also
the heart itself (which is here shown with substracted PTV volume) is much better spared with
carbon ions, resulting in no dose-volume-limit exceeding irradiation for this structure. For pho-
tons on the other hand the limit is exceeded in three out of the four studied data sets. It should
be noted that the analyzed heart volume excludes the irradiated AV node volume and hence
also the highest dose deposition, the target dose of 25 Gy physical dose.
Also in the porcine data sets the body was only partially displayed on the CT scans and hence no
density information could be derived for the calculation of the integral dose. The specific inte-
gral dose for both treatment delivery techniques were determined also for these cases. Thereby
the sum over all dose volume products was calculated for the body contour volume. The results
are shown in table 5.4 and it can be seen that the absorbed energy to the body volume can be
drastically reduced with carbon ions compared to photons.
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(a) Pig 3 : photons (IMRT) (b) Pig 3 : carbon ions (SFUD)
Figure 5.3.: Comparison of dose cuts with photons and carbon ions treatment are shown for pig
3. The photon delivery was planned as IMRT treatment and the carbon irradiation as
SFUD irradiation, respectively. As the AV target volume the CTV is displayed. Photon
treatment plans are courtesy of Dr. Limin Song, Mayo Clinic, USA. The results of both
treatment plans are displayed in the software Slicer.
Table 5.3.: Dose-volume limits for OARs. The volumes are stated in cc, dose values in Gy. The
photon irradiation (IMRT) is compared with SFUD carbon ion irradiation
pig OAR volume dose endpoint IMRT SFUD
1 aorta / great vessels 10 31 aneurysm 1.1 0.0
esophagus 5 11.9 stenosis / fistula 0.2 0.0
heart-PTV 15 16 pericarditis 18 6.3
trachea 4 10.5 stenosis / fistula 6.5 0.0
2 aorta / great vessels 10 31 aneurysm 2.1 0.0
esophagus 5 11.9 stenosis / fistula 0.4 0.0
heart-PTV 15 16 pericarditis 16.1 6.5
trachea 4 10.5 stenosis / fistula 2.6 0.0
3 aorta / great vessels 10 31 aneurysm 0.9 0.0
esophagus 5 11.9 stenosis / fistula 0.3 0.0
heart-PTV 15 16 pericarditis 23 4.8
trachea 4 10.5 stenosis / fistula 0.2 0.0
4 aorta / great vessels 10 31 aneurysm 0.7 0.0
esophagus 5 11.9 stenosis / fistula 0.3 0.0
heart-PTV 15 16 pericarditis 14.3 7.3
trachea 4 10.5 stenosis / fistula 4.6 0.0
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(a) Pig 1 (b) Pig 2
(c) Pig 3 (d) Pig 4
Figure 5.4.: Comparison of DVH results with photons (solid) and carbon ions (dashed). The pho-
ton delivery was planned as IMRT treatment and the carbon irradiation as SFUD
irradiation, respectively. The target dose to the AV node is displayed in black, the
dose to the esophagus in red, to the trachea in green, the aorta in blue and the
irradiated heart (with the substracted PTV volume) is shown in orange. In case of
carbon SFUD deliveries, the esophagus and trachea do not receive any dose. Photon
treatment plans are courtesy of Dr. Limin Song, Mayo Clinic, USA.
Table 5.4.: Integral dose in [Gy×cm3], exemplarily for pig 3, for photon irradiation (IMRT) and
carbon ion treatment (SFUD).
Pig OAR IMRT SFUD
3 esophagus 14 0
trachea 62 0
aorta 66 1
heart-PTV 1,374 289
lung 1,195 187
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5.2 Treatment planning of cardiac target volumes with scanned ions
In order to assess the displacement of the cardiac volumes due to respiration and heartbeat,
4DCTs gated on respiration or heartbeat were analyzed and the findings will be discussed in
section 5.2.1. Afterwards the usage of contrast enhanced CT scans due to the poor contrast
between the heart muscle and the contained blood will be discussed in section 5.2.2 and possible
experimental solutions for resulting range uncertainties will be proposed. In section 5.2.3 the
result of the used motion mitigation techniques for the irradition of cardiac target volumes with
a scanned carbon ion beam will be deliberated.
5.2.1 Motion of cardiac volumes
Target volumes in the heart move on one hand due to the respiration of the patient, a motion
with a large amplitude and a slow cycle time of ten to fifteen respiratory cycles per minute, and
on the other hand due to heartbeat, a motion with a small amplitude and cycle time of sixty to
eighty beats per minutes. Even though both motions occur simultaneously in patients, they were
studied independently in the here presented treatment planning studies. This can be justified
as a CT gated to both motion types would require long CT acquisitions and hence unnecessary
dose exposures to the patient.
PVs motion in humans
The motion of PVs ablation sites in humans due to respiration were studied based on respiratory
gated time resolved computed tomographies (4DCTs) of nine lung cancer patients, recorded for
radiotherapy at MD Anderson Cancer Center (MDACC), USA. The heartbeat influence was stud-
ied on cardiac gated 4DCTs of five AF patients, recorded at Mayo Clinic, USA.
The movement of the ablation sites of the PVs were studied in the three motion directions
(superior-inferior (SI), anterior-posterior (AP) and left-right (LR)) as well as for the absolute
displacement. Different studies concerning the PVs displacement due to respiration can also be
found in literature [Ect08, Nos05], as breathing is also relevant for cather ablation due to the
reduction in catheter tip contact force [Kum12]. While Ector et al. stated an absolute mean
displacement of (19.1 ± 8.6) mm for both LPV and RPV, a much smaller absolute mean dis-
placement of (6.8 ± 3.6) mm and (6.8 ± 2.5) mm was found in the here studied patient cohort
for LPV and RPV, respectively. The SI motion was the biggest motion direction with a mean
displacement of (-6.4 ± 3.8) mm for LPV and (-6.6 ± 2.4) mm for RPV. AP and LR directions
were almost negligible with a mean motion of less than 2 mm. The difference between the
two cardiac sites is more pronounced in AP and LR, so that, e.g., the LPV move more in ante-
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rior direction. In LR direction a difference between LPV and RPV motion resulted, where the
mean displacement of the LPV is almost double compared to the RPV. Ector et al. on the other
hand found a mean displacement of (14.6 ± 7.7) mm in inferior direction, (9.7 ± 7.6) mm in
anterior direction and (0.4 ± 3.8) mm in the left direction, hence concluding a much bigger
displacement in SI and AP directions. It remains to be analyzed if this discrepancy is due to the
here studied lung tumor patient cohort in comparison to the AF patients studied by Ector et al..
Nevertheless it should be noted that both analyses are based on a small patient number (nine
patients and sixteen patients, respectively).
The motion of the ablation sites for the PVs due to heartbeat was studied for the left and right
structures, respectively, in the three above stated motion directions. Only a small mean absolute
displacement over all patients of less than 3 mm was observed. The biggest absolute displac-
ment reached a mean value of up to (6.5 ± 3.0) mm in one patient case for the RPV and (5.5
± 3.1) mm for the LPV. No dominant motion direction was found, even though a tendency to
a bigger motion in AP direction could be assumed. Furthermore, no motion pattern could be
derived from the five studied patient data sets, indicating that the underlying motion causing
the PV ablation sites to move is much more complex and the result of different motion influ-
ences. For further studies concerning the PV displacement due to heartbeat, the reader should
be refered to Lickfett et al. [Lic05] and Patel et al. [Pat08]. Lickfett et al. found comparable
maximal displacements of up to 7.2 mm in some of the healthy volunteers. Patel et al., who
studied the displacement in thirty AF patients, stated mean values in the order of 3 mm. The
here presented results are hence in good agreement with the literature values.
Motion in porcine due to heartbeat
The motion of different potential cardiac ablation sites (AV node, CTI and PVs) were studied in
pigs based on cardiac gated 4DCTs of four swines, recorded at Mayo Clinic, USA. The acquired
CT scans were both native and contrast enhanced. It was found that native CT scans do not
enable an assessment of the cardiac target volume displacement due the low contrast between
the cardiac muscle and the contained blood. Analysis was hence carried out on the contrast
enhanced CT scans. Concerning the motion of the three studied potential target sites it could
be stated that the PVs moved to the smallest extent (maximal displacement of up to 5 mm),
followed by the AV node (maximal displacement of up to 6 mm) and that the CTI moved the
most (maximal displacement of 7 mm). It was speculated that this is due to the location of
the volumes, where a proximal location on or near the ventricles lead to a larger movement.
Even though also in the porcine data sets no maximal motion phase or motion pattern could be
observed due to heartbeat it was found that the displacement was shallower between certain
motion phases (motion phase 6 to 13) and hence, contrary to the studied human data, gating
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could be an optional motion mitigation technique. Moreover, in comparison to the human data,
the displacement in AP direction in the porcine data was clearly larger than in the other two
studied directions.
5.2.2 Contrast enhanced CT scans
Particle treatment planning needs to be carried out on native CT scans in order to obtain the
correct range information [Wer04]. In case of the intended irradiation of cardiac target volumes
it was found that native CT scans do not provide sufficient contrast between the heart muscle
and the contained blood. As stated, the motion information can thus only be assessed from
contrast-enhanced CT scans. It needs to be studied if the displacement vector field obtained
from registration on the contrast enhanced CT scans yield a good enough agreement when
directly used on the native data sets for the actual treatment planning. The resulting range
uncertainties need to be carefully considered, especially regarding the dose to critical structures
like the esophagus. Analog to studies by e.g. el Bentefour et al. [Bent12], where in vivo range
verifications were successfully achieved with a small dose deposition (<0.5 cGy) in silicone
diodes, a possible solution could be to predeposit the resulting treatment plan with a small dose
in the order of mGy. By placing such an detector with a catheter inside the patient, either in front
of or inside the esophagus, it would allow to test for range of the planned energies and hence
for potential miscalculation or interfractional changes of the organs. Range uncertainties to the
target area could furthermore be corrected before irradiation with the total single fraction dose.
By using in-beam PET monitoring with 11C and 10C fragments (see chapter 1, section 1.1.2) it
would be possible to irradiate a low dose in order to detect the range and position uncertainties.
This was already carried out at GSI, where 10C resulted to be best suited as a probing beam for
range verifications [Lin12]. The accuracy of PET monitoring for ion range determination was
studied by Fiedler et al. [Fie10] for more than 80 of the 400 patients irradiated in the GSI pilot
project. It was stated that in-beam PET method demonstrated a high sensitivity for the detection
of range deviations and would thus be beneficial for the here presented treatment modality.
5.2.3 Motion mitigation techniques
Due to the large motion of the PV ablation sites induced by the respiratory motion in the studied
patient cohort, interplay was observed to lead to strong underdosage, so that in some cases only
V95 of 70 % was achieved with no safety margin and of 80 % with safety margins of 5 mm. Due
to the large motion amplitude of more than 1 cm gating was studied as potential motion mit-
igation technique (see next paragraph). For the displacements induced by heartbeat a smaller
motion of less than 1 cm was observed in all studied human data, so that rescanning was stud-
ied as an adequate motion mitigation technique for this case. As expected, the interplay effect
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in this case was smaller than for respiration, with minimal dose coverage of 85 % for no safety
margin and a minimal V95 of 92 % for 5 mm and 7 mm margin, respectively. Even though this
underdosage with safety margin already yields a clinically acceptable dose coverage the usage
of an additional motion mitigation technique leads to a more robust treatment delivery. For the
porcine data, where the motion influence of the heartbeat on the AV node target volume was
studied and only a single margin of 5 mm was used, the interplay effect led to larger minimal
underdosages of 56 % in some of the studied pig data sets. Hence the usage of rescanning as
motion mitigation technique was needed in this case as well.
Respiratory motion
In the animal model studies by Sharma et al. [Sha10] the target displacement due to respiration
was tracked with the CyberKnife system. In the study by Blanck et al. [Bla13] an ITV approach
was used for the respiratory motion. Here, gating was used as a potential motion mitigation
technique. It is suited for larger target displacments, since only a fraction of the motion cycle is
used. The gating window is positioned at end exhale, enabling a more robust delivery with only
a small amount of residual motion. To this date, gating is already used in ion beam centers with
passive particle delivery [Min00] as well as in IMRT treatments in photon centers [Kea06]. A
pilot study with scanned carbon ions was recently conducted on liver patients at HIT by using
gating and abdominal compression [Ric12]. In the here studied case, gating was found to
be an adequate motion mitigation technique so that underdosages could be increased up to a
minimum of 98 % for all studied safety margins and patient cases. Even in cases with no safety
margin underdosage could be increased to a minimum of 94 %. It can nevertheless be stated that
safety margins, which are needed in order to account for e.g. position inaccuracies, improved
the outcome and made the delivery more robust. It was furthermore studied in two patient
data sets if the treatment outcome improved when rescanning was applied for the residual
motion inside the gating window. This is proposed as phase-controlled rescanning [Fur07]
or breath-sampled rescanning [Sec09]. It resulted in a marginal improvement compared to
only gating, whereas no improvement was observed when using more than ten rescans. Since
the irradiation of the PV ablation sites were also studied to include rescanning as mitigation
for heartbeat motion, the combination of these two techniques will be automatically achieved.
Concerning the treatment time it was expected that gating would increase the treatment time
dependence on the used gating window. Since only 30 % of the motion cycle was used for
irradiation, the treatment resulted into a delivery time of about 30 min with a high intensity
of 55,000 minimum particles per beam spot and for a safety margin of 3 mm. Compared to
the radiofrequency ablation procedure which takes up to a couple of hours, and to the photon
irradiation of up to two hours [Sha10], the treatment time is drastically reduced. This was found
for the HIT beam parameters, where a relatively long time for an energy change is needed.
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The particle intensity could be further increased, leading to an even further reduced treatment
time. Nevertheless it was shown that very high intensities can endanger a homogenous dose
coverage [Mue14]. New accelerator concepts with variable excitation cycles [Tsu08] or faster
energy changes [Iwa10] might hence be needed. An alternative to gating could be the usage of
apneic oxygenation, which is currently used at the Rinecker Proton Therapy Center in Munich
[Ber11, RPTC12] for the treatment of tumors in the upper abdomen and thorax. This approach
will also be used in the planned animal experiments with pigs which will be carried out at GSI
in the summer of 2014.
Heartbeat motion
In the animal model studies by Sharma et al. [Sha10] and by Blanck et al. [Bla13] an ITV
approach was used for the heartbeat motion. In the here presented study rescanning was used
as a motion mitigation technique for heartbeat motion, both in human as well as for the porcine
data sets. Especially in human data only rescanning seemed to be an adequate technique due
to the lack of a motion pattern or a region of shallower motion. For the porcine data on the
contrary, cardiac gating might be another option, which needs to be investigated. In the human
data it was found that the dose coverage was higher than 99 % in about 96 % of the studied
cases with safety margins over 3 mm. This result could be even further improved if ten or more
rescans were applied. Nevertheless it can be argued that five rescans already yield a very good
dose deposition in the target volume. For the porcine data and the studied AV node ablation
it was found that the dose coverage was higher than 99 % in 85 % of the studied cases with a
safety margin of 5 mm. This finding could be slightly improved to 91 % of the studied cases
for ten rescans. A higher rescan number of fifteen rescans did not lead to a significant improve-
ment. The finding indicates that ten rescans are already sufficient to enable a robust and stable
irradiation of the cardiac target volume in the presence of heartbeat. Due to the high single dose
the resulting intensity per rescan is expected to be large and hence the application should be
feasible without further prolonging the treatment time. All the studied rescanning results were
obtained for slice-by-slice rescanning. This means that each IES is rescanned independently
with the predefined numbers of rescans. In other studies it has nevertheless be found that other
rescan methods, like e.g. breath-sampled rescanning [Sec09] or phase-controlled rescanning
[Fur07], result in an increased robustness while requiring fewer rescan numbers compared to
slice-by-slice rescanning as it breaks up possible synchronicities between beam application and
target motion [Mue14]. In breath-sampled rescanning the IES are rescanned individually, but
the rescans are sampled according the motion phase of the breathing period, so that every mo-
tion phase receives dose appliactions. An analog delivery according to the heartbeat and hence
an ECG-sampled rescanning might be feasible and could lead to improved results.
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6 Conclusion and outlook
This is the first work to study the irradiation of intrafractionally moving, non-cancerous target
volumes with carbon ions. Its aim was to investigate the feasibility of a non-invasive treatment
for cardiac arrhythmias like atrial fibrillation using particle radiosurgery.
The search for a new treatment modality for this condition is motivated by the current limi-
tations of catheter ablation, which has varying success rates and can lead to severe side effects
[Cap05, Cap10, Jong05, Her13, Gai10, Med13]. Studies on the potential of a non-invasive
treatment with photon irradiation already exist [Sha10]. Due to differing interaction mecha-
nisms of photons with matter in comparison to ions, a better sparing of the surrounding tissue
was expected for radiosurgery with ions [Ber12]. This was demonstrated in this thesis, where
carbon ion and photon delivery were compared on the same data sets. The difference in dose
deposition to the organs at risk was significant and made a strong case to use ions in cardiac
radiosurgery.
Due to successful treatment outcomes in cancer radiotherapy, an increasing number of therapy
centers treat patients with scanned particle therapy [PTCOG13]. Up to now clinical applications
of these centers have been mostly conducted on tumors which showed no intrafractional dis-
placements [Loe13]. This is due to the otherwise occuring interference effects between the exist-
ing target motion and the actively applied particle beam, leading to local over and under dosages
(interplay effect) and hence to the need of motion mitigation techniques [Phi92, Ber08].
The intrafractional motion of the pulmonary veins atria junction was studied separately in hu-
man data with regard to the underlying respiratory and heartbeat motion. These intrafractional
motion types differ in motion period and amplitude. While the respiration is a rather slow
motion which causes the pulmonary vein junction to move in particular in the superior-inferior
direction up to more than 2 cm, the heartbeat displays a fast motion period causing a fairly irreg-
ular motion of the ablation site with an amplitude of up to 1 cm. The interplay effect caused by
respiration was hence found to be more pronounced than in case of heartbeat motion. In order
to guarantee a robust treatment delivery, motion mitigation techniques have also been studied
in case of heartbeat displacements. For the influence of the respiratory motion, the interrupted
irradiation during a selected part of the motion cycle (gating) [Kub96] was studied and was
found to be an adequate technique for a 30 % gating window around end exhale. Nevertheless,
gating always results in a prolonged treatment time. Alternative methods could be jet ventila-
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tion [Hof03] or apneic oxygenation [RPTC12], where the patient is kept in a steady respiratory
phase and which would result in a shorter treatment time. In order to mitigate the influence of
the heartbeat motion, an averaging effect of different interplay patterns by scanning the same
slice multiple times (rescanning) [Phi92] was applied. Also, this motion mitigation technique
resulted in a good dose coverage, even for small rescan numbers. This delivery would not pro-
long the treatment time. Other rescanning techniques are nevertheless known to result in an
increased robustness while requiring fewer rescan numbers, like e.g. breath-sampled rescan-
ning [Sec09] or phase-controlled rescanning [Fur07], where the rescans are equally distributed
over the motion cycle. Thus a similar technique should be investigated in the future for the
cardiac motion (ECG-sampled rescanning). In case of the studied porcine data, where the car-
diac target volumes also displayed an irregular motion but had a more shallow motion region
in common, cardiac gating could furthermore be a potential application. This would require the
application of a fast beam extraction modality for synchrotrons with radiofrequency knock-out
exciters, which exist, e.g., at NIRS [Nod96, Fur05] and HIT [Schoe11], and have been tested
in first studies at GSI [Ber09]. In preparation for the planned animal experiments with pigs
at GSI, which will be an experimental validation of these treatment planning results, rescan-
ning was found to be a well suited technique to overcome the heartbeat motion influence in the
atrioventricular node of swine. For the breathing motion of the animals a respirator will be used.
In all presented treatment planning results a physical dose of 25 Gy was used. Biological
effects leading to an increased biological effectiveness might occur, even though preliminary
studies did not support this assumption and a RBE of 1.1 was found. It is expected that the
RBE reaches a plateau for high single fraction doses [Cara07], in which case the physical dose
could be considered proportional to the biological dose and the deposition in the organs at risk
could be directly scaled to the desired value. Older photon studied suggested that a dose of 20
Gy is sufficient to induce fibrotic tissue in the heart [Faj70, Faj73]. Nevertheless higher doses
than that might be needed to create a complete electrophysiological block in the desired tar-
get area. The planned dose escalation studies in the animal models will offer valuable data in
respect to this question. The treatment planning results were obtained on contrast-enhanced
CT scans, since the contrast between cardiac muscle and blood was not sufficient in native CT
scans. A closer analysis on the resulting range uncertainties is needed. Potential experimental
validations like small dose depositions in silicon diodes [Bent12] or PET probing beams [Lin12]
were suggested in order to test for potential range differences which might endanger critical
structures. These need to be investigated and tested for suitability.
In general it became obvious that a non-invasive treatment is challenging due to the amount
of OAR which are in direct proximity of the desired target area. Intensity modulated particle
therapy was hence needed in order to adhere to dose-volume limits stated for these structures
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[RTOG0631, RTOG0915]. Furthermore a delivery with an ion beam gantry would be beneficial
as this allows to choose suitable beam entry channels, enabling a sparing of the critical struc-
tures.
Besides the potential ablation sites of the pulmonary veins junction and the atrioventricular
node, other applications are also conceivable in the future. Cather ablation has also recently
been used for isolation of low-voltage areas in the ventricles of patients who suffered a my-
ocardial infarction in order to prevent the formation of life-threatening ventricular tachycardias
[Til14, Mad14]. It has furthermore been shown that the underlying myocardial scar and border
zones can be visualized in contrast-enhanced CT scans [Tia14]. Treatment planning for this
condition is therefore potentially feasible. Due to the larger distance of the ventricles to many
critical structures this delivery might even be easier achievable than a non-invasive isolation of
the pulmonary veins.
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A Appendix of chapter 2
A.1 Motion of PV due to respiration
The mean relative displacement and standard deviation of the target volumes (LPV and RPV)
to the reference phase five will be shown for the three studied motion directions (SI: superior-
inferior, AP: anterior-posterior, LR: left-right) and the absolute (ABS) displacement.
Table A.1.: Patient 1, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 5.17 ± 0.48 -5.16 ± 0.48 -0.05 ± 0.18 -0.14 ± 0.15
01 4.88 ± 0.33 -4.87 ± 0.34 -0.09 ± 0.26 -0.01 ± 0.09
02 3.73 ± 0.24 -3.72 ± 0.24 -0.21 ± 0.13 0.12 ± 0.08
03 1.62 ± 0.14 -1.61 ± 0.15 -0.14 ± 0.13 0.05 ± 0.08
04 0.76 ± 0.13 -0.75 ± 0.13 -0.01 ± 0.07 -0.04 ± 0.05
06 0.28 ± 0.09 0.12 ± 0.04 0.10 ± 0.15 -0.19 ± 0.05
07 0.69 ± 0.26 -0.30 ± 0.27 0.52 ± 0.17 -0.27 ± 0.11
08 1.46 ± 0.67 -1.35 ± 0.66 0.49 ± 0.16 -0.24 ± 0.12
09 4.51 ± 0.91 -4.49 ± 0.89 0.26 ± 0.18 -0.20 ± 0.20
Table A.2.: Patient 1, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 6.12 ± 1.43 -6.03 ± 1.41 -1.00 ± 0.37 -0.11 ± 0.16
01 4.61 ± 0.63 -4.44 ± 0.61 -1.10 ± 0.33 0.45 ± 0.11
02 3.61 ± 0.28 -3.46 ± 0.28 -0.96 ± 0.16 0.31 ± 0.10
03 1.70 ± 0.41 -1.58 ± 0.38 -0.57 ± 0.16 0.24 ± 0.09
04 0.34 ± 0.23 -0.20 ± 0.30 -0.13 ± 0.05 -0.09 ± 0.09
06 0.39 ± 0.12 0.33 ± 0.15 0.11 ± 0.04 -0.13 ± 0.04
07 0.73 ± 0.18 0.47 ± 0.28 0.41 ± 0.09 -0.29 ± 0.05
08 0.89 ± 0.27 -0.48 ± 0.42 0.49 ± 0.13 -0.43 ± 0.08
09 5.06 ± 1.27 -5.03 ± 1.24 -0.44 ± 0.42 0.01 ± 0.13
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Table A.3.: Patient 2, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 5.37 ± 0.62 -5.33 ± 0.62 -0.38 ± 0.22 -0.45 ± 0.22
01 3.36 ± 0.30 -3.32 ± 0.29 -0.15 ± 0.14 -0.44 ± 0.18
02 1.86 ± 0.20 -1.81 ± 0.21 -0.22 ± 0.22 -0.27 ± 0.09
03 1.82 ± 0.53 -1.78 ± 0.54 -0.30 ± 0.05 -0.05 ± 0.07
04 1.08 ± 0.44 -1.07 ± 0.44 -0.09 ± 0.06 -0.06 ± 0.07
06 1.50 ± 0.36 -1.50 ± 0.36 0.01 ± 0.04 -0.07 ± 0.10
07 2.05 ± 0.29 -2.03 ± 0.29 0.12 ± 0.20 -0.08 ± 0.12
08 3.63 ± 0.50 -3.61 ± 0.49 -0.15 ± 0.11 -0.22 ± 0.16
09 4.94 ± 0.62 -4.92 ± 0.62 -0.27 ± 0.08 -0.22 ± 0.22
Table A.4.: Patient 2, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 7.51 ± 1.35 -7.47 ± 1.35 0.14 ± 0.32 0.46 ± 0.41
01 4.96 ± 1.06 -4.94 ± 1.06 0.11 ± 0.11 -0.21 ± 0.24
02 2.65 ± 0.59 -2.61 ± 0.59 -0.27 ± 0.16 -0.24 ± 0.24
03 1.28 ± 0.23 -1.26 ± 0.23 -0.11 ± 0.06 -0.15 ± 0.08
04 0.31 ± 0.20 -0.25 ± 0.23 0.04 ± 0.06 -0.06 ± 0.09
06 1.34 ± 0.22 -1.25 ± 0.17 0.14 ± 0.17 0.41 ± 0.18
07 3.39 ± 0.34 -3.34 ± 0.32 0.11 ± 0.23 0.49 ± 0.24
08 5.25 ± 0.70 -5.22 ± 0.69 0.18 ± 0.26 0.38 ± 0.26
09 6.78 ± 0.88 -6.75 ± 0.87 0.18 ± 0.25 0.54 ± 0.35
Table A.5.: Patient 3, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 7.14 ± 0.85 -7.09 ± 0.85 -0.39 ± 0.40 -0.51 ± 0.37
01 5.22 ± 0.94 -5.17 ± 0.93 -0.47 ± 0.35 -0.21 ± 0.27
02 2.71 ± 0.43 -2.65 ± 0.42 -0.19 ± 0.25 -0.36 ± 0.29
03 0.85 ± 0.29 -0.68 ± 0.33 0.07 ± 0.27 0.15 ± 0.37
04 0.33 ± 0.12 0.08 ± 0.23 0.07 ± 0.19 0.07 ± 0.14
06 1.52 ± 0.33 -1.47 ± 0.33 0.31 ± 0.15 0.18 ± 0.11
07 3.82 ± 0.41 -3.81 ± 0.41 0.16 ± 0.23 -0.03 ± 0.09
08 5.93 ± 0.84 -5.92 ± 0.85 0.25 ± 0.34 0.03 ± 0.16
09 7.13 ± 0.97 -7.09 ± 0.97 -0.16 ± 0.37 -0.50 ± 0.28
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Table A.6.: Patient 3, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 8.12 ± 0.98 -7.94 ± 0.95 -1.45 ± 0.28 0.88 ± 0.33
01 6.28 ± 0.79 -6.03 ± 0.83 -1.58 ± 0.29 0.68 ± 0.29
02 3.32 ± 0.45 -3.06 ± 0.51 -1.19 ± 0.16 0.37 ± 0.13
03 1.52 ± 0.49 -1.25 ± 0.59 -0.76 ± 0.17 0.05 ± 0.15
04 0.41 ± 0.15 0.14 ± 0.21 -0.30 ± 0.15 -0.06 ± 0.09
06 1.04 ± 0.23 -1.02 ± 0.25 0.08 ± 0.07 0.11 ± 0.10
07 4.13 ± 0.34 -4.06 ± 0.35 -0.51 ± 0.13 0.54 ± 0.12
08 6.32 ± 0.65 -6.25 ± 0.65 -0.77 ± 0.12 0.56 ± 0.14
09 9.10 ± 1.09 -8.90 ± 1.10 -1.48 ± 0.24 1.13 ± 0.18
Table A.7.: Patient 4, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 3.03 ± 0.39 -1.53 ± 0.26 -1.85 ± 0.32 -1.78 ± 0.47
01 2.56 ± 0.32 -1.34 ± 0.35 -1.44 ± 0.17 -1.56 ± 0.41
02 1.53 ± 0.40 -0.83 ± 0.33 -0.80 ± 0.23 -0.97 ± 0.29
03 0.89 ± 0.20 -0.46 ± 0.15 -0.57 ± 0.09 -0.47 ± 0.21
04 0.24 ± 0.10 -0.13 ± 0.12 -0.06 ± 0.13 -0.10 ± 0.09
06 0.35 ± 0.15 -0.02 ± 0.24 -0.14 ± 0.11 -0.20 ± 0.12
07 1.04 ± 0.16 -0.21 ± 0.31 -0.70 ± 0.10 -0.66 ± 0.16
08 1.73 ± 0.25 -0.62 ± 0.17 -1.07 ± 0.24 -1.17 ± 0.25
09 2.78 ± 0.35 -1.30 ± 0.25 -1.71 ± 0.30 -1.71 ± 0.40
Table A.8.: Patient 4, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 5.46 ± 0.57 -5.33 ± 0.59 -1.09 ± 0.22 0.36 ± 0.23
01 4.21 ± 0.32 -4.06 ± 0.33 -1.02 ± 0.24 0.26 ± 0.27
02 2.47 ± 0.40 -2.30 ± 0.38 -0.84 ± 0.19 0.20 ± 0.19
03 1.51 ± 0.35 -1.38 ± 0.30 -0.56 ± 0.20 0.21 ± 0.11
04 0.59 ± 0.20 -0.56 ± 0.20 -0.16 ± 0.08 0.06 ± 0.07
06 0.26 ± 0.04 0.04 ± 0.12 0.12 ± 0.05 -0.19 ± 0.04
07 0.99 ± 0.17 -0.95 ± 0.19 -0.04 ± 0.11 -0.24 ± 0.06
08 2.57 ± 0.49 -2.54 ± 0.50 -0.35 ± 0.13 -0.15 ± 0.15
09 4.89 ± 0.79 -4.79 ± 0.82 -0.91 ± 0.20 0.15 ± 0.20
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Table A.9.: Patient 5, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 5.06 ± 0.57 -4.55 ± 0.48 -0.75 ± 0.19 -2.07 ± 0.32
01 4.07 ± 0.27 -3.61 ± 0.23 -0.92 ± 0.13 -1.63 ± 0.23
02 2.84 ± 0.32 -2.62 ± 0.29 -0.84 ± 0.16 -0.68 ± 0.18
03 1.62 ± 0.37 -1.51 ± 0.34 -0.52 ± 0.12 -0.19 ± 0.19
04 0.94 ± 0.23 -0.86 ± 0.23 -0.36 ± 0.05 0.06 ± 0.10
06 0.83 ± 0.33 0.77 ± 0.32 0.30 ± 0.11 0.00 ± 0.07
07 0.79 ± 0.10 -0.53 ± 0.15 0.26 ± 0.06 -0.50 ± 0.07
08 3.06 ± 0.29 -2.66 ± 0.23 0.06 ± 0.17 -1.51 ± 0.21
09 4.56 ± 0.38 -4.14 ± 0.29 -0.43 ± 0.19 -1.85 ± 0.28
Table A.10.: Patient 5, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 5.37 ± 1.51 -4.96 ± 1.44 -1.89 ± 0.56 -0.77 ± 0.12
01 3.88 ± 1.12 -3.45 ± 1.05 -1.69 ± 0.46 -0.48 ± 0.09
02 2.26 ± 0.52 -1.88 ± 0.45 -1.24 ± 0.27 -0.13 ± 0.09
03 1.48 ± 0.37 -1.15 ± 0.28 -0.91 ± 0.26 0.15 ± 0.06
04 0.77 ± 0.15 -0.60 ± 0.15 -0.47 ± 0.09 -0.01 ± 0.07
06 0.47 ± 0.12 0.31 ± 0.15 0.22 ± 0.09 -0.24 ± 0.02
07 1.37 ± 0.11 -1.14 ± 0.13 0.22 ± 0.14 -0.71 ± 0.04
08 4.12 ± 1.06 -3.85 ± 1.06 -0.80 ± 0.33 -1.18 ± 0.13
09 5.24 ± 1.40 -4.85 ± 1.35 -1.51 ± 0.56 -1.18 ± 0.10
Table A.11.: Patient 6, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 6.08 ± 0.61 -5.43 ± 0.68 -1.41 ± 0.20 -2.30 ± 0.19
01 3.60 ± 0.42 -3.30 ± 0.42 -0.45 ± 0.11 -1.36 ± 0.17
02 1.72 ± 0.16 -1.50 ± 0.15 -0.17 ± 0.15 -0.81 ± 0.13
03 1.13 ± 0.20 -1.02 ± 0.24 0.07 ± 0.26 -0.36 ± 0.06
04 0.22 ± 0.06 -0.07 ± 0.10 0.12 ± 0.07 -0.13 ± 0.05
06 1.11 ± 0.12 -1.08 ± 0.12 -0.01 ± 0.13 -0.21 ± 0.08
07 2.81 ± 0.20 -2.70 ± 0.22 -0.15 ± 0.35 -0.67 ± 0.13
08 4.39 ± 0.66 -3.98 ± 0.80 -0.65 ± 0.23 -1.66 ± 0.18
09 6.38 ± 0.71 -5.70 ± 0.84 -1.31 ± 0.27 -2.47 ± 0.25
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Table A.12.: Patient 6, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 3.85 ± 0.46 -3.77 ± 0.48 -0.07 ± 0.20 -0.55 ± 0.52
01 1.72 ± 0.58 -1.59 ± 0.51 0.23 ± 0.31 -0.39 ± 0.46
02 0.98 ± 0.34 -0.87 ± 0.35 0.15 ± 0.15 -0.39 ± 0.08
03 0.57 ± 0.30 -0.38 ± 0.31 0.33 ± 0.18 -0.14 ± 0.14
04 0.36 ± 0.05 -0.19 ± 0.06 0.13 ± 0.04 -0.27 ± 0.05
06 0.99 ± 0.53 0.68 ± 0.66 0.29 ± 0.21 0.29 ± 0.38
07 1.64 ± 0.61 0.05 ± 1.52 0.51 ± 0.39 0.13 ± 0.56
08 2.29 ± 0.90 -1.91 ± 1.18 0.17 ± 0.53 0.06 ± 0.83
09 4.09 ± 0.45 -4.01 ± 0.47 -0.02 ± 0.37 -0.28 ± 0.68
Table A.13.: Patient 7, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 3.87 ± 0.75 -3.55 ± 0.63 -1.03 ± 0.47 -1.11 ± 0.23
01 3.21 ± 0.49 -2.96 ± 0.46 -0.83 ± 0.25 -0.92 ± 0.11
02 2.72 ± 0.55 -2.46 ± 0.47 -0.77 ± 0.29 -0.83 ± 0.17
03 1.74 ± 0.29 -1.56 ± 0.24 -0.57 ± 0.19 -0.48 ± 0.09
04 0.52 ± 0.10 -0.46 ± 0.13 -0.07 ± 0.11 -0.17 ± 0.09
06 0.54 ± 0.18 -0.51 ± 0.17 -0.10 ± 0.06 -0.14 ± 0.09
07 1.28 ± 0.17 -1.21 ± 0.16 -0.19 ± 0.12 -0.34 ± 0.04
08 2.67 ± 0.51 -2.44 ± 0.43 -0.62 ± 0.33 -0.83 ± 0.19
09 3.34 ± 0.63 -3.08 ± 0.58 -0.70 ± 0.30 -1.04 ± 0.17
Table A.14.: Patient 7, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 3.25 ± 1.08 -3.21 ± 1.06 -0.38 ± 0.34 -0.12 ± 0.10
01 2.88 ± 0.76 -2.84 ± 0.73 -0.39 ± 0.30 -0.01 ± 0.14
02 2.08 ± 0.57 -2.04 ± 0.54 -0.36 ± 0.23 0.09 ± 0.09
03 1.74 ± 0.37 -1.70 ± 0.35 -0.27 ± 0.16 0.09 ± 0.19
04 0.54 ± 0.11 -0.53 ± 0.11 -0.06 ± 0.07 0.01 ± 0.09
06 1.30 ± 0.23 -1.23 ± 0.21 0.17 ± 0.08 -0.36 ± 0.14
07 1.76 ± 0.57 -1.71 ± 0.58 0.12 ± 0.16 -0.33 ± 0.08
08 2.43 ± 0.77 -2.40 ± 0.77 0.03 ± 0.21 -0.35 ± 0.08
09 3.26 ± 0.94 -3.24 ± 0.93 -0.18 ± 0.28 -0.17 ± 0.10
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Table A.15.: Patient 8, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 9.61 ± 0.90 -9.53 ± 0.86 -1.02 ± 0.52 0.47 ± 0.38
01 8.45 ± 0.50 -8.37 ± 0.51 -0.96 ± 0.39 0.12 ± 0.30
02 4.62 ± 0.59 -4.56 ± 0.58 -0.67 ± 0.28 0.08 ± 0.27
03 3.06 ± 0.18 -2.99 ± 0.17 -0.60 ± 0.21 -0.02 ± 0.15
04 0.65 ± 0.21 -0.50 ± 0.20 -0.26 ± 0.17 -0.27 ± 0.10
06 0.56 ± 0.21 -0.52 ± 0.21 0.06 ± 0.08 -0.15 ± 0.07
07 1.58 ± 0.32 -1.53 ± 0.35 0.12 ± 0.10 0.29 ± 0.20
08 6.28 ± 0.59 -6.24 ± 0.60 -0.31 ± 0.25 0.51 ± 0.14
09 7.66 ± 0.68 -7.63 ± 0.69 -0.31 ± 0.29 0.47 ± 0.19
Table A.16.: Patient 8, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 10.30 ± 1.91 -9.89 ± 1.74 -2.47 ± 0.64 1.58 ± 0.85
01 9.25 ± 1.34 -8.60 ± 1.16 -2.78 ± 0.58 1.88 ± 0.71
02 5.21 ± 1.06 -4.69 ± 0.86 -1.99 ± 0.56 0.93 ± 0.66
03 3.17 ± 0.56 -2.59 ± 0.39 -1.54 ± 0.35 0.88 ± 0.46
04 0.75 ± 0.30 -0.44 ± 0.18 -0.44 ± 0.20 0.33 ± 0.28
06 0.80 ± 0.27 -0.60 ± 0.27 0.38 ± 0.23 0.07 ± 0.26
07 3.04 ± 0.46 -2.93 ± 0.46 0.44 ± 0.34 0.43 ± 0.42
08 8.21 ± 0.57 -8.11 ± 0.56 -0.77 ± 0.15 0.93 ± 0.33
09 9.06 ± 0.95 -8.80 ± 0.86 -1.47 ± 0.32 1.46 ± 0.64
Table A.17.: Patient 9, LPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 15.50 ± 3.02 -15.40 ± 3.01 -0.39 ± 0.46 -0.44 ± 0.96
01 13.30 ± 2.83 -13.30 ± 2.83 -0.29 ± 0.44 -0.12 ± 0.77
02 8.57 ± 2.21 -8.54 ± 2.21 -0.17 ± 0.40 0.12 ± 0.56
03 3.75 ± 1.17 -3.71 ± 1.19 -0.01 ± 0.15 0.32 ± 0.38
04 1.19 ± 0.24 -1.19 ± 0.25 -0.03 ± 0.04 0.07 ± 0.05
06 0.22 ± 0.08 0.19 ± 0.12 0.02 ± 0.03 0.02 ± 0.05
07 3.26 ± 1.38 -3.12 ± 1.50 0.12 ± 0.17 0.55 ± 0.40
08 10.40 ± 3.05 -10.40 ± 3.07 -0.24 ± 0.33 0.21 ± 0.61
09 14.10 ± 3.07 -14.00 ± 3.06 -0.41 ± 0.45 -0.24 ± 0.88
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Table A.18.: Patient 9, RPV: Mean and standard deviation of target motion in all phases of the
respiration, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
00 10.90 ± 1.06 -10.50 ± 1.06 -0.21 ± 0.19 2.62 ± 0.54
01 7.79 ± 0.86 -7.38 ± 0.81 -0.13 ± 0.15 2.44 ± 0.58
02 4.58 ± 0.64 -4.04 ± 0.55 -0.12 ± 0.13 2.09 ± 0.57
03 2.40 ± 0.50 -1.87 ± 0.32 -0.10 ± 0.12 1.47 ± 0.46
04 0.61 ± 0.17 -0.47 ± 0.11 -0.04 ± 0.05 0.37 ± 0.18
06 0.17 ± 0.11 -0.11 ± 0.14 0.00 ± 0.03 0.02 ± 0.08
07 2.69 ± 0.62 -2.28 ± 0.58 -0.08 ± 0.10 1.38 ± 0.38
08 5.75 ± 0.78 -5.30 ± 0.74 -0.24 ± 0.14 2.18 ± 0.55
09 9.36 ± 0.96 -8.99 ± 0.97 -0.26 ± 0.18 2.52 ± 0.54
A.2 Values of dose analysis parameters for all patients
In the following the D5-D95, V95 and V107 values will be presented for all patient data sets
(patient 1 to 9) and target volumes (LPV and RPV). All studied techniques (static, interplay and
gating inbetween motion phase four and six) will be shown for four different motion patterns
and all studied safety margins (0 mm, 3 mm, 5 mm, 7 mm). Moreover rescanning within the
gating window was studied for the target volumes of patient 2 (medium absolute displacment
of the PVs due to respiration) and patient 9 (largest studied absolute displacement of the PVs
due to respiration).
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Table A.19.: Patient 1, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 2.00 100.00 0.00
STATIC - - 3mm 1.83 100.00 0.00
STATIC - - 5mm 1.86 100.00 0.00
STATIC - - 7mm 1.82 100.00 0.00
INTERPLAY 6s 0 0mm 16.23 75.30 5.01
INTERPLAY 6s 90 0mm 11.37 98.81 8.47
INTERPLAY 8s 0 0mm 14.51 89.74 7.28
INTERPLAY 8s 90 0mm 15.31 85.32 7.88
INTERPLAY 6s 0 3mm 11.73 86.52 1.31
INTERPLAY 6s 90 3mm 10.60 97.37 4.30
INTERPLAY 8s 0 3mm 8.75 92.24 0.24
INTERPLAY 8s 90 3mm 9.98 96.90 3.10
INTERPLAY 6s 0 5mm 8.91 94.15 0.24
INTERPLAY 6s 90 5mm 7.98 97.97 0.36
INTERPLAY 8s 0 5mm 8.69 98.57 0.36
INTERPLAY 8s 90 5mm 10.02 97.49 0.60
INTERPLAY 6s 0 7mm 5.79 100.00 0.00
INTERPLAY 6s 90 7mm 6.86 99.88 0.00
INTERPLAY 8s 0 7mm 7.74 98.09 0.00
INTERPLAY 8s 90 7mm 8.09 96.78 0.12
GATING 6s 0 0mm 5.37 99.40 0.00
GATING 6s 90 0mm 5.53 99.28 0.00
GATING 8s 0 0mm 5.65 99.40 0.00
GATING 8s 90 0mm 5.57 99.28 0.00
GATING 6s 0 3mm 4.41 99.88 0.00
GATING 6s 90 3mm 4.41 99.88 0.00
GATING 8s 0 3mm 4.39 99.52 0.00
GATING 8s 90 3mm 4.43 99.64 0.00
GATING 6s 0 5mm 3.88 100.00 0.00
GATING 6s 90 5mm 3.76 100.00 0.00
GATING 8s 0 5mm 3.77 99.76 0.00
GATING 8s 90 5mm 4.36 99.88 0.00
GATING 6s 0 7mm 3.50 100.00 0.00
GATING 6s 90 7mm 3.47 100.00 0.00
GATING 8s 0 7mm 3.29 100.00 0.00
GATING 8s 90 7mm 3.17 100.00 0.00
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Table A.20.: Patient 1, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 2.36 100.00 0.00
STATIC - - 3mm 1.81 100.00 0.00
STATIC - - 5mm 1.85 100.00 0.00
STATIC - - 7mm 1.84 100.00 0.00
INTERPLAY 6s 0 0mm 20.62 69.21 6.22
INTERPLAY 6s 90 0mm 16.39 75.47 1.08
INTERPLAY 8s 0 0mm 18.83 80.30 8.57
INTERPLAY 8s 90 0mm 15.38 76.42 3.47
INTERPLAY 6s 0 3mm 10.54 91.03 0.54
INTERPLAY 6s 90 3mm 11.63 92.38 1.49
INTERPLAY 8s 0 3mm 11.86 88.68 1.71
INTERPLAY 8s 90 3mm 10.59 96.48 2.39
INTERPLAY 6s 0 5mm 9.46 96.71 1.13
INTERPLAY 6s 90 5mm 9.72 94.54 0.32
INTERPLAY 8s 0 5mm 12.43 79.80 0.72
INTERPLAY 8s 90 5mm 9.11 99.10 1.40
INTERPLAY 6s 0 7mm 9.29 97.88 1.22
INTERPLAY 6s 90 7mm 10.18 89.59 0.00
INTERPLAY 8s 0 7mm 11.44 87.65 0.50
INTERPLAY 8s 90 7mm 9.92 91.61 0.45
GATING 6s 0 0mm 3.62 99.95 0.00
GATING 6s 90 0mm 3.63 99.95 0.00
GATING 8s 0 0mm 4.02 99.95 0.00
GATING 8s 90 0mm 4.03 99.91 0.00
GATING 6s 0 3mm 3.40 100.00 0.00
GATING 6s 90 3mm 3.40 100.00 0.00
GATING 8s 0 3mm 3.51 100.00 0.00
GATING 8s 90 3mm 3.45 100.00 0.00
GATING 6s 0 5mm 3.40 100.00 0.00
GATING 6s 90 5mm 3.37 100.00 0.00
GATING 8s 0 5mm 3.04 100.00 0.00
GATING 8s 90 5mm 2.98 100.00 0.00
GATING 6s 0 7mm 3.00 100.00 0.00
GATING 6s 90 7mm 3.08 100.00 0.00
GATING 8s 0 7mm 3.09 100.00 0.00
GATING 8s 90 7mm 3.22 100.00 0.00
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Table A.21.: Patient 2, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.89 100.00 0.00
STATIC - - 3mm 1.85 100.00 0.00
STATIC - - 5mm 1.85 100.00 0.00
STATIC - - 7mm 1.86 100.00 0.00
INTERPLAY 6s 0 0mm 10.82 92.42 1.37
INTERPLAY 6s 90 0mm 10.68 94.97 2.35
INTERPLAY 8s 0 0mm 8.70 97.78 1.31
INTERPLAY 8s 90 0mm 8.56 96.54 1.31
INTERPLAY 6s 0 3mm 8.38 98.82 0.07
INTERPLAY 6s 90 3mm 8.41 98.63 0.33
INTERPLAY 8s 0 3mm 6.98 99.41 0.00
INTERPLAY 8s 90 3mm 7.77 98.76 1.11
INTERPLAY 6s 0 5mm 7.34 97.71 0.13
INTERPLAY 6s 90 5mm 7.15 99.28 0.00
INTERPLAY 8s 0 5mm 7.20 100.00 0.13
INTERPLAY 8s 90 5mm 7.32 98.69 0.00
INTERPLAY 6s 0 7mm 6.07 99.87 0.00
INTERPLAY 6s 90 7mm 7.01 99.48 0.20
INTERPLAY 8s 0 7mm 6.40 99.48 0.00
INTERPLAY 8s 90 7mm 6.44 99.08 0.00
GATING 6s 0 0mm 6.96 99.41 0.13
GATING 6s 90 0mm 6.93 99.28 0.00
GATING 8s 0 0mm 6.71 99.87 0.00
GATING 8s 90 0mm 7.12 99.67 0.00
GATING 6s 0 3mm 6.81 98.43 0.07
GATING 6s 90 3mm 6.79 98.37 0.07
GATING 8s 0 3mm 4.94 99.93 0.00
GATING 8s 90 3mm 5.10 99.93 0.00
GATING 6s 0 5mm 5.27 100.00 0.00
GATING 6s 90 5mm 4.98 99.93 0.00
GATING 8s 0 5mm 5.39 99.41 0.00
GATING 8s 90 5mm 5.54 99.22 0.00
GATING 6s 0 7mm 4.60 100.00 0.00
GATING 6s 90 7mm 4.53 100.00 0.00
GATING 8s 0 7mm 4.89 100.00 0.00
GATING 8s 90 7mm 4.30 100.00 0.00
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Table A.22.: Patient 2, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.85 100.00 0.00
STATIC - - 3mm 1.82 100.00 0.00
STATIC - - 5mm 1.84 100.00 0.00
STATIC - - 7mm 1.81 100.00 0.00
INTERPLAY 6s 0 0mm 10.03 98.51 3.32
INTERPLAY 6s 90 0mm 9.87 97.52 1.78
INTERPLAY 8s 0 0mm 9.31 96.53 0.74
INTERPLAY 8s 90 0mm 10.27 96.14 1.44
INTERPLAY 6s 0 3mm 6.64 97.92 0.00
INTERPLAY 6s 90 3mm 7.38 99.01 0.00
INTERPLAY 8s 0 3mm 7.43 96.53 0.00
INTERPLAY 8s 90 3mm 7.67 95.84 0.00
INTERPLAY 6s 0 5mm 8.73 97.77 0.64
INTERPLAY 6s 90 5mm 8.84 96.73 0.64
INTERPLAY 8s 0 5mm 7.29 98.47 0.20
INTERPLAY 8s 90 5mm 7.80 99.50 0.20
INTERPLAY 6s 0 7mm 6.61 98.61 0.00
INTERPLAY 6s 90 7mm 7.38 98.07 0.00
INTERPLAY 8s 0 7mm 7.01 99.01 0.00
INTERPLAY 8s 90 7mm 7.53 97.77 1.24
GATING 6s 0 0mm 6.04 97.57 0.00
GATING 6s 90 0mm 6.02 98.07 0.00
GATING 8s 0 0mm 6.32 98.17 0.00
GATING 8s 90 0mm 6.19 98.27 0.00
GATING 6s 0 3mm 4.87 99.01 0.00
GATING 6s 90 3mm 4.95 99.70 0.00
GATING 8s 0 3mm 4.27 99.90 0.00
GATING 8s 90 3mm 4.37 99.75 0.00
GATING 6s 0 5mm 4.26 100.00 0.00
GATING 6s 90 5mm 4.05 100.00 0.00
GATING 8s 0 5mm 4.28 99.95 0.00
GATING 8s 90 5mm 3.92 99.95 0.10
GATING 6s 0 7mm 3.70 100.00 0.00
GATING 6s 90 7mm 3.73 100.00 0.00
GATING 8s 0 7mm 3.81 99.95 0.00
GATING 8s 90 7mm 3.81 99.85 0.00
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Table A.23.: Patient 3, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 2.24 100.00 0.00
STATIC - - 3mm 1.84 100.00 0.00
STATIC - - 5mm 1.82 100.00 0.00
STATIC - - 7mm 1.82 100.00 0.00
INTERPLAY 6s 0 0mm 15.27 89.72 8.00
INTERPLAY 6s 90 0mm 13.25 89.24 4.35
INTERPLAY 8s 0 0mm 15.22 88.98 7.56
INTERPLAY 8s 90 0mm 13.31 88.72 3.80
INTERPLAY 6s 0 3mm 10.89 93.14 1.51
INTERPLAY 6s 90 3mm 11.06 90.93 1.36
INTERPLAY 8s 0 3mm 10.35 96.06 1.22
INTERPLAY 8s 90 3mm 11.36 93.25 1.58
INTERPLAY 6s 0 5mm 11.44 89.50 1.14
INTERPLAY 6s 90 5mm 10.98 96.83 3.83
INTERPLAY 8s 0 5mm 10.54 92.41 0.63
INTERPLAY 8s 90 5mm 10.86 94.36 2.73
INTERPLAY 6s 0 7mm 9.75 97.09 1.58
INTERPLAY 6s 90 7mm 8.92 96.31 0.55
INTERPLAY 8s 0 7mm 10.81 98.45 4.50
INTERPLAY 8s 90 7mm 11.06 94.25 2.43
GATING 6s 0 0mm 7.09 99.04 0.22
GATING 6s 90 0mm 7.45 98.93 0.18
GATING 8s 0 0mm 7.53 98.16 0.44
GATING 8s 90 0mm 8.06 96.98 0.22
GATING 6s 0 3mm 6.43 99.93 0.00
GATING 6s 90 3mm 6.43 100.00 0.04
GATING 8s 0 3mm 6.27 99.93 0.15
GATING 8s 90 3mm 6.27 99.85 0.15
GATING 6s 0 5mm 6.44 99.89 0.04
GATING 6s 90 5mm 6.35 99.85 0.04
GATING 8s 0 5mm 5.82 99.71 0.00
GATING 8s 90 5mm 6.40 98.71 0.07
GATING 6s 0 7mm 5.22 99.96 0.04
GATING 6s 90 7mm 5.16 100.00 0.00
GATING 8s 0 7mm 5.02 100.00 0.00
GATING 8s 90 7mm 5.00 100.00 0.00
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Table A.24.: Patient 3, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.89 100.00 0.00
STATIC - - 3mm 1.82 100.00 0.00
STATIC - - 5mm 1.81 100.00 0.00
STATIC - - 7mm 1.86 100.00 0.00
INTERPLAY 6s 0 0mm 12.34 88.95 1.01
INTERPLAY 6s 90 0mm 12.23 91.57 3.84
INTERPLAY 8s 0 0mm 12.39 91.63 3.69
INTERPLAY 8s 90 0mm 11.66 93.24 3.05
INTERPLAY 6s 0 3mm 9.29 95.81 0.56
INTERPLAY 6s 90 3mm 9.46 97.11 1.26
INTERPLAY 8s 0 3mm 12.20 92.64 3.05
INTERPLAY 8s 90 3mm 12.80 92.04 5.07
INTERPLAY 6s 0 5mm 8.79 98.39 1.42
INTERPLAY 6s 90 5mm 9.26 97.42 0.91
INTERPLAY 8s 0 5mm 10.30 97.01 1.88
INTERPLAY 8s 90 5mm 9.88 96.19 1.15
INTERPLAY 6s 0 7mm 9.31 97.32 1.09
INTERPLAY 6s 90 7mm 8.63 98.78 0.49
INTERPLAY 8s 0 7mm 10.44 94.89 1.79
INTERPLAY 8s 90 7mm 9.97 95.98 0.72
GATING 6s 0 0mm 5.00 99.86 0.00
GATING 6s 90 0mm 5.02 99.86 0.00
GATING 8s 0 0mm 5.31 99.86 0.00
GATING 8s 90 0mm 5.57 99.77 0.06
GATING 6s 0 3mm 4.49 100.00 0.00
GATING 6s 90 3mm 4.58 100.00 0.00
GATING 8s 0 3mm 4.49 100.00 0.06
GATING 8s 90 3mm 4.88 100.00 0.02
GATING 6s 0 5mm 4.94 100.00 0.00
GATING 6s 90 5mm 4.89 100.00 0.00
GATING 8s 0 5mm 4.45 100.00 0.00
GATING 8s 90 5mm 4.29 100.00 0.00
GATING 6s 0 7mm 4.08 100.00 0.00
GATING 6s 90 7mm 3.89 100.00 0.00
GATING 8s 0 7mm 3.85 99.98 0.00
GATING 8s 90 7mm 3.84 100.00 0.00
171
Table A.25.: Patient 4, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.90 100.00 0.00
STATIC - - 3mm 1.83 100.00 0.00
STATIC - - 5mm 1.87 100.00 0.00
STATIC - - 7mm 1.82 100.00 0.00
INTERPLAY 6s 0 0mm 11.02 93.01 1.20
INTERPLAY 6s 90 0mm 10.34 93.08 1.13
INTERPLAY 8s 0 0mm 16.87 84.43 7.32
INTERPLAY 8s 90 0mm 14.22 85.89 4.92
INTERPLAY 6s 0 3mm 6.43 99.40 0.00
INTERPLAY 6s 90 3mm 7.46 98.74 0.07
INTERPLAY 8s 0 3mm 11.73 90.69 2.53
INTERPLAY 8s 90 3mm 12.31 85.43 0.86
INTERPLAY 6s 0 5mm 6.66 98.20 0.00
INTERPLAY 6s 90 5mm 7.47 98.94 0.00
INTERPLAY 8s 0 5mm 9.12 96.67 0.73
INTERPLAY 8s 90 5mm 9.91 94.48 0.47
INTERPLAY 6s 0 7mm 6.21 97.94 0.00
INTERPLAY 6s 90 7mm 7.09 98.60 0.00
INTERPLAY 8s 0 7mm 7.18 98.14 0.00
INTERPLAY 8s 90 7mm 6.74 99.53 0.60
GATING 6s 0 0mm 3.89 99.93 0.00
GATING 6s 90 0mm 3.81 99.93 0.00
GATING 8s 0 0mm 3.94 99.93 0.00
GATING 8s 90 0mm 4.48 99.87 0.00
GATING 6s 0 3mm 2.87 100.00 0.00
GATING 6s 90 3mm 2.88 100.00 0.00
GATING 8s 0 3mm 3.20 100.00 0.00
GATING 8s 90 3mm 3.10 100.00 0.00
GATING 6s 0 5mm 2.90 100.00 0.00
GATING 6s 90 5mm 3.03 100.00 0.00
GATING 8s 0 5mm 2.94 100.00 0.00
GATING 8s 90 5mm 3.13 100.00 0.00
GATING 6s 0 7mm 2.99 100.00 0.00
GATING 6s 90 7mm 3.01 100.00 0.00
GATING 8s 0 7mm 2.88 100.00 0.00
GATING 8s 90 7mm 2.83 100.00 0.00
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Table A.26.: Patient 4, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.83 100.00 0.00
STATIC - - 3mm 1.80 100.00 0.00
STATIC - - 5mm 1.80 100.00 0.00
STATIC - - 7mm 1.80 100.00 0.00
INTERPLAY 6s 0 0mm 12.60 89.91 1.94
INTERPLAY 6s 90 0mm 11.01 90.89 1.82
INTERPLAY 8s 0 0mm 13.99 87.18 5.29
INTERPLAY 8s 90 0mm 13.89 86.21 3.71
INTERPLAY 6s 0 3mm 9.72 93.13 0.30
INTERPLAY 6s 90 3mm 9.21 96.60 0.61
INTERPLAY 8s 0 3mm 10.68 91.92 1.46
INTERPLAY 8s 90 3mm 11.23 91.07 1.52
INTERPLAY 6s 0 5mm 9.77 95.57 0.18
INTERPLAY 6s 90 5mm 8.60 98.12 0.24
INTERPLAY 8s 0 5mm 9.75 94.47 0.43
INTERPLAY 8s 90 5mm 9.55 97.21 1.28
INTERPLAY 6s 0 7mm 6.84 96.17 0.00
INTERPLAY 6s 90 7mm 6.25 99.70 0.00
INTERPLAY 8s 0 7mm 8.04 98.66 0.00
INTERPLAY 8s 90 7mm 8.81 93.92 0.00
GATING 6s 0 0mm 4.81 100.00 0.00
GATING 6s 90 0mm 4.86 100.00 0.00
GATING 8s 0 0mm 5.46 100.00 0.06
GATING 8s 90 0mm 5.21 99.94 0.12
GATING 6s 0 3mm 4.04 100.00 0.00
GATING 6s 90 3mm 4.03 100.00 0.00
GATING 8s 0 3mm 4.10 100.00 0.00
GATING 8s 90 3mm 4.26 100.00 0.00
GATING 6s 0 5mm 3.61 100.00 0.00
GATING 6s 90 5mm 3.64 100.00 0.00
GATING 8s 0 5mm 3.59 100.00 0.00
GATING 8s 90 5mm 3.62 100.00 0.00
GATING 6s 0 7mm 2.79 100.00 0.00
GATING 6s 90 7mm 2.81 100.00 0.00
GATING 8s 0 7mm 3.29 100.00 0.00
GATING 8s 90 7mm 3.24 100.00 0.00
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Table A.27.: Patient 5, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.94 100.00 0.00
STATIC - - 3mm 1.84 100.00 0.00
STATIC - - 5mm 1.83 100.00 0.00
STATIC - - 7mm 1.82 100.00 0.00
INTERPLAY 6s 0 0mm 18.21 89.36 18.18
INTERPLAY 6s 90 0mm 14.34 88.25 5.10
INTERPLAY 8s 0 0mm 16.67 81.26 7.87
INTERPLAY 8s 90 0mm 14.40 92.13 8.98
INTERPLAY 6s 0 3mm 14.58 89.14 6.32
INTERPLAY 6s 90 3mm 12.31 88.58 1.66
INTERPLAY 8s 0 3mm 14.69 85.92 6.98
INTERPLAY 8s 90 3mm 14.49 90.02 6.76
INTERPLAY 6s 0 5mm 10.64 83.92 0.11
INTERPLAY 6s 90 5mm 13.25 95.57 7.76
INTERPLAY 8s 0 5mm 14.70 92.35 14.74
INTERPLAY 8s 90 5mm 11.10 87.92 0.44
INTERPLAY 6s 0 7mm 8.34 99.89 1.44
INTERPLAY 6s 90 7mm 7.34 96.01 0.00
INTERPLAY 8s 0 7mm 10.66 96.34 1.77
INTERPLAY 8s 90 7mm 10.14 95.57 0.22
GATING 6s 0 0mm 7.22 99.45 0.67
GATING 6s 90 0mm 7.21 99.45 0.67
GATING 8s 0 0mm 8.88 95.23 0.33
GATING 8s 90 0mm 9.18 95.23 0.11
GATING 6s 0 3mm 6.10 98.78 0.00
GATING 6s 90 3mm 6.16 98.56 0.11
GATING 8s 0 3mm 7.27 99.78 0.00
GATING 8s 90 3mm 7.71 99.45 0.00
GATING 6s 0 5mm 6.81 98.45 0.00
GATING 6s 90 5mm 6.76 98.45 0.00
GATING 8s 0 5mm 7.44 97.34 0.00
GATING 8s 90 5mm 7.25 97.56 0.00
GATING 6s 0 7mm 5.28 98.89 0.00
GATING 6s 90 7mm 5.43 99.00 0.00
GATING 8s 0 7mm 5.60 100.00 0.00
GATING 8s 90 7mm 5.36 100.00 0.00
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Table A.28.: Patient 5, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.85 100.00 0.00
STATIC - - 3mm 1.85 100.00 0.00
STATIC - - 5mm 1.81 100.00 0.00
STATIC - - 7mm 1.81 100.00 0.00
INTERPLAY 6s 0 0mm 12.27 95.36 6.05
INTERPLAY 6s 90 0mm 11.59 93.63 2.38
INTERPLAY 8s 0 0mm 16.30 86.88 8.91
INTERPLAY 8s 90 0mm 12.29 94.87 5.35
INTERPLAY 6s 0 3mm 11.61 95.52 4.16
INTERPLAY 6s 90 3mm 9.22 94.98 0.92
INTERPLAY 8s 0 3mm 12.87 87.53 2.86
INTERPLAY 8s 90 3mm 12.27 97.68 7.02
INTERPLAY 6s 0 5mm 11.58 92.98 1.46
INTERPLAY 6s 90 5mm 11.04 95.25 2.70
INTERPLAY 8s 0 5mm 12.42 86.77 1.84
INTERPLAY 8s 90 5mm 12.55 86.45 2.05
INTERPLAY 6s 0 7mm 9.05 99.08 0.59
INTERPLAY 6s 90 7mm 8.15 98.92 0.11
INTERPLAY 8s 0 7mm 8.60 98.11 0.65
INTERPLAY 8s 90 7mm 8.96 98.87 1.46
GATING 6s 0 0mm 5.79 99.89 0.00
GATING 6s 90 0mm 5.78 99.89 0.00
GATING 8s 0 0mm 5.44 99.62 0.00
GATING 8s 90 0mm 5.38 99.68 0.00
GATING 6s 0 3mm 5.19 100.00 0.00
GATING 6s 90 3mm 5.10 100.00 0.00
GATING 8s 0 3mm 5.99 100.00 0.00
GATING 8s 90 3mm 5.67 100.00 0.00
GATING 6s 0 5mm 4.54 99.89 0.00
GATING 6s 90 5mm 4.57 99.95 0.00
GATING 8s 0 5mm 4.62 100.00 0.00
GATING 8s 90 5mm 4.92 100.00 0.00
GATING 6s 0 7mm 3.86 100.00 0.00
GATING 6s 90 7mm 3.83 100.00 0.00
GATING 8s 0 7mm 4.27 100.00 0.00
GATING 8s 90 7mm 4.68 100.00 0.00
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Table A.29.: Patient 6, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.86 100.00 0.00
STATIC - - 3mm 1.84 100.00 0.00
STATIC - - 5mm 1.81 100.00 0.00
STATIC - - 7mm 1.83 100.00 0.00
INTERPLAY 6s 0 0mm 12.07 91.36 4.04
INTERPLAY 6s 90 0mm 12.94 86.83 1.13
INTERPLAY 8s 0 0mm 17.12 75.14 5.17
INTERPLAY 8s 90 0mm 16.66 81.02 4.32
INTERPLAY 6s 0 3mm 11.39 95.25 3.54
INTERPLAY 6s 90 3mm 8.61 96.60 0.35
INTERPLAY 8s 0 3mm 10.19 93.41 0.42
INTERPLAY 8s 90 3mm 11.22 94.41 2.62
INTERPLAY 6s 0 5mm 8.22 97.80 0.57
INTERPLAY 6s 90 5mm 8.17 96.32 0.00
INTERPLAY 8s 0 5mm 11.32 90.37 1.20
INTERPLAY 8s 90 5mm 10.66 92.42 1.20
INTERPLAY 6s 0 7mm 7.62 97.52 0.00
INTERPLAY 6s 90 7mm 8.20 96.88 0.14
INTERPLAY 8s 0 7mm 9.18 92.78 0.71
INTERPLAY 8s 90 7mm 8.25 94.83 0.00
GATING 6s 0 0mm 7.75 96.32 0.00
GATING 6s 90 0mm 7.83 95.96 0.00
GATING 8s 0 0mm 7.48 97.95 0.00
GATING 8s 90 0mm 7.49 98.37 0.00
GATING 6s 0 3mm 4.92 100.00 0.00
GATING 6s 90 3mm 4.92 100.00 0.00
GATING 8s 0 3mm 5.04 100.00 0.00
GATING 8s 90 3mm 4.63 100.00 0.00
GATING 6s 0 5mm 4.21 100.00 0.00
GATING 6s 90 5mm 4.17 100.00 0.00
GATING 8s 0 5mm 4.34 100.00 0.00
GATING 8s 90 5mm 4.21 100.00 0.00
GATING 6s 0 7mm 4.13 100.00 0.00
GATING 6s 90 7mm 4.12 100.00 0.00
GATING 8s 0 7mm 4.45 100.00 0.00
GATING 8s 90 7mm 4.26 100.00 0.00
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Table A.30.: Patient 6, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.84 100.00 0.00
STATIC - - 3mm 1.81 100.00 0.00
STATIC - - 5mm 1.81 100.00 0.00
STATIC - - 7mm 1.82 100.00 0.00
INTERPLAY 6s 0 0mm 10.31 96.14 3.00
INTERPLAY 6s 90 0mm 10.75 91.82 0.60
INTERPLAY 8s 0 0mm 10.86 95.68 2.93
INTERPLAY 8s 90 0mm 8.92 98.27 1.31
INTERPLAY 6s 0 3mm 10.26 98.05 3.75
INTERPLAY 6s 90 3mm 7.78 98.05 0.08
INTERPLAY 8s 0 3mm 9.51 97.07 1.73
INTERPLAY 8s 90 3mm 8.26 98.80 0.64
INTERPLAY 6s 0 5mm 7.57 99.10 1.05
INTERPLAY 6s 90 5mm 7.80 99.44 0.83
INTERPLAY 8s 0 5mm 8.46 95.68 0.26
INTERPLAY 8s 90 5mm 7.17 98.16 0.15
INTERPLAY 6s 0 7mm 6.83 99.77 0.00
INTERPLAY 6s 90 7mm 8.54 99.70 2.03
INTERPLAY 8s 0 7mm 7.30 97.82 0.08
INTERPLAY 8s 90 7mm 7.45 97.07 0.08
GATING 6s 0 0mm 6.72 98.20 0.08
GATING 6s 90 0mm 6.85 98.20 0.00
GATING 8s 0 0mm 6.47 99.59 0.04
GATING 8s 90 0mm 6.06 99.74 0.26
GATING 6s 0 3mm 5.09 100.00 0.00
GATING 6s 90 3mm 5.23 99.96 0.00
GATING 8s 0 3mm 5.84 98.69 0.00
GATING 8s 90 3mm 5.04 99.96 0.08
GATING 6s 0 5mm 4.57 100.00 0.00
GATING 6s 90 5mm 4.60 100.00 0.00
GATING 8s 0 5mm 4.91 100.00 0.00
GATING 8s 90 5mm 4.87 100.00 0.04
GATING 6s 0 7mm 4.79 99.14 0.00
GATING 6s 90 7mm 4.89 99.14 0.00
GATING 8s 0 7mm 4.03 100.00 0.00
GATING 8s 90 7mm 4.10 99.96 0.00
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Table A.31.: Patient 7, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.94 100.00 0.00
STATIC - - 3mm 1.91 100.00 0.00
STATIC - - 5mm 1.82 100.00 0.00
STATIC - - 7mm 1.83 100.00 0.00
INTERPLAY 6s 0 0mm 9.82 96.78 2.00
INTERPLAY 6s 90 0mm 13.32 89.78 4.16
INTERPLAY 8s 0 0mm 9.07 98.61 1.78
INTERPLAY 8s 90 0mm 9.51 97.89 2.44
INTERPLAY 6s 0 3mm 6.04 99.94 0.06
INTERPLAY 6s 90 3mm 7.69 95.78 0.00
INTERPLAY 8s 0 3mm 10.55 94.45 2.61
INTERPLAY 8s 90 3mm 8.83 94.45 0.50
INTERPLAY 6s 0 5mm 7.87 98.45 0.00
INTERPLAY 6s 90 5mm 5.85 99.50 0.00
INTERPLAY 8s 0 5mm 8.96 96.67 0.78
INTERPLAY 8s 90 5mm 8.23 96.72 0.11
INTERPLAY 6s 0 7mm 5.48 99.83 0.00
INTERPLAY 6s 90 7mm 6.16 99.44 0.00
INTERPLAY 8s 0 7mm 6.63 98.94 0.00
INTERPLAY 8s 90 7mm 7.18 99.78 0.06
GATING 6s 0 0mm 6.55 99.28 0.00
GATING 6s 90 0mm 6.60 99.11 0.00
GATING 8s 0 0mm 5.70 99.78 0.06
GATING 8s 90 0mm 5.55 99.72 0.00
GATING 6s 0 3mm 3.46 100.00 0.00
GATING 6s 90 3mm 3.51 100.00 0.00
GATING 8s 0 3mm 3.66 100.00 0.00
GATING 8s 90 3mm 3.71 100.00 0.00
GATING 6s 0 5mm 3.66 100.00 0.00
GATING 6s 90 5mm 3.63 100.00 0.00
GATING 8s 0 5mm 3.65 100.00 0.00
GATING 8s 90 5mm 3.56 100.00 0.00
GATING 6s 0 7mm 3.70 99.94 0.00
GATING 6s 90 7mm 3.69 99.94 0.00
GATING 8s 0 7mm 3.40 99.94 0.00
GATING 8s 90 7mm 3.41 100.00 0.00
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Table A.32.: Patient 7, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.98 100.00 0.00
STATIC - - 3mm 1.80 100.00 0.00
STATIC - - 5mm 1.81 100.00 0.00
STATIC - - 7mm 1.80 100.00 0.00
INTERPLAY 6s 0 0mm 9.07 96.63 0.81
INTERPLAY 6s 90 0mm 8.12 98.80 0.46
INTERPLAY 8s 0 0mm 9.16 97.10 0.39
INTERPLAY 8s 90 0mm 9.57 95.28 0.31
INTERPLAY 6s 0 3mm 6.02 100.00 0.00
INTERPLAY 6s 90 3mm 6.76 99.23 0.00
INTERPLAY 8s 0 3mm 7.28 99.69 0.39
INTERPLAY 8s 90 3mm 7.52 99.23 0.04
INTERPLAY 6s 0 5mm 6.53 99.26 0.00
INTERPLAY 6s 90 5mm 5.62 99.77 0.00
INTERPLAY 8s 0 5mm 7.31 98.68 0.00
INTERPLAY 8s 90 5mm 6.23 99.81 0.00
INTERPLAY 6s 0 7mm 5.87 99.73 0.00
INTERPLAY 6s 90 7mm 6.25 99.81 0.00
INTERPLAY 8s 0 7mm 6.06 99.73 0.00
INTERPLAY 8s 90 7mm 5.99 99.34 0.04
GATING 6s 0 0mm 7.19 98.95 0.58
GATING 6s 90 0mm 7.05 98.99 0.50
GATING 8s 0 0mm 6.05 100.00 0.08
GATING 8s 90 0mm 6.14 100.00 0.35
GATING 6s 0 3mm 5.23 100.00 0.00
GATING 6s 90 3mm 5.23 100.00 0.00
GATING 8s 0 3mm 5.29 99.77 0.00
GATING 8s 90 3mm 5.25 99.92 0.00
GATING 6s 0 5mm 5.34 99.96 0.00
GATING 6s 90 5mm 5.29 100.00 0.00
GATING 8s 0 5mm 3.92 99.92 0.00
GATING 8s 90 5mm 4.03 99.85 0.00
GATING 6s 0 7mm 4.06 100.00 0.00
GATING 6s 90 7mm 4.06 100.00 0.00
GATING 8s 0 7mm 3.76 100.00 0.00
GATING 8s 90 7mm 4.27 100.00 0.00
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Table A.33.: Patient 8, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.87 100.00 0.00
STATIC - - 3mm 1.83 100.00 0.00
STATIC - - 5mm 1.82 100.00 0.00
STATIC - - 7mm 1.87 100.00 0.00
INTERPLAY 6s 0 0mm 14.40 90.64 6.93
INTERPLAY 6s 90 0mm 13.52 87.62 2.64
INTERPLAY 8s 0 0mm 12.77 90.54 4.64
INTERPLAY 8s 90 0mm 13.36 92.68 6.16
INTERPLAY 6s 0 3mm 11.81 89.48 0.70
INTERPLAY 6s 90 3mm 9.36 96.55 1.23
INTERPLAY 8s 0 3mm 11.30 92.16 1.48
INTERPLAY 8s 90 3mm 11.67 90.78 1.93
INTERPLAY 6s 0 5mm 9.04 97.96 0.46
INTERPLAY 6s 90 5mm 9.32 94.58 0.25
INTERPLAY 8s 0 5mm 10.09 95.81 2.00
INTERPLAY 8s 90 5mm 10.69 94.69 1.93
INTERPLAY 6s 0 7mm 8.53 98.49 1.06
INTERPLAY 6s 90 7mm 9.93 98.03 1.51
INTERPLAY 8s 0 7mm 8.46 97.50 0.56
INTERPLAY 8s 90 7mm 9.27 96.62 0.49
GATING 6s 0 0mm 8.30 94.55 0.00
GATING 6s 90 0mm 8.43 94.44 0.00
GATING 8s 0 0mm 7.57 95.29 0.04
GATING 8s 90 0mm 7.77 95.15 0.07
GATING 6s 0 3mm 4.51 99.93 0.00
GATING 6s 90 3mm 4.51 99.93 0.00
GATING 8s 0 3mm 4.72 99.96 0.04
GATING 8s 90 3mm 4.86 100.00 0.04
GATING 6s 0 5mm 4.70 100.00 0.00
GATING 6s 90 5mm 4.66 100.00 0.00
GATING 8s 0 5mm 4.34 100.00 0.00
GATING 8s 90 5mm 4.36 100.00 0.00
GATING 6s 0 7mm 3.86 100.00 0.00
GATING 6s 90 7mm 3.86 100.00 0.00
GATING 8s 0 7mm 3.80 100.00 0.00
GATING 8s 90 7mm 3.79 100.00 0.00
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Table A.34.: Patient 8, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.85 100.00 0.00
STATIC - - 3mm 1.82 100.00 0.00
STATIC - - 5mm 1.81 100.00 0.00
STATIC - - 7mm 1.81 100.00 0.00
INTERPLAY 6s 0 0mm 16.96 86.51 11.76
INTERPLAY 6s 90 0mm 14.01 89.57 5.64
INTERPLAY 8s 0 0mm 12.52 95.65 7.61
INTERPLAY 8s 90 0mm 12.15 92.63 3.61
INTERPLAY 6s 0 3mm 11.49 87.99 2.47
INTERPLAY 6s 90 3mm 15.13 81.07 6.72
INTERPLAY 8s 0 3mm 13.77 86.16 3.86
INTERPLAY 8s 90 3mm 10.66 90.36 1.48
INTERPLAY 6s 0 5mm 12.35 89.72 1.43
INTERPLAY 6s 90 5mm 12.44 96.69 6.87
INTERPLAY 8s 0 5mm 8.72 96.19 0.30
INTERPLAY 8s 90 5mm 9.45 98.52 1.68
INTERPLAY 6s 0 7mm 12.64 96.89 7.12
INTERPLAY 6s 90 7mm 10.21 94.02 0.84
INTERPLAY 8s 0 7mm 9.53 99.90 3.71
INTERPLAY 8s 90 7mm 10.06 98.37 2.97
GATING 6s 0 0mm 5.64 99.06 0.00
GATING 6s 90 0mm 5.63 99.11 0.00
GATING 8s 0 0mm 5.67 99.21 0.15
GATING 8s 90 0mm 6.06 99.11 0.20
GATING 6s 0 3mm 4.29 100.00 0.00
GATING 6s 90 3mm 4.29 100.00 0.00
GATING 8s 0 3mm 4.83 100.00 0.00
GATING 8s 90 3mm 4.87 100.00 0.00
GATING 6s 0 5mm 4.85 99.85 0.00
GATING 6s 90 5mm 4.79 99.80 0.00
GATING 8s 0 5mm 5.23 99.85 0.00
GATING 8s 90 5mm 5.09 100.00 0.00
GATING 6s 0 7mm 4.62 99.95 0.00
GATING 6s 90 7mm 4.38 100.00 0.00
GATING 8s 0 7mm 4.72 99.90 0.00
GATING 8s 90 7mm 4.60 99.95 0.00
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Table A.35.: Patient 9, LPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.83 100.00 0.00
STATIC - - 3mm 1.86 100.00 0.00
STATIC - - 5mm 1.82 100.00 0.00
STATIC - - 7mm 1.81 100.00 0.00
INTERPLAY 6s 0 0mm 22.96 73.82 4.62
INTERPLAY 6s 90 0mm 15.96 83.98 5.95
INTERPLAY 8s 0 0mm 17.89 77.70 9.08
INTERPLAY 8s 90 0mm 24.83 84.15 19.08
INTERPLAY 6s 0 3mm 19.57 72.91 5.70
INTERPLAY 6s 90 3mm 20.93 84.31 13.46
INTERPLAY 8s 0 3mm 12.89 89.18 2.06
INTERPLAY 8s 90 3mm 12.54 90.01 0.58
INTERPLAY 6s 0 5mm 16.02 83.15 4.87
INTERPLAY 6s 90 5mm 13.18 90.50 3.72
INTERPLAY 8s 0 5mm 13.85 90.17 7.10
INTERPLAY 8s 90 5mm 13.01 83.98 0.91
INTERPLAY 6s 0 7mm 14.77 84.48 3.96
INTERPLAY 6s 90 7mm 16.28 87.70 3.39
INTERPLAY 8s 0 7mm 14.30 82.74 3.55
INTERPLAY 8s 90 7mm 15.55 91.08 15.28
GATING 6s 0 0mm 8.03 94.14 0.08
GATING 6s 90 0mm 7.77 94.55 0.08
GATING 8s 0 0mm 7.79 95.21 0.00
GATING 8s 90 0mm 6.71 96.94 0.00
GATING 6s 0 3mm 4.90 99.92 0.00
GATING 6s 90 3mm 5.01 100.00 0.00
GATING 8s 0 3mm 4.72 99.83 0.00
GATING 8s 90 3mm 4.12 100.00 0.00
GATING 6s 0 5mm 4.70 100.00 0.00
GATING 6s 90 5mm 4.42 100.00 0.00
GATING 8s 0 5mm 3.92 100.00 0.00
GATING 8s 90 5mm 4.42 100.00 0.00
GATING 6s 0 7mm 3.96 100.00 0.00
GATING 6s 90 7mm 4.18 99.92 0.00
GATING 8s 0 7mm 3.47 100.00 0.00
GATING 8s 90 7mm 3.59 100.00 0.00
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Table A.36.: Patient 9, RPV
Case motion period motion starting phase Margin D5-D95 V95 V107
STATIC - - 0mm 1.81 100.00 0.00
STATIC - - 3mm 1.81 100.00 0.00
STATIC - - 5mm 1.82 100.00 0.00
STATIC - - 7mm 1.80 100.00 0.00
INTERPLAY 6s 0 0mm 21.06 81.96 15.73
INTERPLAY 6s 90 0mm 16.08 95.00 16.37
INTERPLAY 8s 0 0mm 14.47 82.98 4.44
INTERPLAY 8s 90 0mm 13.16 92.88 5.83
INTERPLAY 6s 0 3mm 12.22 90.38 1.85
INTERPLAY 6s 90 3mm 12.82 92.41 3.52
INTERPLAY 8s 0 3mm 9.28 97.04 1.20
INTERPLAY 8s 90 3mm 8.07 99.17 0.09
INTERPLAY 6s 0 5mm 10.72 95.93 2.31
INTERPLAY 6s 90 5mm 9.86 99.44 3.89
INTERPLAY 8s 0 5mm 9.57 96.85 1.02
INTERPLAY 8s 90 5mm 11.19 93.62 1.30
INTERPLAY 6s 0 7mm 8.96 99.54 1.02
INTERPLAY 6s 90 7mm 9.63 97.87 1.20
INTERPLAY 8s 0 7mm 10.82 96.67 3.15
INTERPLAY 8s 90 7mm 13.80 95.65 11.38
GATING 6s 0 0mm 6.18 98.98 0.00
GATING 6s 90 0mm 6.05 99.07 0.00
GATING 8s 0 0mm 5.35 98.98 0.00
GATING 8s 90 0mm 5.19 99.17 0.00
GATING 6s 0 3mm 4.14 100.00 0.00
GATING 6s 90 3mm 4.42 99.91 0.00
GATING 8s 0 3mm 5.07 99.91 0.00
GATING 8s 90 3mm 4.82 99.82 0.00
GATING 6s 0 5mm 3.43 100.00 0.00
GATING 6s 90 5mm 3.38 100.00 0.00
GATING 8s 0 5mm 3.87 100.00 0.00
GATING 8s 90 5mm 3.85 100.00 0.00
GATING 6s 0 7mm 3.18 100.00 0.00
GATING 6s 90 7mm 3.33 100.00 0.00
GATING 8s 0 7mm 3.59 100.00 0.00
GATING 8s 90 7mm 3.48 100.00 0.00
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Table A.37.: Patient 2, LPV
Case Rescan no. motion period motion starting phase Margin D5-D95 V95 V107
RESCANNING 5 6s 0 0mm 6.08 98.89 0.52
RESCANNING 10 6s 0 0mm 5.69 98.63 0.13
RESCANNING 15 6s 0 0mm 5.56 98.76 0.13
RESCANNING 20 6s 0 0mm 5.63 98.63 0.07
RESCANNING 5 6s 90 0mm 6.08 98.89 0.52
RESCANNING 10 6s 90 0mm 5.69 98.63 0.13
RESCANNING 15 6s 90 0mm 5.56 98.76 0.13
RESCANNING 20 6s 90 0mm 5.63 98.63 0.07
RESCANNING 5 8s 0 0mm 5.97 98.30 0.13
RESCANNING 10 8s 0 0mm 5.69 98.30 0.26
RESCANNING 15 8s 0 0mm 5.91 97.97 0.26
RESCANNING 20 8s 0 0mm 6.14 98.82 0.20
RESCANNING 5 8s 90 0mm 5.78 98.17 0.13
RESCANNING 10 8s 90 0mm 5.65 98.30 0.26
RESCANNING 15 8s 90 0mm 5.82 98.50 0.13
RESCANNING 20 8s 90 0mm 5.95 98.95 0.13
RESCANNING 5 6s 0 3mm 4.72 100.00 0.00
RESCANNING 10 6s 0 3mm 3.64 100.00 0.00
RESCANNING 15 6s 0 3mm 3.78 99.93 0.00
RESCANNING 20 6s 0 3mm 3.74 99.80 0.00
RESCANNING 5 6s 90 3mm 4.69 100.00 0.00
RESCANNING 10 6s 90 3mm 3.75 99.87 0.00
RESCANNING 15 6s 90 3mm 3.95 100.00 0.00
RESCANNING 20 6s 90 3mm 3.71 99.87 0.00
RESCANNING 5 8s 0 3mm 4.54 99.80 0.00
RESCANNING 10 8s 0 3mm 3.89 100.00 0.00
RESCANNING 15 8s 0 3mm 3.80 100.00 0.00
RESCANNING 20 8s 0 3mm 3.88 100.00 0.00
RESCANNING 5 8s 90 3mm 4.71 99.74 0.00
RESCANNING 10 8s 90 3mm 3.85 100.00 0.00
RESCANNING 15 8s 90 3mm 3.85 100.00 0.00
RESCANNING 20 8s 90 3mm 4.24 100.00 0.00
RESCANNING 5 6s 0 5mm 3.70 100.00 0.00
RESCANNING 10 6s 0 5mm 3.83 100.00 0.00
RESCANNING 15 6s 0 5mm 3.74 100.00 0.00
RESCANNING 20 6s 0 5mm 3.63 100.00 0.00
RESCANNING 5 6s 90 5mm 3.70 100.00 0.00
RESCANNING 10 6s 90 5mm 3.83 100.00 0.00
RESCANNING 15 6s 90 5mm 3.74 100.00 0.00
RESCANNING 20 6s 90 5mm 3.63 100.00 0.00
RESCANNING 5 8s 0 5mm 3.81 100.00 0.00
RESCANNING 10 8s 0 5mm 3.64 100.00 0.00
RESCANNING 15 8s 0 5mm 3.58 100.00 0.00
RESCANNING 20 8s 0 5mm 3.70 100.00 0.00
RESCANNING 5 8s 90 5mm 4.02 99.93 0.00
RESCANNING 10 8s 90 5mm 3.66 100.00 0.00
RESCANNING 15 8s 90 5mm 3.54 100.00 0.00
RESCANNING 20 8s 90 5mm 3.66 100.00 0.00
RESCANNING 5 6s 0 7mm 3.63 100.00 0.00
RESCANNING 10 6s 0 7mm 3.46 100.00 0.00
RESCANNING 15 6s 0 7mm 3.43 100.00 0.00
RESCANNING 20 6s 0 7mm 3.43 100.00 0.00
RESCANNING 5 6s 90 7mm 3.63 100.00 0.00
RESCANNING 10 6s 90 7mm 3.48 100.00 0.00
RESCANNING 15 6s 90 7mm 3.44 100.00 0.00
RESCANNING 20 6s 90 7mm 3.46 100.00 0.00
RESCANNING 5 8s 0 7mm 3.56 100.00 0.00
RESCANNING 10 8s 0 7mm 3.46 100.00 0.00
RESCANNING 15 8s 0 7mm 3.70 100.00 0.00
RESCANNING 20 8s 0 7mm 3.55 100.00 0.00
RESCANNING 5 8s 90 7mm 3.62 100.00 0.00
RESCANNING 10 8s 90 7mm 3.46 100.00 0.00
RESCANNING 15 8s 90 7mm 3.67 100.00 0.00
RESCANNING 20 8s 90 7mm 3.52 100.00 0.00
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Table A.38.: Patient 2, RPV
Case Rescan no. motion period motion starting phase Margin D5-D95 V95 V107
RESCANNING 5 6s 0 0mm 6.68 96.29 0.00
RESCANNING 10 6s 0 0mm 6.29 95.89 0.05
RESCANNING 15 6s 0 0mm 6.01 96.24 0.05
RESCANNING 20 6s 0 0mm 5.62 96.14 0.05
RESCANNING 5 6s 90 0mm 6.70 96.29 0.00
RESCANNING 10 6s 90 0mm 6.33 95.94 0.05
RESCANNING 15 6s 90 0mm 5.84 96.34 0.05
RESCANNING 20 6s 90 0mm 5.62 96.09 0.05
RESCANNING 5 8s 0 0mm 5.92 97.52 0.15
RESCANNING 10 8s 0 0mm 6.37 95.74 0.10
RESCANNING 15 8s 0 0mm 5.75 95.99 0.10
RESCANNING 20 8s 0 0mm 6.13 95.89 0.10
RESCANNING 5 8s 90 0mm 6.11 97.62 0.15
RESCANNING 10 8s 90 0mm 6.54 95.69 0.10
RESCANNING 15 8s 90 0mm 5.85 95.94 0.05
RESCANNING 20 8s 90 0mm 6.10 96.14 0.05
RESCANNING 5 6s 0 3mm 4.84 99.85 0.10
RESCANNING 10 6s 0 3mm 4.02 100.00 0.00
RESCANNING 15 6s 0 3mm 3.85 99.95 0.00
RESCANNING 20 6s 0 3mm 4.09 99.90 0.00
RESCANNING 5 6s 90 3mm 4.78 99.85 0.15
RESCANNING 10 6s 90 3mm 4.11 100.00 0.00
RESCANNING 15 6s 90 3mm 3.82 99.95 0.00
RESCANNING 20 6s 90 3mm 4.01 99.90 0.00
RESCANNING 5 8s 0 3mm 4.41 100.00 0.00
RESCANNING 10 8s 0 3mm 4.11 100.00 0.00
RESCANNING 15 8s 0 3mm 4.30 100.00 0.00
RESCANNING 20 8s 0 3mm 4.05 99.90 0.00
RESCANNING 5 8s 90 3mm 4.47 100.00 0.00
RESCANNING 10 8s 90 3mm 4.38 100.00 0.00
RESCANNING 15 8s 90 3mm 4.26 100.00 0.00
RESCANNING 20 8s 90 3mm 4.10 99.90 0.00
RESCANNING 5 6s 0 5mm 3.82 100.00 0.00
RESCANNING 10 6s 0 5mm 3.77 100.00 0.00
RESCANNING 15 6s 0 5mm 3.63 100.00 0.00
RESCANNING 20 6s 0 5mm 3.57 100.00 0.00
RESCANNING 5 6s 90 5mm 3.82 100.00 0.00
RESCANNING 10 6s 90 5mm 3.77 100.00 0.00
RESCANNING 15 6s 90 5mm 3.64 100.00 0.00
RESCANNING 20 6s 90 5mm 3.57 100.00 0.00
RESCANNING 5 8s 0 5mm 5.16 100.00 0.10
RESCANNING 10 8s 0 5mm 3.71 100.00 0.00
RESCANNING 15 8s 0 5mm 3.61 100.00 0.00
RESCANNING 20 8s 0 5mm 3.87 100.00 0.05
RESCANNING 5 8s 90 5mm 4.87 100.00 0.00
RESCANNING 10 8s 90 5mm 3.77 100.00 0.00
RESCANNING 15 8s 90 5mm 3.60 100.00 0.00
RESCANNING 20 8s 90 5mm 3.83 99.95 0.05
RESCANNING 5 6s 0 7mm 3.75 100.00 0.00
RESCANNING 10 6s 0 7mm 3.48 100.00 0.00
RESCANNING 15 6s 0 7mm 3.26 100.00 0.00
RESCANNING 20 6s 0 7mm 3.48 100.00 0.00
RESCANNING 5 6s 90 7mm 3.75 100.00 0.00
RESCANNING 10 6s 90 7mm 3.48 100.00 0.00
RESCANNING 15 6s 90 7mm 3.32 100.00 0.00
RESCANNING 20 6s 90 7mm 3.50 100.00 0.00
RESCANNING 5 8s 0 7mm 3.94 100.00 0.00
RESCANNING 10 8s 0 7mm 3.39 100.00 0.00
RESCANNING 15 8s 0 7mm 3.43 100.00 0.00
RESCANNING 20 8s 0 7mm 3.46 100.00 0.00
RESCANNING 5 8s 90 7mm 3.78 100.00 0.00
RESCANNING 10 8s 90 7mm 3.39 100.00 0.00
RESCANNING 15 8s 90 7mm 3.43 100.00 0.00
RESCANNING 20 8s 90 7mm 3.46 100.00 0.00
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Table A.39.: Patient 9, LPV
Case Rescan no. motion period motion starting phase Margin D5-D95 V95 V107
RESCANNING 5 6s 0 0mm 7.70 93.97 0.00
RESCANNING 10 6s 0 0mm 7.91 93.89 0.00
RESCANNING 15 6s 0 0mm 7.64 94.30 0.00
RESCANNING 20 6s 0 0mm 7.98 94.30 0.00
RESCANNING 5 6s 90 0mm 7.86 93.97 0.08
RESCANNING 10 6s 90 0mm 7.80 93.97 0.00
RESCANNING 15 6s 90 0mm 7.66 94.30 0.00
RESCANNING 20 6s 90 0mm 7.93 94.30 0.00
RESCANNING 5 8s 0 0mm 8.73 94.30 0.00
RESCANNING 10 8s 0 0mm 8.39 93.81 0.08
RESCANNING 15 8s 0 0mm 8.75 93.56 0.08
RESCANNING 20 8s 0 0mm 7.96 94.38 0.08
RESCANNING 5 8s 90 0mm 8.57 94.30 0.00
RESCANNING 10 8s 90 0mm 8.70 93.97 0.08
RESCANNING 15 8s 90 0mm 7.46 94.30 0.08
RESCANNING 20 8s 90 0mm 8.03 94.80 0.08
RESCANNING 5 6s 0 3mm 3.86 100.00 0.00
RESCANNING 10 6s 0 3mm 4.06 100.00 0.00
RESCANNING 15 6s 0 3mm 3.75 100.00 0.00
RESCANNING 20 6s 0 3mm 3.69 100.00 0.00
RESCANNING 5 6s 90 3mm 3.83 100.00 0.00
RESCANNING 10 6s 90 3mm 4.10 100.00 0.00
RESCANNING 15 6s 90 3mm 3.74 100.00 0.00
RESCANNING 20 6s 90 3mm 3.70 100.00 0.00
RESCANNING 5 8s 0 3mm 4.26 100.00 0.00
RESCANNING 10 8s 0 3mm 3.92 100.00 0.00
RESCANNING 15 8s 0 3mm 3.93 100.00 0.00
RESCANNING 20 8s 0 3mm 4.08 100.00 0.00
RESCANNING 5 8s 90 3mm 4.26 100.00 0.00
RESCANNING 10 8s 90 3mm 3.96 100.00 0.00
RESCANNING 15 8s 90 3mm 4.02 99.92 0.00
RESCANNING 20 8s 90 3mm 3.89 100.00 0.00
RESCANNING 5 6s 0 5mm 3.73 100.00 0.00
RESCANNING 10 6s 0 5mm 3.61 100.00 0.00
RESCANNING 15 6s 0 5mm 3.50 100.00 0.00
RESCANNING 20 6s 0 5mm 3.65 100.00 0.00
RESCANNING 5 6s 90 5mm 3.73 100.00 0.00
RESCANNING 10 6s 90 5mm 3.63 100.00 0.00
RESCANNING 15 6s 90 5mm 3.52 100.00 0.00
RESCANNING 20 6s 90 5mm 3.67 100.00 0.00
RESCANNING 5 8s 0 5mm 3.73 100.00 0.00
RESCANNING 10 8s 0 5mm 3.63 100.00 0.00
RESCANNING 15 8s 0 5mm 3.59 100.00 0.00
RESCANNING 20 8s 0 5mm 3.58 100.00 0.00
RESCANNING 5 8s 90 5mm 3.73 100.00 0.00
RESCANNING 10 8s 90 5mm 3.68 100.00 0.00
RESCANNING 15 8s 90 5mm 3.61 100.00 0.00
RESCANNING 20 8s 90 5mm 3.58 100.00 0.00
RESCANNING 5 6s 0 7mm 3.89 100.00 0.00
RESCANNING 10 6s 0 7mm 3.45 100.00 0.00
RESCANNING 15 6s 0 7mm 3.19 100.00 0.00
RESCANNING 20 6s 0 7mm 3.22 100.00 0.00
RESCANNING 5 6s 90 7mm 3.83 100.00 0.00
RESCANNING 10 6s 90 7mm 3.45 100.00 0.00
RESCANNING 15 6s 90 7mm 3.16 100.00 0.00
RESCANNING 20 6s 90 7mm 3.23 100.00 0.00
RESCANNING 5 8s 0 7mm 3.56 100.00 0.00
RESCANNING 10 8s 0 7mm 3.81 100.00 0.00
RESCANNING 15 8s 0 7mm 3.48 100.00 0.00
RESCANNING 20 8s 0 7mm 3.34 100.00 0.00
RESCANNING 5 8s 90 7mm 3.77 100.00 0.00
RESCANNING 10 8s 90 7mm 3.61 100.00 0.00
RESCANNING 15 8s 90 7mm 3.41 100.00 0.00
RESCANNING 20 8s 90 7mm 3.42 100.00 0.00
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Table A.40.: Patient 9, RPV
Case Rescan no. motion period motion starting phase Margin D5-D95 V95 V107
RESCANNING 5 6s 0 0mm 4.72 99.26 0.00
RESCANNING 10 6s 0 0mm 4.48 99.26 0.00
RESCANNING 15 6s 0 0mm 4.22 99.35 0.00
RESCANNING 20 6s 0 0mm 4.07 99.17 0.00
RESCANNING 5 6s 90 0mm 4.81 99.26 0.00
RESCANNING 10 6s 90 0mm 4.47 99.26 0.00
RESCANNING 15 6s 90 0mm 4.31 99.17 0.00
RESCANNING 20 6s 90 0mm 3.98 99.17 0.00
RESCANNING 5 8s 0 0mm 4.94 99.07 0.00
RESCANNING 10 8s 0 0mm 4.68 98.70 0.00
RESCANNING 15 8s 0 0mm 4.50 99.17 0.00
RESCANNING 20 8s 0 0mm 4.50 99.17 0.00
RESCANNING 5 8s 90 0mm 5.11 99.17 0.00
RESCANNING 10 8s 90 0mm 4.63 98.89 0.00
RESCANNING 15 8s 90 0mm 4.27 99.17 0.00
RESCANNING 20 8s 90 0mm 4.58 99.17 0.00
RESCANNING 5 6s 0 3mm 3.93 100.00 0.00
RESCANNING 10 6s 0 3mm 3.64 100.00 0.00
RESCANNING 15 6s 0 3mm 3.47 100.00 0.00
RESCANNING 20 6s 0 3mm 3.60 100.00 0.00
RESCANNING 5 6s 90 3mm 3.94 100.00 0.00
RESCANNING 10 6s 90 3mm 3.64 100.00 0.00
RESCANNING 15 6s 90 3mm 3.49 100.00 0.00
RESCANNING 20 6s 90 3mm 3.57 100.00 0.00
RESCANNING 5 8s 0 3mm 3.94 99.91 0.00
RESCANNING 10 8s 0 3mm 3.75 100.00 0.00
RESCANNING 15 8s 0 3mm 3.84 100.00 0.00
RESCANNING 20 8s 0 3mm 4.03 100.00 0.00
RESCANNING 5 8s 90 3mm 4.05 100.00 0.00
RESCANNING 10 8s 90 3mm 3.69 100.00 0.00
RESCANNING 15 8s 90 3mm 3.63 100.00 0.00
RESCANNING 20 8s 90 3mm 3.59 100.00 0.00
RESCANNING 5 6s 0 5mm 3.60 100.00 0.00
RESCANNING 10 6s 0 5mm 3.11 100.00 0.00
RESCANNING 15 6s 0 5mm 3.06 100.00 0.00
RESCANNING 20 6s 0 5mm 3.20 100.00 0.00
RESCANNING 5 6s 90 5mm 3.61 100.00 0.00
RESCANNING 10 6s 90 5mm 3.16 100.00 0.00
RESCANNING 15 6s 90 5mm 3.22 100.00 0.00
RESCANNING 20 6s 90 5mm 3.19 100.00 0.00
RESCANNING 5 8s 0 5mm 3.75 100.00 0.00
RESCANNING 10 8s 0 5mm 2.97 100.00 0.00
RESCANNING 15 8s 0 5mm 3.69 100.00 0.00
RESCANNING 20 8s 0 5mm 2.93 100.00 0.00
RESCANNING 5 8s 90 5mm 3.78 100.00 0.00
RESCANNING 10 8s 90 5mm 3.48 100.00 0.00
RESCANNING 15 8s 90 5mm 3.71 100.00 0.00
RESCANNING 20 8s 90 5mm 4.15 100.00 0.00
RESCANNING 5 6s 0 7mm 3.74 100.00 0.00
RESCANNING 10 6s 0 7mm 3.58 100.00 0.00
RESCANNING 15 6s 0 7mm 3.43 100.00 0.00
RESCANNING 20 6s 0 7mm 3.42 100.00 0.00
RESCANNING 5 6s 90 7mm 3.74 100.00 0.00
RESCANNING 10 6s 90 7mm 3.58 100.00 0.00
RESCANNING 15 6s 90 7mm 3.45 100.00 0.00
RESCANNING 20 6s 90 7mm 3.43 100.00 0.00
RESCANNING 5 8s 0 7mm 3.57 100.00 0.00
RESCANNING 10 8s 0 7mm 3.51 100.00 0.00
RESCANNING 15 8s 0 7mm 3.61 100.00 0.00
RESCANNING 20 8s 0 7mm 3.57 100.00 0.00
RESCANNING 5 8s 90 7mm 3.61 100.00 0.00
RESCANNING 10 8s 90 7mm 3.47 100.00 0.00
RESCANNING 15 8s 90 7mm 3.55 100.00 0.00
RESCANNING 20 8s 90 7mm 3.31 100.00 0.00
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B Appendix of chapter 3
B.1 Motion of PV due to heartbeat
The mean relative displacement and standard deviation of the target volumes (LPV and RPV)
to the reference phase zero will be shown for the three studied motion directions (SI: superior-
inferior, AP: anterior-posterior, LR: left-right) and the absolute (ABS) displacement.
Table B.1.: Patient 1, LPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.62 ± 0.27 -0.22 ± 0.15 0.39 ± 0.26 -0.28 ± 0.30
02 1.78 ± 0.81 -1.00 ± 0.48 0.97 ± 0.62 -0.86 ± 0.71
03 2.79 ± 0.98 -1.65 ± 0.78 1.55 ± 1.03 -1.08 ± 0.87
04 3.15 ± 1.22 -1.61 ± 1.11 1.78 ± 1.19 -1.48 ± 0.91
05 3.36 ± 1.28 -0.79 ± 0.93 2.32 ± 1.39 -1.83 ± 0.90
06 4.50 ± 1.72 -0.27 ± 1.13 3.25 ± 1.49 -2.76 ± 1.19
07 4.39 ± 1.68 0.26 ± 0.93 3.05 ± 1.56 -2.84 ± 1.15
08 4.17 ± 1.82 -0.32 ± 1.02 2.95 ± 1.58 -2.64 ± 1.19
09 4.39 ± 1.68 0.26 ± 0.93 3.05 ± 1.56 -2.84 ± 1.15
10 2.85 ± 1.26 -1.81 ± 0.88 1.61 ± 1.42 -0.82 ± 0.61
11 2.76 ± 1.08 -2.30 ± 0.98 1.18 ± 1.04 0.02 ± 0.24
12 2.68 ± 1.02 -2.16 ± 1.05 1.31 ± 0.82 0.06 ± 0.29
13 2.11 ± 0.71 -1.53 ± 0.89 0.88 ± 0.82 -0.28 ± 0.56
14 2.44 ± 1.02 -2.01 ± 0.99 0.66 ± 0.86 -0.65 ± 0.61
15 2.58 ± 1.16 -2.29 ± 1.12 0.39 ± 0.88 -0.46 ± 0.59
16 2.49 ± 1.23 -2.25 ± 1.18 0.36 ± 0.85 -0.24 ± 0.57
17 2.15 ± 1.20 -1.91 ± 1.06 0.33 ± 0.85 0.44 ± 0.48
18 1.61 ± 0.41 -0.88 ± 0.38 -0.26 ± 0.60 1.15 ± 0.33
19 0.60 ± 0.20 0.32 ± 0.19 -0.18 ± 0.21 0.39 ± 0.20
Table B.2.: Patient 1, RPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.25 ± 0.13 -0.03 ± 0.12 -0.02 ± 0.14 0.18 ± 0.11
02 0.62 ± 0.20 -0.23 ± 0.33 0.06 ± 0.37 0.31 ± 0.17
03 1.68 ± 0.31 -1.28 ± 0.42 0.73 ± 0.40 0.61 ± 0.24
04 2.22 ± 0.42 -1.18 ± 0.73 1.26 ± 0.65 0.91 ± 0.54
05 2.77 ± 0.76 -1.11 ± 0.77 2.05 ± 1.02 0.57 ± 0.94
06 3.99 ± 1.40 -0.35 ± 0.90 3.63 ± 1.57 0.65 ± 0.93
07 3.70 ± 1.24 0.04 ± 0.80 3.36 ± 1.41 0.51 ± 1.02
08 3.10 ± 1.12 0.12 ± 0.72 2.68 ± 1.31 0.79 ± 0.92
09 3.70 ± 1.24 0.04 ± 0.80 3.36 ± 1.41 0.51 ± 1.02
10 2.77 ± 0.71 -1.52 ± 0.52 1.77 ± 1.01 0.95 ± 0.74
11 2.08 ± 0.34 -1.51 ± 0.61 0.49 ± 0.77 0.87 ± 0.47
12 1.93 ± 0.45 -1.64 ± 0.62 0.20 ± 0.53 0.64 ± 0.31
13 1.42 ± 0.44 -1.25 ± 0.57 -0.02 ± 0.45 0.18 ± 0.31
14 1.99 ± 0.41 -1.68 ± 0.63 0.13 ± 0.64 0.55 ± 0.45
15 2.18 ± 0.49 -1.87 ± 0.72 0.05 ± 0.62 0.59 ± 0.49
16 2.27 ± 0.74 -1.90 ± 1.00 0.04 ± 0.75 0.57 ± 0.45
17 1.98 ± 0.40 -1.25 ± 0.69 0.46 ± 0.73 1.11 ± 0.26
18 1.14 ± 0.51 -0.27 ± 0.38 0.58 ± 0.59 0.68 ± 0.42
19 0.48 ± 0.21 0.18 ± 0.24 0.28 ± 0.23 0.20 ± 0.13
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Table B.3.: Patient 2, LPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.67 ± 0.48 -0.03 ± 0.21 -0.10 ± 0.17 -0.38 ± 0.67
02 1.86 ± 0.88 -0.62 ± 0.66 -0.32 ± 0.59 -1.31 ± 1.12
03 2.62 ± 1.20 1.43 ± 1.41 0.59 ± 1.06 -1.39 ± 0.94
04 3.94 ± 1.86 2.46 ± 1.71 1.68 ± 0.92 -2.35 ± 0.92
05 5.21 ± 1.80 3.52 ± 1.90 1.82 ± 0.61 -3.03 ± 1.23
06 5.26 ± 1.92 3.21 ± 1.58 1.51 ± 0.58 -3.65 ± 1.62
07 4.64 ± 1.94 2.25 ± 1.77 0.44 ± 0.76 -3.74 ± 1.53
08 4.52 ± 1.72 1.78 ± 1.84 0.57 ± 0.82 -3.71 ± 1.47
09 4.64 ± 1.94 2.25 ± 1.77 0.44 ± 0.76 -3.74 ± 1.53
10 2.68 ± 0.70 1.66 ± 0.59 0.90 ± 0.27 -1.84 ± 0.56
11 2.03 ± 0.61 1.39 ± 0.70 0.96 ± 0.28 -0.89 ± 0.51
12 1.43 ± 0.38 1.03 ± 0.53 0.78 ± 0.24 -0.32 ± 0.28
13 1.03 ± 0.28 0.53 ± 0.47 0.70 ± 0.25 0.06 ± 0.27
14 0.84 ± 0.28 0.48 ± 0.42 0.52 ± 0.12 -0.09 ± 0.28
15 0.75 ± 0.27 0.47 ± 0.42 0.37 ± 0.09 -0.19 ± 0.23
16 0.52 ± 0.10 0.18 ± 0.27 0.35 ± 0.07 -0.16 ± 0.15
17 0.47 ± 0.13 0.13 ± 0.23 0.35 ± 0.11 0.07 ± 0.16
18 0.56 ± 0.49 -0.19 ± 0.29 0.28 ± 0.23 0.36 ± 0.42
19 0.26 ± 0.09 0.05 ± 0.15 0.11 ± 0.12 0.07 ± 0.13
Table B.4.: Patient 2, RPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.56 ± 0.32 0.07 ± 0.25 0.34 ± 0.40 -0.12 ± 0.23
02 2.62 ± 0.87 0.69 ± 1.07 1.66 ± 0.66 -1.49 ± 0.76
03 4.17 ± 1.55 0.83 ± 1.87 1.84 ± 0.84 -3.05 ± 1.48
04 5.20 ± 1.80 1.48 ± 1.70 2.55 ± 1.36 -3.92 ± 1.22
05 5.04 ± 2.35 1.61 ± 1.93 2.77 ± 1.69 -3.25 ± 1.87
06 4.88 ± 1.71 1.36 ± 1.64 2.76 ± 1.54 -3.22 ± 1.35
07 3.82 ± 1.83 1.02 ± 1.17 2.09 ± 1.57 -2.45 ± 1.64
08 3.52 ± 2.09 0.89 ± 1.11 2.04 ± 2.08 -1.80 ± 1.74
09 3.82 ± 1.83 1.02 ± 1.17 2.09 ± 1.57 -2.45 ± 1.64
10 2.08 ± 1.40 0.89 ± 1.53 0.76 ± 1.27 -0.67 ± 0.74
11 1.72 ± 1.17 0.86 ± 1.40 0.24 ± 1.03 -0.42 ± 0.59
12 1.34 ± 0.86 0.77 ± 1.11 -0.07 ± 0.76 -0.14 ± 0.34
13 1.04 ± 0.66 0.53 ± 0.83 0.05 ± 0.65 0.09 ± 0.36
14 0.79 ± 0.44 0.42 ± 0.59 -0.08 ± 0.46 0.01 ± 0.26
15 0.64 ± 0.33 0.37 ± 0.41 -0.15 ± 0.36 -0.05 ± 0.26
16 0.54 ± 0.29 0.31 ± 0.36 -0.18 ± 0.25 -0.06 ± 0.22
17 0.38 ± 0.23 0.19 ± 0.25 -0.17 ± 0.21 0.04 ± 0.15
18 0.24 ± 0.14 0.04 ± 0.13 -0.10 ± 0.18 0.07 ± 0.10
19 0.39 ± 0.15 -0.06 ± 0.15 -0.23 ± 0.14 0.23 ± 0.14
Table B.5.: Patient 3, LPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.72 ± 0.48 -0.29 ± 0.51 0.09 ± 0.19 -0.33 ± 0.50
02 1.59 ± 1.12 -0.24 ± 0.70 0.48 ± 0.32 -1.17 ± 1.25
03 2.04 ± 1.34 0.09 ± 0.52 1.43 ± 0.61 -0.82 ± 1.61
04 3.06 ± 1.79 0.83 ± 0.92 1.89 ± 0.75 -1.42 ± 2.21
05 3.23 ± 1.73 0.74 ± 0.88 2.02 ± 0.67 -1.75 ± 2.13
06 3.22 ± 1.82 1.17 ± 1.24 1.73 ± 0.88 -1.26 ± 2.32
07 3.26 ± 2.06 1.01 ± 1.32 1.55 ± 0.82 -1.79 ± 2.42
08 3.39 ± 2.24 0.44 ± 1.17 1.62 ± 0.84 -2.38 ± 2.44
09 3.26 ± 2.06 1.01 ± 1.32 1.55 ± 0.82 -1.79 ± 2.42
10 2.91 ± 2.37 -1.26 ± 1.25 0.58 ± 0.80 -1.98 ± 2.45
11 2.73 ± 2.11 -1.43 ± 1.32 0.25 ± 0.98 -1.54 ± 2.16
12 2.47 ± 1.92 -1.09 ± 1.12 0.12 ± 0.95 -1.33 ± 2.15
13 2.55 ± 1.94 -1.43 ± 1.22 -0.42 ± 0.96 -1.42 ± 1.91
14 2.68 ± 2.02 -1.72 ± 1.25 -0.46 ± 0.88 -1.37 ± 1.96
15 2.82 ± 2.07 -1.70 ± 1.33 -0.50 ± 1.01 -1.46 ± 2.05
16 2.63 ± 1.99 -1.80 ± 1.11 -0.47 ± 0.86 -1.18 ± 2.02
17 1.86 ± 1.19 -0.83 ± 0.47 -0.67 ± 0.80 -0.55 ± 1.61
18 1.99 ± 0.66 -0.76 ± 1.20 -0.45 ± 0.75 0.60 ± 1.13
19 0.80 ± 0.62 0.48 ± 0.50 -0.06 ± 0.28 0.45 ± 0.51
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Table B.6.: Patient 3, RPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 1.06 ± 0.66 -0.40 ± 0.92 -0.12 ± 0.67 0.21 ± 0.25
02 1.30 ± 0.85 -0.39 ± 1.21 0.01 ± 0.82 -0.09 ± 0.31
03 1.97 ± 1.01 0.52 ± 1.01 0.68 ± 1.52 -0.48 ± 0.80
04 2.38 ± 1.18 0.66 ± 1.18 0.85 ± 1.80 -0.58 ± 0.95
05 2.38 ± 1.34 0.56 ± 1.10 1.21 ± 1.82 -0.92 ± 0.56
06 2.45 ± 1.40 0.71 ± 1.53 1.30 ± 1.75 -0.35 ± 0.52
07 2.66 ± 1.57 0.82 ± 1.55 1.42 ± 2.04 -0.30 ± 0.47
08 2.54 ± 1.73 0.81 ± 1.60 1.35 ± 2.03 0.23 ± 0.55
09 2.66 ± 1.57 0.82 ± 1.55 1.42 ± 2.04 -0.30 ± 0.47
10 2.62 ± 1.51 0.03 ± 1.29 0.65 ± 2.33 1.06 ± 0.73
11 2.93 ± 1.35 -0.28 ± 1.35 0.54 ± 2.45 1.21 ± 0.86
12 2.92 ± 1.29 -0.15 ± 1.38 0.38 ± 2.48 1.06 ± 0.93
13 2.62 ± 0.98 -0.14 ± 1.35 -0.06 ± 2.01 1.08 ± 0.85
14 2.53 ± 1.11 -0.10 ± 1.38 0.03 ± 2.01 0.99 ± 0.82
15 2.62 ± 1.10 -0.27 ± 1.42 -0.12 ± 2.03 1.15 ± 0.75
16 2.09 ± 0.92 -0.12 ± 0.93 -0.14 ± 1.60 1.15 ± 0.63
17 1.49 ± 0.63 0.53 ± 0.57 -0.10 ± 0.82 0.99 ± 0.58
18 1.97 ± 0.91 0.49 ± 1.03 0.03 ± 0.53 1.39 ± 1.10
19 0.99 ± 0.64 0.23 ± 0.74 0.08 ± 0.74 -0.12 ± 0.47
Table B.7.: Patient 4, LPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 1.31 ± 0.54 -1.07 ± 0.67 0.23 ± 0.28 -0.36 ± 0.39
02 2.73 ± 0.90 -2.06 ± 1.06 0.46 ± 0.68 -1.04 ± 1.07
03 4.04 ± 1.73 -3.06 ± 1.69 1.09 ± 0.96 -1.07 ± 1.96
04 4.54 ± 2.11 -3.38 ± 1.91 1.13 ± 1.20 -0.93 ± 2.53
05 4.41 ± 2.41 -2.97 ± 2.01 1.08 ± 1.34 -1.37 ± 2.76
06 4.94 ± 2.74 -3.27 ± 2.29 1.29 ± 1.43 -1.97 ± 2.90
07 5.13 ± 3.09 -3.52 ± 2.40 1.27 ± 1.82 -2.00 ± 2.96
08 5.39 ± 3.44 -3.66 ± 2.89 0.68 ± 1.97 -1.63 ± 3.48
09 5.13 ± 3.09 -3.52 ± 2.40 1.27 ± 1.82 -2.00 ± 2.96
10 5.87 ± 3.53 -4.43 ± 3.15 0.27 ± 2.13 -1.49 ± 3.25
11 5.52 ± 3.06 -4.39 ± 2.94 0.18 ± 1.81 -0.27 ± 2.93
12 5.09 ± 2.83 -3.82 ± 3.15 -0.16 ± 1.64 -0.26 ± 2.58
13 4.87 ± 2.87 -3.73 ± 3.16 -0.24 ± 1.37 -0.32 ± 2.45
14 4.84 ± 2.83 -3.64 ± 3.22 -0.43 ± 1.28 -0.21 ± 2.45
15 4.94 ± 2.95 -3.78 ± 3.30 -0.20 ± 1.27 -0.40 ± 2.49
16 5.10 ± 2.90 -3.73 ± 3.35 -0.35 ± 1.42 -0.21 ± 2.68
17 4.32 ± 2.42 -3.06 ± 2.76 -0.36 ± 1.44 0.09 ± 2.32
18 2.57 ± 0.99 -1.23 ± 1.34 -0.63 ± 1.30 0.44 ± 1.43
19 0.47 ± 0.24 -0.01 ± 0.26 -0.07 ± 0.22 0.26 ± 0.30
Table B.8.: Patient 4, RPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 1.31 ± 0.92 -0.85 ± 1.17 0.03 ± 0.62 0.21 ± 0.19
02 2.07 ± 1.03 -0.90 ± 1.66 0.65 ± 1.04 0.43 ± 0.34
03 3.56 ± 2.05 -1.50 ± 2.11 1.99 ± 2.11 1.24 ± 0.48
04 4.59 ± 2.44 -1.82 ± 2.81 2.28 ± 2.68 1.71 ± 0.70
05 4.76 ± 2.66 -1.30 ± 2.81 2.62 ± 3.11 1.72 ± 0.84
06 5.30 ± 3.05 -1.59 ± 3.20 2.90 ± 3.48 1.68 ± 1.13
07 5.82 ± 3.35 -1.63 ± 3.51 3.30 ± 3.75 1.70 ± 1.50
08 6.18 ± 3.19 -1.78 ± 3.93 3.02 ± 3.74 2.10 ± 1.51
09 5.82 ± 3.35 -1.63 ± 3.51 3.30 ± 3.75 1.70 ± 1.50
10 6.49 ± 3.00 -1.78 ± 4.11 2.68 ± 3.85 2.70 ± 1.38
11 6.43 ± 2.55 -2.25 ± 3.95 2.20 ± 3.41 3.14 ± 0.98
12 5.94 ± 2.18 -2.32 ± 3.65 1.52 ± 3.11 2.94 ± 0.87
13 5.54 ± 2.05 -2.35 ± 3.58 1.12 ± 2.76 2.67 ± 0.75
14 5.23 ± 2.13 -2.34 ± 3.58 0.73 ± 2.57 2.41 ± 0.81
15 5.25 ± 2.25 -2.42 ± 3.69 0.63 ± 2.73 2.22 ± 0.61
16 5.62 ± 2.23 -2.35 ± 3.81 0.93 ± 2.86 2.61 ± 0.84
17 4.61 ± 1.70 -1.80 ± 3.02 1.03 ± 2.56 1.88 ± 0.82
18 2.66 ± 0.54 -1.03 ± 1.15 0.72 ± 1.19 1.64 ± 0.60
19 0.62 ± 0.33 -0.20 ± 0.47 0.06 ± 0.33 0.17 ± 0.30
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Table B.9.: Patient 5, LPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.38 ± 0.23 0.12 ± 0.29 0.03 ± 0.25 0.09 ± 0.17
02 1.13 ± 0.51 0.32 ± 0.80 0.07 ± 0.68 0.20 ± 0.52
03 1.63 ± 0.64 -0.03 ± 1.23 0.35 ± 0.79 -0.53 ± 0.73
04 1.86 ± 0.72 0.03 ± 1.22 0.49 ± 0.85 -0.59 ± 1.10
05 1.77 ± 0.69 0.04 ± 1.20 0.43 ± 0.87 -0.51 ± 0.98
06 2.12 ± 1.25 0.30 ± 1.18 0.73 ± 1.28 -1.03 ± 1.17
07 2.46 ± 1.33 0.05 ± 1.34 0.85 ± 1.68 -1.27 ± 0.92
08 2.76 ± 1.27 -0.11 ± 1.19 0.98 ± 1.86 -1.63 ± 0.88
09 2.46 ± 1.33 0.05 ± 1.34 0.85 ± 1.68 -1.27 ± 0.92
10 2.58 ± 1.56 -1.13 ± 1.57 1.32 ± 1.60 -0.43 ± 0.94
11 2.56 ± 1.37 -1.31 ± 1.85 0.98 ± 0.99 -0.31 ± 1.12
12 2.68 ± 1.58 -1.58 ± 2.07 0.84 ± 0.91 -0.06 ± 1.17
13 2.73 ± 1.68 -1.62 ± 2.11 0.77 ± 0.92 0.46 ± 1.24
14 2.48 ± 1.46 -1.63 ± 1.78 0.70 ± 0.93 0.36 ± 0.97
15 2.70 ± 1.55 -1.90 ± 1.83 0.90 ± 0.95 0.38 ± 0.91
16 2.92 ± 1.54 -2.16 ± 1.72 0.91 ± 0.94 0.44 ± 1.17
17 2.70 ± 1.63 -2.10 ± 1.61 0.97 ± 0.90 0.56 ± 0.94
18 2.13 ± 0.90 -1.15 ± 1.03 0.52 ± 0.94 1.13 ± 0.72
19 0.84 ± 0.47 -0.38 ± 0.37 0.08 ± 0.32 0.53 ± 0.52
Table B.10.: Patient 5, RPV: Mean and standard deviation of target motion in all phases of the
heartbeat, relative to the reference phase.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.61 ± 0.33 0.22 ± 0.50 0.04 ± 0.22 0.17 ± 0.32
02 1.56 ± 0.82 0.61 ± 1.15 0.10 ± 0.57 0.63 ± 0.82
03 2.21 ± 1.10 0.77 ± 1.61 0.22 ± 0.67 0.95 ± 1.24
04 2.42 ± 1.48 1.12 ± 1.37 0.60 ± 0.89 1.49 ± 1.23
05 2.69 ± 2.22 1.27 ± 1.62 1.23 ± 1.26 1.29 ± 1.78
06 2.89 ± 2.15 1.32 ± 1.23 1.75 ± 1.81 0.85 ± 1.65
07 3.08 ± 2.12 1.29 ± 1.54 1.87 ± 1.69 0.89 ± 1.69
08 3.14 ± 2.11 1.17 ± 1.59 1.96 ± 1.85 0.50 ± 1.69
09 3.08 ± 2.12 1.29 ± 1.54 1.87 ± 1.69 0.89 ± 1.69
10 3.05 ± 1.96 0.79 ± 1.99 1.75 ± 1.60 0.94 ± 1.44
11 2.98 ± 1.74 0.12 ± 1.99 1.24 ± 1.29 1.34 ± 1.73
12 3.24 ± 1.63 -0.15 ± 2.09 1.19 ± 1.36 1.96 ± 1.28
13 3.61 ± 1.58 -0.28 ± 2.26 1.09 ± 1.30 2.48 ± 1.15
14 3.73 ± 1.97 -0.78 ± 2.57 1.01 ± 1.16 2.49 ± 1.41
15 3.95 ± 2.27 -1.16 ± 2.83 0.92 ± 1.15 2.54 ± 1.68
16 3.65 ± 1.84 -1.11 ± 2.18 0.94 ± 1.14 2.46 ± 1.59
17 3.54 ± 1.95 -1.11 ± 2.06 1.02 ± 1.18 2.39 ± 1.65
18 2.53 ± 0.93 -0.77 ± 1.02 0.53 ± 0.85 2.00 ± 0.81
19 0.74 ± 0.45 -0.35 ± 0.32 0.17 ± 0.33 0.31 ± 0.54
B.2 Values of dose analysis parameters for all patients
In the following the D5-D95, V95 and V107 values will be presented for all patient data sets
(patient 1 to 5) and target volumes (LPV and RPV). All studied techniques (static, interplay and
rescanning with five, ten, fifteen and twenty rescans) will be shown for four different motion
patterns and all studied safety margins (0 mm, 3 mm, 5 mm, 7 mm).
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Table B.11.: Patient 1, LPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 5.94 98.16 0.00
STATIC - - 3mm - 3.31 100.00 0.00
STATIC - - 5mm - 3.32 100.00 0.00
STATIC - - 7mm - 3.06 100.00 0.26
INTERPLAY 1s 0 0mm - 14.84 87.93 6.30
INTERPLAY 1s 90 0mm - 12.05 91.86 2.89
INTERPLAY 0.7s 0 0mm - 12.16 91.60 2.10
INTERPLAY 0.7s 90 0mm - 10.54 93.44 0.52
INTERPLAY 1s 0 3mm - 13.68 91.34 5.25
INTERPLAY 1s 90 3mm - 14.30 86.88 5.25
INTERPLAY 0.7s 0 3mm - 10.45 93.18 1.31
INTERPLAY 0.7s 90 3mm - 9.04 97.38 1.05
INTERPLAY 1s 0 5mm - 7.59 98.43 0.00
INTERPLAY 1s 90 5mm - 7.45 99.48 0.79
INTERPLAY 0.7s 0 5mm - 10.24 95.01 1.31
INTERPLAY 0.7s 90 5mm - 9.22 96.85 0.52
INTERPLAY 1s 0 7mm - 7.46 98.16 0.00
INTERPLAY 1s 90 7mm - 7.48 98.95 0.79
INTERPLAY 0.7s 0 7mm - 9.67 95.54 1.05
INTERPLAY 0.7s 90 7mm - 9.29 97.38 0.79
RESCANNING 1s 0 0mm 5 9.07 97.38 0.79
RESCANNING 1s 0 0mm 10 8.28 98.16 0.00
RESCANNING 1s 0 0mm 15 7.95 97.64 0.00
RESCANNING 1s 0 0mm 20 7.49 97.90 0.00
RESCANNING 1s 90 0mm 5 8.34 96.06 0.26
RESCANNING 1s 90 0mm 10 7.37 98.43 0.26
RESCANNING 1s 90 0mm 15 7.12 98.95 0.26
RESCANNING 1s 90 0mm 20 6.75 98.43 0.26
RESCANNING 0.7s 0 0mm 5 7.71 97.64 0.26
RESCANNING 0.7s 0 0mm 10 5.79 99.48 0.00
RESCANNING 0.7s 0 0mm 15 6.43 99.21 0.00
RESCANNING 0.7s 0 0mm 20 5.90 99.21 0.00
RESCANNING 0.7s 90 0mm 5 7.29 96.59 0.00
RESCANNING 0.7s 90 0mm 10 6.46 99.21 0.00
RESCANNING 0.7s 90 0mm 15 5.82 98.95 0.00
RESCANNING 0.7s 90 0mm 20 6.08 98.95 0.00
RESCANNING 1s 0 3mm 5 7.52 100.00 1.05
RESCANNING 1s 0 3mm 10 5.41 100.00 0.00
RESCANNING 1s 0 3mm 15 4.63 100.00 0.00
RESCANNING 1s 0 3mm 20 5.22 100.00 0.00
RESCANNING 1s 90 3mm 5 8.83 93.18 0.00
RESCANNING 1s 90 3mm 10 6.19 99.21 0.00
RESCANNING 1s 90 3mm 15 5.40 100.00 0.00
RESCANNING 1s 90 3mm 20 5.17 100.00 0.00
RESCANNING 0.7s 0 3mm 5 5.68 100.00 0.00
RESCANNING 0.7s 0 3mm 10 4.49 100.00 0.00
RESCANNING 0.7s 0 3mm 15 3.95 100.00 0.00
RESCANNING 0.7s 0 3mm 20 3.59 100.00 0.00
RESCANNING 0.7s 90 3mm 5 6.34 99.74 0.00
RESCANNING 0.7s 90 3mm 10 3.98 100.00 0.00
RESCANNING 0.7s 90 3mm 15 3.53 100.00 0.00
RESCANNING 0.7s 90 3mm 20 3.47 100.00 0.00
RESCANNING 1s 0 5mm 5 6.49 100.00 0.00
RESCANNING 1s 0 5mm 10 4.21 100.00 0.00
RESCANNING 1s 0 5mm 15 4.11 100.00 0.00
RESCANNING 1s 0 5mm 20 3.26 100.00 0.00
RESCANNING 1s 90 5mm 5 9.00 98.16 1.05
RESCANNING 1s 90 5mm 10 7.27 100.00 0.00
RESCANNING 1s 90 5mm 15 6.34 100.00 0.26
RESCANNING 1s 90 5mm 20 6.26 100.00 0.26
RESCANNING 0.7s 0 5mm 5 6.45 99.74 0.00
RESCANNING 0.7s 0 5mm 10 3.77 100.00 0.00
RESCANNING 0.7s 0 5mm 15 2.77 100.00 0.00
RESCANNING 0.7s 0 5mm 20 2.54 100.00 0.00
RESCANNING 0.7s 90 5mm 5 5.04 100.00 0.00
RESCANNING 0.7s 90 5mm 10 3.75 100.00 0.00
RESCANNING 0.7s 90 5mm 15 2.88 100.00 0.00
RESCANNING 0.7s 90 5mm 20 3.00 100.00 0.00
RESCANNING 1s 0 7mm 5 5.35 100.00 0.00
RESCANNING 1s 0 7mm 10 4.10 100.00 0.00
RESCANNING 1s 0 7mm 15 3.74 100.00 0.00
RESCANNING 1s 0 7mm 20 3.69 100.00 0.00
RESCANNING 1s 90 7mm 5 7.05 96.85 0.00
RESCANNING 1s 90 7mm 10 7.30 97.11 0.00
RESCANNING 1s 90 7mm 15 5.47 100.00 0.00
RESCANNING 1s 90 7mm 20 4.97 100.00 0.00
RESCANNING 0.7s 0 7mm 5 5.60 99.48 0.00
RESCANNING 0.7s 0 7mm 10 3.41 100.00 0.00
RESCANNING 0.7s 0 7mm 15 3.18 100.00 0.00
RESCANNING 0.7s 0 7mm 20 2.72 100.00 0.00
RESCANNING 0.7s 90 7mm 5 5.61 100.00 0.00
RESCANNING 0.7s 90 7mm 10 3.90 100.00 0.00
RESCANNING 0.7s 90 7mm 15 3.35 100.00 0.00
RESCANNING 0.7s 90 7mm 20 2.87 100.00 0.00
Table B.12.: Patient 1, RPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 4.86 98.88 0.00
STATIC - - 3mm - 3.63 100.00 0.00
STATIC - - 5mm - 3.08 100.00 0.00
STATIC - - 7mm - 3.23 100.00 0.00
INTERPLAY 1s 0 0mm - 12.50 89.29 3.57
INTERPLAY 1s 90 0mm - 11.64 91.74 1.12
INTERPLAY 0.7s 0 0mm - 11.57 90.40 2.01
INTERPLAY 0.7s 90 0mm - 9.08 96.43 0.22
INTERPLAY 1s 0 3mm - 11.01 92.63 1.56
INTERPLAY 1s 90 3mm - 10.40 96.65 1.56
INTERPLAY 0.7s 0 3mm - 10.55 94.64 1.12
INTERPLAY 0.7s 90 3mm - 8.24 97.77 0.00
INTERPLAY 1s 0 5mm - 9.34 95.98 0.00
INTERPLAY 1s 90 5mm - 7.92 98.66 0.22
INTERPLAY 0.7s 0 5mm - 6.41 98.88 0.00
INTERPLAY 0.7s 90 5mm - 6.07 100.00 0.00
INTERPLAY 1s 0 7mm - 9.21 95.76 0.00
INTERPLAY 1s 90 7mm - 7.78 98.21 0.00
INTERPLAY 0.7s 0 7mm - 6.20 98.44 0.00
INTERPLAY 0.7s 90 7mm - 6.10 99.78 0.00
RESCANNING 1s 0 0mm 5 8.32 95.09 0.00
RESCANNING 1s 0 0mm 10 6.81 96.88 0.00
RESCANNING 1s 0 0mm 15 7.15 96.43 0.00
RESCANNING 1s 0 0mm 20 6.85 96.43 0.00
RESCANNING 1s 90 0mm 5 8.61 94.64 0.00
RESCANNING 1s 90 0mm 10 6.91 96.65 0.00
RESCANNING 1s 90 0mm 15 7.26 96.21 0.22
RESCANNING 1s 90 0mm 20 7.45 96.21 0.00
RESCANNING 0.7s 0 0mm 5 7.96 96.65 0.22
RESCANNING 0.7s 0 0mm 10 6.70 96.21 0.00
RESCANNING 0.7s 0 0mm 15 6.52 96.88 0.00
RESCANNING 0.7s 0 0mm 20 6.52 96.43 0.00
RESCANNING 0.7s 90 0mm 5 8.30 93.97 0.00
RESCANNING 0.7s 90 0mm 10 7.46 94.87 0.00
RESCANNING 0.7s 90 0mm 15 6.28 97.10 0.00
RESCANNING 0.7s 90 0mm 20 6.28 96.43 0.00
RESCANNING 1s 0 3mm 5 5.59 100.00 0.00
RESCANNING 1s 0 3mm 10 4.61 100.00 0.00
RESCANNING 1s 0 3mm 15 3.90 100.00 0.00
RESCANNING 1s 0 3mm 20 3.94 100.00 0.00
RESCANNING 1s 90 3mm 5 6.41 100.00 0.00
RESCANNING 1s 90 3mm 10 4.90 99.78 0.00
RESCANNING 1s 90 3mm 15 4.24 100.00 0.00
RESCANNING 1s 90 3mm 20 4.36 100.00 0.00
RESCANNING 0.7s 0 3mm 5 5.79 100.00 0.00
RESCANNING 0.7s 0 3mm 10 3.75 100.00 0.00
RESCANNING 0.7s 0 3mm 15 3.54 100.00 0.00
RESCANNING 0.7s 0 3mm 20 3.67 100.00 0.00
RESCANNING 0.7s 90 3mm 5 5.59 99.33 0.00
RESCANNING 0.7s 90 3mm 10 4.18 100.00 0.00
RESCANNING 0.7s 90 3mm 15 3.67 100.00 0.00
RESCANNING 0.7s 90 3mm 20 3.48 100.00 0.00
RESCANNING 1s 0 5mm 5 6.01 100.00 0.00
RESCANNING 1s 0 5mm 10 4.16 100.00 0.00
RESCANNING 1s 0 5mm 15 3.96 100.00 0.00
RESCANNING 1s 0 5mm 20 3.86 100.00 0.00
RESCANNING 1s 90 5mm 5 6.67 97.99 0.00
RESCANNING 1s 90 5mm 10 4.37 100.00 0.00
RESCANNING 1s 90 5mm 15 4.00 100.00 0.00
RESCANNING 1s 90 5mm 20 4.01 100.00 0.00
RESCANNING 0.7s 0 5mm 5 4.21 100.00 0.00
RESCANNING 0.7s 0 5mm 10 3.52 100.00 0.00
RESCANNING 0.7s 0 5mm 15 2.79 100.00 0.00
RESCANNING 0.7s 0 5mm 20 3.02 100.00 0.00
RESCANNING 0.7s 90 5mm 5 4.83 100.00 0.00
RESCANNING 0.7s 90 5mm 10 3.38 100.00 0.00
RESCANNING 0.7s 90 5mm 15 3.00 100.00 0.00
RESCANNING 0.7s 90 5mm 20 2.54 100.00 0.00
RESCANNING 1s 0 7mm 5 5.61 100.00 0.22
RESCANNING 1s 0 7mm 10 4.34 100.00 0.00
RESCANNING 1s 0 7mm 15 4.10 100.00 0.00
RESCANNING 1s 0 7mm 20 3.71 100.00 0.00
RESCANNING 1s 90 7mm 5 6.77 98.44 0.00
RESCANNING 1s 90 7mm 10 3.75 100.00 0.00
RESCANNING 1s 90 7mm 15 3.80 100.00 0.00
RESCANNING 1s 90 7mm 20 3.74 100.00 0.00
RESCANNING 0.7s 0 7mm 5 5.37 100.00 0.00
RESCANNING 0.7s 0 7mm 10 3.22 100.00 0.00
RESCANNING 0.7s 0 7mm 15 2.75 100.00 0.00
RESCANNING 0.7s 0 7mm 20 2.20 100.00 0.00
RESCANNING 0.7s 90 7mm 5 5.23 100.00 0.00
RESCANNING 0.7s 90 7mm 10 3.33 100.00 0.00
RESCANNING 0.7s 90 7mm 15 2.74 100.00 0.00
RESCANNING 0.7s 90 7mm 20 2.09 100.00 0.00
Table B.13.: Patient 2, LPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 14.19 89.75 0.00
STATIC - - 3mm - 2.93 100.00 0.00
STATIC - - 5mm - 2.64 100.00 0.00
STATIC - - 7mm - 2.42 100.00 0.00
INTERPLAY 1s 0 0mm - 8.27 96.93 0.41
INTERPLAY 1s 90 0mm - 9.61 95.29 2.66
INTERPLAY 0.7s 0 0mm - 9.22 94.88 0.82
INTERPLAY 0.7s 90 0mm - 6.65 99.39 0.20
INTERPLAY 1s 0 3mm - 11.75 93.65 2.87
INTERPLAY 1s 90 3mm - 11.56 94.88 3.89
INTERPLAY 0.7s 0 3mm - 7.90 99.80 1.64
INTERPLAY 0.7s 90 3mm - 7.07 99.80 0.20
INTERPLAY 1s 0 5mm - 8.06 97.75 0.20
INTERPLAY 1s 90 5mm - 9.78 95.49 2.66
INTERPLAY 0.7s 0 5mm - 8.89 95.29 0.82
INTERPLAY 0.7s 90 5mm - 6.54 98.98 0.00
INTERPLAY 1s 0 7mm - 6.78 98.16 0.00
INTERPLAY 1s 90 7mm - 7.06 99.59 0.20
INTERPLAY 0.7s 0 7mm - 8.90 95.08 1.02
INTERPLAY 0.7s 90 7mm - 6.41 99.18 0.20
RESCANNING 1s 0 0mm 5 17.86 89.55 7.99
RESCANNING 1s 0 0mm 10 13.98 90.78 2.87
RESCANNING 1s 0 0mm 15 13.00 90.57 0.20
RESCANNING 1s 0 0mm 20 12.15 90.57 0.20
RESCANNING 1s 90 0mm 5 10.86 87.30 0.00
RESCANNING 1s 90 0mm 10 11.21 88.93 0.00
RESCANNING 1s 90 0mm 15 10.70 88.73 0.00
RESCANNING 1s 90 0mm 20 10.65 88.93 0.00
RESCANNING 0.7s 0 0mm 5 11.05 91.80 0.20
RESCANNING 0.7s 0 0mm 10 10.21 90.98 0.00
RESCANNING 0.7s 0 0mm 15 10.46 90.98 0.00
RESCANNING 0.7s 0 0mm 20 10.29 90.78 0.00
RESCANNING 0.7s 90 0mm 5 11.30 91.39 0.20
RESCANNING 0.7s 90 0mm 10 10.28 91.39 0.00
RESCANNING 0.7s 90 0mm 15 10.33 90.98 0.00
RESCANNING 0.7s 90 0mm 20 10.18 91.39 0.00
RESCANNING 1s 0 3mm 5 6.72 100.00 0.20
RESCANNING 1s 0 3mm 10 5.28 100.00 0.00
RESCANNING 1s 0 3mm 15 4.54 100.00 0.00
RESCANNING 1s 0 3mm 20 4.41 100.00 0.00
RESCANNING 1s 90 3mm 5 5.67 98.57 0.00
RESCANNING 1s 90 3mm 10 4.67 100.00 0.00
RESCANNING 1s 90 3mm 15 4.33 100.00 0.00
RESCANNING 1s 90 3mm 20 4.34 100.00 0.00
RESCANNING 0.7s 0 3mm 5 4.89 99.39 0.00
RESCANNING 0.7s 0 3mm 10 4.09 100.00 0.00
RESCANNING 0.7s 0 3mm 15 3.13 100.00 0.00
RESCANNING 0.7s 0 3mm 20 2.79 100.00 0.00
RESCANNING 0.7s 90 3mm 5 6.72 100.00 0.41
RESCANNING 0.7s 90 3mm 10 4.54 99.80 0.00
RESCANNING 0.7s 90 3mm 15 2.94 100.00 0.00
RESCANNING 0.7s 90 3mm 20 2.91 100.00 0.00
RESCANNING 1s 0 5mm 5 5.50 100.00 0.00
RESCANNING 1s 0 5mm 10 3.87 100.00 0.00
RESCANNING 1s 0 5mm 15 3.43 100.00 0.00
RESCANNING 1s 0 5mm 20 2.92 100.00 0.00
RESCANNING 1s 90 5mm 5 5.31 99.59 0.00
RESCANNING 1s 90 5mm 10 4.35 100.00 0.00
RESCANNING 1s 90 5mm 15 3.63 100.00 0.00
RESCANNING 1s 90 5mm 20 3.53 100.00 0.00
RESCANNING 0.7s 0 5mm 5 5.23 100.00 0.00
RESCANNING 0.7s 0 5mm 10 3.65 100.00 0.00
RESCANNING 0.7s 0 5mm 15 3.03 100.00 0.00
RESCANNING 0.7s 0 5mm 20 2.88 100.00 0.00
RESCANNING 0.7s 90 5mm 5 4.18 100.00 0.00
RESCANNING 0.7s 90 5mm 10 3.17 100.00 0.00
RESCANNING 0.7s 90 5mm 15 2.73 100.00 0.00
RESCANNING 0.7s 90 5mm 20 2.12 100.00 0.00
RESCANNING 1s 0 7mm 5 5.42 100.00 0.00
RESCANNING 1s 0 7mm 10 2.90 100.00 0.00
RESCANNING 1s 0 7mm 15 3.26 100.00 0.00
RESCANNING 1s 0 7mm 20 2.51 100.00 0.00
RESCANNING 1s 90 7mm 5 5.85 99.59 0.00
RESCANNING 1s 90 7mm 10 3.76 100.00 0.00
RESCANNING 1s 90 7mm 15 3.32 100.00 0.00
RESCANNING 1s 90 7mm 20 3.73 100.00 0.00
RESCANNING 0.7s 0 7mm 5 3.68 100.00 0.00
RESCANNING 0.7s 0 7mm 10 2.89 100.00 0.00
RESCANNING 0.7s 0 7mm 15 3.01 100.00 0.00
RESCANNING 0.7s 0 7mm 20 2.16 100.00 0.00
RESCANNING 0.7s 90 7mm 5 4.56 100.00 0.00
RESCANNING 0.7s 90 7mm 10 3.22 100.00 0.00
RESCANNING 0.7s 90 7mm 15 2.51 100.00 0.00
RESCANNING 0.7s 90 7mm 20 2.07 100.00 0.00
Table B.14.: Patient 2, RPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 12.37 89.27 0.00
STATIC - - 3mm - 3.47 99.58 0.00
STATIC - - 5mm - 3.17 99.79 0.00
STATIC - - 7mm - 3.18 99.79 0.00
INTERPLAY 1s 0 0mm - 9.41 94.38 1.15
INTERPLAY 1s 90 0mm - 10.47 92.19 1.15
INTERPLAY 0.7s 0 0mm - 8.64 97.71 0.31
INTERPLAY 0.7s 90 0mm - 7.85 98.54 0.10
INTERPLAY 1s 0 3mm - 11.05 93.33 1.67
INTERPLAY 1s 90 3mm - 11.73 91.15 1.46
INTERPLAY 0.7s 0 3mm - 9.84 92.08 0.73
INTERPLAY 0.7s 90 3mm - 9.66 95.10 0.73
INTERPLAY 1s 0 5mm - 9.29 94.38 1.15
INTERPLAY 1s 90 5mm - 10.39 91.98 1.25
INTERPLAY 0.7s 0 5mm - 8.71 98.23 0.52
INTERPLAY 0.7s 90 5mm - 7.74 99.06 0.10
INTERPLAY 1s 0 7mm - 8.48 97.40 0.42
INTERPLAY 1s 90 7mm - 9.19 95.94 0.10
INTERPLAY 0.7s 0 7mm - 8.91 97.60 0.73
INTERPLAY 0.7s 90 7mm - 7.87 98.54 0.31
RESCANNING 1s 0 0mm 5 12.09 86.35 0.21
RESCANNING 1s 0 0mm 10 10.92 88.02 0.00
RESCANNING 1s 0 0mm 15 10.94 87.40 0.00
RESCANNING 1s 0 0mm 20 10.60 88.65 0.00
RESCANNING 1s 90 0mm 5 12.14 84.58 0.31
RESCANNING 1s 90 0mm 10 12.24 87.60 0.00
RESCANNING 1s 90 0mm 15 11.13 87.71 0.00
RESCANNING 1s 90 0mm 20 11.21 88.96 0.00
RESCANNING 0.7s 0 0mm 5 12.06 87.40 0.10
RESCANNING 0.7s 0 0mm 10 11.01 90.10 0.00
RESCANNING 0.7s 0 0mm 15 10.87 90.42 0.00
RESCANNING 0.7s 0 0mm 20 10.12 91.25 0.00
RESCANNING 0.7s 90 0mm 5 12.50 89.27 0.62
RESCANNING 0.7s 90 0mm 10 10.91 90.42 0.00
RESCANNING 0.7s 90 0mm 15 10.45 90.83 0.00
RESCANNING 0.7s 90 0mm 20 10.35 90.62 0.00
RESCANNING 1s 0 3mm 5 8.82 94.69 0.10
RESCANNING 1s 0 3mm 10 5.45 99.06 0.00
RESCANNING 1s 0 3mm 15 4.74 99.58 0.00
RESCANNING 1s 0 3mm 20 4.63 99.58 0.00
RESCANNING 1s 90 3mm 5 7.45 97.50 0.00
RESCANNING 1s 90 3mm 10 6.43 99.69 0.00
RESCANNING 1s 90 3mm 15 5.33 99.38 0.00
RESCANNING 1s 90 3mm 20 5.09 99.48 0.00
RESCANNING 0.7s 0 3mm 5 5.78 99.27 0.21
RESCANNING 0.7s 0 3mm 10 4.53 99.58 0.00
RESCANNING 0.7s 0 3mm 15 3.91 99.48 0.00
RESCANNING 0.7s 0 3mm 20 3.50 99.58 0.00
RESCANNING 0.7s 90 3mm 5 5.88 99.06 0.00
RESCANNING 0.7s 90 3mm 10 4.34 99.79 0.10
RESCANNING 0.7s 90 3mm 15 4.35 99.38 0.00
RESCANNING 0.7s 90 3mm 20 3.66 99.58 0.00
RESCANNING 1s 0 5mm 5 9.22 99.06 3.02
RESCANNING 1s 0 5mm 10 5.18 99.58 0.00
RESCANNING 1s 0 5mm 15 4.89 99.79 0.00
RESCANNING 1s 0 5mm 20 4.16 99.79 0.00
RESCANNING 1s 90 5mm 5 7.67 99.58 0.73
RESCANNING 1s 90 5mm 10 5.36 99.69 0.00
RESCANNING 1s 90 5mm 15 4.88 99.79 0.00
RESCANNING 1s 90 5mm 20 4.62 99.79 0.00
RESCANNING 0.7s 0 5mm 5 6.76 99.06 0.10
RESCANNING 0.7s 0 5mm 10 4.43 99.90 0.00
RESCANNING 0.7s 0 5mm 15 3.87 99.69 0.00
RESCANNING 0.7s 0 5mm 20 3.35 99.69 0.00
RESCANNING 0.7s 90 5mm 5 5.31 99.38 0.00
RESCANNING 0.7s 90 5mm 10 4.33 99.69 0.00
RESCANNING 0.7s 90 5mm 15 3.49 99.79 0.00
RESCANNING 0.7s 90 5mm 20 3.28 99.90 0.00
RESCANNING 1s 0 7mm 5 6.68 99.48 0.00
RESCANNING 1s 0 7mm 10 5.61 99.58 0.10
RESCANNING 1s 0 7mm 15 3.83 99.79 0.00
RESCANNING 1s 0 7mm 20 4.13 99.90 0.00
RESCANNING 1s 90 7mm 5 8.62 99.17 1.04
RESCANNING 1s 90 7mm 10 5.34 99.58 0.00
RESCANNING 1s 90 7mm 15 3.79 100.00 0.00
RESCANNING 1s 90 7mm 20 4.22 99.90 0.00
RESCANNING 0.7s 0 7mm 5 5.92 99.79 0.00
RESCANNING 0.7s 0 7mm 10 4.01 99.90 0.00
RESCANNING 0.7s 0 7mm 15 3.75 99.90 0.00
RESCANNING 0.7s 0 7mm 20 3.35 99.79 0.00
RESCANNING 0.7s 90 7mm 5 5.60 99.79 0.00
RESCANNING 0.7s 90 7mm 10 4.37 99.69 0.00
RESCANNING 0.7s 90 7mm 15 3.70 99.90 0.00
RESCANNING 0.7s 90 7mm 20 2.96 100.00 0.00
Table B.15.: Patient 3, LPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 4.67 100.00 0.29
STATIC - - 3mm - 4.14 100.00 0.00
STATIC - - 5mm - 3.47 100.00 0.00
STATIC - - 7mm - 3.08 100.00 0.00
INTERPLAY 1s 0 0mm - 13.88 87.71 2.00
INTERPLAY 1s 90 0mm - 10.18 77.14 0.00
INTERPLAY 0.7s 0 0mm - 10.92 89.14 1.43
INTERPLAY 0.7s 90 0mm - 10.96 86.57 0.29
INTERPLAY 1s 0 3mm - 7.79 100.00 0.86
INTERPLAY 1s 90 3mm - 8.30 97.14 0.00
INTERPLAY 0.7s 0 3mm - 9.59 95.71 0.29
INTERPLAY 0.7s 90 3mm - 7.41 99.43 2.00
INTERPLAY 1s 0 5mm - 7.79 100.00 1.14
INTERPLAY 1s 90 5mm - 8.40 96.86 0.00
INTERPLAY 0.7s 0 5mm - 9.47 95.71 0.00
INTERPLAY 0.7s 90 5mm - 7.55 99.43 1.14
INTERPLAY 1s 0 7mm - 7.82 100.00 1.43
INTERPLAY 1s 90 7mm - 8.33 96.57 0.00
INTERPLAY 0.7s 0 7mm - 9.42 96.00 0.29
INTERPLAY 0.7s 90 7mm - 7.81 98.86 1.14
RESCANNING 1s 0 0mm 5 8.88 96.00 0.29
RESCANNING 1s 0 0mm 10 8.90 95.71 0.00
RESCANNING 1s 0 0mm 15 8.63 96.86 0.29
RESCANNING 1s 0 0mm 20 8.46 97.43 0.29
RESCANNING 1s 90 0mm 5 9.42 92.00 0.57
RESCANNING 1s 90 0mm 10 9.27 93.71 0.00
RESCANNING 1s 90 0mm 15 8.93 94.00 0.29
RESCANNING 1s 90 0mm 20 8.35 93.71 0.00
RESCANNING 0.7s 0 0mm 5 8.86 92.00 0.00
RESCANNING 0.7s 0 0mm 10 8.19 95.71 0.00
RESCANNING 0.7s 0 0mm 15 7.61 95.14 0.00
RESCANNING 0.7s 0 0mm 20 7.36 96.29 0.00
RESCANNING 0.7s 90 0mm 5 8.88 94.00 0.00
RESCANNING 0.7s 90 0mm 10 6.94 95.71 0.00
RESCANNING 0.7s 90 0mm 15 6.40 97.14 0.00
RESCANNING 0.7s 90 0mm 20 5.96 98.00 0.00
RESCANNING 1s 0 3mm 5 6.57 100.00 0.29
RESCANNING 1s 0 3mm 10 6.50 100.00 0.57
RESCANNING 1s 0 3mm 15 5.61 100.00 0.00
RESCANNING 1s 0 3mm 20 5.32 100.00 0.00
RESCANNING 1s 90 3mm 5 6.86 100.00 0.29
RESCANNING 1s 90 3mm 10 5.89 100.00 0.00
RESCANNING 1s 90 3mm 15 5.94 100.00 0.29
RESCANNING 1s 90 3mm 20 5.17 100.00 0.00
RESCANNING 0.7s 0 3mm 5 5.78 99.43 0.00
RESCANNING 0.7s 0 3mm 10 4.23 99.71 0.00
RESCANNING 0.7s 0 3mm 15 3.69 99.71 0.00
RESCANNING 0.7s 0 3mm 20 3.34 99.71 0.00
RESCANNING 0.7s 90 3mm 5 5.85 99.43 0.00
RESCANNING 0.7s 90 3mm 10 4.57 99.71 0.00
RESCANNING 0.7s 90 3mm 15 4.14 100.00 0.00
RESCANNING 0.7s 90 3mm 20 3.62 99.71 0.00
RESCANNING 1s 0 5mm 5 8.21 100.00 3.71
RESCANNING 1s 0 5mm 10 4.89 100.00 0.00
RESCANNING 1s 0 5mm 15 4.73 100.00 0.00
RESCANNING 1s 0 5mm 20 4.20 100.00 0.00
RESCANNING 1s 90 5mm 5 7.77 99.14 0.86
RESCANNING 1s 90 5mm 10 5.17 100.00 0.00
RESCANNING 1s 90 5mm 15 4.91 100.00 0.00
RESCANNING 1s 90 5mm 20 4.08 100.00 0.00
RESCANNING 0.7s 0 5mm 5 5.81 100.00 0.00
RESCANNING 0.7s 0 5mm 10 4.83 100.00 0.00
RESCANNING 0.7s 0 5mm 15 4.02 100.00 0.00
RESCANNING 0.7s 0 5mm 20 4.23 100.00 0.00
RESCANNING 0.7s 90 5mm 5 5.57 100.00 0.00
RESCANNING 0.7s 90 5mm 10 4.37 100.00 0.00
RESCANNING 0.7s 90 5mm 15 4.52 100.00 0.00
RESCANNING 0.7s 90 5mm 20 4.65 100.00 0.00
RESCANNING 1s 0 7mm 5 5.24 100.00 0.00
RESCANNING 1s 0 7mm 10 6.37 100.00 0.00
RESCANNING 1s 0 7mm 15 5.31 100.00 0.00
RESCANNING 1s 0 7mm 20 5.39 100.00 0.00
RESCANNING 1s 90 7mm 5 5.87 99.43 0.00
RESCANNING 1s 90 7mm 10 5.61 99.71 0.00
RESCANNING 1s 90 7mm 15 5.35 100.00 0.00
RESCANNING 1s 90 7mm 20 5.19 99.71 0.00
RESCANNING 0.7s 0 7mm 5 5.89 100.00 0.00
RESCANNING 0.7s 0 7mm 10 4.29 100.00 0.00
RESCANNING 0.7s 0 7mm 15 3.90 100.00 0.00
RESCANNING 0.7s 0 7mm 20 3.84 100.00 0.00
RESCANNING 0.7s 90 7mm 5 5.72 100.00 0.00
RESCANNING 0.7s 90 7mm 10 4.22 100.00 0.00
RESCANNING 0.7s 90 7mm 15 3.62 100.00 0.00
RESCANNING 0.7s 90 7mm 20 3.75 100.00 0.00
Table B.16.: Patient 3, RPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 3.87 98.81 0.10
STATIC - - 3mm - 1.99 100.00 0.00
STATIC - - 5mm - 2.14 100.00 0.00
STATIC - - 7mm - 1.94 99.90 0.00
INTERPLAY 1s 0 0mm - 9.50 95.03 0.50
INTERPLAY 1s 90 0mm - 10.30 95.53 1.79
INTERPLAY 0.7s 0 0mm - 8.79 93.35 0.10
INTERPLAY 0.7s 90 0mm - 9.74 94.64 0.20
INTERPLAY 1s 0 3mm - 6.12 99.90 0.10
INTERPLAY 1s 90 3mm - 7.18 99.60 0.79
INTERPLAY 0.7s 0 3mm - 6.07 100.00 0.10
INTERPLAY 0.7s 90 3mm - 6.56 100.00 0.79
INTERPLAY 1s 0 5mm - 6.09 99.60 0.00
INTERPLAY 1s 90 5mm - 7.27 99.60 0.70
INTERPLAY 0.7s 0 5mm - 6.09 100.00 0.10
INTERPLAY 0.7s 90 5mm - 6.46 100.00 0.60
INTERPLAY 1s 0 7mm - 6.15 99.70 0.00
INTERPLAY 1s 90 7mm - 7.26 99.50 0.30
INTERPLAY 0.7s 0 7mm - 6.20 99.90 0.40
INTERPLAY 0.7s 90 7mm - 6.47 100.00 0.50
RESCANNING 1s 0 0mm 5 8.60 94.64 0.20
RESCANNING 1s 0 0mm 10 6.64 98.21 0.00
RESCANNING 1s 0 0mm 15 6.30 98.61 0.00
RESCANNING 1s 0 0mm 20 6.18 98.71 0.00
RESCANNING 1s 90 0mm 5 8.73 95.73 0.60
RESCANNING 1s 90 0mm 10 7.11 97.32 0.00
RESCANNING 1s 90 0mm 15 6.55 98.21 0.00
RESCANNING 1s 90 0mm 20 6.29 98.61 0.00
RESCANNING 0.7s 0 0mm 5 6.89 95.63 0.00
RESCANNING 0.7s 0 0mm 10 4.98 99.01 0.00
RESCANNING 0.7s 0 0mm 15 4.31 99.11 0.00
RESCANNING 0.7s 0 0mm 20 4.33 99.30 0.00
RESCANNING 0.7s 90 0mm 5 7.03 97.42 0.00
RESCANNING 0.7s 90 0mm 10 5.39 98.51 0.00
RESCANNING 0.7s 90 0mm 15 4.66 99.40 0.00
RESCANNING 0.7s 90 0mm 20 4.55 99.21 0.00
RESCANNING 1s 0 3mm 5 6.94 99.90 0.79
RESCANNING 1s 0 3mm 10 4.55 99.90 0.00
RESCANNING 1s 0 3mm 15 3.88 99.90 0.00
RESCANNING 1s 0 3mm 20 4.00 99.90 0.00
RESCANNING 1s 90 3mm 5 5.86 99.70 0.00
RESCANNING 1s 90 3mm 10 4.82 100.00 0.00
RESCANNING 1s 90 3mm 15 4.19 100.00 0.00
RESCANNING 1s 90 3mm 20 4.05 100.00 0.00
RESCANNING 0.7s 0 3mm 5 4.87 99.90 0.10
RESCANNING 0.7s 0 3mm 10 3.82 100.00 0.00
RESCANNING 0.7s 0 3mm 15 3.17 100.00 0.00
RESCANNING 0.7s 0 3mm 20 2.93 100.00 0.00
RESCANNING 0.7s 90 3mm 5 5.65 98.81 0.00
RESCANNING 0.7s 90 3mm 10 4.50 100.00 0.00
RESCANNING 0.7s 90 3mm 15 3.36 100.00 0.00
RESCANNING 0.7s 90 3mm 20 2.65 100.00 0.00
RESCANNING 1s 0 5mm 5 7.18 100.00 1.49
RESCANNING 1s 0 5mm 10 4.62 100.00 0.00
RESCANNING 1s 0 5mm 15 3.76 100.00 0.00
RESCANNING 1s 0 5mm 20 3.66 100.00 0.00
RESCANNING 1s 90 5mm 5 4.85 100.00 0.00
RESCANNING 1s 90 5mm 10 4.30 100.00 0.00
RESCANNING 1s 90 5mm 15 4.07 100.00 0.00
RESCANNING 1s 90 5mm 20 3.39 100.00 0.00
RESCANNING 0.7s 0 5mm 5 4.97 100.00 0.00
RESCANNING 0.7s 0 5mm 10 4.12 100.00 0.00
RESCANNING 0.7s 0 5mm 15 3.10 100.00 0.00
RESCANNING 0.7s 0 5mm 20 2.98 100.00 0.00
RESCANNING 0.7s 90 5mm 5 5.46 100.00 0.00
RESCANNING 0.7s 90 5mm 10 3.85 100.00 0.00
RESCANNING 0.7s 90 5mm 15 3.19 100.00 0.00
RESCANNING 0.7s 90 5mm 20 3.02 100.00 0.00
RESCANNING 1s 0 7mm 5 8.50 100.00 0.30
RESCANNING 1s 0 7mm 10 4.30 100.00 0.00
RESCANNING 1s 0 7mm 15 4.59 100.00 0.00
RESCANNING 1s 0 7mm 20 4.32 100.00 0.00
RESCANNING 1s 90 7mm 5 6.61 100.00 0.50
RESCANNING 1s 90 7mm 10 4.42 100.00 0.00
RESCANNING 1s 90 7mm 15 3.73 100.00 0.00
RESCANNING 1s 90 7mm 20 3.71 100.00 0.00
RESCANNING 0.7s 0 7mm 5 4.93 100.00 0.00
RESCANNING 0.7s 0 7mm 10 3.53 100.00 0.00
RESCANNING 0.7s 0 7mm 15 3.24 100.00 0.00
RESCANNING 0.7s 0 7mm 20 3.16 100.00 0.00
RESCANNING 0.7s 90 7mm 5 4.64 100.00 0.10
RESCANNING 0.7s 90 7mm 10 3.53 100.00 0.00
RESCANNING 0.7s 90 7mm 15 3.36 100.00 0.00
RESCANNING 0.7s 90 7mm 20 3.16 100.00 0.00
Table B.17.: Patient 4, LPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 7.36 95.76 0.25
STATIC - - 3mm - 3.92 99.75 0.00
STATIC - - 5mm - 3.63 100.00 0.00
STATIC - - 7mm - 3.49 100.00 0.00
INTERPLAY 1s 0 0mm - 13.55 89.03 2.99
INTERPLAY 1s 90 0mm - 14.82 80.30 1.00
INTERPLAY 0.7s 0 0mm - 14.10 84.79 1.75
INTERPLAY 0.7s 90 0mm - 10.66 91.27 1.25
INTERPLAY 1s 0 3mm - 7.73 99.25 0.25
INTERPLAY 1s 90 3mm - 10.01 95.76 0.75
INTERPLAY 0.7s 0 3mm - 9.86 90.02 0.00
INTERPLAY 0.7s 90 3mm - 9.94 95.76 1.75
INTERPLAY 1s 0 5mm - 9.38 98.50 0.25
INTERPLAY 1s 90 5mm - 9.57 95.26 0.75
INTERPLAY 0.7s 0 5mm - 7.35 98.75 0.00
INTERPLAY 0.7s 90 5mm - 6.73 98.25 0.00
INTERPLAY 1s 0 7mm - 11.59 91.77 2.49
INTERPLAY 1s 90 7mm - 10.69 89.03 0.25
INTERPLAY 0.7s 0 7mm - 8.97 94.26 0.00
INTERPLAY 0.7s 90 7mm - 7.44 98.25 0.00
RESCANNING 1s 0 0mm 5 9.37 94.01 0.25
RESCANNING 1s 0 0mm 10 9.43 88.03 0.00
RESCANNING 1s 0 0mm 15 8.56 86.78 0.00
RESCANNING 1s 0 0mm 20 8.89 85.79 0.00
RESCANNING 1s 90 0mm 5 8.74 91.27 0.50
RESCANNING 1s 90 0mm 10 8.88 91.77 0.00
RESCANNING 1s 90 0mm 15 8.54 92.77 0.00
RESCANNING 1s 90 0mm 20 8.46 92.77 0.00
RESCANNING 0.7s 0 0mm 5 8.87 91.27 0.25
RESCANNING 0.7s 0 0mm 10 8.20 92.27 0.00
RESCANNING 0.7s 0 0mm 15 7.89 91.02 0.00
RESCANNING 0.7s 0 0mm 20 8.08 91.77 0.00
RESCANNING 0.7s 90 0mm 5 10.18 89.03 0.25
RESCANNING 0.7s 90 0mm 10 8.33 93.27 0.00
RESCANNING 0.7s 90 0mm 15 7.59 94.76 0.00
RESCANNING 0.7s 90 0mm 20 7.85 94.26 0.00
RESCANNING 1s 0 3mm 5 6.77 98.50 0.00
RESCANNING 1s 0 3mm 10 5.30 99.25 0.00
RESCANNING 1s 0 3mm 15 5.27 99.00 0.00
RESCANNING 1s 0 3mm 20 4.75 99.50 0.00
RESCANNING 1s 90 3mm 5 7.77 99.50 2.00
RESCANNING 1s 90 3mm 10 5.94 99.50 0.00
RESCANNING 1s 90 3mm 15 6.11 99.50 0.00
RESCANNING 1s 90 3mm 20 5.90 99.50 0.00
RESCANNING 0.7s 0 3mm 5 5.52 99.75 0.00
RESCANNING 0.7s 0 3mm 10 4.62 99.75 0.00
RESCANNING 0.7s 0 3mm 15 4.44 100.00 0.00
RESCANNING 0.7s 0 3mm 20 3.93 100.00 0.00
RESCANNING 0.7s 90 3mm 5 5.50 99.25 0.00
RESCANNING 0.7s 90 3mm 10 4.21 99.25 0.00
RESCANNING 0.7s 90 3mm 15 4.85 99.50 0.00
RESCANNING 0.7s 90 3mm 20 3.72 99.50 0.00
RESCANNING 1s 0 5mm 5 6.45 100.00 0.00
RESCANNING 1s 0 5mm 10 5.15 99.75 0.00
RESCANNING 1s 0 5mm 15 4.70 99.75 0.00
RESCANNING 1s 0 5mm 20 4.27 99.75 0.00
RESCANNING 1s 90 5mm 5 8.63 92.02 0.00
RESCANNING 1s 90 5mm 10 6.15 97.51 0.00
RESCANNING 1s 90 5mm 15 5.18 99.50 0.00
RESCANNING 1s 90 5mm 20 5.93 99.50 0.00
RESCANNING 0.7s 0 5mm 5 5.61 99.50 0.00
RESCANNING 0.7s 0 5mm 10 3.64 99.50 0.00
RESCANNING 0.7s 0 5mm 15 3.47 99.75 0.00
RESCANNING 0.7s 0 5mm 20 3.23 99.50 0.00
RESCANNING 0.7s 90 5mm 5 5.07 99.50 0.00
RESCANNING 0.7s 90 5mm 10 4.18 99.50 0.00
RESCANNING 0.7s 90 5mm 15 3.63 99.25 0.00
RESCANNING 0.7s 90 5mm 20 3.30 99.50 0.00
RESCANNING 1s 0 7mm 5 5.26 100.00 0.00
RESCANNING 1s 0 7mm 10 4.14 100.00 0.00
RESCANNING 1s 0 7mm 15 4.03 100.00 0.00
RESCANNING 1s 0 7mm 20 4.15 100.00 0.00
RESCANNING 1s 90 7mm 5 5.59 99.25 0.00
RESCANNING 1s 90 7mm 10 5.34 99.75 0.00
RESCANNING 1s 90 7mm 15 4.57 100.00 0.00
RESCANNING 1s 90 7mm 20 4.35 99.75 0.00
RESCANNING 0.7s 0 7mm 5 5.00 99.75 0.00
RESCANNING 0.7s 0 7mm 10 3.66 99.75 0.00
RESCANNING 0.7s 0 7mm 15 3.28 100.00 0.00
RESCANNING 0.7s 0 7mm 20 3.41 100.00 0.00
RESCANNING 0.7s 90 7mm 5 4.74 99.75 0.00
RESCANNING 0.7s 90 7mm 10 3.04 99.75 0.00
RESCANNING 0.7s 90 7mm 15 3.12 100.00 0.00
RESCANNING 0.7s 90 7mm 20 2.76 100.00 0.00
Table B.18.: Patient 4, RPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 5.46 97.80 0.00
STATIC - - 3mm - 3.65 100.00 0.00
STATIC - - 5mm - 3.07 100.00 0.00
STATIC - - 7mm - 2.63 99.40 0.00
INTERPLAY 1s 0 0mm - 11.43 89.80 0.40
INTERPLAY 1s 90 0mm - 11.22 94.00 2.00
INTERPLAY 0.7s 0 0mm - 11.12 94.60 2.00
INTERPLAY 0.7s 90 0mm - 13.29 84.20 1.80
INTERPLAY 1s 0 3mm - 9.67 95.20 0.60
INTERPLAY 1s 90 3mm - 9.16 96.60 0.20
INTERPLAY 0.7s 0 3mm - 9.68 97.00 1.20
INTERPLAY 0.7s 90 3mm - 9.55 96.80 0.40
INTERPLAY 1s 0 5mm - 8.83 96.80 0.40
INTERPLAY 1s 90 5mm - 8.88 92.20 0.00
INTERPLAY 0.7s 0 5mm - 8.56 96.80 0.00
INTERPLAY 0.7s 90 5mm - 7.55 99.60 0.40
INTERPLAY 1s 0 7mm - 8.88 98.80 1.60
INTERPLAY 1s 90 7mm - 8.05 97.60 0.00
INTERPLAY 0.7s 0 7mm - 7.81 97.00 0.00
INTERPLAY 0.7s 90 7mm - 7.66 99.80 0.20
RESCANNING 1s 0 0mm 5 10.05 94.00 0.80
RESCANNING 1s 0 0mm 10 8.77 94.80 0.40
RESCANNING 1s 0 0mm 15 8.47 94.40 0.00
RESCANNING 1s 0 0mm 20 8.27 94.60 0.20
RESCANNING 1s 90 0mm 5 9.65 95.20 1.00
RESCANNING 1s 90 0mm 10 9.35 95.80 0.40
RESCANNING 1s 90 0mm 15 8.28 96.00 0.40
RESCANNING 1s 90 0mm 20 8.35 96.40 0.20
RESCANNING 0.7s 0 0mm 5 8.51 94.00 0.00
RESCANNING 0.7s 0 0mm 10 7.67 95.80 0.00
RESCANNING 0.7s 0 0mm 15 7.24 96.20 0.00
RESCANNING 0.7s 0 0mm 20 7.13 95.80 0.00
RESCANNING 0.7s 90 0mm 5 8.77 94.60 0.20
RESCANNING 0.7s 90 0mm 10 6.86 96.20 0.00
RESCANNING 0.7s 90 0mm 15 6.98 96.60 0.20
RESCANNING 0.7s 90 0mm 20 6.46 96.40 0.20
RESCANNING 1s 0 3mm 5 7.05 99.40 0.00
RESCANNING 1s 0 3mm 10 5.62 100.00 0.00
RESCANNING 1s 0 3mm 15 5.10 100.00 0.00
RESCANNING 1s 0 3mm 20 4.86 99.80 0.00
RESCANNING 1s 90 3mm 5 5.56 99.60 0.00
RESCANNING 1s 90 3mm 10 5.62 100.00 0.20
RESCANNING 1s 90 3mm 15 5.14 99.80 0.00
RESCANNING 1s 90 3mm 20 5.36 100.00 0.00
RESCANNING 0.7s 0 3mm 5 5.69 100.00 0.00
RESCANNING 0.7s 0 3mm 10 3.71 100.00 0.00
RESCANNING 0.7s 0 3mm 15 3.54 100.00 0.00
RESCANNING 0.7s 0 3mm 20 3.59 100.00 0.00
RESCANNING 0.7s 90 3mm 5 6.53 99.60 0.00
RESCANNING 0.7s 90 3mm 10 4.21 100.00 0.00
RESCANNING 0.7s 90 3mm 15 4.37 100.00 0.00
RESCANNING 0.7s 90 3mm 20 4.23 100.00 0.00
RESCANNING 1s 0 5mm 5 7.82 100.00 1.80
RESCANNING 1s 0 5mm 10 4.77 100.00 0.20
RESCANNING 1s 0 5mm 15 4.98 100.00 0.00
RESCANNING 1s 0 5mm 20 5.16 100.00 0.00
RESCANNING 1s 90 5mm 5 7.26 94.20 0.00
RESCANNING 1s 90 5mm 10 5.12 99.60 0.00
RESCANNING 1s 90 5mm 15 5.27 100.00 0.00
RESCANNING 1s 90 5mm 20 4.74 100.00 0.00
RESCANNING 0.7s 0 5mm 5 5.87 100.00 0.00
RESCANNING 0.7s 0 5mm 10 3.72 100.00 0.00
RESCANNING 0.7s 0 5mm 15 3.09 100.00 0.00
RESCANNING 0.7s 0 5mm 20 3.14 100.00 0.00
RESCANNING 0.7s 90 5mm 5 5.34 99.80 0.00
RESCANNING 0.7s 90 5mm 10 3.52 100.00 0.00
RESCANNING 0.7s 90 5mm 15 3.53 100.00 0.00
RESCANNING 0.7s 90 5mm 20 2.93 100.00 0.00
RESCANNING 1s 0 7mm 5 5.44 100.00 0.20
RESCANNING 1s 0 7mm 10 4.23 100.00 0.20
RESCANNING 1s 0 7mm 15 3.95 99.80 0.00
RESCANNING 1s 0 7mm 20 3.84 100.00 0.00
RESCANNING 1s 90 7mm 5 6.29 99.20 0.20
RESCANNING 1s 90 7mm 10 5.31 100.00 0.00
RESCANNING 1s 90 7mm 15 4.04 100.00 0.00
RESCANNING 1s 90 7mm 20 3.69 100.00 0.00
RESCANNING 0.7s 0 7mm 5 5.03 100.00 0.00
RESCANNING 0.7s 0 7mm 10 4.37 100.00 0.00
RESCANNING 0.7s 0 7mm 15 3.03 100.00 0.00
RESCANNING 0.7s 0 7mm 20 2.81 100.00 0.00
RESCANNING 0.7s 90 7mm 5 4.49 100.00 0.00
RESCANNING 0.7s 90 7mm 10 3.68 100.00 0.00
RESCANNING 0.7s 90 7mm 15 3.62 100.00 0.00
RESCANNING 0.7s 90 7mm 20 3.12 100.00 0.00
Table B.19.: Patient 5, LPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 4.65 100.00 0.00
STATIC - - 3mm - 2.52 100.00 0.00
STATIC - - 5mm - 2.95 100.00 0.00
STATIC - - 7mm - 4.29 100.00 0.00
INTERPLAY 1s 0 0mm - 10.55 93.41 0.94
INTERPLAY 1s 90 0mm - 10.79 93.68 0.94
INTERPLAY 0.7s 0 0mm - 9.18 91.40 0.27
INTERPLAY 0.7s 90 0mm - 9.34 89.65 0.00
INTERPLAY 1s 0 3mm - 8.09 97.31 0.27
INTERPLAY 1s 90 3mm - 9.60 98.39 2.55
INTERPLAY 0.7s 0 3mm - 7.84 95.43 0.13
INTERPLAY 0.7s 90 3mm - 7.95 97.85 0.13
INTERPLAY 1s 0 5mm - 6.48 99.73 0.81
INTERPLAY 1s 90 5mm - 7.43 95.97 0.13
INTERPLAY 0.7s 0 5mm - 6.99 97.58 0.00
INTERPLAY 0.7s 90 5mm - 8.00 99.87 0.40
INTERPLAY 1s 0 7mm - 6.71 99.46 0.13
INTERPLAY 1s 90 7mm - 9.40 96.24 0.81
INTERPLAY 0.7s 0 7mm - 8.18 93.95 0.00
INTERPLAY 0.7s 90 7mm - 7.38 98.25 0.00
RESCANNING 1s 0 0mm 5 9.34 88.58 0.00
RESCANNING 1s 0 0mm 10 7.44 91.94 0.00
RESCANNING 1s 0 0mm 15 6.78 94.89 0.00
RESCANNING 1s 0 0mm 20 6.57 95.30 0.00
RESCANNING 1s 90 0mm 5 8.62 97.04 1.61
RESCANNING 1s 90 0mm 10 8.47 96.51 0.54
RESCANNING 1s 90 0mm 15 6.67 97.72 0.13
RESCANNING 1s 90 0mm 20 6.82 97.58 0.27
RESCANNING 0.7s 0 0mm 5 7.95 96.10 0.00
RESCANNING 0.7s 0 0mm 10 6.38 98.12 0.00
RESCANNING 0.7s 0 0mm 15 6.20 97.98 0.00
RESCANNING 0.7s 0 0mm 20 5.74 97.98 0.00
RESCANNING 0.7s 90 0mm 5 7.87 95.16 0.13
RESCANNING 0.7s 90 0mm 10 6.10 96.77 0.00
RESCANNING 0.7s 90 0mm 15 6.01 97.18 0.00
RESCANNING 0.7s 90 0mm 20 5.84 96.37 0.00
RESCANNING 1s 0 3mm 5 5.44 99.87 0.00
RESCANNING 1s 0 3mm 10 4.47 100.00 0.00
RESCANNING 1s 0 3mm 15 3.79 100.00 0.00
RESCANNING 1s 0 3mm 20 3.33 100.00 0.00
RESCANNING 1s 90 3mm 5 7.74 91.94 0.00
RESCANNING 1s 90 3mm 10 4.42 99.87 0.00
RESCANNING 1s 90 3mm 15 3.67 100.00 0.00
RESCANNING 1s 90 3mm 20 3.78 100.00 0.00
RESCANNING 0.7s 0 3mm 5 5.64 99.87 0.00
RESCANNING 0.7s 0 3mm 10 4.74 100.00 0.00
RESCANNING 0.7s 0 3mm 15 3.68 100.00 0.00
RESCANNING 0.7s 0 3mm 20 3.45 100.00 0.00
RESCANNING 0.7s 90 3mm 5 5.58 99.73 0.00
RESCANNING 0.7s 90 3mm 10 3.86 99.87 0.00
RESCANNING 0.7s 90 3mm 15 3.46 100.00 0.00
RESCANNING 0.7s 90 3mm 20 3.38 100.00 0.00
RESCANNING 1s 0 5mm 5 6.69 99.06 0.00
RESCANNING 1s 0 5mm 10 4.19 100.00 0.00
RESCANNING 1s 0 5mm 15 3.85 100.00 0.00
RESCANNING 1s 0 5mm 20 3.67 100.00 0.00
RESCANNING 1s 90 5mm 5 4.90 99.60 0.00
RESCANNING 1s 90 5mm 10 4.63 99.87 0.00
RESCANNING 1s 90 5mm 15 3.60 100.00 0.00
RESCANNING 1s 90 5mm 20 3.49 100.00 0.00
RESCANNING 0.7s 0 5mm 5 4.64 100.00 0.00
RESCANNING 0.7s 0 5mm 10 3.83 100.00 0.00
RESCANNING 0.7s 0 5mm 15 3.25 100.00 0.00
RESCANNING 0.7s 0 5mm 20 2.60 100.00 0.00
RESCANNING 0.7s 90 5mm 5 5.04 100.00 0.00
RESCANNING 0.7s 90 5mm 10 3.66 99.73 0.00
RESCANNING 0.7s 90 5mm 15 2.97 100.00 0.00
RESCANNING 0.7s 90 5mm 20 2.58 100.00 0.00
RESCANNING 1s 0 7mm 5 5.11 100.00 0.00
RESCANNING 1s 0 7mm 10 5.04 99.73 0.00
RESCANNING 1s 0 7mm 15 3.86 100.00 0.00
RESCANNING 1s 0 7mm 20 4.02 100.00 0.00
RESCANNING 1s 90 7mm 5 6.23 98.52 0.00
RESCANNING 1s 90 7mm 10 5.25 98.12 0.00
RESCANNING 1s 90 7mm 15 5.12 98.39 0.00
RESCANNING 1s 90 7mm 20 4.80 98.52 0.00
RESCANNING 0.7s 0 7mm 5 4.98 99.87 0.00
RESCANNING 0.7s 0 7mm 10 4.18 99.87 0.00
RESCANNING 0.7s 0 7mm 15 4.29 99.33 0.00
RESCANNING 0.7s 0 7mm 20 3.64 100.00 0.00
RESCANNING 0.7s 90 7mm 5 5.45 99.46 0.00
RESCANNING 0.7s 90 7mm 10 4.10 99.60 0.00
RESCANNING 0.7s 90 7mm 15 3.74 100.00 0.00
RESCANNING 0.7s 90 7mm 20 3.51 99.87 0.00
Table B.20.: Patient 5, RPV
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 0mm - 3.94 99.85 0.00
STATIC - - 3mm - 2.26 100.00 0.00
STATIC - - 5mm - 2.46 100.00 0.00
STATIC - - 7mm - 2.83 100.00 0.00
INTERPLAY 1s 0 0mm - 12.04 90.52 0.87
INTERPLAY 1s 90 0mm - 9.83 94.02 1.17
INTERPLAY 0.7s 0 0mm - 10.12 96.79 2.19
INTERPLAY 0.7s 90 0mm - 9.12 92.57 0.15
INTERPLAY 1s 0 3mm - 7.44 99.42 0.00
INTERPLAY 1s 90 3mm - 7.43 97.67 0.00
INTERPLAY 0.7s 0 3mm - 6.13 99.71 0.00
INTERPLAY 0.7s 90 3mm - 8.35 96.21 0.15
INTERPLAY 1s 0 5mm - 7.34 98.83 0.00
INTERPLAY 1s 90 5mm - 8.23 98.11 0.87
INTERPLAY 0.7s 0 5mm - 5.79 99.27 0.00
INTERPLAY 0.7s 90 5mm - 7.86 97.52 0.00
INTERPLAY 1s 0 7mm - 6.45 99.13 0.15
INTERPLAY 1s 90 7mm - 8.99 94.90 0.15
INTERPLAY 0.7s 0 7mm - 6.18 97.38 0.00
INTERPLAY 0.7s 90 7mm - 6.82 99.85 0.00
RESCANNING 1s 0 0mm 5 8.32 91.55 0.15
RESCANNING 1s 0 0mm 10 8.53 88.48 0.00
RESCANNING 1s 0 0mm 15 8.04 91.55 0.00
RESCANNING 1s 0 0mm 20 8.30 90.52 0.00
RESCANNING 1s 90 0mm 5 8.14 99.13 0.58
RESCANNING 1s 90 0mm 10 7.53 99.56 0.73
RESCANNING 1s 90 0mm 15 8.16 97.81 0.44
RESCANNING 1s 90 0mm 20 7.82 98.69 0.44
RESCANNING 0.7s 0 0mm 5 7.65 92.57 0.00
RESCANNING 0.7s 0 0mm 10 6.75 95.34 0.00
RESCANNING 0.7s 0 0mm 15 6.24 96.21 0.00
RESCANNING 0.7s 0 0mm 20 6.19 95.77 0.00
RESCANNING 0.7s 90 0mm 5 8.18 97.23 0.15
RESCANNING 0.7s 90 0mm 10 6.45 97.81 0.00
RESCANNING 0.7s 90 0mm 15 6.04 97.38 0.00
RESCANNING 0.7s 90 0mm 20 5.46 97.96 0.00
RESCANNING 1s 0 3mm 5 6.04 100.00 0.00
RESCANNING 1s 0 3mm 10 4.16 100.00 0.00
RESCANNING 1s 0 3mm 15 4.39 100.00 0.00
RESCANNING 1s 0 3mm 20 4.21 100.00 0.00
RESCANNING 1s 90 3mm 5 6.01 98.69 0.00
RESCANNING 1s 90 3mm 10 5.38 100.00 0.15
RESCANNING 1s 90 3mm 15 4.65 100.00 0.29
RESCANNING 1s 90 3mm 20 4.65 100.00 0.00
RESCANNING 0.7s 0 3mm 5 5.52 100.00 0.00
RESCANNING 0.7s 0 3mm 10 4.20 100.00 0.00
RESCANNING 0.7s 0 3mm 15 3.12 100.00 0.00
RESCANNING 0.7s 0 3mm 20 2.99 100.00 0.00
RESCANNING 0.7s 90 3mm 5 5.10 99.85 0.00
RESCANNING 0.7s 90 3mm 10 3.49 100.00 0.00
RESCANNING 0.7s 90 3mm 15 2.83 100.00 0.00
RESCANNING 0.7s 90 3mm 20 2.85 100.00 0.00
RESCANNING 1s 0 5mm 5 4.83 100.00 0.00
RESCANNING 1s 0 5mm 10 4.56 100.00 0.00
RESCANNING 1s 0 5mm 15 3.96 100.00 0.00
RESCANNING 1s 0 5mm 20 3.87 100.00 0.00
RESCANNING 1s 90 5mm 5 6.37 96.94 0.00
RESCANNING 1s 90 5mm 10 4.26 99.85 0.00
RESCANNING 1s 90 5mm 15 4.18 100.00 0.00
RESCANNING 1s 90 5mm 20 3.94 100.00 0.00
RESCANNING 0.7s 0 5mm 5 4.21 100.00 0.00
RESCANNING 0.7s 0 5mm 10 3.38 100.00 0.00
RESCANNING 0.7s 0 5mm 15 3.24 100.00 0.00
RESCANNING 0.7s 0 5mm 20 2.66 100.00 0.00
RESCANNING 0.7s 90 5mm 5 4.47 100.00 0.00
RESCANNING 0.7s 90 5mm 10 3.26 100.00 0.00
RESCANNING 0.7s 90 5mm 15 2.93 100.00 0.00
RESCANNING 0.7s 90 5mm 20 2.37 100.00 0.00
RESCANNING 1s 0 7mm 5 5.23 100.00 0.00
RESCANNING 1s 0 7mm 10 4.50 99.42 0.00
RESCANNING 1s 0 7mm 15 4.01 100.00 0.00
RESCANNING 1s 0 7mm 20 4.29 100.00 0.00
RESCANNING 1s 90 7mm 5 5.15 99.27 0.00
RESCANNING 1s 90 7mm 10 4.81 99.42 0.00
RESCANNING 1s 90 7mm 15 4.47 98.54 0.00
RESCANNING 1s 90 7mm 20 4.44 98.83 0.00
RESCANNING 0.7s 0 7mm 5 5.04 100.00 0.00
RESCANNING 0.7s 0 7mm 10 3.43 99.85 0.00
RESCANNING 0.7s 0 7mm 15 3.04 99.71 0.00
RESCANNING 0.7s 0 7mm 20 2.84 100.00 0.00
RESCANNING 0.7s 90 7mm 5 4.58 100.00 0.00
RESCANNING 0.7s 90 7mm 10 3.81 99.42 0.00
RESCANNING 0.7s 90 7mm 15 3.53 100.00 0.00
RESCANNING 0.7s 90 7mm 20 3.23 99.71 0.00
C Appendix of chapter 4
C.1 Motion of target volumes in constrast enhanced CT scans
The mean relative displacement and standard deviation of the target volumes (PVs, CTI and
AV node) to the reference phase zero of the contrast enhanced CT scans will be shown for the
three studied motion directions (SI: superior-inferior, AP: anterior-posterior, LR: left-right) and
the absolute (ABS) displacement.
Table C.1.: PV: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 1.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.43 ± 0.23 0.30 ± 0.25 0.03 ± 0.13 -0.10 ± 0.24
02 1.76 ± 0.52 0.49 ± 0.28 1.29 ± 0.33 -0.79 ± 0.79
03 2.61 ± 0.30 0.62 ± 0.39 2.00 ± 0.49 -1.16 ± 0.89
04 3.10 ± 0.28 0.51 ± 0.41 2.47 ± 0.68 -1.27 ± 1.03
05 3.46 ± 0.39 0.40 ± 0.57 2.77 ± 0.90 -1.42 ± 1.07
06 3.52 ± 0.59 0.54 ± 0.64 2.78 ± 1.09 -1.31 ± 1.19
07 3.80 ± 0.77 0.46 ± 0.86 3.06 ± 1.32 -1.32 ± 1.12
08 3.85 ± 0.98 0.34 ± 1.04 3.04 ± 1.60 -1.13 ± 1.23
09 3.80 ± 0.77 0.46 ± 0.86 3.06 ± 1.32 -1.32 ± 1.12
10 4.02 ± 1.09 0.10 ± 1.42 2.88 ± 1.85 -1.01 ± 1.62
11 4.04 ± 1.14 0.25 ± 1.57 2.66 ± 2.09 -1.11 ± 1.56
12 4.12 ± 1.13 0.48 ± 1.68 2.49 ± 2.25 -1.16 ± 1.61
13 4.22 ± 1.07 0.79 ± 1.56 2.42 ± 2.22 -1.40 ± 1.79
14 3.83 ± 0.88 0.31 ± 1.76 2.26 ± 1.58 -1.77 ± 1.26
15 2.97 ± 0.72 -0.00 ± 1.16 2.02 ± 1.08 -1.46 ± 0.77
16 1.94 ± 0.76 -0.01 ± 0.75 1.37 ± 0.79 -1.01 ± 0.53
17 1.67 ± 0.55 -0.60 ± 0.43 1.12 ± 0.37 -0.79 ± 0.72
18 1.17 ± 0.46 -0.58 ± 0.30 0.69 ± 0.39 -0.34 ± 0.65
19 0.48 ± 0.23 -0.36 ± 0.20 0.05 ± 0.24 -0.04 ± 0.23
Table C.2.: CTI: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 1.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.49 ± 0.21 -0.02 ± 0.13 0.20 ± 0.23 0.39 ± 0.16
02 0.87 ± 0.26 0.46 ± 0.24 0.04 ± 0.43 0.55 ± 0.28
03 1.75 ± 0.66 1.35 ± 0.53 0.70 ± 0.48 0.61 ± 0.54
04 1.92 ± 0.62 1.18 ± 0.45 0.99 ± 0.51 0.91 ± 0.63
05 2.82 ± 0.94 0.93 ± 0.57 2.00 ± 0.58 1.56 ± 0.93
06 5.05 ± 0.80 0.39 ± 0.45 4.20 ± 0.66 2.63 ± 0.93
07 5.79 ± 0.98 0.62 ± 0.58 4.48 ± 0.73 3.47 ± 1.06
08 5.36 ± 1.06 0.42 ± 0.60 3.95 ± 1.31 3.31 ± 0.99
09 5.79 ± 0.98 0.62 ± 0.58 4.48 ± 0.73 3.47 ± 1.06
10 5.73 ± 0.94 -0.20 ± 0.66 4.92 ± 0.81 2.58 ± 1.29
11 5.40 ± 1.01 0.75 ± 0.65 4.60 ± 1.13 2.46 ± 0.82
12 5.67 ± 1.07 0.84 ± 0.98 4.90 ± 1.20 2.37 ± 0.70
13 5.25 ± 1.14 0.80 ± 1.11 4.60 ± 1.30 1.82 ± 0.91
14 3.83 ± 1.10 1.43 ± 0.95 2.92 ± 1.38 0.86 ± 1.35
15 3.78 ± 0.83 1.92 ± 1.71 2.32 ± 0.76 0.76 ± 1.35
16 3.29 ± 0.44 1.46 ± 1.52 1.28 ± 0.74 1.56 ± 1.40
17 1.97 ± 0.60 0.70 ± 1.30 -0.80 ± 0.47 0.62 ± 0.90
18 1.82 ± 0.43 0.31 ± 0.71 -1.46 ± 0.30 -0.76 ± 0.33
19 0.76 ± 0.37 -0.01 ± 0.17 -0.60 ± 0.32 -0.40 ± 0.23
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Table C.3.: AV node: Mean and standard deviation of target motion in all phases of the heart-
beat, relative to the reference phase. The values are taken from the contrast CTs of
Pig 1.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.15 ± 0.09 -0.01 ± 0.06 -0.01 ± 0.04 0.12 ± 0.10
02 0.66 ± 0.27 -0.01 ± 0.14 0.51 ± 0.12 -0.08 ± 0.46
03 2.38 ± 0.24 0.52 ± 0.31 2.25 ± 0.21 -0.28 ± 0.41
04 2.95 ± 0.34 0.87 ± 0.11 2.80 ± 0.37 -0.25 ± 0.18
05 3.12 ± 0.40 0.79 ± 0.60 2.90 ± 0.56 -0.42 ± 0.21
06 3.60 ± 0.53 0.64 ± 0.38 3.46 ± 0.62 -0.44 ± 0.36
07 3.79 ± 0.56 0.33 ± 0.55 3.62 ± 0.70 -0.63 ± 0.50
08 4.14 ± 0.69 0.29 ± 0.39 4.03 ± 0.80 -0.44 ± 0.56
09 3.79 ± 0.56 0.33 ± 0.55 3.62 ± 0.70 -0.63 ± 0.50
10 4.25 ± 0.66 0.36 ± 0.33 4.10 ± 0.80 -0.64 ± 0.63
11 4.33 ± 0.57 0.54 ± 0.39 4.08 ± 0.76 -1.06 ± 0.56
12 4.67 ± 0.29 0.49 ± 0.40 4.43 ± 0.41 -1.21 ± 0.50
13 4.93 ± 0.26 1.70 ± 0.35 4.46 ± 0.39 -1.11 ± 0.27
14 4.27 ± 0.30 0.00 ± 0.44 3.84 ± 0.34 -1.76 ± 0.31
15 3.57 ± 0.24 0.03 ± 0.42 3.33 ± 0.23 -1.20 ± 0.15
16 2.25 ± 0.21 1.00 ± 0.46 1.86 ± 0.28 -0.56 ± 0.27
17 1.91 ± 0.35 -0.30 ± 0.78 -0.41 ± 0.40 -1.61 ± 0.38
18 1.14 ± 0.40 -0.29 ± 0.41 -0.32 ± 0.25 -0.88 ± 0.51
19 0.37 ± 0.15 0.06 ± 0.06 -0.27 ± 0.12 -0.14 ± 0.22
Table C.4.: PV: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 2.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.37 ± 0.25 0.02 ± 0.27 0.14 ± 0.20 -0.10 ± 0.24
02 1.16 ± 0.69 0.40 ± 0.42 0.78 ± 0.58 -0.43 ± 0.60
03 2.06 ± 0.57 0.73 ± 0.47 1.61 ± 0.63 -0.61 ± 0.69
04 2.26 ± 0.64 0.79 ± 0.47 1.74 ± 0.75 -0.77 ± 0.69
05 2.50 ± 0.66 1.09 ± 0.65 1.82 ± 0.80 -0.61 ± 0.89
06 2.71 ± 0.96 1.26 ± 0.85 1.89 ± 1.04 -0.51 ± 1.02
07 3.02 ± 1.11 1.33 ± 0.95 2.14 ± 1.35 -0.67 ± 0.91
08 3.09 ± 1.22 1.20 ± 0.96 2.18 ± 1.50 -0.47 ± 1.22
09 3.02 ± 1.11 1.33 ± 0.95 2.14 ± 1.35 -0.67 ± 0.91
10 3.30 ± 1.12 1.21 ± 1.24 1.81 ± 1.72 -0.64 ± 1.57
11 3.24 ± 1.14 1.33 ± 1.33 1.60 ± 1.68 -0.68 ± 1.57
12 3.71 ± 1.55 1.50 ± 1.46 2.08 ± 2.05 -0.81 ± 1.61
13 3.37 ± 1.23 1.67 ± 1.41 1.62 ± 1.58 -0.92 ± 1.46
14 2.92 ± 1.11 1.55 ± 1.26 1.42 ± 1.25 -0.97 ± 1.12
15 2.19 ± 1.00 1.12 ± 1.00 1.27 ± 0.87 -0.70 ± 0.83
16 1.80 ± 0.70 0.10 ± 0.61 0.87 ± 0.86 -1.01 ± 0.90
17 1.52 ± 0.69 -0.19 ± 0.61 0.72 ± 0.71 -0.86 ± 0.79
18 1.11 ± 0.57 -0.23 ± 0.58 0.21 ± 0.65 -0.50 ± 0.66
19 0.39 ± 0.25 -0.04 ± 0.32 0.10 ± 0.21 -0.03 ± 0.23
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Table C.5.: CTI: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 2.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.29 ± 0.13 -0.00 ± 0.13 0.19 ± 0.11 0.16 ± 0.11
02 1.89 ± 0.49 0.25 ± 0.87 1.55 ± 0.56 0.25 ± 0.48
03 2.21 ± 0.55 0.48 ± 0.85 1.79 ± 0.46 0.51 ± 0.72
04 2.17 ± 0.43 0.84 ± 0.65 1.56 ± 0.39 -0.49 ± 0.98
05 4.12 ± 1.29 2.00 ± 1.31 3.40 ± 0.82 0.01 ± 0.85
06 4.43 ± 0.60 0.07 ± 1.42 4.10 ± 0.55 0.66 ± 0.68
07 4.92 ± 0.57 -0.75 ± 1.49 4.26 ± 0.54 1.47 ± 1.06
08 6.34 ± 0.54 1.26 ± 1.32 5.09 ± 0.60 3.04 ± 1.25
09 4.92 ± 0.57 -0.75 ± 1.49 4.26 ± 0.54 1.47 ± 1.06
10 4.33 ± 1.08 1.28 ± 1.14 3.50 ± 0.80 1.46 ± 1.38
11 4.41 ± 1.19 1.72 ± 1.11 3.45 ± 0.72 1.41 ± 1.51
12 4.89 ± 0.95 2.34 ± 0.86 3.68 ± 0.48 0.76 ± 2.06
13 5.53 ± 0.80 3.12 ± 0.96 4.11 ± 0.34 0.23 ± 1.87
14 4.70 ± 1.00 3.17 ± 0.96 3.03 ± 0.57 0.26 ± 1.60
15 4.31 ± 0.67 3.22 ± 0.81 2.45 ± 0.73 -0.19 ± 1.20
16 2.03 ± 0.77 0.89 ± 0.94 0.65 ± 0.62 -1.00 ± 1.12
17 2.35 ± 0.99 -0.70 ± 0.64 -0.63 ± 0.27 -2.01 ± 1.04
18 2.09 ± 0.78 -0.41 ± 0.60 -0.88 ± 0.25 -1.67 ± 0.92
19 0.71 ± 0.23 0.28 ± 0.18 -0.48 ± 0.18 -0.39 ± 0.19
Table C.6.: AV node: Mean and standard deviation of target motion in all phases of the heart-
beat, relative to the reference phase. The values are taken from the contrast CTs of
Pig 2.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.53 ± 0.10 0.34 ± 0.09 0.40 ± 0.07 -0.04 ± 0.05
02 1.83 ± 0.49 0.08 ± 0.10 1.73 ± 0.42 0.46 ± 0.46
03 2.10 ± 0.08 0.68 ± 0.25 1.97 ± 0.14 0.06 ± 0.09
04 3.32 ± 0.17 1.62 ± 0.37 2.86 ± 0.09 -0.11 ± 0.30
05 3.95 ± 0.29 1.35 ± 0.20 3.68 ± 0.33 0.12 ± 0.37
06 3.94 ± 0.28 1.56 ± 0.30 3.56 ± 0.20 -0.56 ± 0.20
07 4.89 ± 0.36 2.48 ± 0.23 4.20 ± 0.41 -0.09 ± 0.24
08 5.44 ± 0.25 2.68 ± 0.37 4.71 ± 0.33 0.14 ± 0.27
09 4.89 ± 0.36 2.48 ± 0.23 4.20 ± 0.41 -0.09 ± 0.24
10 5.83 ± 0.25 2.79 ± 0.41 5.08 ± 0.11 -0.21 ± 0.49
11 6.04 ± 0.19 3.71 ± 0.36 4.71 ± 0.17 -0.38 ± 0.51
12 5.86 ± 0.23 3.27 ± 0.28 4.85 ± 0.11 0.12 ± 0.22
13 5.47 ± 0.46 3.55 ± 0.56 4.13 ± 0.21 0.07 ± 0.21
14 5.25 ± 0.53 3.01 ± 0.51 4.25 ± 0.35 0.23 ± 0.50
15 4.15 ± 0.48 1.99 ± 0.28 3.52 ± 0.34 0.56 ± 0.76
16 2.98 ± 0.43 1.82 ± 0.40 2.30 ± 0.26 0.30 ± 0.36
17 2.52 ± 0.53 1.84 ± 0.45 1.45 ± 0.23 0.89 ± 0.28
18 1.05 ± 0.61 0.70 ± 0.46 0.21 ± 0.24 0.73 ± 0.38
19 0.21 ± 0.06 -0.10 ± 0.06 -0.03 ± 0.08 -0.14 ± 0.09
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Table C.7.: PV: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 3.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.59 ± 0.27 0.05 ± 0.22 -0.07 ± 0.42 0.25 ± 0.35
02 1.39 ± 0.85 -0.21 ± 0.41 1.13 ± 0.85 0.46 ± 0.50
03 2.09 ± 0.80 -0.15 ± 0.48 1.67 ± 0.70 0.69 ± 1.01
04 2.17 ± 0.85 -0.27 ± 0.50 1.64 ± 0.73 0.81 ± 1.11
05 2.21 ± 0.89 -0.41 ± 0.57 1.94 ± 0.81 0.41 ± 0.79
06 2.39 ± 0.89 -0.48 ± 0.58 2.10 ± 0.80 0.42 ± 0.85
07 2.36 ± 0.91 -0.48 ± 0.65 2.00 ± 0.83 0.44 ± 0.92
08 2.23 ± 0.97 -0.55 ± 0.67 1.77 ± 0.89 0.47 ± 1.01
09 2.36 ± 0.91 -0.48 ± 0.65 2.00 ± 0.83 0.44 ± 0.92
10 1.79 ± 0.74 -0.19 ± 0.54 1.29 ± 0.77 0.32 ± 1.03
11 1.61 ± 0.76 0.06 ± 0.56 0.92 ± 0.85 0.16 ± 1.12
12 1.54 ± 0.57 -0.13 ± 0.43 0.53 ± 1.03 -0.17 ± 1.07
13 1.21 ± 0.52 0.01 ± 0.41 0.31 ± 0.82 -0.44 ± 0.77
14 1.53 ± 0.59 0.09 ± 0.45 -0.52 ± 1.31 -0.42 ± 0.58
15 1.38 ± 0.59 -0.13 ± 0.49 -0.52 ± 1.09 -0.59 ± 0.46
16 1.58 ± 0.77 -0.16 ± 0.59 -0.80 ± 1.21 -0.56 ± 0.53
17 1.76 ± 1.05 -0.13 ± 0.76 -1.08 ± 1.35 -0.54 ± 0.60
18 1.65 ± 0.98 -0.11 ± 0.81 -1.12 ± 1.15 -0.25 ± 0.59
19 0.63 ± 0.43 0.03 ± 0.36 -0.22 ± 0.33 -0.29 ± 0.47
Table C.8.: CTI: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 3.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.40 ± 0.16 0.26 ± 0.21 -0.08 ± 0.18 0.10 ± 0.15
02 1.30 ± 0.59 -0.85 ± 0.50 0.84 ± 0.43 0.20 ± 0.38
03 1.59 ± 0.38 -0.56 ± 0.45 1.37 ± 0.32 0.05 ± 0.40
04 1.63 ± 0.43 -0.16 ± 0.60 1.41 ± 0.52 0.02 ± 0.45
05 1.84 ± 0.70 0.37 ± 0.82 1.53 ± 0.74 0.19 ± 0.36
06 1.58 ± 0.67 0.08 ± 0.64 1.26 ± 0.82 0.02 ± 0.53
07 1.73 ± 0.78 -0.02 ± 0.46 1.54 ± 0.91 0.28 ± 0.36
08 1.66 ± 0.63 0.19 ± 0.47 1.08 ± 1.22 0.39 ± 0.31
09 1.73 ± 0.78 -0.02 ± 0.46 1.54 ± 0.91 0.28 ± 0.36
10 1.92 ± 0.58 0.36 ± 0.38 1.44 ± 1.17 0.04 ± 0.56
11 2.23 ± 0.63 0.89 ± 0.46 1.30 ± 0.79 1.16 ± 0.83
12 2.08 ± 0.58 0.09 ± 0.55 1.45 ± 0.42 1.03 ± 0.99
13 1.44 ± 0.55 0.90 ± 0.51 0.48 ± 0.35 0.60 ± 0.76
14 1.83 ± 0.69 1.50 ± 0.73 -0.06 ± 0.49 0.16 ± 0.86
15 1.43 ± 0.49 1.06 ± 0.49 -0.00 ± 0.46 0.17 ± 0.83
16 1.60 ± 0.29 1.25 ± 0.41 -0.48 ± 0.48 -0.10 ± 0.67
17 1.97 ± 0.40 1.48 ± 0.43 -0.68 ± 0.46 -0.88 ± 0.45
18 1.10 ± 0.48 0.77 ± 0.41 -0.44 ± 0.19 -0.44 ± 0.51
19 0.42 ± 0.14 0.08 ± 0.18 -0.22 ± 0.14 -0.12 ± 0.27
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Table C.9.: AV node: Mean and standard deviation of target motion in all phases of the heart-
beat, relative to the reference phase. The values are taken from the contrast CTs of
Pig 3.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.97 ± 0.23 0.25 ± 0.24 -0.58 ± 0.14 -0.66 ± 0.30
02 3.86 ± 0.24 -0.46 ± 0.45 3.19 ± 0.54 -1.72 ± 1.06
03 3.38 ± 0.23 -0.62 ± 0.41 3.06 ± 0.18 -1.15 ± 0.48
04 2.87 ± 0.48 0.15 ± 0.20 1.97 ± 0.33 -2.06 ± 0.43
05 4.35 ± 0.10 -0.30 ± 0.41 3.88 ± 0.23 -1.85 ± 0.42
06 4.15 ± 0.14 0.08 ± 0.40 3.60 ± 0.26 -1.94 ± 0.54
07 3.84 ± 0.16 0.02 ± 0.31 3.40 ± 0.29 -1.68 ± 0.41
08 3.17 ± 0.17 0.04 ± 0.24 2.71 ± 0.24 -1.51 ± 0.55
09 3.84 ± 0.16 0.02 ± 0.31 3.40 ± 0.29 -1.68 ± 0.41
10 3.16 ± 0.13 0.28 ± 0.13 2.85 ± 0.20 -1.18 ± 0.59
11 3.40 ± 0.26 1.46 ± 0.54 2.18 ± 0.52 -1.91 ± 0.76
12 2.47 ± 0.37 0.04 ± 0.20 2.26 ± 0.20 -0.79 ± 0.68
13 1.56 ± 0.43 0.24 ± 0.39 1.24 ± 0.23 -0.70 ± 0.57
14 2.07 ± 0.44 0.06 ± 0.23 1.80 ± 0.30 -0.68 ± 0.78
15 2.30 ± 0.65 0.04 ± 0.26 0.60 ± 0.17 -2.20 ± 0.66
16 2.49 ± 0.63 -0.07 ± 0.17 0.19 ± 0.18 -2.47 ± 0.64
17 2.89 ± 0.74 -0.10 ± 0.13 0.41 ± 0.17 -2.84 ± 0.76
18 1.26 ± 0.26 -0.22 ± 0.11 0.73 ± 0.17 0.72 ± 0.72
19 0.85 ± 0.12 -0.18 ± 0.28 0.67 ± 0.14 0.34 ± 0.21
Table C.10.: PV: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 4.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.52 ± 0.31 0.22 ± 0.31 0.29 ± 0.27 -0.07 ± 0.22
02 1.72 ± 0.39 0.09 ± 0.27 1.56 ± 0.32 -0.44 ± 0.53
03 2.21 ± 0.28 0.07 ± 0.29 1.96 ± 0.22 -0.73 ± 0.66
04 2.39 ± 0.23 0.22 ± 0.32 2.14 ± 0.33 -0.63 ± 0.75
05 2.48 ± 0.38 0.14 ± 0.34 2.24 ± 0.53 -0.37 ± 0.86
06 2.48 ± 0.56 0.14 ± 0.33 2.24 ± 0.71 -0.23 ± 0.86
07 2.38 ± 0.68 0.29 ± 0.33 2.12 ± 0.86 -0.25 ± 0.80
08 2.34 ± 0.80 0.41 ± 0.38 1.99 ± 1.00 -0.30 ± 0.86
09 2.38 ± 0.68 0.29 ± 0.33 2.12 ± 0.86 -0.25 ± 0.80
10 3.05 ± 1.06 0.70 ± 0.59 2.45 ± 1.36 -0.59 ± 1.19
11 3.13 ± 1.03 0.81 ± 0.67 2.64 ± 1.17 -0.49 ± 1.09
12 2.82 ± 0.80 0.80 ± 0.63 2.44 ± 0.84 -0.37 ± 0.87
13 2.38 ± 0.74 0.56 ± 0.62 2.19 ± 0.68 -0.08 ± 0.51
14 2.17 ± 0.63 0.45 ± 0.52 2.02 ± 0.58 0.13 ± 0.48
15 2.05 ± 0.45 0.22 ± 0.37 1.92 ± 0.46 0.30 ± 0.47
16 1.98 ± 0.41 -0.10 ± 0.43 1.79 ± 0.37 0.32 ± 0.68
17 1.68 ± 0.51 -0.03 ± 0.56 1.42 ± 0.41 0.41 ± 0.64
18 1.12 ± 0.43 -0.02 ± 0.32 0.87 ± 0.39 0.37 ± 0.54
19 0.48 ± 0.22 -0.11 ± 0.19 0.29 ± 0.29 0.09 ± 0.22
207
Table C.11.: CTI: Mean and standard deviation of target motion in all phases of the heartbeat,
relative to the reference phase. The values are taken from the contrast CTs of Pig 4.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.24 ± 0.07 0.11 ± 0.16 0.01 ± 0.11 0.07 ± 0.07
02 0.73 ± 0.16 0.55 ± 0.20 0.26 ± 0.29 -0.10 ± 0.24
03 1.47 ± 0.47 0.41 ± 0.41 1.19 ± 0.36 -0.59 ± 0.39
04 1.66 ± 0.47 0.50 ± 0.34 1.46 ± 0.37 -0.09 ± 0.59
05 2.18 ± 0.34 0.44 ± 0.26 2.04 ± 0.31 0.20 ± 0.54
06 2.64 ± 0.36 0.09 ± 0.13 2.55 ± 0.40 0.53 ± 0.39
07 2.63 ± 0.43 0.07 ± 0.26 2.54 ± 0.41 0.51 ± 0.43
08 2.70 ± 0.61 0.46 ± 0.48 2.56 ± 0.56 0.26 ± 0.52
09 2.63 ± 0.43 0.07 ± 0.26 2.54 ± 0.41 0.51 ± 0.43
10 3.52 ± 0.53 1.76 ± 0.65 2.86 ± 0.58 0.12 ± 0.75
11 3.52 ± 0.49 2.02 ± 0.56 2.71 ± 0.56 0.10 ± 0.74
12 3.67 ± 0.63 1.97 ± 0.51 2.96 ± 0.59 0.47 ± 0.64
13 3.95 ± 0.83 2.27 ± 0.59 3.12 ± 0.77 0.36 ± 0.57
14 3.11 ± 0.69 1.72 ± 0.66 2.44 ± 0.75 -0.17 ± 0.43
15 1.98 ± 0.40 0.98 ± 0.37 1.56 ± 0.51 -0.16 ± 0.53
16 1.42 ± 0.32 0.70 ± 0.29 1.05 ± 0.49 -0.34 ± 0.29
17 1.19 ± 0.32 0.55 ± 0.28 0.55 ± 0.38 -0.69 ± 0.46
18 0.94 ± 0.23 0.66 ± 0.25 0.02 ± 0.24 -0.54 ± 0.30
19 0.46 ± 0.20 0.12 ± 0.07 0.12 ± 0.20 -0.29 ± 0.31
Table C.12.: AV node: Mean and standard deviation of target motion in all phases of the heart-
beat, relative to the reference phase. The values are taken from the contrast CTs of
Pig 4.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.27 ± 0.08 0.17 ± 0.05 -0.17 ± 0.12 0.01 ± 0.07
02 0.52 ± 0.18 0.11 ± 0.04 0.16 ± 0.25 -0.36 ± 0.27
03 2.19 ± 0.21 0.13 ± 0.17 1.99 ± 0.18 -0.82 ± 0.38
04 2.30 ± 0.23 0.17 ± 0.12 2.16 ± 0.22 -0.71 ± 0.27
05 2.30 ± 0.23 0.17 ± 0.08 2.22 ± 0.24 -0.52 ± 0.22
06 2.52 ± 0.32 0.24 ± 0.17 2.44 ± 0.32 -0.40 ± 0.36
07 2.42 ± 0.37 0.28 ± 0.10 2.32 ± 0.39 -0.50 ± 0.36
08 3.05 ± 0.33 0.42 ± 0.13 2.84 ± 0.40 -0.86 ± 0.52
09 2.42 ± 0.37 0.28 ± 0.10 2.32 ± 0.39 -0.50 ± 0.36
10 3.63 ± 0.67 0.77 ± 0.22 3.18 ± 0.44 -1.43 ± 0.81
11 3.49 ± 0.55 0.98 ± 0.20 3.16 ± 0.47 -0.95 ± 0.62
12 2.92 ± 0.60 1.03 ± 0.30 2.59 ± 0.47 -0.66 ± 0.59
13 2.39 ± 0.55 0.75 ± 0.31 2.16 ± 0.42 -0.56 ± 0.48
14 1.96 ± 0.40 0.65 ± 0.18 1.72 ± 0.34 -0.54 ± 0.41
15 2.04 ± 0.46 0.40 ± 0.21 1.67 ± 0.28 -1.04 ± 0.48
16 2.01 ± 0.39 0.69 ± 0.27 1.37 ± 0.25 -1.24 ± 0.40
17 1.31 ± 0.38 0.64 ± 0.24 0.62 ± 0.20 -0.89 ± 0.41
18 0.74 ± 0.40 0.55 ± 0.31 0.09 ± 0.27 -0.36 ± 0.31
19 0.41 ± 0.15 0.13 ± 0.09 -0.06 ± 0.19 -0.26 ± 0.25
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C.2 Motion of AV node in native CT scan
The mean relative displacement of the AV node to the reference phase zero of the native CT
scan of pig 3 will be shown four the three studied motion directions (SI: superior-inferior, AP:
anterior-posterior, LR: left-right) and the absolute (ABS) displacement.
Table C.13.: AV node: Mean and standard deviation of target motion in all phases of the heart-
beat, relative to the reference phase. The values are taken from the native CTs of
Pig 3.
motion phase ABS [mm] SI [mm] AP [mm] LR [mm]
01 0.07 ± 0.02 0.01 ± 0.03 -0.03 ± 0.03 -0.02 ± 0.03
02 0.12 ± 0.06 0.09 ± 0.06 0.04 ± 0.04 -0.04 ± 0.03
03 0.09 ± 0.05 -0.02 ± 0.03 0.05 ± 0.05 -0.01 ± 0.06
04 0.19 ± 0.07 0.13 ± 0.07 0.09 ± 0.08 0.03 ± 0.05
05 0.16 ± 0.07 0.05 ± 0.07 0.11 ± 0.08 -0.00 ± 0.06
06 0.18 ± 0.08 0.12 ± 0.10 0.06 ± 0.08 -0.01 ± 0.05
07 0.19 ± 0.08 0.16 ± 0.09 0.03 ± 0.05 -0.04 ± 0.05
08 0.13 ± 0.05 0.06 ± 0.08 -0.01 ± 0.05 -0.06 ± 0.06
09 0.19 ± 0.08 0.16 ± 0.09 0.03 ± 0.05 -0.04 ± 0.05
10 0.17 ± 0.05 0.10 ± 0.05 -0.10 ± 0.08 -0.03 ± 0.07
11 0.16 ± 0.07 0.05 ± 0.03 -0.12 ± 0.08 0.05 ± 0.05
12 0.23 ± 0.08 0.11 ± 0.03 -0.14 ± 0.09 0.11 ± 0.06
13 0.13 ± 0.04 -0.00 ± 0.05 -0.06 ± 0.08 0.06 ± 0.05
14 0.10 ± 0.04 -0.05 ± 0.02 0.01 ± 0.07 0.03 ± 0.06
15 0.11 ± 0.05 0.01 ± 0.04 0.01 ± 0.07 -0.01 ± 0.09
16 0.12 ± 0.06 0.03 ± 0.03 0.04 ± 0.07 -0.02 ± 0.10
17 0.08 ± 0.04 -0.01 ± 0.03 0.01 ± 0.07 -0.01 ± 0.04
18 0.10 ± 0.04 -0.06 ± 0.03 -0.00 ± 0.06 -0.03 ± 0.03
19 0.05 ± 0.02 0.01 ± 0.03 -0.02 ± 0.04 -0.00 ± 0.03
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Values of dose analysis parameters for all pigs
In the following the D5-D95, V95 and V107 values will be presented for the irradiation of the AV
node in all porcine data sets (pig 1 to 4). All studied techniques (static, interplay and rescanning
with five, ten and fifteen rescans) will be shown for four different motion patterns and for the
studied safety margin of 5 mm.
Table C.14.: Pig 1, AV node: Dose analysis parameters D5-D95 (dose homogeneity), V95 (dose
coverage) and V107 (over dosage) for all studied techniques and motion patterns
for an irradiation with 5 mm margin.
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 5mm - 5.66 100.00 0.00
INTERPLAY 0.7s 0 5mm - 13.94 100.00 51.85
INTERPLAY 0.7s 90 5mm - 13.64 90.74 6.67
INTERPLAY 0.5s 0 5mm - 16.37 73.33 4.81
INTERPLAY 0.5s 90 5mm - 8.19 100.00 32.96
RESCANNING 0.7s 0 5mm 5 11.09 100.00 9.63
RESCANNING 0.7s 90 5mm 5 7.08 100.00 0.00
RESCANNING 0.5s 0 5mm 5 8.55 93.70 0.00
RESCANNING 0.5s 90 5mm 5 11.01 97.41 3.33
RESCANNING 0.7s 0 5mm 10 6.26 100.00 0.00
RESCANNING 0.7s 90 5mm 10 4.70 100.00 0.00
RESCANNING 0.5s 0 5mm 10 5.79 100.00 0.00
RESCANNING 0.5s 90 5mm 10 4.24 100.00 0.00
RESCANNING 0.7s 0 5mm 15 4.88 100.00 0.00
RESCANNING 0.7s 90 5mm 15 3.91 100.00 0.00
RESCANNING 0.5s 0 5mm 15 5.37 100.00 0.00
RESCANNING 0.5s 90 5mm 15 5.80 100.00 0.00
Table C.15.: Pig 2, AV node: Dose analysis parameters D5-D95 (dose homogeneity), V95 (dose
coverage) and V107 (over dosage) for all studied techniques and motion patterns
for an irradiation with 5 mm margin.
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 5mm - 4.41 100.00 0.00
INTERPLAY 0.7s 0 5mm - 7.20 97.55 0.00
INTERPLAY 0.7s 90 5mm - 6.19 99.02 0.00
INTERPLAY 0.5s 0 5mm - 9.33 91.18 0.00
INTERPLAY 0.5s 90 5mm - 10.90 99.51 4.90
RESCANNING 0.7s 0 5mm 5 5.65 100.00 3.43
RESCANNING 0.7s 90 5mm 5 8.20 43.63 0.00
RESCANNING 0.5s 0 5mm 5 5.66 100.00 0.00
RESCANNING 0.5s 90 5mm 5 7.24 99.51 0.00
RESCANNING 0.7s 0 5mm 10 3.66 100.00 0.00
RESCANNING 0.7s 90 5mm 10 7.90 98.53 0.00
RESCANNING 0.5s 0 5mm 10 6.20 100.00 9.31
RESCANNING 0.5s 90 5mm 10 4.03 100.00 0.00
RESCANNING 0.7s 0 5mm 15 4.35 100.00 0.00
RESCANNING 0.7s 90 5mm 15 6.98 100.00 0.00
RESCANNING 0.5s 0 5mm 15 7.27 99.51 0.00
RESCANNING 0.5s 90 5mm 15 3.61 100.00 0.00
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Table C.16.: Pig 3, AV node: Dose analysis parameters D5-D95 (dose homogeneity), V95 (dose
coverage) and V107 (over dosage) for all studied techniques and motion patterns
for an irradiation with 5 mm margin.
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 5mm - 2.20 100.00 0.00
INTERPLAY 0.7s 0 5mm - 5.64 55.88 0.00
INTERPLAY 0.7s 90 5mm - 6.98 100.00 0.00
INTERPLAY 0.5s 0 5mm - 8.83 92.94 0.00
INTERPLAY 0.5s 90 5mm - 5.22 100.00 0.00
RESCANNING 0.7s 0 5mm 5 8.49 98.24 0.00
RESCANNING 0.7s 90 5mm 5 7.13 100.00 0.00
RESCANNING 0.5s 0 5mm 5 5.68 100.00 77.65
RESCANNING 0.5s 90 5mm 5 4.27 51.76 0.00
RESCANNING 0.7s 0 5mm 10 4.89 100.00 0.00
RESCANNING 0.7s 90 5mm 10 6.22 100.00 0.00
RESCANNING 0.5s 0 5mm 10 4.42 100.00 0.00
RESCANNING 0.5s 90 5mm 10 3.42 100.00 0.00
RESCANNING 0.7s 0 5mm 15 5.85 99.41 0.00
RESCANNING 0.7s 90 5mm 15 5.57 100.00 0.00
RESCANNING 0.5s 0 5mm 15 4.70 100.00 0.00
RESCANNING 0.5s 90 5mm 15 5.38 100.00 0.00
Table C.17.: Pig 4, AV node: Dose analysis parameters D5-D95 (dose homogeneity), V95 (dose
coverage) and V107 (over dosage) for all studied techniques and motion patterns
for an irradiation with 5 mm margin.
Case motion period motion starting phase Margin rescan no. D5-D95 [%] V95 [%] V107 [%]
STATIC - - 5mm - 5.53 100.00 0.00
INTERPLAY 0.7s 0 5mm - 13.82 83.67 0.00
INTERPLAY 0.7s 90 5mm - 12.81 74.29 0.41
INTERPLAY 0.5s 0 5mm - 17.58 80.61 17.14
INTERPLAY 0.5s 90 5mm - 21.75 44.49 0.00
RESCANNING 0.7s 0 5mm 5 6.79 100.00 0.00
RESCANNING 0.7s 90 5mm 5 7.08 96.73 0.00
RESCANNING 0.5s 0 5mm 5 4.90 86.33 0.00
RESCANNING 0.5s 90 5mm 5 7.90 100.00 3.47
RESCANNING 0.7s 0 5mm 10 5.25 100.00 0.00
RESCANNING 0.7s 90 5mm 10 5.95 97.76 0.00
RESCANNING 0.5s 0 5mm 10 5.09 100.00 0.20
RESCANNING 0.5s 90 5mm 10 5.44 98.37 0.00
RESCANNING 0.7s 0 5mm 15 4.99 100.00 0.00
RESCANNING 0.7s 90 5mm 15 5.55 100.00 0.00
RESCANNING 0.5s 0 5mm 15 2.96 100.00 0.00
RESCANNING 0.5s 90 5mm 15 4.69 100.00 0.00
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